<SEC-DOCUMENT>0001274737-23-000049.txt : 20230515
<SEC-HEADER>0001274737-23-000049.hdr.sgml : 20230515
<ACCEPTANCE-DATETIME>20230515171609
ACCESSION NUMBER:		0001274737-23-000049
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230515
DATE AS OF CHANGE:		20230515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXAGEN INC.
		CENTRAL INDEX KEY:			0001274737
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39049
		FILM NUMBER:		23924339

	BUSINESS ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
		BUSINESS PHONE:		(760) 560-1501

	MAIL ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXAGEN DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20031230
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exdx-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:986b824d-5d9a-48e8-aa5f-764c09336517,g:f595c211-a573-4e45-813e-7a98f9aeca2c,d:c6a5e7b0edc94c399549fe8f80e94568--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exdx="http://www.exagen.com/20230331" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exdx-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80L2ZyYWc6MWNjNzNlNmI2ZTc1NDkwYjliODIxZDU3NDRiZGVlYzQvdGFibGU6NTk0Y2FlNzY0NzRlNGJmNWI5NzEwY2NjZGFhMDg0MTMvdGFibGVyYW5nZTo1OTRjYWU3NjQ3NGU0YmY1Yjk3MTBjY2NkYWEwODQxM18zLTEtMS0xLTYyNDU1_c976eea4-9008-421c-a6c2-6a7c26e6d0e8">0001274737</ix:nonNumeric><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80L2ZyYWc6MWNjNzNlNmI2ZTc1NDkwYjliODIxZDU3NDRiZGVlYzQvdGFibGU6NTk0Y2FlNzY0NzRlNGJmNWI5NzEwY2NjZGFhMDg0MTMvdGFibGVyYW5nZTo1OTRjYWU3NjQ3NGU0YmY1Yjk3MTBjY2NkYWEwODQxM180LTEtMS0xLTYyNDU1_b01c11e1-0541-4645-9c01-eda7fc2a0a61">12-31</ix:nonNumeric><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80L2ZyYWc6MWNjNzNlNmI2ZTc1NDkwYjliODIxZDU3NDRiZGVlYzQvdGFibGU6NTk0Y2FlNzY0NzRlNGJmNWI5NzEwY2NjZGFhMDg0MTMvdGFibGVyYW5nZTo1OTRjYWU3NjQ3NGU0YmY1Yjk3MTBjY2NkYWEwODQxM181LTEtMS0xLTYyNDU1_fe2a64a3-3b93-4a20-a72c-c99f6d19d248">2023</ix:nonNumeric><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80L2ZyYWc6MWNjNzNlNmI2ZTc1NDkwYjliODIxZDU3NDRiZGVlYzQvdGFibGU6NTk0Y2FlNzY0NzRlNGJmNWI5NzEwY2NjZGFhMDg0MTMvdGFibGVyYW5nZTo1OTRjYWU3NjQ3NGU0YmY1Yjk3MTBjY2NkYWEwODQxM182LTEtMS0xLTYyNDU1_d3a1d039-2965-4f22-bebc-4c9a28f825cb">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80L2ZyYWc6MWNjNzNlNmI2ZTc1NDkwYjliODIxZDU3NDRiZGVlYzQvdGFibGU6NTk0Y2FlNzY0NzRlNGJmNWI5NzEwY2NjZGFhMDg0MTMvdGFibGVyYW5nZTo1OTRjYWU3NjQ3NGU0YmY1Yjk3MTBjY2NkYWEwODQxM183LTEtMS0xLTYyNDU1_e6fef1d0-ea13-43c3-a6ea-40771a718829">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exdx-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbe60ad4860843a2ab64b5cd330ef707_I20230511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i7dbf9a0fcf934366948459c15f4770d1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bb6db3028e64addadc73284bff78b54_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0649efcb68545c6b7b9b7ec6425a6bf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0705a248fabf483b8d91cb9179b97e90_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fe0be00ef494161bd0549b671f2fe9b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62b1db4c0c1d4c9f841e4594fe97bc2a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if71859fd80494dddb569b483b53c0f5b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b09d1c772d642c2be65db1440589466_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84709c32e10840689d3198791460cf9b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c57b87359174c8ba8490118ae86e8ea_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90a82a0082294a76aa4b428dfc020494_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f0a7eb3bdd5459aac214c6226b676a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if296323417ca4b029d7a11232e87aad2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i140c8595c10a41eeb48e5be8f884c4cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c10b316a5a146458ede9d5dc729ac84_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b616351de9643b99134e16eafc041e6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bc0bf262ca04963b27d2f261ce272bd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2395d65c2f04e0c82d354b532c429b4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72308a08a4614029a1a34e29777d8a6b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia408b342e58a47b4b9fab75709a394d2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic10d09e997d04be59819eb9f739c540e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icde0546e33bc4e4dbdee35365b9dbeec_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i53feb630091f4619a5126ec58f43ca87_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd65ad1f84754ac2be24f4c994f8f3cd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6abda9f9e6d446892e7c0f30b5d60d3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib670f4a2e3f647279e6c9c81af57ffc1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife65d382ae2a47219439e25b9543c648_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4838d54052ca4b00a39f1c6ae8f5cfd5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdb3a7f4fb2b4a099c8ab9a2651f42d9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d88ab7784214d388b2b50fb5bb4c7b3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2a4f1732f624b489e8f50c6d6b4e485_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecd13c786620474fa63cd266b54a3b74_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i309af3d1bef54a83aaa50e2c61f71a24_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90730eb7530d4cc89a0fc5a794ff71a1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae6ce9aaec2a446c9c116ff73b70f8b3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6a670771b95429a8cb648b92575b810_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35095a09a8d844129623d819fcf1cacb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i705da3eb6365425bb71d37b40211def3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i939a0caa5e764269961b35c18b4916a0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30fc00a42642408badd375838de42222_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8df9a05d543b42d696a2487ba38b7424_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if846aeeb8f314bd9a6bf240c914de52a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f88c29ff5974403bff253575a02defd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6610d7c73b1f4958b659b907335a85a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c3e2b7da46c423383b2883aad5f1fba_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">exdx:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia543ba88573a4f76b3f29f77c2c449a3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96b7c50405024efea4bb7ce5ef47adb3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i895d656b22474a18a403f1fd341b6467_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b4f7177650b41ea9633024d9953c438_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d8153a1b8c047f5ba1ab683df79cb7f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30edb0fc3f0c427ab5994bec9d4cb64a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafc6e1b4e06e45fcb9b81908405af3e3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19225060b0864579b9f675d97dd4b83b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i574ca98624ca4a4b9e2538fbfee1fab3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32c2432d847f4430ba1a0adb828fc7e5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exdx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i7cb9b15bd3534c7b959fafc69dd136ca_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad556f0486564986b0fe232198d50b00_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea90a46da8b0473b81bd14734a0e680a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8b419bb6ccf44b485236b67f0570541_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifffe2a329326445ebf186d1dbfc97983_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dbff6a1aa00481ca92a92d62756b86b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c7b49c0d49e41acb5a83a3b738931e7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecd2c1906e2f4109b2230036ad76ebce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice0b71e76bbd4e2e84837c2eba278fff_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf0198dc6d684b77b81f517d3508fe26_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94ecd2ce87e1410596492d2b66fe3d3d_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb33abf78bcd4170a8b0655f9f35138a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i859e111840c844b0912ab35300e78234_I20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d50b70a9daa46a5b489435a77934c85_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>exdx:installment</xbrli:measure></xbrli:unit><xbrli:context id="iabe905c72ff84d589835e599cc035ca4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a372fdfdb7a4826a6cbffa763f05288_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a7f825dbe7d4f5c828334d605f13e10_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66d0781c430544b080c8b6a0138f9b6e_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bf8defbc1fa44d882189373b2849672_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5c76f81d9cd409eb1b8a90d4fe48c57_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4931e73aebd8406f8a9334dd51dbbc52_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3350c67771f646c6b53fca4a8f67d638_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3e0014fc8a94ef0953febf2e7cf24ad_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:AlleghenyHealthNetworkResearchInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e499e7ea6aa4310baa5eca3da4d604b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d3bd6c4fe2242cf87f21e0213354a26_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4fc1eac300c43b6a7327014b06ddfa9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i523c8d55aeb0417e85e726ce80798a7c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieff95e26dba14d95a8f3cd8ee4182372_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f4ffb1c43554f1a90dfd599025b8c9e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9625bbb62da645d980dedf056fae0d11_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i173e25ca60a14e9eb6d2a3839cd12de8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i626b7154acb34ccaafa6ab945abf40c9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie210aad638e548c4870de1627ee59314_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id41f690f8baf4faba442062c5cd09d97_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3981775f29d04856b8989e7532c82c09_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15ae8bd4f38347fb8cd1eda4e1828338_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d9435b79cd7491eaf962b33022de57f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7a2e37140ea4e5d964b371b5b2e678e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdbc12a0fd3349cea91fc35053c905ac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a4807b9a98e45a1ba7d94b95b6cf1db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2057c462f3f407fac03e7ed09fbf60b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c407749d2e847a7803b2c710bcc16b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75e67690fd9847e1aaece1d7ff577378_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69fb565bd3a94c019700911026c93178_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aff556ef6e84baa8337afc2d1b6be3c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90e1b44e5ed44cc28aa97c0d68594467_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f4f95f45fbb40f4a140c25ba96bc721_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9b6627751494aab9971b2c3202d9569_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b6b812b1a86449d836330f0d3b625bb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie95865dfdf5b4540b73e69eb6e14d14b_D20220915-20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:CowenEquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-15</xbrli:startDate><xbrli:endDate>2022-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ff0d03d717e4fe3bc16e2a5c900dc45_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3de710b92f4485e825c6c2d1c6fb10a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2912cd445faf49c38783149855c13b6d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie36f5616d2e44e80a9e03af14c0045a4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationSep72024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02a6a7e72b5342cfb6df8c09e1146039_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0885affce6b54cc8bb7d28029c8146fa_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:NoExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4840a5daec942e9baf60b20b64f05d2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f4d0fe871b84f4bbc6b2e49f7ca8aa6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35ee5d15536b446d8e71cf4f2712b1ad_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cd5e724cdb246d89edfa68105eaed87_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55497019afe7489891af1088e9d0a6da_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1acc384230fc42e6a9d187464e747867_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i385f1d93cdab453180c8c50401ec671d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1400e06e8cb4cce8e16afdae774fbd6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59cad19a4f2e4767b2e7f56240d61b72_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic458c78631fa444ea666b52d5645ae1d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic58dee38f10d467fbc953d0b8e7713b1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23da898f496444b2a82b5eefd3e7d4f2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f1e21f8e6db4d83b4cb8e0ef40e4ebe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie60dda0bce3a4221b4328da9ade954c1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e8041ed528a46088f0c79a375de1fae_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0587f1e7aef2471cb273055cd67d1cb1_D20230428-20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-28</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib55a36a6d42741f28786ba980d9e68d7_D20230428-20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-28</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e4dbcbbf1954393ba5599909a82c6ed_I20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGV4dHJlZ2lvbjphY2RhOTIyMjQyMmI0N2I3YmZkMDhhMThkMDA0ZjA1OF84NA_01fe438c-8745-4052-9013-368725c3d8f4">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Mark One) </span></div><div><span style="font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:115%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:2.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.026%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6Y2IxZTA4N2UzMWEwNDU0Y2E3ZjRkMWMyMWM3NTZhZTUvdGFibGVyYW5nZTpjYjFlMDg3ZTMxYTA0NTRjYTdmNGQxYzIxYzc1NmFlNV8wLTAtMS0xLTYyNDU1_f4ce9aa2-df7b-4442-963a-095158c35b98">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the quarterly period ended <ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6Y2IxZTA4N2UzMWEwNDU0Y2E3ZjRkMWMyMWM3NTZhZTUvdGFibGVyYW5nZTpjYjFlMDg3ZTMxYTA0NTRjYTdmNGQxYzIxYzc1NmFlNV8xLTAtMS0xLTYyNDU1L3RleHRyZWdpb246MjRhMmQ5MmZjYWQ5NGM1MTg1MzNkNzE1MDU5OGU4MzhfMzY_e1b667e2-816a-4e8c-8313-158b99ac34b3">March&#160;31, 2023</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6Y2IxZTA4N2UzMWEwNDU0Y2E3ZjRkMWMyMWM3NTZhZTUvdGFibGVyYW5nZTpjYjFlMDg3ZTMxYTA0NTRjYTdmNGQxYzIxYzc1NmFlNV8yLTAtMS0xLTYyNDU1_e3954413-b3ed-486c-9f70-57cb2f11e1f1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Commission File Number: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGV4dHJlZ2lvbjphY2RhOTIyMjQyMmI0N2I3YmZkMDhhMThkMDA0ZjA1OF8xMjk_6734e76b-e13c-444d-89df-d702c4da5e9d">001-39049</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGV4dHJlZ2lvbjphY2RhOTIyMjQyMmI0N2I3YmZkMDhhMThkMDA0ZjA1OF8xMzM_c7128671-43b4-43ad-9d4b-41290321996a">EXAGEN INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:0.1%"></td><td style="width:1.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZWE4ODdhODlkM2NlNGM1ZmJmODMxYTlmMDlhMzBkMjYvdGFibGVyYW5nZTplYTg4N2E4OWQzY2U0YzVmYmY4MzFhOWYwOWEzMGQyNl8wLTAtMS0xLTYyNDU1_57c349cc-53e4-44ee-8eeb-e92848336d27">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZWE4ODdhODlkM2NlNGM1ZmJmODMxYTlmMDlhMzBkMjYvdGFibGVyYW5nZTplYTg4N2E4OWQzY2U0YzVmYmY4MzFhOWYwOWEzMGQyNl8wLTYtMS0xLTYyNDU1_4665655a-223c-4e51-86a5-0d058aeab607">20-0434866</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZWE4ODdhODlkM2NlNGM1ZmJmODMxYTlmMDlhMzBkMjYvdGFibGVyYW5nZTplYTg4N2E4OWQzY2U0YzVmYmY4MzFhOWYwOWEzMGQyNl8zLTEtMS0xLTYyNDU1_aba4e774-1508-44fa-95e3-6747cd7f9187">1261 Liberty Way</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZWE4ODdhODlkM2NlNGM1ZmJmODMxYTlmMDlhMzBkMjYvdGFibGVyYW5nZTplYTg4N2E4OWQzY2U0YzVmYmY4MzFhOWYwOWEzMGQyNl80LTEtMS0xLTYyNDU1_1f20471f-64d4-4ee4-aec7-a98fe683755f">Vista,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZWE4ODdhODlkM2NlNGM1ZmJmODMxYTlmMDlhMzBkMjYvdGFibGVyYW5nZTplYTg4N2E4OWQzY2U0YzVmYmY4MzFhOWYwOWEzMGQyNl80LTItMS0xLTYyNDU1_c910d055-ff1b-4304-b1d4-a44975a628a5">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZWE4ODdhODlkM2NlNGM1ZmJmODMxYTlmMDlhMzBkMjYvdGFibGVyYW5nZTplYTg4N2E4OWQzY2U0YzVmYmY4MzFhOWYwOWEzMGQyNl80LTYtMS0xLTYyNDU1_88bfb1b4-b6e8-4f40-a53e-779c98caa7d3">92081</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.982%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6M2RkODIzYjMwZDYyNGQ3MTg1OWFhZTAyOGNmZTQ0MGUvdGFibGVyYW5nZTozZGQ4MjNiMzBkNjI0ZDcxODU5YWFlMDI4Y2ZlNDQwZV8wLTAtMS0xLTYyNDU1_0b9fe69e-00dd-435e-9722-3c80534d310f">(760)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6M2RkODIzYjMwZDYyNGQ3MTg1OWFhZTAyOGNmZTQ0MGUvdGFibGVyYW5nZTozZGQ4MjNiMzBkNjI0ZDcxODU5YWFlMDI4Y2ZlNDQwZV8wLTEtMS0xLTYyNDU1_6b096c8d-0878-407c-893d-c711a9e7bda4">560-1501</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant's Telephone Number, Including Area Code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6Y2ZlNjc4OTFjZDkyNDgzNjhiYjRjZTIxMzJmOGM1MmEvdGFibGVyYW5nZTpjZmU2Nzg5MWNkOTI0ODM2OGJiNGNlMjEzMmY4YzUyYV8xLTAtMS0xLTYyNDU1_2b1f161e-75ee-4e18-8d06-851e5d144529">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6Y2ZlNjc4OTFjZDkyNDgzNjhiYjRjZTIxMzJmOGM1MmEvdGFibGVyYW5nZTpjZmU2Nzg5MWNkOTI0ODM2OGJiNGNlMjEzMmY4YzUyYV8xLTItMS0xLTYyNDU1_68c32927-4466-4fcc-af56-737385d0751d">XGN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6Y2ZlNjc4OTFjZDkyNDgzNjhiYjRjZTIxMzJmOGM1MmEvdGFibGVyYW5nZTpjZmU2Nzg5MWNkOTI0ODM2OGJiNGNlMjEzMmY4YzUyYV8xLTQtMS0xLTYyNDU1_9b6eb524-ce73-42b0-b644-6e2823d42e93">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGV4dHJlZ2lvbjphY2RhOTIyMjQyMmI0N2I3YmZkMDhhMThkMDA0ZjA1OF81OTk_f881ff18-454d-4609-9959-8c546ac8af7e">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGV4dHJlZ2lvbjphY2RhOTIyMjQyMmI0N2I3YmZkMDhhMThkMDA0ZjA1OF85MDE_3cfeb529-2287-44c0-ad5c-85a46f1ff9cb">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Securities Exchange Act of 1934. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZDg1YTA2OTA5MWE1NDZhOGI5NmU3MzQwYzVlNGYxZTgvdGFibGVyYW5nZTpkODVhMDY5MDkxYTU0NmE4Yjk2ZTczNDBjNWU0ZjFlOF8yLTAtMS0xLTYyNDU1_70aab985-0034-4550-98f3-04dea7d7be13">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZDg1YTA2OTA5MWE1NDZhOGI5NmU3MzQwYzVlNGYxZTgvdGFibGVyYW5nZTpkODVhMDY5MDkxYTU0NmE4Yjk2ZTczNDBjNWU0ZjFlOF8yLTQtMS0xLTYyNDU1_ca72eac2-cb32-457a-8e62-91732b589773">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZDg1YTA2OTA5MWE1NDZhOGI5NmU3MzQwYzVlNGYxZTgvdGFibGVyYW5nZTpkODVhMDY5MDkxYTU0NmE4Yjk2ZTczNDBjNWU0ZjFlOF80LTQtMS0xLTYyNDU1_32f02cfe-50a2-4087-8179-9c724424003c">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Securities Act&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGV4dHJlZ2lvbjphY2RhOTIyMjQyMmI0N2I3YmZkMDhhMThkMDA0ZjA1OF8xNTM0_9f2a14d5-23db-4617-b2b7-e1f96e9f0339">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGV4dHJlZ2lvbjphY2RhOTIyMjQyMmI0N2I3YmZkMDhhMThkMDA0ZjA1OF8xNzQz_8c15bfa0-455c-4786-a3b3-3b11e09c4d67">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total shares of common stock outstanding as of the close of business on May&#160;11, 2023 was <ix:nonFraction unitRef="shares" contextRef="icbe60ad4860843a2ab64b5cd330ef707_I20230511" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGV4dHJlZ2lvbjphY2RhOTIyMjQyMmI0N2I3YmZkMDhhMThkMDA0ZjA1OF8xNzQx_1dc19de1-071e-48df-a9b7-b5557e15ab3c">16,825,696</ix:nonFraction>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_13">Unaudited Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_16">Unaudited Condensed Balance Sheets as of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_16">March 31, 2023</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_16"> and December 31, 20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_16">2</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_16">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_19">Unaudited Condensed Statements of Operations for the Three </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_19">Months ended </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_16">March 31, 2023</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_19"> and 20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_19">2</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_19">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_22">Unaudited Condensed Statements of Stockholders' Equity for the Three</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_22"> Months ended </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_16">March 31, 2023</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_22"> and 2</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_22">022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_25">Unaudited Condensed Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_25">Three</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_25"> Months ended </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_16">March 31, 2023</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_25"> and 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_25">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_28">Notes to Unaudited Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_64">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_64">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_79">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_79">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_82">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_82">28</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_88">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_88">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_91">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_91">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_97">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_97">32</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_100">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic6a5e7b0edc94c399549fe8f80e94568_100">33</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_13"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I. Financial Information</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Unaudited Condensed Financial Statements</span></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Condensed Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfNC00LTEtMS02MjQ1NQ_3a417c74-6d96-4459-b96a-a9b4d66e43ef">52,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfNC02LTEtMS02MjQ1NQ_dc14c98a-a45f-46fd-ba82-4e73ec98f059">62,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfNi00LTEtMS02MjQ1NQ_82c534e5-7e01-48fd-8184-31f4abc9b565">9,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfNi02LTEtMS02MjQ1NQ_943c27d0-df87-409c-8f90-d474febfc361">6,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfNy00LTEtMS02MjQ1NQ_7c2c36d6-7840-4c31-85fc-9445b96f9de0">4,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfNy02LTEtMS02MjQ1NQ_6466e42a-101a-48b4-a03b-7d8d78646187">4,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfOC00LTEtMS02MjQ1NQ_07ef5c99-6788-415b-87a1-308c3ad5596b">65,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfOC02LTEtMS02MjQ1NQ_cb78c76b-81cd-4982-b6d8-fc14ceccf365">72,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfOS00LTEtMS02MjQ1NQ_126233d6-e885-4864-ac5e-1687fbbe7545">8,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfOS02LTEtMS02MjQ1NQ_c18f4f91-79e4-4f02-911a-4f9503feef68">8,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTAtNC0xLTEtNjI0NTU_8b48a7aa-a1eb-49e3-a289-fc67fbcf73d4">4,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTAtNi0xLTEtNjI0NTU_9280ced3-e5fb-4b09-97eb-437367861d4c">4,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTItNC0xLTEtNjI0NTU_60b00b68-c741-4514-9fc0-24d7a4f425cd">603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTItNi0xLTEtNjI0NTU_9b1a09e7-cf03-4ec7-8f7d-9af1a331caca">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTMtNC0xLTEtNjI0NTU_f2d1782e-0a5c-4912-ba22-ff98405d9c29">79,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTMtNi0xLTEtNjI0NTU_e31f7561-d08b-4be6-8f7a-6848818b096f">86,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTYtNC0xLTEtNjI0NTU_8ee0abad-4b74-4761-a39c-92f5f7f59ce7">1,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTYtNi0xLTEtNjI0NTU_1c4e82b1-b60c-4397-88ae-b8db55c2aae3">3,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTUtMi0xLTEtOTQ1NTU_dad4bf9d-4c52-49b7-ad97-46bbe6a40815">6,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTUtNC0xLTEtOTQ1NTU_852202a2-3f4f-47b0-bdb7-152f6fe35ccd">5,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTctNC0xLTEtNjI0NTU_5353ce4f-7318-4645-a5cd-0cb2a6858e6c">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTctNi0xLTEtNjI0NTU_37e679c7-c62e-4d67-9939-c07939172014">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTctMi0xLTEtODM1NDM_47680adb-fc85-45de-8e5b-7c2b9cf61967">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTctNC0xLTEtODM1NzI_1f28ede4-d620-4fbb-acbb-771b816a0616">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTktNC0xLTEtNjI0NTU_00566448-68f7-4e8e-8401-254f100de540">9,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTktNi0xLTEtNjI0NTU_484c9c12-f16a-4608-8764-24f8d35e326d">9,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjAtNC0xLTEtNjI0NTU_46c62a5b-187a-4b52-97a6-839c49c2f682">29,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjAtNi0xLTEtNjI0NTU_8ee9c369-7cdf-43aa-ae69-2d0fb7e15ee1">28,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjItNC0xLTEtNjI0NTU_1579a40e-ecc2-4934-bba3-7285ab946a8b">4,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjItNi0xLTEtNjI0NTU_d4f4be57-5fc6-4b02-a68f-7f5068259a38">4,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjQtNC0xLTEtNjI0NTU_dd9ca9e3-3f8a-441c-87a2-a4e98207724d">726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjQtNi0xLTEtNjI0NTU_2accc5ee-c8c9-4b49-94da-9dde811b52a6">867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjUtNC0xLTEtNjI0NTU_13d07a4a-91e9-451d-9344-c09a12e498de">43,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjUtNi0xLTEtNjI0NTU_e1c01228-2a04-4b52-8b39-d2a67c9268ac">43,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjYtNC0xLTEtNjI0NTU_cf34c3bf-ad05-4b01-88bb-0e1213b5b749"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjYtNi0xLTEtNjI0NTU_8350e157-92ae-4c32-a5df-4a1659640ed5"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoyNDRlOTU1MjQwYWQ0MzY3YTJjYWE5YjgwNjVhYWZlN18yMQ_1bc260b8-461a-4eb0-bfb0-d486c8e78697"><ix:nonFraction unitRef="usdPerShare" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoyNDRlOTU1MjQwYWQ0MzY3YTJjYWE5YjgwNjVhYWZlN18yMQ_ad4ba43d-9e0b-46ad-b9bc-a8421333dd55">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoyNDRlOTU1MjQwYWQ0MzY3YTJjYWE5YjgwNjVhYWZlN18zNQ_8f120046-fd65-4d03-88cd-bd5c421872fd"><ix:nonFraction unitRef="shares" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoyNDRlOTU1MjQwYWQ0MzY3YTJjYWE5YjgwNjVhYWZlN18zNQ_a5b1051b-1851-4085-ac8c-a49cb0ae7d4e">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoyNDRlOTU1MjQwYWQ0MzY3YTJjYWE5YjgwNjVhYWZlN181Nw_490a2754-d14f-4fe8-b217-8c5eb9949763"><ix:nonFraction unitRef="shares" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoyNDRlOTU1MjQwYWQ0MzY3YTJjYWE5YjgwNjVhYWZlN181Nw_540f5aa8-de82-4cb5-847e-25716d84117d"><ix:nonFraction unitRef="shares" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoyNDRlOTU1MjQwYWQ0MzY3YTJjYWE5YjgwNjVhYWZlN181Nw_553bc712-f377-4648-88bb-5c22bb65e360"><ix:nonFraction unitRef="shares" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoyNDRlOTU1MjQwYWQ0MzY3YTJjYWE5YjgwNjVhYWZlN181Nw_e2290cb2-9794-490d-b35e-1c7999ba1ee7">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of March&#160;31, 2023 and December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktNC0xLTEtNjI0NTU_fc3cd102-8180-4659-a341-d4a4476d4934">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktNi0xLTEtNjI0NTU_32ff3baa-d07a-466c-86fc-92ba923898f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoxNzBhNDBiODY0YWI0ODJlOTEzMDQ5N2QyOWVjMjI5ZV8xOA_67018913-40c1-45d0-b545-e0a259ce40e4"><ix:nonFraction unitRef="usdPerShare" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoxNzBhNDBiODY0YWI0ODJlOTEzMDQ5N2QyOWVjMjI5ZV8xOA_8466aef3-b433-4fd3-b99c-77a83497f812">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoxNzBhNDBiODY0YWI0ODJlOTEzMDQ5N2QyOWVjMjI5ZV8zMg_392f0fb6-61f5-4601-b3f6-fe4655bda954"><ix:nonFraction unitRef="shares" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoxNzBhNDBiODY0YWI0ODJlOTEzMDQ5N2QyOWVjMjI5ZV8zMg_c82ef24c-7da3-4aca-8eac-f63c35bcd886">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of March&#160;31, 2023 and December 31, 2022; <ix:nonFraction unitRef="shares" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoxNzBhNDBiODY0YWI0ODJlOTEzMDQ5N2QyOWVjMjI5ZV83MA_6c686b2c-57e7-4f8a-8a87-dbaf282cc3dc"><ix:nonFraction unitRef="shares" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoxNzBhNDBiODY0YWI0ODJlOTEzMDQ5N2QyOWVjMjI5ZV83MA_911031f9-62c8-4fd6-90f4-044bea48cbb6">16,827,014</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoxNzBhNDBiODY0YWI0ODJlOTEzMDQ5N2QyOWVjMjI5ZV83Nw_364467e7-8b9d-4e19-8a28-6b9b478dd679"><ix:nonFraction unitRef="shares" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoxNzBhNDBiODY0YWI0ODJlOTEzMDQ5N2QyOWVjMjI5ZV83Nw_91e36345-134e-4142-a599-027d3e6419d5">16,549,984</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2023 and December 31, 2022, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtNC0xLTEtNjI0NTU_d900a5cf-4fbc-4f01-bd91-f9e8c2e97aef">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtNi0xLTEtNjI0NTU_77a1db73-8295-44a6-9cbf-4679110756fb">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional paid-in capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzEtNC0xLTEtNjI0NTU_cb261bcb-a858-477c-b689-2018c5e70c96">299,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzEtNi0xLTEtNjI0NTU_0a1c7edb-d191-42dc-9302-f8299d253cb4">297,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzItNC0xLTEtNjI0NTU_aa39eb3b-1244-483d-9814-6b8ccbdd46aa">263,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzItNi0xLTEtNjI0NTU_44064e48-b220-4da3-a54c-a64223b4f102">255,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzMtNC0xLTEtNjI0NTU_a57a31b2-e257-47d9-9ffe-da8a77c5a28c">35,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzMtNi0xLTEtNjI0NTU_cdf23ecf-e94e-4208-be3c-6aeabbe5352d">42,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzQtNC0xLTEtNjI0NTU_a14e5adf-ee12-4486-8edd-410b5d61fdec">79,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzQtNi0xLTEtNjI0NTU_5deb3ae9-bfc0-4674-965d-bb699f707a51">86,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Condensed Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.709%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMy0yLTEtMS02MjQ1NQ_24f9e664-0e6c-4693-905c-db949f8f923a">11,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMy00LTEtMS02MjQ1NQ_712ee752-7ebc-432b-90f2-16bdc7976ea7">10,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfNS0yLTEtMS02MjQ1NQ_dc5b054b-9b56-4a63-a23b-e06b4b190a87">5,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfNS00LTEtMS02MjQ1NQ_ec507c8f-8b1d-4f5c-8dcf-78d44c52ed21">5,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfNi0yLTEtMS02MjQ1NQ_fa093adb-50e9-4f65-9aa8-2e8e333d29d8">11,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfNi00LTEtMS02MjQ1NQ_e13c29fa-cab6-4438-908c-0110a396b90c">12,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfNy0yLTEtMS02MjQ1NQ_3bc6bcf3-229a-44b6-a256-e780acfef81c">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfNy00LTEtMS02MjQ1NQ_52f4db0b-c111-477d-b9da-88e4c80ed4c2">2,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTAtMi0xLTEtNjI0NTU_aab69174-46ee-460f-b8ea-2f787d751a21">18,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTAtNC0xLTEtNjI0NTU_5bcaed4e-ee35-4a51-9538-8f3315fef84c">20,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTEtMi0xLTEtNjI0NTU_7d3a2050-7264-4005-8b15-00e9cf60949a">7,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTEtNC0xLTEtNjI0NTU_14639a4b-50c6-40a0-95d1-93cb7c8c8ee4">9,679</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTItMi0xLTEtNjI0NTU_8823b4c7-a026-4955-94c0-86f3d9d08ff5">638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTItNC0xLTEtNjI0NTU_b884cd61-3e40-4ab6-929c-141a085749c2">598</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTQtMi0xLTEtNjI0NTU_4ba05424-4141-4024-bb11-75b012427dcd">656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTQtNC0xLTEtNjI0NTU_93cf6875-caf1-4830-ba72-ef1144ce63b9">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTctMi0xLTEtNjI0NTU_b696de95-e71c-4752-bd25-036b062882b5">7,688</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTctNC0xLTEtNjI0NTU_1515e9ff-0c07-4da7-9326-04da4a2f53c0">10,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMjEtMi0xLTEtNjI0NTU_596efe73-2ae9-4536-8056-76bb9ea938fb"><ix:nonFraction unitRef="usdPerShare" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMjEtMi0xLTEtNjI0NTU_5f00201c-980b-4341-a1ba-035b3d961078">0.44</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMjEtNC0xLTEtNjI0NTU_311c1d57-4d55-4df4-8bc5-450c2122e9fe"><ix:nonFraction unitRef="usdPerShare" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMjEtNC0xLTEtNjI0NTU_c9e77a11-df29-4e22-b7a1-f979990e74b2">0.60</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of shares used to compute net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMjItMi0xLTEtNjI0NTU_8fae21c5-8ae7-4d7b-858b-782182b1d259"><ix:nonFraction unitRef="shares" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMjItMi0xLTEtNjI0NTU_cdfc05a0-fb79-41e0-b6fd-7248bd20656d">17,526,763</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMjItNC0xLTEtNjI0NTU_ee45ba83-44ed-4cf4-af43-a5a15aa7d279"><ix:nonFraction unitRef="shares" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMjItNC0xLTEtNjI0NTU_fe102ac8-36b1-4fa6-9169-c1870c254a53">16,992,391</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Unaudited Condensed Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances as of December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bb6db3028e64addadc73284bff78b54_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfMi0yLTEtMS02MjQ1NQ_2fd33906-fb65-4c4c-9889-20e498ffdc0c">16,549,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bb6db3028e64addadc73284bff78b54_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfMi00LTEtMS02MjQ1NQ_b292dada-8738-4c61-a182-afdbbf81aa15">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0649efcb68545c6b7b9b7ec6425a6bf_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfMi02LTEtMS02MjQ1NQ_36fe6760-c332-4e6d-a1c2-849c488364fa">297,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0705a248fabf483b8d91cb9179b97e90_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfMi04LTEtMS02MjQ1NQ_d50a3690-fe2b-402c-974c-d44b746e17f6">255,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfMi0xMC0xLTEtNjI0NTU_95381946-b735-4f93-9d3d-bcae03c5f976">42,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock from vested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fe0be00ef494161bd0549b671f2fe9b_D20230101-20230331" decimals="INF" name="exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfMy0yLTEtMS02MjQ1NQ_03fcc488-2831-428d-afd0-33e55a17e3d5">113,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b1db4c0c1d4c9f841e4594fe97bc2a_D20230101-20230331" decimals="-3" name="exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfMy02LTEtMS02MjQ1NQ_c07f88a8-239a-4b5e-92b3-81a8dc0cc054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfMy0xMC0xLTEtNjI0NTU_45751978-fbee-47da-af66-6757a952f6e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fe0be00ef494161bd0549b671f2fe9b_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNC0yLTEtMS02MjQ1NQ_d71804d2-407c-4fee-9699-e2ff5a7bff7c">70,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b1db4c0c1d4c9f841e4594fe97bc2a_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNC02LTEtMS02MjQ1NQ_8297010e-97db-4cd4-807f-a48092f32721">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNC0xMC0xLTEtNjI0NTU_fa9bfa4e-4a39-446b-8786-a72bfb97bac6">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fe0be00ef494161bd0549b671f2fe9b_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNS0yLTEtMS05MjA2Mw_0d14843b-881a-468d-a8bd-9cdc31ecde0b">93,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b1db4c0c1d4c9f841e4594fe97bc2a_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNS02LTEtMS05MjA3OQ_efc7efc2-ab38-4c43-a0ad-5d7bb8ea9970">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNS0xMC0xLTEtOTIwOTU_9d81c411-f1da-4ec8-b96b-c2938a237735">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b1db4c0c1d4c9f841e4594fe97bc2a_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNS02LTEtMS02MjQ1NQ_8892e54b-894e-46a3-bf80-409f92284527">986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNS0xMC0xLTEtNjI0NTU_0138b4b8-91dc-49e6-809a-f5a1623b17dc">986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if71859fd80494dddb569b483b53c0f5b_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNi04LTEtMS02MjQ1NQ_1cddeeb3-4c2f-4dfb-b352-be7ba22b7b47">7,688</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNi0xMC0xLTEtNjI0NTU_00c4b5de-dee2-480d-b327-7523a095b37d">7,688</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances as of March&#160;31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b09d1c772d642c2be65db1440589466_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNy0yLTEtMS02MjQ1NQ_5b168387-b354-4f44-9d87-85f3c85283de">16,827,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b09d1c772d642c2be65db1440589466_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNy00LTEtMS02MjQ1NQ_365dc866-c087-4a54-a834-51829768475b">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84709c32e10840689d3198791460cf9b_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNy02LTEtMS02MjQ1NQ_78c1c6f7-139d-496a-bb00-86ad75569e49">299,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c57b87359174c8ba8490118ae86e8ea_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNy04LTEtMS02MjQ1NQ_a7ee5ce3-7ab7-46f0-b06d-4630c59db674">263,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNy0xMC0xLTEtNjI0NTU_03b7cf81-9fa4-4431-8bc0-8b7d845db212">35,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Unaudited Condensed Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances as of December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90a82a0082294a76aa4b428dfc020494_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfMi0yLTEtMS02MjQ1NQ_123ea122-95b0-4b63-b487-2319c92b4dd2">16,164,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a82a0082294a76aa4b428dfc020494_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfMi00LTEtMS02MjQ1NQ_700007f4-db2c-44be-870f-62ad4769ae04">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f0a7eb3bdd5459aac214c6226b676a4_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfMi02LTEtMS02MjQ1NQ_b8af2fa6-cb04-469c-9e66-f7691c673785">293,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if296323417ca4b029d7a11232e87aad2_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfMi04LTEtMS02MjQ1NQ_32c4b3e4-1145-4318-996d-1d957c2a28f4">208,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140c8595c10a41eeb48e5be8f884c4cb_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfMi0xMC0xLTEtNjI0NTU_9a5c1afd-21d3-4c5d-be88-1e1c04a9d6ac">84,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock from vested restricted stock units and payment of employees' taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c10b316a5a146458ede9d5dc729ac84_D20220101-20220331" decimals="INF" name="exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNC0yLTEtMS02MjQ1NQ_076a1fb7-163a-4577-8847-111e10e1f1a7">30,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b616351de9643b99134e16eafc041e6_D20220101-20220331" decimals="-3" name="exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNC02LTEtMS02MjQ1NQ_8c6ef092-15b4-4475-9cc4-68fc8bbdadc0">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNC0xMC0xLTEtNjI0NTU_317e386a-d365-4ffc-8f7c-7ff51406ab0f">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c10b316a5a146458ede9d5dc729ac84_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNS0yLTEtMS02MjQ1NQ_09e0bf3f-3273-44ee-be60-186132f77fe2">35,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b616351de9643b99134e16eafc041e6_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNS02LTEtMS02MjQ1NQ_4209870e-c8ce-4ca7-bbf7-ec39b1e86c87">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNS0xMC0xLTEtNjI0NTU_32623267-57ba-4680-ae47-ef5e28700873">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b616351de9643b99134e16eafc041e6_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNi02LTEtMS02MjQ1NQ_c12e5cc2-e640-4954-aaaf-7e2bdb7d33f0">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNi0xMC0xLTEtNjI0NTU_959e8760-6f06-4dd9-9342-9bbab0c19c02">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bc0bf262ca04963b27d2f261ce272bd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNy04LTEtMS02MjQ1NQ_da29cef7-66b1-4b24-bbf1-e3c1b60fa14e">10,272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNy0xMC0xLTEtNjI0NTU_80e72399-8dc6-4130-ac24-e3f8010c8cb1">10,272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances as of March&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2395d65c2f04e0c82d354b532c429b4_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfOC0yLTEtMS02MjQ1NQ_1f3a592e-ecb5-4b40-aa9a-0904794dc11f">16,231,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2395d65c2f04e0c82d354b532c429b4_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfOC00LTEtMS02MjQ1NQ_911c72aa-48b0-47f1-adc8-3edb5e1215c4">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72308a08a4614029a1a34e29777d8a6b_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfOC02LTEtMS02MjQ1NQ_2d0d33f8-bbcb-4860-b8f6-e39cdb2042a3">294,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia408b342e58a47b4b9fab75709a394d2_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfOC04LTEtMS02MjQ1NQ_a31d4bd5-b36c-4a62-b7fc-00b0e7015b90">218,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic10d09e997d04be59819eb9f739c540e_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfOC0xMC0xLTEtNjI0NTU_ce793b86-774a-4947-97a9-6630f428e467">76,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Unaudited Condensed Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.540%"><tr><td style="width:1.0%"></td><td style="width:67.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNC02LTEtMS02MjQ1NQ_76879320-3f6f-4774-941e-a8aa71bae434">7,688</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNC04LTEtMS02MjQ1NQ_99054852-a743-40d4-a20d-47a03791bc45">10,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNi02LTEtMS02MjQ1NQ_55afb10a-056e-400e-b7b3-77dabb6bc3be">553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNi04LTEtMS02MjQ1NQ_f4f5c889-2f41-40d2-9443-98afe4579b53">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNy02LTEtMS02MjQ1NQ_29b904be-9362-4c71-8cff-71ee1efbccb3">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNy04LTEtMS02MjQ1NQ_46207261-cee8-4e22-979e-e44e630e98ae">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfOC02LTEtMS02MjQ1NQ_b02aeebc-58e7-4b04-ae0b-9cd9be34e2e9">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfOC04LTEtMS02MjQ1NQ_c59f3cd3-d8f6-4a62-b6a8-dfbd18864537">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on disposal of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTEtNi0xLTEtNjI0NTU_5d3f36b1-eae5-491e-82c7-e5f041dae054">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTEtOC0xLTEtNjI0NTU_4d8453cd-3180-4e55-879a-a975fe881cd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="exdx:NonCashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTItNi0xLTEtNjI0NTU_faddf3e3-6260-44d3-ab60-73966b46642d">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="exdx:NonCashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTItOC0xLTEtNjI0NTU_804e4d01-a245-4d2d-9f14-c2cceef968fe">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTMtNi0xLTEtNjI0NTU_415e83c9-b39e-440e-9cb0-22439a6de2bf">986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTMtOC0xLTEtNjI0NTU_71b3c020-150f-4d53-885f-0c2fcaf2da26">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTYtNi0xLTEtNjI0NTU_4f1d0cd3-ea89-48f8-81fe-60ef1b03c791">3,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTYtOC0xLTEtNjI0NTU_75cbadbe-284a-4c9b-b471-4a89ebab87b2">1,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTctNi0xLTEtNjI0NTU_1ecb7c03-0594-486d-9db4-c496a9fd298f">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" sign="-" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTctOC0xLTEtNjI0NTU_aca8c456-6fd6-45b3-9f8a-4527159c0199">664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTgtNi0xLTEtNjI0NTU_17ac98b8-62d5-4497-967c-acd793d4d8bc">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTgtOC0xLTEtNjI0NTU_4b939fc5-8009-481a-bd40-be8f99b5e7e4">273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTktNi0xLTEtNjI0NTU_16c1a1dc-38db-4a69-acb4-a1b5349a6923">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTktOC0xLTEtNjI0NTU_24ee1132-bf7f-47e2-9976-b2c7a5f69a02">155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMjAtNi0xLTEtNjI0NTU_bc8e9e18-ab6e-4a66-bb1e-4faf5a3494cd">1,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMjAtOC0xLTEtNjI0NTU_bbc76f10-7a14-4a9e-9790-39268dc6c424">579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMjEtNi0xLTEtNjI0NTU_fb4f69c3-bde5-468d-aac4-5d4b6c7896d2">893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMjEtOC0xLTEtNjI0NTU_66ea471c-ea3b-43de-ba38-2298b4265498">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMjMtNi0xLTEtNjI0NTU_79ab3cc7-208d-43f2-a122-8afc6a61f611">9,749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMjMtOC0xLTEtNjI0NTU_306b7ad0-5d1d-4487-afde-6a39c6c484c4">8,574</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMjUtNi0xLTEtNjI0NTU_32c543cc-56cb-4972-a2cd-c417cc5cdfb6">396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMjUtOC0xLTEtNjI0NTU_25be1937-6a2d-4505-9ac8-cf42ab463d5f">1,087</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzAtNi0xLTEtNjI0NTU_47d290c3-12db-42a3-afbd-4f5906c8e025">396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzAtOC0xLTEtNjI0NTU_31cc5e2c-e235-4614-b40a-04d245ef2964">1,087</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzItNi0xLTEtNjI0NTU_f27026da-e446-45e8-849c-4fc5110b3601">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzItOC0xLTEtNjI0NTU_49f94cd7-583e-4261-a3ec-70375aa361a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of taxes withheld on vested restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzMtNi0xLTEtNjI0NTU_12b55a24-9e1b-4f15-8567-b3674fb495d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzMtOC0xLTEtNjI0NTU_ec074650-eb8c-433c-8195-4ed10708ac4a">115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from common stock issued under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzQtNi0xLTEtNjI0NTU_b64f9a81-a072-4b6b-b9a5-56e6dd2c152b">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzQtOC0xLTEtNjI0NTU_22021a77-d631-4d7d-a8a6-16049a78370c">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payments on finance lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzYtNi0xLTEtNjI0NTU_7d10f480-93ab-48f0-8544-f6afbf8a2760">189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzYtOC0xLTEtNjI0NTU_bfa4c8c0-8052-46c6-9d27-7053e18073d6">146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payment on note payable obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzItMi0xLTEtOTIxNDQ_d8e80abb-45b8-47ba-873b-48dfa32952b5">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzItNC0xLTEtOTIxNTI_2a90ff40-b1c9-423b-b717-7127e9be2714">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNDctNi0xLTEtNjI0NTU_6411fbbd-8179-49c9-98b7-d8c956d913f4">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNDctOC0xLTEtNjI0NTU_daeac3ea-34e9-4e04-a046-ab791414b449">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNDgtNi0xLTEtNjI0NTU_d4480f64-cdb7-44b1-a1f6-2dc0e9b91de3">10,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNDgtOC0xLTEtNjI0NTU_5a059f36-ed50-4266-a7e3-721990901b12">9,691</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNDktNi0xLTEtNjI0NTU_b5f873f1-438a-41b0-82ff-410cdd0f9311">62,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140c8595c10a41eeb48e5be8f884c4cb_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNDktOC0xLTEtNjI0NTU_3686ec82-97cf-4d54-b029-8d728c2a481f">99,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNTAtNi0xLTEtNjI0NTU_07e70cb4-d2b4-4f08-acf4-95a19e230da9">52,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic10d09e997d04be59819eb9f739c540e_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNTAtOC0xLTEtNjI0NTU_08004eb1-dd68-4987-8327-33b87c09d58e">89,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNTItNi0xLTEtNjI0NTU_53c7f705-bc93-404e-bd2b-6d0de21a6dc0">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNTItOC0xLTEtNjI0NTU_efa184bd-2fe5-4989-872e-8f0645b8b295">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment purchased under notes payable obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="exdx:EquipmentPurchasedUnderNotesPayableObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNDQtMi0xLTEtOTIxNzA_dbb3017b-77dd-4f23-a784-f9b33974383d">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="exdx:EquipmentPurchasedUnderNotesPayableObligations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNDQtNC0xLTEtOTIxNzg_1a7a6424-7114-4871-9e71-ea39d518f0a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs incurred, but not paid, in connection with capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNTctNi0xLTEtNjI0NTU_fb04ac37-f598-4595-9518-8aff1479b25a">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNTctOC0xLTEtNjI0NTU_9971440f-449a-4f2d-8dae-d6aa8ec9ded7">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_31"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Financial Statements</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zMS9mcmFnOmQyYTNmZjJlZjQwYjRmOTk5NjRmMjJiZjdjNzNmODU3L3RleHRyZWdpb246ZDJhM2ZmMmVmNDBiNGY5OTk2NGYyMmJmN2M3M2Y4NTdfMjIwNA_abccf801-9662-430f-9814-56a84899579f" continuedAt="i2b46789c5cb24edb9b852b84a5b44184" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i2b46789c5cb24edb9b852b84a5b44184"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exagen Inc. (the Company) is a commercial-stage diagnostics company dedicated to helping patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. As of March&#160;31, 2023, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zMS9mcmFnOmQyYTNmZjJlZjQwYjRmOTk5NjRmMjJiZjdjNzNmODU3L3RleHRyZWdpb246ZDJhM2ZmMmVmNDBiNGY5OTk2NGYyMmJmN2M3M2Y4NTdfNjIx_ad088d16-1074-40ae-91bf-59458b5900d2">52.2</ix:nonFraction> million and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zMS9mcmFnOmQyYTNmZjJlZjQwYjRmOTk5NjRmMjJiZjdjNzNmODU3L3RleHRyZWdpb246ZDJhM2ZmMmVmNDBiNGY5OTk2NGYyMmJmN2M3M2Y4NTdfNjU4_0c524b98-ba7e-419c-9559-ef35b2bc36d1">263.2</ix:nonFraction> million. Since inception, the Company has financed its operations primarily through a combination of equity financings, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMzg0ODI5MDc4Mjg2MQ_2d306f19-96ae-4952-8d2e-d3c427f64086" continuedAt="i67ab1403fb33481da62a7861937fad71" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i67ab1403fb33481da62a7861937fad71" continuedAt="iabf2cf96735942f49e39463cd83d8e13"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed balance sheet as of March&#160;31, 2023, condensed statements of operations, stockholders' equity and cash flows for the three months ended March&#160;31, 2023 and the related footnote disclosures are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. These unaudited condensed financial statements and related footnote disclosures should be read in conjunction with the Company&#8217;s audited financial statements for the year ended December 31, 2022, included in its Annual Report on Form 10-K filed with the SEC on March 20, 2023. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all normal adjustments, necessary for the fair presentation of the Company's financial position as of March&#160;31, 2023 and its results of operations for the periods presented. The results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iabf2cf96735942f49e39463cd83d8e13" continuedAt="i7ead9566b7364e05b4873ada6dff9f78"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the recoverability of its long-lived assets and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMzU_5174cccb-ed3d-443c-b950-676e83213e80" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. <ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMTk_1de624e0-70ca-430a-a92d-9eb04e9d95dd" continuedAt="i9237302cdb934b3e82b003b7df3e8a5f" escape="true">For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</ix:nonNumeric></span></div><ix:continuation id="i9237302cdb934b3e82b003b7df3e8a5f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icde0546e33bc4e4dbdee35365b9dbeec_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjJjYWI5ZTk2MGMwMTQ5YmNiZDI5OTE4NTRkOTJmZWQyL3RhYmxlcmFuZ2U6MmNhYjllOTYwYzAxNDliY2JkMjk5MTg1NGQ5MmZlZDJfNC0yLTEtMS02MjQ1NQ_65ce9377-542a-4b75-af63-01ff653560ca">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53feb630091f4619a5126ec58f43ca87_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjJjYWI5ZTk2MGMwMTQ5YmNiZDI5OTE4NTRkOTJmZWQyL3RhYmxlcmFuZ2U6MmNhYjllOTYwYzAxNDliY2JkMjk5MTg1NGQ5MmZlZDJfNC00LTEtMS02MjQ1NQ_8de8415e-09da-4ff3-90f9-f72fb835974e">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd65ad1f84754ac2be24f4c994f8f3cd_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjJjYWI5ZTk2MGMwMTQ5YmNiZDI5OTE4NTRkOTJmZWQyL3RhYmxlcmFuZ2U6MmNhYjllOTYwYzAxNDliY2JkMjk5MTg1NGQ5MmZlZDJfNS0yLTEtMS02MjQ1NQ_25a53e0c-2de3-4306-b1a5-3e15d5ed8c1d">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6abda9f9e6d446892e7c0f30b5d60d3_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjJjYWI5ZTk2MGMwMTQ5YmNiZDI5OTE4NTRkOTJmZWQyL3RhYmxlcmFuZ2U6MmNhYjllOTYwYzAxNDliY2JkMjk5MTg1NGQ5MmZlZDJfNS00LTEtMS02MjQ1NQ_bcf448dc-5b9f-4596-a2af-ae7a0835770a">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib670f4a2e3f647279e6c9c81af57ffc1_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjJjYWI5ZTk2MGMwMTQ5YmNiZDI5OTE4NTRkOTJmZWQyL3RhYmxlcmFuZ2U6MmNhYjllOTYwYzAxNDliY2JkMjk5MTg1NGQ5MmZlZDJfNS00LTEtMS05NTE2NQ_abb70f7b-fb9a-4a5c-94b0-f562df58b1e6">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable, Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife65d382ae2a47219439e25b9543c648_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjcwMTVjMDRlNGM1OTQ3YzRhNDVkZjViM2EzMTg5ZDE2L3RhYmxlcmFuZ2U6NzAxNWMwNGU0YzU5NDdjNGE0NWRmNWIzYTMxODlkMTZfMy00LTEtMS02MjQ1NQ_56e1982e-78db-417a-a59b-249bbc10ef50">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4838d54052ca4b00a39f1c6ae8f5cfd5_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjcwMTVjMDRlNGM1OTQ3YzRhNDVkZjViM2EzMTg5ZDE2L3RhYmxlcmFuZ2U6NzAxNWMwNGU0YzU5NDdjNGE0NWRmNWIzYTMxODlkMTZfMy02LTEtMS02MjQ1NQ_2a5c74fd-9913-4a83-bfd5-654c0a21fce1">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibdb3a7f4fb2b4a099c8ab9a2651f42d9_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjcwMTVjMDRlNGM1OTQ3YzRhNDVkZjViM2EzMTg5ZDE2L3RhYmxlcmFuZ2U6NzAxNWMwNGU0YzU5NDdjNGE0NWRmNWIzYTMxODlkMTZfNC00LTEtMS02MjQ1NQ_5025e048-c36e-4a56-88f6-84d263414181">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d88ab7784214d388b2b50fb5bb4c7b3_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjcwMTVjMDRlNGM1OTQ3YzRhNDVkZjViM2EzMTg5ZDE2L3RhYmxlcmFuZ2U6NzAxNWMwNGU0YzU5NDdjNGE0NWRmNWIzYTMxODlkMTZfNC02LTEtMS02MjQ1NQ_6d7f330b-90d5-4116-9a5e-b08003736da0">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, approximately <ix:nonFraction unitRef="number" contextRef="ia2a4f1732f624b489e8f50c6d6b4e485_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMzM5Mw_72181471-7b9d-4866-8a93-13206d379a64">87</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="iecd13c786620474fa63cd266b54a3b74_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMzQwMA_fff9aad0-530f-4ce1-b8b8-6aae1886d0d2">84</ix:nonFraction>%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on key suppliers for certain laboratory materials. For the three months ended March&#160;31, 2023 and 2022, approximately <ix:nonFraction unitRef="number" contextRef="i309af3d1bef54a83aaa50e2c61f71a24_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMzc0NA_b0460719-507b-483e-8ff2-677063bf27c4">97</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i90730eb7530d4cc89a0fc5a794ff71a1_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMzc1MQ_970d0d58-109e-4c84-b64b-02c8ef6cba4f">95</ix:nonFraction>%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMzE_07a69a22-90ea-418a-ade5-1784d726a4e6" continuedAt="i506a7121d4ae488f8abc68e53df85c2e" escape="true">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7ead9566b7364e05b4873ada6dff9f78" continuedAt="i807385b713a248bf83fe42e72aff172c"><ix:continuation id="i506a7121d4ae488f8abc68e53df85c2e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6ce9aaec2a446c9c116ff73b70f8b3_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfMy0yLTEtMS02MjQ1NQ_89f13d62-4faf-4916-970e-fa83fcbb66c6">4,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a670771b95429a8cb648b92575b810_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfMy00LTEtMS02MjQ1NQ_e642ff03-6053-4f8b-8761-89d81b583871">6,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35095a09a8d844129623d819fcf1cacb_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfNC0yLTEtMS02MjQ1NQ_344a0718-ca46-45af-9bef-ebdac88dcab4">4,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i705da3eb6365425bb71d37b40211def3_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfNC00LTEtMS02MjQ1NQ_b0c84455-5504-45c7-b8f7-2f387b920b83">2,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939a0caa5e764269961b35c18b4916a0_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfNS0yLTEtMS02MjQ1NQ_7f213c7d-8985-431b-9f64-f3f6a42474f4">2,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30fc00a42642408badd375838de42222_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfNS00LTEtMS02MjQ1NQ_2d7e8aa1-a4ec-4197-b369-119db3a68fdd">1,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8df9a05d543b42d696a2487ba38b7424_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfNi0yLTEtMS02MjQ1NQ_84efffcd-b217-4ed1-84e7-38c84192008f">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if846aeeb8f314bd9a6bf240c914de52a_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfNi00LTEtMS02MjQ1NQ_9c9e55fa-dde6-4568-a355-a3866c400c94">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfOC0yLTEtMS02MjQ1NQ_eca8c0f2-88ef-452b-8e2f-b1ec85b344da">11,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfOC00LTEtMS02MjQ1NQ_db76a802-ba0d-4da7-97c3-8fb6ca932f4c">10,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMjA_e485ad8a-cdf3-4860-9759-903dae87cb41" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature, which are determined to be a Level 1 measurement (see Note 6). The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for the same or similar issues. As of March&#160;31, 2023, the 2017 Term Loan (as defined below) had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i3f88c29ff5974403bff253575a02defd_I20230331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTA5OTUxMTcyNDU0Mg_20d631ae-0d7c-4818-98c6-7cc0a65730e0">28.4</ix:nonFraction>&#160;million and a fair value of $<ix:nonFraction unitRef="usd" contextRef="i3f88c29ff5974403bff253575a02defd_I20230331" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTA5OTUxMTcyNDU2Ng_74904591-e331-4b74-be4f-2b564ce3a806">27.1</ix:nonFraction>&#160;million. As of December 31, 2022, the 2017 Term Loan had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i6610d7c73b1f4958b659b907335a85a0_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfNTQ5NzU1OTE1NjYy_1d1fc955-f397-4aba-b02d-6c067035fea0">28.3</ix:nonFraction>&#160;million and a fair value of $<ix:nonFraction unitRef="usd" contextRef="i6610d7c73b1f4958b659b907335a85a0_I20221231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfNTQ5NzU1OTE1Njc3_82b1c028-bf95-4be5-a825-f82480f6aa5f">26.9</ix:nonFraction>&#160;million The estimated fair value of the 2017 Term Loan, was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The recorded value of the Company's other long-term borrowing was $<ix:nonFraction unitRef="usd" contextRef="i9c3e2b7da46c423383b2883aad5f1fba_I20230331" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfODI0NjMzNzMwOTk1Mg_65f86aea-022f-42e9-a8d5-6d64d0182f85">0.7</ix:nonFraction>&#160;million and approximated its fair value as of March&#160;31, 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMTE_de61e24f-3d6d-46da-9c3a-61f34aca7d01" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an arrangement with a financial institution with which it has an existing banking relationship, whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a certificate of deposit with this financial institution as collateral for the balances borrowed on these cards ($<ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfNjQyNA_8e03799b-d8ab-4ba8-b993-7b2fcb2ed26f"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfNjQyNA_c8e374c3-e5fe-481d-93b0-c8f4b1d9a7b8">0.2</ix:nonFraction></ix:nonFraction> million at March&#160;31, 2023 and December 31, 2022). The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyNDE_e90c5084-6ddf-442c-8d70-26952f29995f" escape="true"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyNDE_fa9ca9f3-d8fd-41a4-9689-7fb02cd1ea56" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOmRiMzg5OTk4MDYyNDRlMjhhMDhiM2ZmYTViY2U1M2UwL3RhYmxlcmFuZ2U6ZGIzODk5OTgwNjI0NGUyOGEwOGIzZmZhNWJjZTUzZTBfMS0yLTEtMS02MjQ1NQ_7ce558b0-164d-4cc5-a5e4-76e9e44990f5">52,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic10d09e997d04be59819eb9f739c540e_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOmRiMzg5OTk4MDYyNDRlMjhhMDhiM2ZmYTViY2U1M2UwL3RhYmxlcmFuZ2U6ZGIzODk5OTgwNjI0NGUyOGEwOGIzZmZhNWJjZTUzZTBfMS00LTEtMS02MjQ1NQ_b21d2fab-eaee-4c4a-854f-c74422c7663c">89,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOmRiMzg5OTk4MDYyNDRlMjhhMDhiM2ZmYTViY2U1M2UwL3RhYmxlcmFuZ2U6ZGIzODk5OTgwNjI0NGUyOGEwOGIzZmZhNWJjZTUzZTBfMi0yLTEtMS02MjQ1NQ_516c5a49-ba5d-4aad-affc-fa16daf65dcb">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic10d09e997d04be59819eb9f739c540e_I20220331" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOmRiMzg5OTk4MDYyNDRlMjhhMDhiM2ZmYTViY2U1M2UwL3RhYmxlcmFuZ2U6ZGIzODk5OTgwNjI0NGUyOGEwOGIzZmZhNWJjZTUzZTBfMi00LTEtMS02MjQ1NQ_430f3341-54a7-411a-a49b-77f86658e746">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOmRiMzg5OTk4MDYyNDRlMjhhMDhiM2ZmYTViY2U1M2UwL3RhYmxlcmFuZ2U6ZGIzODk5OTgwNjI0NGUyOGEwOGIzZmZhNWJjZTUzZTBfMy0yLTEtMS02MjQ1NQ_bcf52d7f-8790-4bcf-8f04-1ac095d90f2d">52,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic10d09e997d04be59819eb9f739c540e_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOmRiMzg5OTk4MDYyNDRlMjhhMDhiM2ZmYTViY2U1M2UwL3RhYmxlcmFuZ2U6ZGIzODk5OTgwNjI0NGUyOGEwOGIzZmZhNWJjZTUzZTBfMy00LTEtMS02MjQ1NQ_76350cfd-5cfd-4d67-9d64-f59fbb9f7467">89,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfODI0NjMzNzMwNjg1NA_20a09e88-1d08-4b8f-8a25-d89d2b8f1383" continuedAt="id50b963dc5e346d3ba23925870c416c4" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Long-lived Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, we combine our intangible assets and other long-lived assets, into groupings, a determination which we principally make on the basis of whether the assets are specific to a particular test we offer or technology we are developing. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i807385b713a248bf83fe42e72aff172c" continuedAt="ibfc24598657b4418a85082159b6937cb"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="id50b963dc5e346d3ba23925870c416c4">long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Management&#8217;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.</ix:continuation> </span></div><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMzA_db5ab1ad-2358-48c7-8db4-ab107fefacd4" escape="true"><div style="margin-top:16pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.) and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the three months ended March&#160;31, 2023 and 2022 was a $<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTA1NzA_49f10fd2-2340-4088-8448-0b6f92e6ec89">0.3</ix:nonFraction>&#160;million net revenue increase and a $<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfNTQ5NzU1OTE1NzM5_33f3defa-0e7e-42ae-ada8-2ea2222b1c1e">0.2</ix:nonFraction>&#160;million net revenue decrease, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#8217;s balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue an allowance for credit losses against our accounts receivable based on management&#8217;s current estimate of amounts that will not be collected. Management&#8217;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was zero as of March&#160;31, 2023. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.</span></div><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMzc_618038ba-7527-4f8d-86ce-9e066897095d" continuedAt="iae17da5ac121401c948ad4f2e25c7e31" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibfc24598657b4418a85082159b6937cb" continuedAt="i2f103e9a20db4bd7b611adb6c305292f"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iae17da5ac121401c948ad4f2e25c7e31">supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</ix:continuation></span></div><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMzY_4a3ee2df-671c-4e1d-ac7a-eced0d96d979" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTY0NDQ_9e6bb6da-deec-4cd4-9977-94bee9d5e29a"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTY0NDQ_f676c897-98cc-4c41-b135-106fa304a67d">0.3</ix:nonFraction></ix:nonFraction> million for the three months ended March&#160;31, 2023 and 2022, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMzM_9fc7a61b-480d-4b48-949c-ce8066a01f56" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $<ix:nonFraction unitRef="usd" contextRef="ia543ba88573a4f76b3f29f77c2c449a3_D20230101-20230331" decimals="-5" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTY5MDc_fdd29bb6-2d12-4ab0-b78a-b1b541290575">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i96b7c50405024efea4bb7ce5ef47adb3_D20220101-20220331" decimals="-5" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTY5MTQ_cf832224-80b3-4b32-a082-23673e1d7150">0.6</ix:nonFraction> million for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMzg0ODI5MDc5MTg3NQ_7db580f9-78d5-4cf2-b867-cb94562d3fab" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on that date. The Company's restricted stock units generally vest in equal annual installments over <ix:nonNumeric contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTA5OTUxMTcyMjAyOA_010f9ac1-b3dd-45c2-8c22-19782714d276">four years</ix:nonNumeric> from the date of grant or, for grants to new hires, date of hire. Vesting of restricted stock units is subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMTI_16b2ca11-366a-46d0-b2ce-727ba020c01a" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMzQ_ca246fee-d460-49ac-a781-e23e62a58522" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three months ended March&#160;31, 2023 and 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding, as the inclusion of the potentially dilutive securities would be antidilutive.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMzI_ee168a3e-fbd1-4bdc-8651-127f80609081" continuedAt="i23ea9121344a40979796a57dd572f8d4" escape="true">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2f103e9a20db4bd7b611adb6c305292f"><div><ix:continuation id="i23ea9121344a40979796a57dd572f8d4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.915%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i895d656b22474a18a403f1fd341b6467_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfNC0yLTEtMS02MjQ1NQ_fdf9248f-d40c-4e80-b7e1-7abbd73fb366">409,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b4f7177650b41ea9633024d9953c438_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfNC00LTEtMS02MjQ1NQ_b58ec35c-b491-482d-919a-4d7f673fb84c">409,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d8153a1b8c047f5ba1ab683df79cb7f_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfNS0yLTEtMS02MjQ1NQ_c0f36c98-17ed-4d48-a54c-fc639653fec4">1,019,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i30edb0fc3f0c427ab5994bec9d4cb64a_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfNS00LTEtMS02MjQ1NQ_8c2778c4-8c75-4911-9a00-913745d81c1e">2,002,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafc6e1b4e06e45fcb9b81908405af3e3_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfNi0yLTEtMS02MjQ1NQ_45b10744-2821-4b24-ac09-770b5e4e1891">1,494,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19225060b0864579b9f675d97dd4b83b_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfNi00LTEtMS02MjQ1NQ_628d91ca-0987-4d80-93d7-2ee9ba9075d6">878,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i574ca98624ca4a4b9e2538fbfee1fab3_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfNy0yLTEtMS02MjQ1NQ_195af2e6-9f34-406b-adaa-95110224b0c0">14,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32c2432d847f4430ba1a0adb828fc7e5_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfNy00LTEtMS02MjQ1NQ_834f9d6e-92ea-4d62-95e0-5a67d67c21bc">6,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfOC0yLTEtMS02MjQ1NQ_a7363291-b58a-4d44-b488-1c317331ac0c">2,937,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfOC00LTEtMS02MjQ1NQ_2aabe2e6-e3a8-4a46-bd32-5e012d1e1b71">3,296,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMzg0ODI5MDc5MTg3Ng_501cb53c-e8ba-4175-bc8d-7666db01244d" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Segment Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, <ix:nonFraction unitRef="segment" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTA5OTUxMTcyMjQwMQ_e29ee4b2-65b2-4fe9-a9da-e9cf6fb9f7b4">one</ix:nonFraction> operating segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyNDM_adfb8433-da9c-49f2-9914-6b6a7af1fa9a" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which requires the measurement of expected credit losses (based on historical experience, current conditions and reasonable forecasts) for financial instruments (such as accounts receivable) held at the reporting date which are carried at amortized cost. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Codification Improvements to Topic 326, Financing Instruments-Credit Losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which included an amendment of the effective date for nonpublic entities. For emerging growth companies, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted this pronouncement on January 1, 2023. The adoption did not have an impact on its condensed financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for smaller reporting companies as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2023. The adoption did not have an impact on its condensed financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="ic6a5e7b0edc94c399549fe8f80e94568_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RleHRyZWdpb246YmMyMDA0YzczMzZmNDQ0ZDg5NTZlMDc2ZjJlOTQwZTJfNjM0_3cea36fb-7a41-4111-aa6b-ea3ba18410f9" continuedAt="ie1af6ee402f8407cb0cf2fb3e0c418dc" escape="true">Other Financial Information</ix:nonNumeric></span></div><ix:continuation id="ie1af6ee402f8407cb0cf2fb3e0c418dc" continuedAt="ic256e8ee0cdf43cca76fd10443e2ce76"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RleHRyZWdpb246YmMyMDA0YzczMzZmNDQ0ZDg5NTZlMDc2ZjJlOTQwZTJfNjMz_0136b12f-1ce6-42ea-9b42-c35dd8409f5e" continuedAt="iab22bfeb7f5b425aa9165d75cca8e13c" escape="true">Prepaid expenses and other current assets consist of the following (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic256e8ee0cdf43cca76fd10443e2ce76"><div><ix:continuation id="iab22bfeb7f5b425aa9165d75cca8e13c"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfMS0yLTEtMS02MjQ1NQ_12cd5620-b143-4daf-a9ee-05b545245b89">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfMS00LTEtMS02MjQ1NQ_d8f96640-2013-4dff-b17f-aff97d335c6e">1,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:PrepaidRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfMi0yLTEtMS02MjQ1NQ_f2a02867-d061-4aeb-88fe-4ab3ba44c48f">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:PrepaidRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfMi00LTEtMS02MjQ1NQ_093475a3-2575-4552-899c-10a3ce1030d1">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="exdx:PrepaidMaintenanceAndInsuranceContracts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfMy0yLTEtMS02MjQ1NQ_5b94b35a-e302-4168-921b-146ab4e65348">2,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="exdx:PrepaidMaintenanceAndInsuranceContracts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfMy00LTEtMS02MjQ1NQ_0f64976d-4a27-4aba-a0d1-6eed8f82c286">2,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfNC0yLTEtMS02MjQ1NQ_444bcb1c-5a9c-4264-a134-b24e53be931d">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfNC00LTEtMS02MjQ1NQ_b5182a83-e5e4-4b9b-8f4d-2520368ed973">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfNS0yLTEtMS02MjQ1NQ_073cc288-2353-47fa-b77b-a8545c3373b7">4,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfNS00LTEtMS02MjQ1NQ_ccffad4b-cf26-409b-9482-be8fa7709955">4,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RleHRyZWdpb246YmMyMDA0YzczMzZmNDQ0ZDg5NTZlMDc2ZjJlOTQwZTJfNjI5_5e0a8a53-d115-4c72-8ab4-5f739ede2bff" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb9b15bd3534c7b959fafc69dd136ca_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfMS0yLTEtMS02MjQ1NQ_c8956c39-af30-44c0-94a8-16917768dc1a">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad556f0486564986b0fe232198d50b00_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfMS00LTEtMS02MjQ1NQ_3dfca3cf-988d-4b72-aaa4-9d48f25d4113">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea90a46da8b0473b81bd14734a0e680a_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfMi0yLTEtMS02MjQ1NQ_23308afa-a144-4713-96e8-1b3d7f13e937">5,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8b419bb6ccf44b485236b67f0570541_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfMi00LTEtMS02MjQ1NQ_0459c961-b7c4-4be8-9521-e2c2e1bc0131">5,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffe2a329326445ebf186d1dbfc97983_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfMy0yLTEtMS02MjQ1NQ_c1715f4f-444c-4c85-83c0-ffd0d8527318">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dbff6a1aa00481ca92a92d62756b86b_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfMy00LTEtMS02MjQ1NQ_0888d49f-7445-4ba8-94bd-f8316eec41fd">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c7b49c0d49e41acb5a83a3b738931e7_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfNC0yLTEtMS02MjQ1NQ_3cff8bf4-630a-42b5-beed-6c6b930b341a">5,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd2c1906e2f4109b2230036ad76ebce_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfNC00LTEtMS02MjQ1NQ_715b584b-dc5c-4b72-9708-d6406faca870">5,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice0b71e76bbd4e2e84837c2eba278fff_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfNS0yLTEtMS02MjQ1NQ_e1a286cc-b012-4e97-9bde-0b15dd5df99f">1,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf0198dc6d684b77b81f517d3508fe26_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfNS00LTEtMS02MjQ1NQ_7348e68a-d183-478e-9896-97ac72f063d0">1,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfNi0yLTEtMS02MjQ1NQ_01104ced-68f5-4355-be67-1754f93f8be3">13,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfNi00LTEtMS02MjQ1NQ_a4818ecd-eef2-4bb8-8672-51b8c58c965a">13,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfNy0yLTEtMS02MjQ1NQ_19c7f1ed-4bc7-4bbf-8121-c9b332f6a666">5,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfNy00LTEtMS02MjQ1NQ_f39e70d1-feb4-484d-9693-a2965b92b16c">5,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfOC0yLTEtMS02MjQ1NQ_4efc0ae9-17e3-473f-a0a5-b3fd6d55984b">8,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfOC00LTEtMS02MjQ1NQ_875e4f91-501b-49f8-8399-4e966f7bfd3c">8,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the three months ended March&#160;31, 2023 and 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RleHRyZWdpb246YmMyMDA0YzczMzZmNDQ0ZDg5NTZlMDc2ZjJlOTQwZTJfMzgx_8426ec7a-f111-4db9-8eb6-5f2bc553b455">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RleHRyZWdpb246YmMyMDA0YzczMzZmNDQ0ZDg5NTZlMDc2ZjJlOTQwZTJfMzk2_4f93575b-29c9-4201-805e-162f0e492112">0.3</ix:nonFraction> million, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Other Current Liabilities</span></div><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RleHRyZWdpb246YmMyMDA0YzczMzZmNDQ0ZDg5NTZlMDc2ZjJlOTQwZTJfNjM1_7553bf4f-1585-4d46-acbb-b512c72400b9" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfMS0yLTEtMS02MjQ1NQ_59063371-5959-4ca4-8aa6-25b4baf9a5ba">3,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfMS00LTEtMS02MjQ1NQ_cfa4939c-c4d0-48e6-8318-db4697d03360">2,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfMi0yLTEtMS02MjQ1NQ_8eb31791-ed6b-453b-bb85-35643e7d94eb">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfMi00LTEtMS02MjQ1NQ_3977797a-50a0-4311-8732-f4ed92a0e71d">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="exdx:AccruedPurchaseGoodsAndServicesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfMy0yLTEtMS02MjQ1NQ_c1206a88-2f88-4fee-a6cd-66452dfdd835">665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="exdx:AccruedPurchaseGoodsAndServicesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfMy00LTEtMS02MjQ1NQ_03088f66-9b50-4500-b0ab-be7bbd353a40">803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfNC0yLTEtMS02MjQ1NQ_bac58e8b-ea13-4522-a2ca-c5737d58354b">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfNC00LTEtMS02MjQ1NQ_3e0a274f-e322-417f-a453-495d3726dd96">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="exdx:AccruedLiabilitiesClinicalStudyCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfNS0yLTEtMS02MjQ1NQ_4375638d-6708-42b7-afb3-e4b0d7862163">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="exdx:AccruedLiabilitiesClinicalStudyCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfNS00LTEtMS02MjQ1NQ_4223b0b2-3ca5-4b70-a814-26aefd58d310">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfNi0yLTEtMS02MjQ1NQ_2af93341-82c9-4775-90cc-6ed729bb87ea">650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfNi00LTEtMS02MjQ1NQ_9386be3e-f276-4576-b05c-2786b0612e42">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Refund liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfNy0yLTEtMS02MjQ1NQ_efca9642-968e-41a8-b2bc-03625de0cb20">445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfNy00LTEtMS02MjQ1NQ_dd7b882f-ace6-4f9a-99c3-c4cbe0e9563a">445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfOC0yLTEtMS02MjQ1NQ_701166d8-be70-41d0-aeb5-d9e5abe2065b">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfOC00LTEtMS02MjQ1NQ_712c2822-f7fe-465b-9da0-066c2625b64a">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfOS0yLTEtMS02MjQ1NQ_a444fd81-a535-4762-be18-4cd20d3247bd">6,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfOS00LTEtMS02MjQ1NQ_39422b22-d2b9-44ac-b6ba-d1018d16b937">5,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_43"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNTEyMQ_e54c26e8-fb35-444c-ae54-4214076fa03c" continuedAt="ia5654d8c9b5b43849dfbb9018ae71af7" escape="true">Borrowings</ix:nonNumeric></span></div><ix:continuation id="ia5654d8c9b5b43849dfbb9018ae71af7" continuedAt="i388319e376094dc0b8dfa8680920fe63"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Term Loan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), as amended, pursuant to which the Company borrowed $<ix:nonFraction unitRef="usd" contextRef="i94ecd2ce87e1410596492d2b66fe3d3d_D20170901-20170930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMzg0ODI5MDcwMzE4Ng_c47a92af-8bcc-48ec-aa78-d7691a99b18f">25.0</ix:nonFraction>&#160;million. As of March&#160;31, 2023, <ix:nonFraction unitRef="usd" contextRef="ibb33abf78bcd4170a8b0655f9f35138a_I20230331" decimals="INF" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNTA0_5ce73c5b-bf0a-431e-a69f-d81fcbe473aa">no</ix:nonFraction> additional amounts remained available to borrow under the 2017 Term Loan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company executed the Second Amendment to the Loan and Security Agreement (the 2017 Loan Amendment) and, as further described in Note 9, on April 28, 2023, the Company and Innovatus entered into </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i388319e376094dc0b8dfa8680920fe63" continuedAt="i349c994b21494e808491cd8ad2a8a2c4"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Third Loan Amendment to the 2017 Term Loan (Third Loan Amendment). The interest rate on all borrowings under the 2017 Loan Amendment was <ix:nonFraction unitRef="number" contextRef="i859e111840c844b0912ab35300e78234_I20211130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNzcw_15a13a0c-bcfc-4115-9239-3d08eaa746c3">8.0</ix:nonFraction>%, of which <ix:nonFraction unitRef="number" contextRef="i859e111840c844b0912ab35300e78234_I20211130" decimals="INF" name="exdx:DebtInstrumentStatedInterestRatePaidInKind" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNzgz_09086fb4-a83c-4cda-8fb0-c8722e79aabb">2.0</ix:nonFraction>% was paid in-kind in the form of additional term loans (PIK Loans) until December of 2024, after which interest was scheduled to accrue at an annual rate of <ix:nonFraction unitRef="number" contextRef="i859e111840c844b0912ab35300e78234_I20211130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfOTI1_15a13a0c-bcfc-4115-9239-3d08eaa746c3">8.0</ix:nonFraction>%. The Company estimated the effective interest rate of this loan to be approximately <ix:nonFraction unitRef="number" contextRef="i859e111840c844b0912ab35300e78234_I20211130" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMTAxNg_bc669abb-6a55-406f-9c4e-9a12fb3f1c4e">8.5</ix:nonFraction>%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the 2017 Loan Amendment was to be repaid in <ix:nonFraction unitRef="installment" contextRef="i0d50b70a9daa46a5b489435a77934c85_D20211101-20211130" decimals="INF" name="exdx:DebtInstrumentNumberOfMonthlyInstallments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMTIxMw_e6a3c17e-ab47-46d0-a9a7-24086530c501">twenty-four</ix:nonFraction> equal monthly installments commencing in December 2024. Upon repayment of the final installment under the 2017 Loan Amendment, the Company is required to pay an additional fee of $<ix:nonFraction unitRef="usd" contextRef="ibb33abf78bcd4170a8b0655f9f35138a_I20230331" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMTM5NQ_effe2b99-7616-4c81-b479-e86a557fcef3">1.0</ix:nonFraction> million. This obligation is being accreted into interest expense over the term of the Loan Amendment using the effective interest method. For each of the three months ended March&#160;31, 2023 and 2022, the Company issued PIK Loans totaling $<ix:nonFraction unitRef="usd" contextRef="iabe905c72ff84d589835e599cc035ca4_D20230101-20230331" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMTYxNw_c9002b87-c07e-4b92-bed6-72bf32c32391"><ix:nonFraction unitRef="usd" contextRef="i0a372fdfdb7a4826a6cbffa763f05288_D20220101-20220331" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMTYxNw_fbcafa32-66c3-4a15-aa3f-23cb7b566328">0.1</ix:nonFraction></ix:nonFraction> million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Loan Amendment required a prepayment premium of <ix:nonFraction unitRef="number" contextRef="i859e111840c844b0912ab35300e78234_I20211130" decimals="INF" name="exdx:DebtInstrumentPrepaymentPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMTc2Ng_98350ec2-786d-428f-bfb7-39e3d0a86cc1">2</ix:nonFraction>% of the aggregate outstanding principal and decreased by <ix:nonFraction unitRef="number" contextRef="i859e111840c844b0912ab35300e78234_I20211130" decimals="2" name="exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMzg0ODI5MDcwMzE3Ng_a93d0bee-6644-40ac-a33a-928f722c2014">1</ix:nonFraction>% on each of November 1, 2023 and 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Loan Amendment is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the 2017 Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling <ix:nonNumeric contextRef="i2a7f825dbe7d4f5c828334d605f13e10_D20230101-20230331" name="exdx:DebtInstrumentCovenantRevenuePerformancePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNTExNw_fdbffeca-56f5-4eb8-82fa-0f7070a8fb60">twelve-month</ix:nonNumeric> basis. The consequences of failing to achieve the performance covenant were eligible to be cured if, within <ix:nonNumeric contextRef="i2a7f825dbe7d4f5c828334d605f13e10_D20230101-20230331" name="exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMjc3Mg_4702625b-6335-42e1-8fcd-8d2926f9dd16">sixty days</ix:nonNumeric> of failing to achieve the performance covenant, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The 2017 Loan Amendment requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $<ix:nonFraction unitRef="usd" contextRef="i859e111840c844b0912ab35300e78234_I20211130" decimals="-5" name="exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMzEzNA_3037b4c9-0321-41bb-9ef6-7180360c5335">2.0</ix:nonFraction> million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative covenants provide, among other things, that without the prior consent of Innovatus, subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company was in compliance with all covenants of the 2017 Loan Amendment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an event of default in any of the 2017 Loan Amendment covenants, the repayment of the 2017 Loan Amendment may be accelerated, and the applicable interest rate will be increased by <ix:nonFraction unitRef="number" contextRef="ibb33abf78bcd4170a8b0655f9f35138a_I20230331" decimals="3" name="exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMzg0ODI5MDcwMzE4MA_ce23c00d-595f-4473-a58d-7cfaea9f9d08">4.0</ix:nonFraction>% until the default is cured. Although repayment of the 2017 Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the 2017 Loan Amendment due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2022 Equipment Notes Payable</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2022, the Company purchased laboratory equipment using notes payable. At March&#160;31, 2023, the total notes payable balance related to this financed equipment was $<ix:nonFraction unitRef="usd" contextRef="i66d0781c430544b080c8b6a0138f9b6e_I20220531" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNTQ5NzU1ODI5MjI2_e71bd09e-b4d4-407f-be0c-ed2c0264d3f4">1.0</ix:nonFraction> million, with $<ix:nonFraction unitRef="usd" contextRef="i66d0781c430544b080c8b6a0138f9b6e_I20220531" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNTQ5NzU1ODI5MjE2_0d3b6f76-7762-432c-b668-17f012fd1941">0.3</ix:nonFraction> million classified within borrowings-current portion and $<ix:nonFraction unitRef="usd" contextRef="i66d0781c430544b080c8b6a0138f9b6e_I20220531" decimals="-5" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNTQ5NzU1ODI5MjIx_95d315a3-5726-4a3d-b17b-d299b580cfcc">0.7</ix:nonFraction> million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. The financed equipment is subject to a <ix:nonFraction unitRef="number" contextRef="i66d0781c430544b080c8b6a0138f9b6e_I20220531" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMzg0ODI5MDcxMjM2Ng_2f511c84-ed23-4b1f-b1d5-f694dfbc8338">5.28</ix:nonFraction>% effective interest rate and will mature on October 1, 2026.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Future Minimum Payments on the Outstanding Borrowings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNTExOA_d07cf69e-7706-4d9c-be6a-5ce639b0a680" continuedAt="ifd12ab7ae98c4f4e854e98a422a2e07e" escape="true">As of March&#160;31, 2023, future minimum aggregate payments, including interest, for outstanding borrowings under the 2017 Loan Amendment are as follows (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><ix:continuation id="i349c994b21494e808491cd8ad2a8a2c4"><ix:continuation id="ifd12ab7ae98c4f4e854e98a422a2e07e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfMS0yLTEtMS02MjQ1NQ_274e50e9-204d-40ae-851d-e9116d102424">1,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfMi0yLTEtMS02MjQ1NQ_e16ecb0f-1059-4d8b-96e1-86d74efb3d47">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfMy0yLTEtMS02MjQ1NQ_4594dfab-3453-452b-a687-3d44f9abdd80">16,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfNC0yLTEtMS02MjQ1NQ_33d0897a-36c6-4d18-95ce-e5e12364f3cd">15,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="exdx:LongTermDebtIncludingUndiscountedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfNS0yLTEtMS02MjQ1NQ_6bf16c9d-77cd-47ee-96fb-0a071caefa33">36,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfNy0yLTEtMS02MjQ1NQ_b0cbd55a-f3ab-4931-afcb-c57cbb379c17">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="exdx:LongTermDebtUndiscountedInterestAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfOC0yLTEtMS02MjQ1NQ_9b9bdef1-9880-498d-8130-0030fd81b4aa">6,774</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfOS0yLTEtMS02MjQ1NQ_121a58e3-8fc7-4257-907d-3a53635c2d1a">29,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Borrowings-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfMTAtMi0xLTEtOTQwNjk_dabb464c-c4a3-48c9-8ee5-fbaa991429bb">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfMTEtMi0xLTEtOTQwODk_f3305bdb-1d95-4f43-b490-730c2e96ca9f">29,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfNDgwNg_a629edda-b91f-4ada-8d46-223d1fcc6e8e" continuedAt="ia882e3e8333a47659b4fbef3dccab52e" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ia882e3e8333a47659b4fbef3dccab52e" continuedAt="i481d3284068b49fd87c6492c53f3532b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related liabilities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the medical diagnostics division of Royalty Pharma Collection Trust (Royalty Pharma) (formerly known as Cypress Bioscience, Inc.) in 2010, the Company has ongoing royalty payment obligations of <ix:nonFraction unitRef="number" contextRef="i0bf8defbc1fa44d882189373b2849672_I20230331" decimals="3" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfNTc0_67d721fa-57bc-4971-943c-49a9b3b419b2">2.5</ix:nonFraction>% on net sales of products which incorporate certain acquired technologies. Future royalties payable under these arrangements are limited to the lesser of (i) an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ia5c76f81d9cd409eb1b8a90d4fe48c57_I20230331" decimals="-5" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfNzUw_c0b207a3-b9cf-4582-8058-4caddeff2a7f">1.2</ix:nonFraction> million (including an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ia5c76f81d9cd409eb1b8a90d4fe48c57_I20230331" decimals="-5" name="exdx:AdvancePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfNzk0_ff033fad-2d17-4c38-8bc2-a0877d2d43e5">0.1</ix:nonFraction> million) and (ii) the total royalties earned through January 1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements, individual license agreements generally provide for ongoing royalty payments ranging from <ix:nonFraction unitRef="number" contextRef="i4931e73aebd8406f8a9334dd51dbbc52_I20230331" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfMTEzNA_8e674312-4561-4708-973d-bdb474beaa50">1.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i3350c67771f646c6b53fca4a8f67d638_I20230331" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfMTE0MA_f6dd1f3a-fef8-484e-b98f-912e3c05afcb">7.0</ix:nonFraction>% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when earned and recorded in costs of revenue in the accompanying condensed statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Obligations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a master research collaboration agreement with Allegheny Health Network Research Institute (AHN), pursuant to which the Company is required to pay AHN a collaboration fee of $<ix:nonFraction unitRef="usd" contextRef="ib3e0014fc8a94ef0953febf2e7cf24ad_D20210501-20210531" decimals="-5" name="exdx:CollaborationAgreementAnnualCollaborationFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfMzE5NA_cd244628-7418-4bbd-ab98-aa20fe835bcb">0.4</ix:nonFraction> million for each year during the initial term of the agreement. Collaboration expenses under the master research collaboration agreement were $<ix:nonFraction unitRef="usd" contextRef="i0e499e7ea6aa4310baa5eca3da4d604b_D20230101-20230331" decimals="-5" name="exdx:CollaborationAgreementCollaborationExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfMzMzOQ_19d4ca72-883e-452c-8ba0-2c06b03ad5da"><ix:nonFraction unitRef="usd" contextRef="i6d3bd6c4fe2242cf87f21e0213354a26_D20220101-20220331" decimals="-5" name="exdx:CollaborationAgreementCollaborationExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfMzMzOQ_a8907979-13d4-46c9-8c7e-0a3c80303529">0.1</ix:nonFraction></ix:nonFraction> million for each of the three months ended March&#160;31, 2023 and 2022. Collaboration expenses under the AHN collaboration are included in research and development expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supply Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $<ix:nonFraction unitRef="usd" contextRef="i140c8595c10a41eeb48e5be8f884c4cb_I20211231" decimals="-5" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfNTQ5NzU1ODE5OTc1_4705e57c-5b12-4a77-b513-2b5aa0e24b60">6.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i140c8595c10a41eeb48e5be8f884c4cb_I20211231" decimals="-5" name="us-gaap:PurchaseObligationDueInSecondYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfNTQ5NzU1ODE5OTc5_4f64ee13-edf7-4b4e-97dd-c42899504f1c">8.0</ix:nonFraction> million for the years ending December 31, 2023 and 2024, respectively, with a <ix:nonFraction unitRef="number" contextRef="i140c8595c10a41eeb48e5be8f884c4cb_I20211231" decimals="2" name="exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfNTQ5NzU1ODE5Njk3_c4281fd3-8a50-417e-a5d4-6da7c6642931">15</ix:nonFraction>% annual increase thereafter for unconditional minimum purchase commitments through the year ending December 31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including for subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i481d3284068b49fd87c6492c53f3532b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities. The Company does not believe the outcome of any such matters will have a material effect on its financial position or results of operations.</span></div></ix:continuation><div id="ic6a5e7b0edc94c399549fe8f80e94568_52"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RleHRyZWdpb246NmVlN2VkYmFlZTRiNGU5NDk1M2NhN2ExNDgzYjI4NjZfMjk4_d65762f7-896d-4d32-96c2-e6e7719dd12e" continuedAt="iab848ac98a1149278ed9642ebbabfc66" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="iab848ac98a1149278ed9642ebbabfc66" continuedAt="i38cd8835db98413d90dc4472832a6e8b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. <ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RleHRyZWdpb246NmVlN2VkYmFlZTRiNGU5NDk1M2NhN2ExNDgzYjI4NjZfMjk5_4278ee79-e0bc-4e78-8082-b6f4c37a9eee" continuedAt="id62f423a5c494b7c942629d3a208b57c" escape="true">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</ix:nonNumeric></span></div><ix:continuation id="id62f423a5c494b7c942629d3a208b57c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4fc1eac300c43b6a7327014b06ddfa9_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfMy0yLTEtMS02MjQ1NQ_2b9857b8-f09a-4d71-8c4f-91db4f56f67d">20,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i523c8d55aeb0417e85e726ce80798a7c_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfMy00LTEtMS02MjQ1NQ_61e94137-647f-4447-8a47-66aaa3968dc5">20,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieff95e26dba14d95a8f3cd8ee4182372_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfMy02LTEtMS02MjQ1NQ_8978af1a-0fd3-4539-914e-22d87cc41fc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f4ffb1c43554f1a90dfd599025b8c9e_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfMy04LTEtMS02MjQ1NQ_0496ae14-7eaf-4bac-bb79-2f0007b07f95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificate of deposit, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9625bbb62da645d980dedf056fae0d11_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfNC0yLTEtMS04NDY0Mw_57c3f799-2247-4bdc-bcf3-19bf2e5070b8">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i173e25ca60a14e9eb6d2a3839cd12de8_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfNC00LTEtMS04NDY1NQ_bc543fd4-c87d-4746-b24e-762457ddd441">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626b7154acb34ccaafa6ab945abf40c9_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfNC02LTEtMS04NDY3MQ_3821ec67-4e73-4572-a919-e75f3f364670">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie210aad638e548c4870de1627ee59314_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfNC04LTEtMS04NDY4Mw_1b425607-5b01-4412-8245-520ac617cbaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41f690f8baf4faba442062c5cd09d97_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfNS0yLTEtMS04NDY0Mw_6ff77b86-40ba-4e03-98b2-d35949091f1d">50,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3981775f29d04856b8989e7532c82c09_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfNS00LTEtMS04NDY1NQ_5a6a1fbc-a80b-483a-8419-937e7c9ef7b8">50,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ae8bd4f38347fb8cd1eda4e1828338_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfNS02LTEtMS04NDY3MQ_a30fa08a-3381-4b19-b6d9-afdfb48d9526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d9435b79cd7491eaf962b33022de57f_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfNS04LTEtMS04NDY4Mw_a399bddd-0863-4eba-8a34-f4802eec4bf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a2e37140ea4e5d964b371b5b2e678e_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfMy0yLTEtMS02MjQ1NQ_d0da806a-bad7-471c-a68a-916598759b31">29,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdbc12a0fd3349cea91fc35053c905ac_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfMy00LTEtMS02MjQ1NQ_ce443928-8f84-4d04-8667-48a7c83cd27b">29,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a4807b9a98e45a1ba7d94b95b6cf1db_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfMy02LTEtMS02MjQ1NQ_c1c885de-29ef-48e4-ad16-4e755bcf74b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2057c462f3f407fac03e7ed09fbf60b_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfMy04LTEtMS02MjQ1NQ_bf05d1b5-b2be-4da3-aa24-f15eea749d4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificate of deposit, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c407749d2e847a7803b2c710bcc16b8_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfNC0yLTEtMS04NDY5Mw_a0dd6e87-2e03-409b-a6eb-b13a1289639b">30,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e67690fd9847e1aaece1d7ff577378_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfNC00LTEtMS04NDY5Mw_83d0b3dc-f75e-422f-bf35-3df2a4b97802">30,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69fb565bd3a94c019700911026c93178_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfNC02LTEtMS04NDY5Mw_d1fd616a-b3e6-4023-ab0f-8582f166cbfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aff556ef6e84baa8337afc2d1b6be3c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfNC04LTEtMS04NDY5Mw_fb4ea5c9-b4bf-4b80-990e-bdc9a904f287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90e1b44e5ed44cc28aa97c0d68594467_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfNS0yLTEtMS02MjQ1NQ_61df3664-667f-4b21-bd2d-dd48c85debc4">59,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f4f95f45fbb40f4a140c25ba96bc721_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfNS00LTEtMS02MjQ1NQ_99c0363c-0f46-49e3-914d-bb99ea17e7e2">59,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b6627751494aab9971b2c3202d9569_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfNS02LTEtMS02MjQ1NQ_e3c44a6a-8f35-47f6-a9a0-887d312571ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6b812b1a86449d836330f0d3b625bb_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfNS04LTEtMS02MjQ1NQ_7caf9d86-e080-4f7d-8ccd-eacfb2ca6872">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i38cd8835db98413d90dc4472832a6e8b">The fair value of the Company's money market funds is based on quoted market prices.</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RleHRyZWdpb246YjAyYzFhZTY2Y2E2NDQ5MThkNTJmYmJhODgyNDc5YzdfMzIxMg_3e50efa3-9233-4ca6-8bf3-1e2d8658e7ce" continuedAt="i73244ec19ba94cb9b2d746ccbad57314" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i73244ec19ba94cb9b2d746ccbad57314" continuedAt="idae25d897c474b4992d1833dfff1c12b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At The Market Sales Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 15, 2022, the Company entered into a sales agreement (the Sales Agreement) with Cowen and Company, LLC (the Sales Agent), pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="ie95865dfdf5b4540b73e69eb6e14d14b_D20220915-20220915" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RleHRyZWdpb246YjAyYzFhZTY2Y2E2NDQ5MThkNTJmYmJhODgyNDc5YzdfMzg0ODI5MDcwNjgxOQ_9251a328-d84a-4157-824b-517e1afc25d8">50.0</ix:nonFraction>&#160;million. The Company is not obligated to </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idae25d897c474b4992d1833dfff1c12b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">sell any shares of Company common stock in the offering. As of March&#160;31, 2023, the Company has not sold any shares of its common stock pursuant to the Sales Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Outstanding Warrants</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RleHRyZWdpb246YjAyYzFhZTY2Y2E2NDQ5MThkNTJmYmJhODgyNDc5YzdfMzIxMA_609ed75a-4aff-41ff-8aac-fda07d8026fe" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following equity classified warrants to purchase common stock were outstanding as of March&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ff0d03d717e4fe3bc16e2a5c900dc45_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfMS0xLTEtMS02MjQ1NQ_d26e15bb-7cae-4dd4-9449-d5546933b979">237,169</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ff0d03d717e4fe3bc16e2a5c900dc45_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfMS0zLTEtMS02MjQ1NQ_2122d619-8cc6-4a94-96fe-c0c741523405">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3de710b92f4485e825c6c2d1c6fb10a_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfMi0xLTEtMS02MjQ1NQ_0d7f4386-a8e4-4f93-beca-209b4a460b16">67,086</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3de710b92f4485e825c6c2d1c6fb10a_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfMi0zLTEtMS02MjQ1NQ_755af79a-b4bf-458e-a841-84ecf074846e">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2912cd445faf49c38783149855c13b6d_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfMy0xLTEtMS02MjQ1NQ_390dd613-17d4-4655-b685-4ab12c05f991">131</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2912cd445faf49c38783149855c13b6d_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfMy0zLTEtMS02MjQ1NQ_9f644ee3-a674-41da-90d9-a35d8805f866">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie36f5616d2e44e80a9e03af14c0045a4_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfNC0xLTEtMS02MjQ1NQ_42dac7ae-0ce6-4498-b1a1-01d3b76259a0">83,778</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie36f5616d2e44e80a9e03af14c0045a4_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfNC0zLTEtMS02MjQ1NQ_6965e544-2cff-4dba-9d83-02da1aa8d6d0">14.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02a6a7e72b5342cfb6df8c09e1146039_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfNS0xLTEtMS02MjQ1NQ_0c70400b-b50d-47fb-bcb9-c5964f8bf9ea">20,944</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02a6a7e72b5342cfb6df8c09e1146039_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfNS0zLTEtMS02MjQ1NQ_d2f2fc73-3646-4dbf-820f-51c77deef940">14.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0885affce6b54cc8bb7d28029c8146fa_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfNi0xLTEtMS02MjQ1NQ_b3dc552c-4b4e-4205-bd52-e43418b35459">804,951</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0885affce6b54cc8bb7d28029c8146fa_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfNi0zLTEtMS02MjQ1NQ_35fcb231-b263-4db9-9326-37277dafa5a1">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfNy0xLTEtMS02MjQ1NQ_56746254-5979-4ba9-b6d5-da0621025565">1,214,059</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="INF" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RleHRyZWdpb246YjAyYzFhZTY2Y2E2NDQ5MThkNTJmYmJhODgyNDc5YzdfMzE1OA_870bd7e6-706e-4a6b-a3d7-25affb9f0a52">no</ix:nonFraction> warrants to purchase common stock were exercised.</span></div></ix:continuation><div id="ic6a5e7b0edc94c399549fe8f80e94568_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMjk1Ng_425309de-feba-488a-adb5-4b9031c3aa1b" continuedAt="i91615679ddd044a7b9cbd2f4d0d826bd" escape="true">Stock Option Plan</ix:nonNumeric></span></div><ix:continuation id="i91615679ddd044a7b9cbd2f4d0d826bd" continuedAt="i86e58e6aee304f9ea1341dc46a8946c1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Incentive Award Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire <ix:nonNumeric contextRef="ia4840a5daec942e9baf60b20b64f05d2_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTY0OTI2NzQ0Nzc2MA_e5c2bde3-35b7-42f8-8f79-708758de115f">ten years</ix:nonNumeric> after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally <ix:nonNumeric contextRef="ia4840a5daec942e9baf60b20b64f05d2_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTY0OTI2NzQ0Nzc2Ng_0ca7e9c9-32da-424d-b5de-d410a06feea1">four years</ix:nonNumeric> from the date of grant or, for grants to new hires, date of hire. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) <ix:nonFraction unitRef="number" contextRef="i9f4d0fe871b84f4bbc6b2e49f7ca8aa6_I20230331" decimals="INF" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTY0OTI2NzQ0Nzc3MQ_24de149e-134b-4499-8709-560b7ebcfe47">4</ix:nonFraction>% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board of Directors. As of March&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="i9f4d0fe871b84f4bbc6b2e49f7ca8aa6_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfNzE4_d9239c9e-3544-4350-b6d4-a7e1903ed715">1,851,836</ix:nonFraction> shares of common stock remained available for future awards under the 2019 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, the Board of Directors adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i35ee5d15536b446d8e71cf4f2712b1ad_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTY0OTI2NzQ0ODQ2NA_4b6bd214-2bc2-48a9-beb9-746f7be3d523">20</ix:nonFraction>% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the lesser of (i) <ix:nonFraction unitRef="number" contextRef="i35ee5d15536b446d8e71cf4f2712b1ad_I20230331" decimals="INF" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTY0OTI2NzQ0ODQ3Mg_2e09b011-4a2d-46c4-875d-57f74bd38397">1</ix:nonFraction>% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board of Directors. As of March&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="i35ee5d15536b446d8e71cf4f2712b1ad_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTE0OQ_e43feb42-0cf1-4ce0-8563-278b94519455">508,608</ix:nonFraction> shares of common stock remained available for issuance under the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMjk1OQ_cb6673f8-e79f-4018-91c0-7adeeee8ece6" continuedAt="ia000d17606764503a4646e3124e963ae" escape="true">Stock option activity under the Company's 2019 Plan is set forth below:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i86e58e6aee304f9ea1341dc46a8946c1"><div><ix:continuation id="ia000d17606764503a4646e3124e963ae"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cd5e724cdb246d89edfa68105eaed87_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfMS0yLTEtMS02MjQ1NQ_526ab5d8-b3eb-4a10-a65b-a4aef16a9d37">1,421,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cd5e724cdb246d89edfa68105eaed87_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfMS00LTEtMS02MjQ1NQ_abe5cc60-92c8-427f-93d1-03120e25432d">12.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i55497019afe7489891af1088e9d0a6da_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfMS02LTEtMS02MjQ1NQ_7959b734-cfd6-41f0-8fe0-986496f22d4f">7.09</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cd5e724cdb246d89edfa68105eaed87_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfMS04LTEtMS02MjQ1NQ_6af0144c-61bb-40d8-809d-8cc6d67a9c48">483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfMi0yLTEtMS02MjQ1NQ_599e3d89-46be-4475-b44e-c008cec27dde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfMi00LTEtMS02MjQ1NQ_5e474fb5-b3d4-4147-9bec-6f288a6b7723">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfMy0yLTEtMS02MjQ1NQ_a8c36fd7-1cfc-49d3-9586-2710fec23382">93,335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfMy00LTEtMS02MjQ1NQ_a8000dc7-9597-4dc9-8b96-a565a537c9e7">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNC0yLTEtMS02MjQ1NQ_ab3f01d2-87fe-45c4-aec1-ffdc162e63eb">31,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNC00LTEtMS02MjQ1NQ_e37fdbc7-b0ec-433e-ab64-111733f6da51">14.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNS0yLTEtMS02MjQ1NQ_b2761165-5567-4a3e-844a-6ebf2e74f432">277,805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNS00LTEtMS02MjQ1NQ_a4b7c15c-1f4d-4e30-8d67-d0ab89885b23">17.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNi0yLTEtMS02MjQ1NQ_e8091f7d-9715-459a-90ac-a14f6b7d60e9">1,019,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNi00LTEtMS02MjQ1NQ_7f54e92e-b1d2-4dbb-827b-6bb696f63666">12.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNi02LTEtMS02MjQ1NQ_29fbc8ac-9c31-4360-acee-c147378b4663">6.97</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNi04LTEtMS02MjQ1NQ_c755a2fa-e54b-409b-8cc3-d6e1d4b394f9">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNy0yLTEtMS02MjQ1NQ_6693caa5-d70d-4eec-a929-5efa7e446594">1,019,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNy00LTEtMS02MjQ1NQ_0de947a2-e27c-4798-b0dc-99ebf2ca01bf">12.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNy02LTEtMS02MjQ1NQ_36db5a80-9123-4789-9887-9e97dfb649b1">6.97</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNy04LTEtMS02MjQ1NQ_7bf8cbbf-7447-44b3-bd29-b0b5470d3614">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfOC0yLTEtMS02MjQ1NQ_f0989c13-f5e2-4c05-b274-b9f54912a6e0">804,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfOC00LTEtMS02MjQ1NQ_e1d8cfda-e5fc-49ec-9b0e-b70d9c28b593">12.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfOC02LTEtMS02MjQ1NQ_4fdb9d0a-60b8-4364-935e-3186a50a9b1e">6.64</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfOC04LTEtMS02MjQ1NQ_c092b208-ad54-4399-9ac6-d6c298e9fa23">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were <ix:nonFraction unitRef="shares" contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTA5OTUxMTYzNzM3Mg_2c420f9a-81bd-4bef-bcce-cdebc4c2d7e0"><ix:nonFraction unitRef="shares" contextRef="i1acc384230fc42e6a9d187464e747867_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTA5OTUxMTYzNzM3Mg_538bc143-3e55-4fb6-835b-9b2c9562a7a6">no</ix:nonFraction></ix:nonFraction> stock options granted in the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The aggregate intrinsic value of options exercised during the three months ended March 31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="ic10d09e997d04be59819eb9f739c540e_I20220331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfNTQ5NzU1ODIyNDk0_432cf4ce-2b31-4795-84fe-f4aaf0079fb2">0.2</ix:nonFraction> million. There were no options exercised during the three months ended March 31, 2022. As of March&#160;31, 2023, total unrecognized compensation cost related to option awards was $<ix:nonFraction unitRef="usd" contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTUzOA_0303ec79-910e-4c7a-aa66-e9404f245a2f">1.1</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTYzNw_65b8d828-490e-4966-b316-31b4c65001c0">0.82</ix:nonNumeric>&#160;years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMjk2Mg_0c5e0f2e-a30a-4273-9df5-882dd1167d82" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i385f1d93cdab453180c8c50401ec671d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfMS0yLTEtMS02MjQ1NQ_1cb8ba4e-3b12-4dda-8494-9db66a371963">1,036,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i385f1d93cdab453180c8c50401ec671d_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfMS00LTEtMS02MjQ1NQ_0b964873-ea6b-4090-80a7-d952767adcb4">7.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i385f1d93cdab453180c8c50401ec671d_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfMS02LTEtMS02MjQ1NQ_05af3117-c7fd-48b4-95f3-0ae0217835f2">2,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfMi0yLTEtMS02MjQ1NQ_9ddeb35d-dd49-405c-a0dc-0973435f9efd">638,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfMi00LTEtMS02MjQ1NQ_67dd47f2-0d4b-42a0-87fa-ea6c032d0ae5">2.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfMy0yLTEtMS02MjQ1NQ_590d5795-47c6-4a02-be6d-2e394cc9b090">113,720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfMy00LTEtMS02MjQ1NQ_e87bdb74-1e33-48fb-b8db-80e2d5bd9edf">11.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfNC0yLTEtMS02MjQ1NQ_c83ef3e2-b363-4213-a9ec-b6f67c4531ad">66,903</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfNC00LTEtMS02MjQ1NQ_75ab58c9-49e6-40ca-9f8f-bc6b6406e48f">11.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1400e06e8cb4cce8e16afdae774fbd6_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfNS0yLTEtMS02MjQ1NQ_0b791f9a-4600-4aba-aa96-be9a96326e7c">1,494,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1400e06e8cb4cce8e16afdae774fbd6_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfNS00LTEtMS02MjQ1NQ_77e21367-ab28-4324-82f2-5fa02b3cc8e2">4.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1400e06e8cb4cce8e16afdae774fbd6_I20230331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfNS02LTEtMS02MjQ1NQ_c5d0e6f5-82a6-4d60-8320-827abf7715ce">3,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, all of the outstanding restricted stock units were unvested. The fair value of restricted stock units vested in each of the three months ended March 31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTA5OTUxMTYzNzExNQ_29ab61ca-a365-4cfd-aac7-795e685d9d8f"><ix:nonFraction unitRef="usd" contextRef="i59cad19a4f2e4767b2e7f56240d61b72_D20220101-20220331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTA5OTUxMTYzNzExNQ_89038c12-1973-45ad-abc8-8d89a94b5b69">0.3</ix:nonFraction></ix:nonFraction> million. The weighted average grant date fair value for restricted stock units granted in the three months ended March 31, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfNTQ5NzU1ODIzMTk1_39aaf77a-a32f-4165-bcd6-d604cb2e294b">2.30</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i59cad19a4f2e4767b2e7f56240d61b72_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTA5OTUxMTYzNzA5Mw_84a9ccef-4536-4ae1-b410-9a27976df71d">8.72</ix:nonFraction>, respectively. As of March&#160;31, 2023, total unrecognized compensation cost related to restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="ia1400e06e8cb4cce8e16afdae774fbd6_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTgzOA_10928c0e-8716-4039-9725-3fd56c7458be">6.2</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTkzNw_103a4f46-6c02-407b-8bd9-f9b275339b31">3.5</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMjk2Nw_4319a48a-0382-4016-b8a5-0d8a7ce22d21" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statements of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic458c78631fa444ea666b52d5645ae1d_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjAxMTQxYjdlMjFiOTQ5YTU5ZjA2NDlhZjcyMzczOTc4L3RhYmxlcmFuZ2U6MDExNDFiN2UyMWI5NDlhNTlmMDY0OWFmNzIzNzM5NzhfMi0yLTEtMS02MjQ1NQ_b0d3c9a5-6c8d-47a0-9124-24905315717d">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic58dee38f10d467fbc953d0b8e7713b1_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjAxMTQxYjdlMjFiOTQ5YTU5ZjA2NDlhZjcyMzczOTc4L3RhYmxlcmFuZ2U6MDExNDFiN2UyMWI5NDlhNTlmMDY0OWFmNzIzNzM5NzhfMi00LTEtMS02MjQ1NQ_8d894c99-594b-4f96-8bc7-30d5cc1cdddc">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23da898f496444b2a82b5eefd3e7d4f2_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjAxMTQxYjdlMjFiOTQ5YTU5ZjA2NDlhZjcyMzczOTc4L3RhYmxlcmFuZ2U6MDExNDFiN2UyMWI5NDlhNTlmMDY0OWFmNzIzNzM5NzhfMy0yLTEtMS02MjQ1NQ_ec21bb91-aba4-444c-8484-b980c1698fde">831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1e21f8e6db4d83b4cb8e0ef40e4ebe_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjAxMTQxYjdlMjFiOTQ5YTU5ZjA2NDlhZjcyMzczOTc4L3RhYmxlcmFuZ2U6MDExNDFiN2UyMWI5NDlhNTlmMDY0OWFmNzIzNzM5NzhfMy00LTEtMS02MjQ1NQ_7c2ae6c4-0cd4-422b-895f-787f5e4c7570">1,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie60dda0bce3a4221b4328da9ade954c1_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjAxMTQxYjdlMjFiOTQ5YTU5ZjA2NDlhZjcyMzczOTc4L3RhYmxlcmFuZ2U6MDExNDFiN2UyMWI5NDlhNTlmMDY0OWFmNzIzNzM5NzhfNC0yLTEtMS02MjQ1NQ_da6f9325-813f-46aa-a4f5-4848be15d947">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e8041ed528a46088f0c79a375de1fae_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjAxMTQxYjdlMjFiOTQ5YTU5ZjA2NDlhZjcyMzczOTc4L3RhYmxlcmFuZ2U6MDExNDFiN2UyMWI5NDlhNTlmMDY0OWFmNzIzNzM5NzhfNC00LTEtMS02MjQ1NQ_eb6c9e11-b407-4de0-a5d8-9d253ed00b79">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjAxMTQxYjdlMjFiOTQ5YTU5ZjA2NDlhZjcyMzczOTc4L3RhYmxlcmFuZ2U6MDExNDFiN2UyMWI5NDlhNTlmMDY0OWFmNzIzNzM5NzhfNS0yLTEtMS02MjQ1NQ_4727bcd0-c6f4-4097-9ff8-404d5f0173ea">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjAxMTQxYjdlMjFiOTQ5YTU5ZjA2NDlhZjcyMzczOTc4L3RhYmxlcmFuZ2U6MDExNDFiN2UyMWI5NDlhNTlmMDY0OWFmNzIzNzM5NzhfNS00LTEtMS02MjQ1NQ_9660ebc1-f0fd-4333-bdab-585dbf17bfa2">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ic6a5e7b0edc94c399549fe8f80e94568_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF82MS9mcmFnOmYyMjkzOGFiNjRkNjQ3NDM4NmYzZGY1OGM3ZGY0MmY4L3RleHRyZWdpb246ZjIyOTM4YWI2NGQ2NDc0Mzg2ZjNkZjU4YzdkZjQyZjhfMjIx_0ca4df6d-3d56-4492-982d-eef66d4d623b" continuedAt="ifeeced06d8594245b407f6e737df43e0" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifeeced06d8594245b407f6e737df43e0"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 28, 2023, the Company and Innovatus entered into the Third Loan Amendment.  Pursuant to the Third Loan Amendment, the Company prepaid $<ix:nonFraction unitRef="usd" contextRef="i0587f1e7aef2471cb273055cd67d1cb1_D20230428-20230428" decimals="-5" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF82MS9mcmFnOmYyMjkzOGFiNjRkNjQ3NDM4NmYzZGY1OGM3ZGY0MmY4L3RleHRyZWdpb246ZjIyOTM4YWI2NGQ2NDc0Mzg2ZjNkZjU4YzdkZjQyZjhfMzg0ODI5MDY5OTcyOA_f94e28ad-d083-48ad-9423-97d444fd49d6">10.0</ix:nonFraction>&#160;million of principal (Prepayment) and amended the 2017 Term Loan by, among other things:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">waiving the Prepayment Fee (as defined in the 2017 Term Loan, as amended) with respect to the Prepayment;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">revising the interest rate to the sum (the Basic Rate) of (a) the greater of The Wall Street Journal prime rate (the Prime Rate) or <ix:nonFraction unitRef="number" contextRef="ib55a36a6d42741f28786ba980d9e68d7_D20230428-20230428" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF82MS9mcmFnOmYyMjkzOGFiNjRkNjQ3NDM4NmYzZGY1OGM3ZGY0MmY4L3RleHRyZWdpb246ZjIyOTM4YWI2NGQ2NDc0Mzg2ZjNkZjU4YzdkZjQyZjhfMzg0ODI5MDY5OTc0Mw_08ebea45-64fd-4942-b53f-7a0535065814">8.0</ix:nonFraction>%, plus (b) <ix:nonFraction unitRef="number" contextRef="i7e4dbcbbf1954393ba5599909a82c6ed_I20230428" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF82MS9mcmFnOmYyMjkzOGFiNjRkNjQ3NDM4NmYzZGY1OGM3ZGY0MmY4L3RleHRyZWdpb246ZjIyOTM4YWI2NGQ2NDc0Mzg2ZjNkZjU4YzdkZjQyZjhfMzg0ODI5MDY5OTc0OQ_8118eb80-1f0b-4ce6-8309-3dce5910d0de">2.0</ix:nonFraction>%, of which <ix:nonFraction unitRef="number" contextRef="i7e4dbcbbf1954393ba5599909a82c6ed_I20230428" decimals="INF" name="exdx:DebtInstrumentStatedInterestRatePaidInKind" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF82MS9mcmFnOmYyMjkzOGFiNjRkNjQ3NDM4NmYzZGY1OGM3ZGY0MmY4L3RleHRyZWdpb246ZjIyOTM4YWI2NGQ2NDc0Mzg2ZjNkZjU4YzdkZjQyZjhfMzg0ODI5MDY5OTc1NQ_78a72369-0756-412b-9f45-74997589441b">1.5</ix:nonFraction>% will be payable in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until April 1, 2026;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">extending the interest-only period through March 2026 and the maturity date to December 31, 2026;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">decreasing the specified levels of revenue, as measured on the last day of each quarter on a rolling twelve-month basis, that the Company must achieve to satisfy the related financial covenants (the Revenue Covenant) in the 2017 Term Loan;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">removing the obligation to comply with the Revenue Covenant during any fiscal quarter if the Company maintains a minimum aggregate cash balance equal to fifty percent of the aggregate principal amount of the loan at all times during such quarter;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">providing the Company with a cure period in the event it breaches certain covenants; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">revising the definition of &#8220;Permitted Indebtedness&#8221; to permit the Company to broaden the limits on the Company&#8217;s ability to incur capitalized lease obligations, finance lease obligations, purchase money indebtedness or equipment financings without Innovatus&#8217;s prior written consent.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion of our financial condition and results of operations in conjunction with the unaudited condensed financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited financial statements and notes thereto for the year ended December 31, 2022 included in our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Looking Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and other parts of this quarterly report contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act). All statements other than statements of historical facts contained in this quarterly report, including statements regarding our future results of operations and financial position, business strategy, current and future product offerings, reimbursement and coverage, the expected benefits from our partnership or promotion arrangements with third parties, research and development costs, timing and likelihood of success and plans and objectives of management for future operations, are forward-looking statements. These statements are often identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; or &#8220;continue,&#8221; and similar expressions or variations. The forward-looking statements in this quarterly report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, operating results, business strategy, and short-term and long-term business operations and objectives. These forward-looking statements speak only as of the date of this quarterly report and are subject to a number of risks, uncertainties and assumptions, including those described in Part II, Item 1A, &#8220;Risk Factors.&#8221; The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand, several of which incorporate Cell-Bound Complement Activation Products (CB-CAPs) technology. Our goal is to enable healthcare providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketed under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand, our testing products allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases. We commercially launched our lead testing product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD, in 2012. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD enables differential diagnosis for patients presenting with symptoms indicative of a wide variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. Revenue from this product comprised 87% and 84% of our revenue for the three months ended March&#160;31, 2023 and 2022, respectively. There is an unmet need for rheumatologists to add clarity in their CTD clinical evaluation, and we believe there is a significant opportunity for our tests that enable the differential diagnosis of these diseases, particularly for potentially life-threatening diseases such as SLE.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform all of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tests in our approximately 13,000 square foot laboratory located in Vista, California, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). Our laboratory is certified for performance of high-complexity testing by CMS in accordance with CLIA and is licensed by all states requiring out-of-state licensure. Our clinical laboratory typically reports all AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing product results within five business days.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike many diagnostic sales forces that are trained only to understand the comparative benefits of their tests, the specialized backgrounds of our sales force coupled with our comprehensive training enables our sales representatives to interpret results from our de-identified patient test reports and provide unique insights in a highly tailored discussion with rheumatologists.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement for our testing services comes from several sources, including commercial payors (such as insurance companies and health maintenance organizations), government payors (such as Medicare and Medicaid), and patients. Reimbursement rates vary by product and payor.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception we have devoted substantially all of our efforts to developing and marketing products for the diagnosis, prognosis and monitoring of autoimmune diseases. For the three months ended March&#160;31, 2023 and 2022, we incurred net losses of $7.7 million and $10.3&#160;million, respectively, and we expect to continue to incur operating losses in the near term. Our operations have been funded primarily through equity financings, debt financings and revenue from product sales. We have never been profitable and, as of March&#160;31, 2023, we had $52.2&#160;million of cash and cash equivalents and an accumulated deficit of $263.2&#160;million. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our initial public offering (IPO) was completed in September 2019, raising net proceeds of approximately $50.4 million. In March 2021, we completed a secondary public offering of common stock for net proceeds of approximately $64.7 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the Company entered into a sales agreement (the Sales Agreement) with Cowen and Company, LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of our common stock having an aggregate offering price of up to $50.0 million. The Company is not obligated to sell any shares of common stock in the offering and, as of March&#160;31, 2023, the Company had not sold any shares of its common stock pursuant to the Sales Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Developments</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2023, we discontinued development of our AVISE&#174; RADR platform, including the associated clinical trials.</span></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting Our Performance</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there are several important factors that have impacted, and that we expect will impact, our operating performance and results of operations, including:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Reimbursement for Our Testing Products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payors, including both commercial payors and government payors. Payment from third-party payors differs depending on whether we are considered a "participating provider" (have entered into a contract with the payor) or a "non-participating provider" (do not have a contract with the payor). Payors will often reimburse non-participating providers at a lower amount than participating providers, if at all. We have received a substantial portion of our revenue from a limited number of commercial payors, most of which have not contracted with us to be a participating provider. In addition to the challenges described under the heading "Financial Overview - Revenue" in this Quarterly Report on Form 10-Q, historically, we have experienced situations where commercial payors proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payors have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract to serve as a participating provider, reimbursements are made pursuant to a negotiated fee schedule and are limited to only covered indications. If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payors, we may not be able to effectively increase our testing volume and revenue as expected. Additionally, changes in our estimated reimbursements for tests performed in prior periods can positively or negatively impact our revenue in the current period and cause our financial results to fluctuate.</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Continued Growth of Our Testing Products.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Since the launch of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD in 2012 and through March&#160;31, 2023, we have delivered approximately 750,000 of these tests. During the first quarter of 2023, 37,312 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests were delivered, representing approximately 20.7% growth over the same period in 2022. Revenue growth for our testing products will depend, in part, on our ability to continue to expand our base of ordering healthcare providers and increase our penetration with existing healthcare providers.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Development of Additional Testing Products. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on sales of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test to generate the significant majority of our revenue. We expect to continue to invest in research and development in order to develop additional testing products. Our success in developing new testing products will be important in our efforts to grow our business by expanding the potential market for our testing products and diversifying our sources of revenue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Maintain Meaningful Margin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;We seek to maintain meaningful margin through a continued focus on increasing operating leverage through the implementation of certain internal initiatives, such as leveraging validation, utility and reimbursement oriented clinical studies to facilitate payor coverage of our testing products. We plan to center our efforts around long-term reimbursement and average sales price (ASP) growth and seek to improve our per-test costs by focusing on profitable, core test offerings and limiting fixed costs and overhead. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Timing of Our Research and Development Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We conduct clinical studies to validate our new testing products, as well as ongoing clinical and outcome studies to further expand the published evidence to support our commercialized AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing products. We also expend funds to secure clinical samples that can be used in discovery, product development, clinical validation, utility and outcome studies. Our spending on experiments and clinical studies may vary substantially from quarter to quarter, as the timing of these research and development activities is difficult to predict. If a substantial number of clinical samples are obtained in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses will affect our financial results.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">How We Recognize Revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We record revenue on an accrual basis, using an estimate of the amount that we will ultimately realize, as determined based on a historical analysis of amounts collected by test and by payor, among other factors. Changes to such estimates may increase or decrease revenue recognized in future periods. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While each of these areas present significant opportunities for us, they also pose significant risks and challenges that we must address. We discuss many of these risks, uncertainties and other factors in the section entitled "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our experience to date, we expect some seasonal variations in our financial results due to a variety of factors, such as the year-end holiday period and other major holidays, vacation patterns of both patients and healthcare providers, including medical conferences, climate and weather conditions in our markets (for example excess sun exposure can cause flares in SLE), seasonal conditions that may affect medical practices and provider activity, including for example influenza outbreaks that may reduce the percentage of patients that can be seen, and other factors relating to the timing of patient benefit changes, as well as patient deductibles and co-insurance limits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Inflationary Environment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current inflationary environment has resulted in higher prices, which have impacted our costs incurred to generate revenue from our laboratory testing services, costs to attract and retain personnel, and other operating costs. The severity and duration of the current inflationary environment remains uncertain and may continue to impact our financial condition and results of operations.</span></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_73"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize revenue in accordance with the provisions of ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We record revenue on an accrual basis, using an estimate of the amount we will ultimately receive, as determined based on a historical analysis of amounts collected by test and by payor, among other factors. These assessments require significant judgment by management. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, we have derived nearly all of our revenue from the sale of our testing products, most of which is attributable to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test. We primarily market our testing products to rheumatologists in the United States. The rheumatologists who order our testing products and to whom results are reported are generally not responsible for payment for these products. The parties that pay for these services (payors) consist of commercial payors (e.g. insurance companies, health maintenance organizations, etc.), government payors (primarily Medicare and Medicaid), client payors (e.g. hospitals, other laboratories, etc.), and patient self-pay. Our service is completed upon the delivery of test results to the prescribing rheumatologists which triggers billing for the service.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to increase our revenue will depend on our ability to further penetrate the market for our current and future testing products, and increase our reimbursement and collection rates for tests delivered.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the quarter ended March 31, 2022, CMS agreed, effective April 1, 2022, to recognize a new PLA code for our protein-based test, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus. Noridian, our MAC, priced this PLA code at $1,085 per test. To determine pricing beyond 2022, CMS recommended crosswalking AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (0312U) to Vectra (81490) at a rate of $840.65 per test. This pricing was finalized on the 2023 CLFS and is effective from January 1, 2023 through December 31, 2025. The process for obtaining and maintaining consistent reimbursement for new tests can be uncertain, lengthy and time consuming. A pricing determination is not synonymous with a coverage determination. Having a price associated with the PLA code for any particular test does not secure coverage or reimbursement for that PLA code from Medicare or any other third-party payor.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In an effort to improve transparency regarding Medicare support of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus, on July 29, 2022, we submitted a formal request to Noridian for coverage of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test under the new PLA Code. On September 27, 2022, we received notice that Noridian has deemed our application for an LCD to be valid. Ultimately receiving a favorable LCD is uncertain and may be time-consuming, resource intensive and require multiple quarterly or annual periods to complete. In the meantime, we have continued to submit Medicare claims for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus, appeal denials and respond to requests for additional information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face challenges relating to commercial payor claim processing and revenue. Now that we are billing under our PLA code, we are experiencing an increase in denials due to unfavorable medical policy with certain plans, and we expect this situation to persist.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue represents the expenses associated with obtaining and testing patient specimens. The components of our costs of revenue include materials costs, direct labor, equipment, infrastructure expenses, shipping charges to transport specimens, blood specimen collections fees, royalties, depreciation and allocated overhead (including rent and utilities).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each payor, whether commercial, government, or individual, reimburses us at different amounts. These differences can be significant. As a result, our costs of revenue as a percentage of revenue may vary significantly from period to period due to the composition of payors for each period's billings.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our costs of revenue will increase year-over-year in the near-term as test volume increases. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist of personnel costs (including stock-based compensation expense), direct marketing expenses, accounting and legal expenses, consulting costs, and allocated overhead (including rent, information technology, depreciation and utilities).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our selling, general and administrative expenses will decrease year-over-year in the near-term as a result of cost saving initiatives which began in the fourth quarter of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include costs incurred to develop our technology, test products and product candidates, in addition to costs incurred to collect clinical specimens and conduct clinical studies to develop and support those products and product candidates. These costs consist of personnel costs (including stock-based compensation expense), materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead (including rent and utilities). We expense all research and development costs in the periods in which they are incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our research and development expenses will decrease year-over-year in the near-term as a result of cost saving initiatives which began in the fourth quarter of 2022 and the end of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> RADR program and related clinical studies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of cash and non-cash interest expense associated with our financing arrangements, including the borrowings under our amended loan and security agreement with Innovatus. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest income earned on our cash and cash equivalents.</span></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March&#160;31, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(978)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,936&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,073&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,137)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,706)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,679)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(638)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(598)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,688)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,272)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased $0.8&#160;million, or 8.0%, for the three months ended March&#160;31, 2023 compared to the three months ended March&#160;31, 2022, primarily due to an increase in test volume, partially offset by a decrease in ASP. The number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests delivered, which accounted for 87% of revenue and 84% of revenue in the three months ended March&#160;31, 2023 and 2022, respectively, increased to 37,312 tests delivered in the three months ended March&#160;31, 2023 compared to 30,903 tests delivered in the same 2022 period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Costs of revenue increased $0.1 million, or 1.9%, for the three months ended March&#160;31, 2023 compared to the three months ended March&#160;31, 2022. This increase was primarily due to an increase of $0.3 million in labor costs, partially offset by decreases of $0.1 million in materials and supplies and $0.1 million in allocated overhead. Gross margin as a percentage of revenue increased to 47.2% for the three months ended March&#160;31, 2023, compared to 44.0% for the three months ended March&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses decreased $0.3&#160;million, or 2.2%, for the three months ended March&#160;31, 2023 compared to the three months ended March&#160;31, 2022. This decrease was primarily due to decreases of $1.1 million in employee related expenses (including salaries, benefits and stock-based compensation), partially offset by increases of $0.6 million in commissions, $0.1 million in professional services and $0.1 million in allocated overhead. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased $1.0 million for the three months ended March&#160;31, 2023 compared to the three months ended March&#160;31, 2022. This decrease was primarily due to decreases of $0.7 million in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employee-related expenses (including salaries, benefits and stock based compensation), $0.1 million in clinical trial expenses, $0.1 million in laboratory expenses and $0.1 million in professional service fees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense remained substantially consistent for the three months ended March&#160;31, 2023 compared to the three months ended March&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income increased by $0.7 million for the three months ended March&#160;31, 2023 compared to the three months ended March&#160;31, 2022, primarily due to rising interest rates earned on invested cash and cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception. For the three months ended March&#160;31, 2023 and 2022, we incurred a net loss of $7.7 million and $10.3&#160;million, respectively, and we expect to incur additional losses and increased operating expenses in future periods. To date, we have generated only limited revenue, and we may never achieve revenue sufficient to offset our expenses. As of March&#160;31, 2023, we had an accumulated deficit of $263.2&#160;million and cash and cash equivalents of $52.2 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our funds are held in cash, money market funds and certificates of deposit.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since becoming public, our primary sources of capital have been cash inflows from product sales, sales of our common stock and, to a lesser extent, borrowings under our 2017 Term Loan. In April 2023, we further amended 2017 Term Loan, pursuant to which we prepaid $10.0 million of principal and amended additional terms of the agreement. See Note 9 to the unaudited condensed financial statements included in this Quarterly Report on Form 10-Q for additional information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our obligations under the Amended Loan Agreement are secured by a security interest in substantially all of our assets, including our intellectual property. The Amended Loan Agreement contains customary conditions to borrowing, events of default, and covenants, including covenants requiring us to maintain minimum liquidity of $2.0&#160;million, covenants to achieve certain minimum amounts of revenue (the performance covenant), and covenants limiting our ability to dispose of assets, undergo a change in control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of our capital stock, repurchase stock and make investments, in each case subject to certain exceptions. The consequences of failing to achieve the performance covenant will be cured if, (i) within thirty days of failing to achieve the performance covenant, we submit a new Board approved financial plan to Innovatus under which we are expected to break even on a cash flow basis prior to the maturity date, and (ii) within thirty days of the submission of such financial plan, we issue additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined in the Amended Loan Agreement. As of March&#160;31, 2023, we were in compliance with all covenants of the Amended Loan Agreement with Innovatus. In addition, upon the occurrence of an event of default, Innovatus, among other things, can declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working capital needs, capital expenditures and other general corporate purposes. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 15, 2022, the Company entered into the Sales Agreement, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $50.0 million. The Company is not obligated to sell any shares of Company common stock in the offering. As of March&#160;31, 2023, the Company has not sold any shares of its common stock pursuant to the Sales Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2020, we filed a registration statement on Form S-3 (Shelf Registration Statement) covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units. In March 2021, we completed a public offering of shares of our common stock, which shares were sold under the Shelf Registration Statement. Net proceeds from the offering were approximately $64.7 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Funding Requirements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary use of cash is to fund our operations as we continue to grow our business. We expect to continue to incur operating losses in the near term. In the short-term, we expect costs of revenue to increase year-over-year as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">test volume increases. We expect selling, general and administrative expenses and research and development expenses to decrease year-over-year as a result of cost saving initiatives which began in the fourth quarter of 2022. We believe we have sufficient laboratory capacity to support increased test volume. Cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our near- and longer-term liquidity requirements will continue to consist of working capital and general corporate expenses associated with the growth of our business, including payments we may be required to make upon the achievement of previously negotiated milestones associated with intellectual property we have licensed, payments related to non-cancelable purchase obligations with one supplier for reagents, payments related to our principal and interest under our long term borrowing arrangements, payments for operating leases related to our office and laboratory space in Vista, California and our office space in Carlsbad, California, and payments for finance leases related to our laboratory equipment. Based on our current business plan, we believe that our existing cash and cash equivalents and our anticipated future revenue, will be sufficient to meet our anticipated cash requirements for at least the next 12&#160;months from the date of this filing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimate of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties. Actual results could vary as a result of a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for our testing products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain and grow sales of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our products and support reimbursement efforts;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in working capital;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation, utility and outcome studies as well as the success of our development efforts; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we establish additional partnerships or in-license, acquire or invest in complementary businesses or products as well as the success of our existing partnerships and/or in-licenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate revenue to support our costs structure, we expect to finance our operations through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. If additional funding is required or desired, there can be no assurance that additional funds will be available to us on acceptable terms on a timely basis, if at all, or that we will generate sufficient cash from operations to adequately fund our operating needs or achieve or sustain profitability. If we are unable to raise additional capital or generate sufficient cash from operations to adequately fund our operations, we will need to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion plans or commercialization efforts. Doing so will likely have an unfavorable effect on our ability to execute on our business plan and could have a negative impact on our commercial and strategic relationships. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition, and results of operations could be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,749)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,574)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,087)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,207)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,691)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March&#160;31, 2023 was $9.7 million, primarily resulting from (i) our net loss of $7.7 million adjusted for non-cash charges of $2.0 million primarily related to stock-based compensation, depreciation, amortization, non-cash lease expense and non-cash interest and (ii) changes in our net operating assets of $4.1&#160;million primarily related to net increases in accounts receivable and accrued and other current liabilities, partially offset by net decreases in accounts payable and operating lease liabilities. The increase in accounts receivable was primarily due to our new revenue cycle management initiative to hold first quarter claims until the second quarter in order to optimize our appeals process.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March 31, 2022 was $8.6 million, primarily resulting from (i) our net loss of $10.3 million adjusted for non-cash charges of $2.1 million related to stock-based compensation, depreciation, amortization, non-cash lease expense and non-cash interest and (ii) changes in our net operating assets of $0.4 million primarily related to net increases in accounts receivables, partially offset by net decreases in prepaid expenses and other current assets and net increases in accounts payables.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the three months ended March&#160;31, 2023 and 2022 was $0.4&#160;million and $1.1&#160;million, respectively, due to net purchases of property and equipment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the three months ended March&#160;31, 2023 was $62,000, primarily resulting from payments on finance lease and notes payable obligations, partially offset by proceeds from ESPP purchases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the three months ended March 31, 2022 was $30,000, primarily resulting from payments on finance lease obligations and payment of taxes withheld on vested restricted stock units, partially offset by proceeds from ESPP purchases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Management Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with GAAP. The year-end condensed balance sheets data was derived from audited financial statements, but does not include all disclosures required by GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions, and any such differences may be material.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our critical accounting policies, please see the section entitled "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Estimates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" contained in our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no significant changes in our critical accounting policies and estimates during the three months ended March&#160;31, 2023 as compared to the critical accounting policies and estimates disclosed in the Management&#8217;s Discussion and Analysis of Financial Condition and Operations included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 20, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 2 to the unaudited condensed financial statements included in this Quarterly Report on Form 10-Q for a summary of changes in significant accounting policies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Jumpstart Our Business Startups Act of 2012 (the JOBS Act), contains provisions that, among other things, reduce certain reporting requirements for an "emerging growth company." The JOBS Act permits an "emerging growth company" such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our audited financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the Securities Act), which will occur in 2024. However, if certain events occur prior to the end of this five-year period, including if we become a "large accelerated filer" as defined in Rule&#160;12b-2 under the Exchange Act, our annual gross revenues exceed $1.235&#160;billion or we issue more than $1.0&#160;billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to this anniversary.</span></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_79"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that the information we are required to disclose in such reports is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer have concluded that as of March&#160;31, 2023, our disclosure controls and procedures were not effective at a reasonable level of assurance, to ensure that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, due to the material weakness in our internal control over financial reporting described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Material Weakness</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 13, 2022, management and the audit committee of our board of directors determined that we made certain errors in revenue resulting from erroneous and duplicate billings related to changes in billing practices. The errors were due to the inadequate design, implementation and precision of internal controls and procedures to evaluate and monitor the accounting for revenue recognition. As a result, revenue and accounts receivable were overstated and other liabilities were understated for the quarter and year to date periods ended June 30, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded that these were material errors in the financial statements requiring a restatement of the Form 10-Q for the three and six months ended June 30, 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, management has determined that this control deficiency constituted a material weakness and, as a result, management has concluded that, as of March&#160;31, 2023, our internal control over financial reporting was not effective based on the criteria in Internal Control Integrated Framework (2013) issued by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remediation Plan to Address the Material Weaknesses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has prepared and implemented the following remediation plan to address the material weakness as described below:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evaluated the staffing level, skills and qualification of accounting department personnel and are in the process of hiring an additional employee in our accounting department</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enhanced our existing control structure and processes for revenue recognition and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Improved the detailed review process of our revenue recognition models. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects. The weakness will not be considered remediated, however, until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting during the three months ended March&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls and Procedures</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div style="text-align:center"><span><br/></span></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_88"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently not a party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_91"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There have been no material changes to the risk factors disclosed in Part I, Item 1A, "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2022, other than those set forth below:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have identified a material weakness in our internal control over financial reporting and determined that our disclosure controls and procedures were ineffective as of March&#160;31, 2023, in connection with the restatement of our financial statements as of and for the three and six months ended June 30, 2022. In the future, we may identify additional material weaknesses or otherwise fail to maintain an effective system of internal control over financial reporting or adequate disclosure controls and procedures, which may result in material errors in our financial statements or cause us to fail to meet our period reporting obligations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time period specified in the SEC&#8217;s rules and forms, and that the information required to be disclosed by us in such reports is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2022, management and the audit committee of our board of directors determined that we made certain errors in revenue resulting from erroneous and duplicate billings related to changes in billing practices. The errors were due to the inadequate design, implementation and precision of internal controls and procedures to evaluate and monitor the accounting for revenue recognition. As a result, revenue and accounts receivable were overstated and other liabilities was understated for the quarter and year to date periods ended June 30, 2022. We then determined that there were material errors in the financial statements requiring a restatement of the Form 10-Q for the three and six months ended June 30, 2022. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, management has determined that this control deficiency constituted a material weakness and, as a result, management has concluded that, as of March&#160;31, 2023, our internal control over financial reporting was not effective based on the criteria in Internal Control Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is actively engaged in the planning for, and implementation of, remediation efforts to address the material weakness. The remediation plan includes: (i) evaluating the staffing level, skills and qualification of accounting department personnel, (ii) enhancement of our existing control structure and processes for revenue recognition and (iii) improving the detailed review process of our revenue recognition models. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to comply with the applicable requirements of the Sarbanes-Oxley Act of 2002 or if we are unable to maintain effective internal control over financial reporting, we may not be able to produce timely and accurate financial statements or guarantee that information required to be disclosed by us in the reports that we file with the SEC, is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms. Any failure of our internal control over financial reporting or disclosure controls and procedures could cause our investors to lose confidence in our publicly reported information, cause the market price of our stock to decline, expose us to sanctions or investigations by the SEC or other regulatory authorities, or impact our results of operations.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div><span><br/></span></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_94"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Filing Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519252366/d769261dex31.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/23/2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000017/ex31-amendedandrestatedbyl.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/22/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex41.htm">Specimen stock certificate evidencing the shares of common stock.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex42.htm">Amended and Restated Investors' Rights Agreement, dated July 12, 2019, by and among the Company and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex43.htm">Amended and Restated Stockholders' Agreement, dated July 12, 2019, by and among the Company and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex44.htm">Form of Common Stock Purchase Warrant issued to investors by the Company in connection with private placement financings.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex48.htm">Form of Common Stock Purchase Warrant to purchase common stock issued to investors by the Company in 2016.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000094/ex45-formofprexfundedwarra.htm">Form of Exchange Warrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/9/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473723000041/exhibit101to042823thirdame.htm">Third Amendment to Loan and Security Agreement dated April 28, 2023, by and among Innovatus Life Sciences Lending I, LP, other lenders and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/4/2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn311-33123.htm">Certificate of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn312-33123.htm">Certificate of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn321-33123.htm">Certifications Pursuant to U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023, has been formatted in Inline XBRL.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">* &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="ic6a5e7b0edc94c399549fe8f80e94568_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:52.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.198%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXAGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May&#160;15, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Aballi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Aballi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May&#160;15, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kamal Adawi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>xgn311-33123.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2bf575f3095040b9b2280cfdaf2bcc97_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I, John Aballi, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I have reviewed this Quarterly Report on Form 10-Q of Exagen Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:21pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;15, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Aballi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Aballi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>xgn312-33123.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i18c04eb382ad4eb6b5f979fb043ff50a_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I, Kamal Adawi, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I have reviewed this Quarterly Report on Form 10-Q of Exagen Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:21pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;15, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>xgn321-33123.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6f550e24465e4784b44afb3cd533164c_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:201%">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the &#34;Company&#34;) hereby certifies, to such officer's knowledge, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The accompanying quarterly report on Form 10-Q of the Company for the quarterly period ended March&#160;31, 2023 (the &#34;Report&#34;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; May&#160;15, 2023</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Aballi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Aballi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:20pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the &#34;Company&#34;) hereby certifies, to such officer's knowledge, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The accompanying quarterly report on Form 10-Q of the Company for the quarterly period ended March&#160;31, 2023 (the &#34;Report&#34;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; May&#160;15, 2023</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:20pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>exdx-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:986b824d-5d9a-48e8-aa5f-764c09336517,g:f595c211-a573-4e45-813e-7a98f9aeca2c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exdx="http://www.exagen.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exagen.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.exagen.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedBalanceSheets" roleURI="http://www.exagen.com/role/UnauditedCondensedBalanceSheets">
        <link:definition>0000002 - Statement - Unaudited Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedBalanceSheetsParenthetical" roleURI="http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Unaudited Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedStatementsofOperations" roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations">
        <link:definition>0000004 - Statement - Unaudited Condensed Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedStatementsofStockholdersEquity" roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity">
        <link:definition>0000005 - Statement - Unaudited Condensed Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedStatementsofCashFlows" roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Unaudited Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.exagen.com/role/Organization">
        <link:definition>0000007 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformation" roleURI="http://www.exagen.com/role/OtherFinancialInformation">
        <link:definition>0000009 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.exagen.com/role/Borrowings">
        <link:definition>0000010 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.exagen.com/role/CommitmentandContingencies">
        <link:definition>0000011 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exagen.com/role/FairValueMeasurements">
        <link:definition>0000012 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.exagen.com/role/StockholdersEquity">
        <link:definition>0000013 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlan" roleURI="http://www.exagen.com/role/StockOptionPlan">
        <link:definition>0000014 - Disclosure - Stock Option Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.exagen.com/role/SubsequentEvents">
        <link:definition>0000015 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000016 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000017 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.exagen.com/role/OtherFinancialInformationTables">
        <link:definition>0000018 - Disclosure - Other Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.exagen.com/role/BorrowingsTables">
        <link:definition>0000019 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exagen.com/role/FairValueMeasurementsTables">
        <link:definition>0000020 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.exagen.com/role/StockholdersEquityTables">
        <link:definition>0000021 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanTables" roleURI="http://www.exagen.com/role/StockOptionPlanTables">
        <link:definition>0000022 - Disclosure - Stock Option Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.exagen.com/role/OrganizationDetails">
        <link:definition>0000023 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails">
        <link:definition>0000024 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000025 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails">
        <link:definition>0000026 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>0000027 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSecuritiesDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails">
        <link:definition>0000028 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPrepaidExpensesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails">
        <link:definition>0000029 - Disclosure - Other Financial Information - Prepaid Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPropertyandEquipmentDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails">
        <link:definition>0000030 - Disclosure - Other Financial Information - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationNarrativeDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails">
        <link:definition>0000031 - Disclosure - Other Financial Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails">
        <link:definition>0000032 - Disclosure - Other Financial Information - Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails">
        <link:definition>0000033 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsFutureMinimumPaymentsDetails" roleURI="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails">
        <link:definition>0000034 - Disclosure - Borrowings - Future Minimum Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesDetails" roleURI="http://www.exagen.com/role/CommitmentandContingenciesDetails">
        <link:definition>0000035 - Disclosure - Commitment and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails">
        <link:definition>0000036 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>0000037 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofOutstandingWarrantsDetails" roleURI="http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails">
        <link:definition>0000038 - Disclosure - Stockholders' Equity - Schedule of Outstanding Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanNarrativeDetails" roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails">
        <link:definition>0000039 - Disclosure - Stock Option Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockOptionActivityDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails">
        <link:definition>0000040 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanRestrictedStockUnitsDetails" roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails">
        <link:definition>0000041 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockBasedCompensationExpenseDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails">
        <link:definition>0000042 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.exagen.com/role/SubsequentEventsDetails">
        <link:definition>0000043 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exdx_HealthcareInsurersMember" abstract="true" name="HealthcareInsurersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentPrepaymentPremiumPercentage" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_AlleghenyHealthNetworkResearchInstituteMember" abstract="true" name="AlleghenyHealthNetworkResearchInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AHNCollaborationMember" abstract="true" name="AHNCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exdx_ExpirationDec72025Member" abstract="true" name="ExpirationDec72025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_CollaborationAgreementAnnualCollaborationFee" abstract="false" name="CollaborationAgreementAnnualCollaborationFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_NonCashLeaseExpense" abstract="false" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_PrometheusLaboratoriesIncMember" abstract="true" name="PrometheusLaboratoriesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_NoExpirationMember" abstract="true" name="NoExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" abstract="false" name="DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" abstract="false" name="IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_AVISECTDTestMember" abstract="true" name="AVISECTDTestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercisedNet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_AdvancePayment" abstract="false" name="AdvancePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_AccruedLiabilitiesClinicalStudyCurrent" abstract="false" name="AccruedLiabilitiesClinicalStudyCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_EquipmentPurchasedUnderNotesPayableObligations" abstract="false" name="EquipmentPurchasedUnderNotesPayableObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AccruedPurchaseGoodsAndServicesCurrent" abstract="false" name="AccruedPurchaseGoodsAndServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_EquipmentNotesPayableMember" abstract="true" name="EquipmentNotesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" abstract="false" name="IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExpirationApr12026Member" abstract="true" name="ExpirationApr12026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_ExpirationSep72024Member" abstract="true" name="ExpirationSep72024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_CollaborationAgreementCollaborationExpenses" abstract="false" name="CollaborationAgreementCollaborationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" abstract="false" name="DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_InnovatusLifeSciencesLendingFundMember" abstract="true" name="InnovatusLifeSciencesLendingFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_PrepaidMaintenanceAndInsuranceContracts" abstract="false" name="PrepaidMaintenanceAndInsuranceContracts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" abstract="false" name="PurchaseObligationAnnualIncreaseInCommitmentPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_LongTermDebtUndiscountedInterestAmount" abstract="false" name="LongTermDebtUndiscountedInterestAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_MedicareAdvantageMember" abstract="true" name="MedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_RoyaltyObligationPercentageOfSales" abstract="false" name="RoyaltyObligationPercentageOfSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_DebtInstrumentPaidInKindLoansIssued" abstract="false" name="DebtInstrumentPaidInKindLoansIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_LongTermDebtIncludingUndiscountedInterest" abstract="false" name="LongTermDebtIncludingUndiscountedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_IncentiveAwardPlan2019Member" abstract="true" name="IncentiveAwardPlan2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_ExpirationJan192026Member" abstract="true" name="ExpirationJan192026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentStatedInterestRatePaidInKind" abstract="false" name="DebtInstrumentStatedInterestRatePaidInKind" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" abstract="false" name="DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_BlueShieldMember" abstract="true" name="BlueShieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_OtherLongTermDebtMember" abstract="true" name="OtherLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ClientMember" abstract="true" name="ClientMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_CowenEquityDistributionAgreementMember" abstract="true" name="CowenEquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ExpirationMar312026Member" abstract="true" name="ExpirationMar312026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantRevenuePerformancePeriod" abstract="false" name="DebtInstrumentCovenantRevenuePerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_DebtInstrumentNumberOfMonthlyInstallments" abstract="false" name="DebtInstrumentNumberOfMonthlyInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exdx_Government1Member" abstract="true" name="Government1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_Term2017Member" abstract="true" name="Term2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_TwoMajorSuppliersMember" abstract="true" name="TwoMajorSuppliersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>exdx-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:986b824d-5d9a-48e8-aa5f-764c09336517,g:f595c211-a573-4e45-813e-7a98f9aeca2c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedBalanceSheets" xlink:type="simple" xlink:href="exdx-20230331.xsd#UnauditedCondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5da1da0a-4256-4cfb-8fba-21fd081da241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_afeae530-5fd1-4ed1-9767-a03fc05391dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5da1da0a-4256-4cfb-8fba-21fd081da241" xlink:to="loc_us-gaap_StockholdersEquity_afeae530-5fd1-4ed1-9767-a03fc05391dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d11c585d-0ded-4ed2-b7f3-d984d247e781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5da1da0a-4256-4cfb-8fba-21fd081da241" xlink:to="loc_us-gaap_Liabilities_d11c585d-0ded-4ed2-b7f3-d984d247e781" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2de3e329-abc1-4fef-a5f5-f087efce7e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5da1da0a-4256-4cfb-8fba-21fd081da241" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2de3e329-abc1-4fef-a5f5-f087efce7e7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_34403448-f14e-4344-b41e-da0e73a5673b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ed31eba2-6d6f-45e4-aaaf-69b0a0f9c133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_34403448-f14e-4344-b41e-da0e73a5673b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ed31eba2-6d6f-45e4-aaaf-69b0a0f9c133" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7e0c1dbd-a5c1-4518-a234-69714bdac82f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_34403448-f14e-4344-b41e-da0e73a5673b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7e0c1dbd-a5c1-4518-a234-69714bdac82f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e2413f6c-661a-4c3a-8353-36045e063368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_34403448-f14e-4344-b41e-da0e73a5673b" xlink:to="loc_us-gaap_AssetsCurrent_e2413f6c-661a-4c3a-8353-36045e063368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f331cd3c-e4da-4caf-afe8-c70153db6472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_34403448-f14e-4344-b41e-da0e73a5673b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f331cd3c-e4da-4caf-afe8-c70153db6472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d9e104df-978d-4c78-806f-9b1868827fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c1e50210-e312-469c-895a-1e68ecdd61eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d9e104df-978d-4c78-806f-9b1868827fd2" xlink:to="loc_us-gaap_LongTermDebtCurrent_c1e50210-e312-469c-895a-1e68ecdd61eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_640ef123-9cbf-449f-b330-d1cd5f8d3c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d9e104df-978d-4c78-806f-9b1868827fd2" xlink:to="loc_us-gaap_AccountsPayableCurrent_640ef123-9cbf-449f-b330-d1cd5f8d3c0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_aa52a7b5-9f35-4673-b25c-8228bd93e5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d9e104df-978d-4c78-806f-9b1868827fd2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_aa52a7b5-9f35-4673-b25c-8228bd93e5c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_081e4e43-c92b-43d8-8ba9-7c85ffc096f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d9e104df-978d-4c78-806f-9b1868827fd2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_081e4e43-c92b-43d8-8ba9-7c85ffc096f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_17dcf0a5-479e-46eb-b03c-799038b63fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_bf7831ae-3748-46d4-88ef-95b745e7d24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_17dcf0a5-479e-46eb-b03c-799038b63fa3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_bf7831ae-3748-46d4-88ef-95b745e7d24d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_628d0ad6-7e5f-48db-923b-0c8175479ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_17dcf0a5-479e-46eb-b03c-799038b63fa3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_628d0ad6-7e5f-48db-923b-0c8175479ff5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_59de1c63-69df-4565-8d46-7a62fbf1b0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_17dcf0a5-479e-46eb-b03c-799038b63fa3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_59de1c63-69df-4565-8d46-7a62fbf1b0b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1c1c5c83-bab9-4c85-a86d-d59b4c30d7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_17dcf0a5-479e-46eb-b03c-799038b63fa3" xlink:to="loc_us-gaap_LiabilitiesCurrent_1c1c5c83-bab9-4c85-a86d-d59b4c30d7a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dbd0256c-51eb-4e9c-86c3-81d5ce03bc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_302d99b0-6770-450c-80b3-609806b8b766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbd0256c-51eb-4e9c-86c3-81d5ce03bc9e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_302d99b0-6770-450c-80b3-609806b8b766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ec05e5f6-bad0-41d0-978f-c7005e57446e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbd0256c-51eb-4e9c-86c3-81d5ce03bc9e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ec05e5f6-bad0-41d0-978f-c7005e57446e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_bc9018e1-783a-4d40-889c-8f71f9e7aebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbd0256c-51eb-4e9c-86c3-81d5ce03bc9e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_bc9018e1-783a-4d40-889c-8f71f9e7aebc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eeaa3b4b-7dc6-4dd5-8c35-a6ef75f09523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_88adc478-7609-4653-b4fe-e5a301c91df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eeaa3b4b-7dc6-4dd5-8c35-a6ef75f09523" xlink:to="loc_us-gaap_AdditionalPaidInCapital_88adc478-7609-4653-b4fe-e5a301c91df9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9ac6edfc-8e65-4698-bc71-0ecd8b5810f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eeaa3b4b-7dc6-4dd5-8c35-a6ef75f09523" xlink:to="loc_us-gaap_CommonStockValue_9ac6edfc-8e65-4698-bc71-0ecd8b5810f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e1f24a7f-b4fd-4fef-992b-209f7d20238c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eeaa3b4b-7dc6-4dd5-8c35-a6ef75f09523" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e1f24a7f-b4fd-4fef-992b-209f7d20238c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5c1f1fc9-4efe-4c77-a0ba-42acc8a9b7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eeaa3b4b-7dc6-4dd5-8c35-a6ef75f09523" xlink:to="loc_us-gaap_PreferredStockValue_5c1f1fc9-4efe-4c77-a0ba-42acc8a9b7ea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="simple" xlink:href="exdx-20230331.xsd#UnauditedCondensedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_49cc6d2b-c956-4388-a298-d652728f720d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0eca99e9-9cca-4141-8ecf-8f112c24061b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_49cc6d2b-c956-4388-a298-d652728f720d" xlink:to="loc_us-gaap_CostsAndExpenses_0eca99e9-9cca-4141-8ecf-8f112c24061b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fe2f0076-41f0-4362-83a8-31c200b43be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_49cc6d2b-c956-4388-a298-d652728f720d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fe2f0076-41f0-4362-83a8-31c200b43be1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_53afed2e-3577-4f24-b1aa-9b581036c414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ad39bfb1-3d61-472c-bdee-96518b7eb6be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_53afed2e-3577-4f24-b1aa-9b581036c414" xlink:to="loc_us-gaap_InterestExpense_ad39bfb1-3d61-472c-bdee-96518b7eb6be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8bb05c3b-12b6-477a-9d99-4c36b04cd7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_53afed2e-3577-4f24-b1aa-9b581036c414" xlink:to="loc_us-gaap_OperatingIncomeLoss_8bb05c3b-12b6-477a-9d99-4c36b04cd7ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5cff18f4-9c44-422e-8964-159e178fa530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_53afed2e-3577-4f24-b1aa-9b581036c414" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5cff18f4-9c44-422e-8964-159e178fa530" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f236a544-8cbc-4f6f-bf31-400fc8e9db72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_255dc3ce-1774-4cfe-aaa7-6c978d20a2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f236a544-8cbc-4f6f-bf31-400fc8e9db72" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_255dc3ce-1774-4cfe-aaa7-6c978d20a2d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_79dddea5-2081-4ef1-943b-ff926a238bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f236a544-8cbc-4f6f-bf31-400fc8e9db72" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_79dddea5-2081-4ef1-943b-ff926a238bef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6965ae42-ffd5-4750-8637-8d9fee504eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f236a544-8cbc-4f6f-bf31-400fc8e9db72" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6965ae42-ffd5-4750-8637-8d9fee504eb3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20230331.xsd#UnauditedCondensedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a3b815cf-25df-4a4d-8d57-898e57115ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_44d8b599-5455-4d07-abc6-1076b809c17e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a3b815cf-25df-4a4d-8d57-898e57115ae2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_44d8b599-5455-4d07-abc6-1076b809c17e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_437ac9d1-3aed-426e-a6e2-0d0fa565d985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a3b815cf-25df-4a4d-8d57-898e57115ae2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_437ac9d1-3aed-426e-a6e2-0d0fa565d985" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3ce894e1-353f-4d8b-93c9-b180a1293d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a3b815cf-25df-4a4d-8d57-898e57115ae2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3ce894e1-353f-4d8b-93c9-b180a1293d5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db5f83aa-0978-40ae-94ea-fb5182c27f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NonCashLeaseExpense_b16da8dd-c4b1-4b11-84a7-00ad384339e9" xlink:href="exdx-20230331.xsd#exdx_NonCashLeaseExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db5f83aa-0978-40ae-94ea-fb5182c27f48" xlink:to="loc_exdx_NonCashLeaseExpense_b16da8dd-c4b1-4b11-84a7-00ad384339e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_2faf0608-f00d-46e3-8cb1-65654d38ae63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db5f83aa-0978-40ae-94ea-fb5182c27f48" xlink:to="loc_us-gaap_PaidInKindInterest_2faf0608-f00d-46e3-8cb1-65654d38ae63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0c584023-07ed-4cb9-9e36-f70f3a1f690f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db5f83aa-0978-40ae-94ea-fb5182c27f48" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0c584023-07ed-4cb9-9e36-f70f3a1f690f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_240d9f13-7765-4c37-8714-6ff907485c78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db5f83aa-0978-40ae-94ea-fb5182c27f48" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_240d9f13-7765-4c37-8714-6ff907485c78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1e46caf1-1b08-4f7b-8b2c-fa7ed3891c25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db5f83aa-0978-40ae-94ea-fb5182c27f48" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1e46caf1-1b08-4f7b-8b2c-fa7ed3891c25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_55c554b3-4e7f-4af9-80b2-cbe1001972ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db5f83aa-0978-40ae-94ea-fb5182c27f48" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_55c554b3-4e7f-4af9-80b2-cbe1001972ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_5c86bba8-6a05-4360-ab04-022a5a35ce97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db5f83aa-0978-40ae-94ea-fb5182c27f48" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_5c86bba8-6a05-4360-ab04-022a5a35ce97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_b1fe4b32-0be7-42d5-b59d-a07f75286e9f" xlink:href="exdx-20230331.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db5f83aa-0978-40ae-94ea-fb5182c27f48" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_b1fe4b32-0be7-42d5-b59d-a07f75286e9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d9fd77e0-3177-4805-a57f-d47e392131da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db5f83aa-0978-40ae-94ea-fb5182c27f48" xlink:to="loc_us-gaap_NetIncomeLoss_d9fd77e0-3177-4805-a57f-d47e392131da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_45cff85e-081f-4e77-973d-212eb7f5db65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db5f83aa-0978-40ae-94ea-fb5182c27f48" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_45cff85e-081f-4e77-973d-212eb7f5db65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_acefcadc-b1e6-423d-a9c3-330fdc85ea9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db5f83aa-0978-40ae-94ea-fb5182c27f48" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_acefcadc-b1e6-423d-a9c3-330fdc85ea9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7bb89445-6d21-4156-a3c7-c1053a1659a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db5f83aa-0978-40ae-94ea-fb5182c27f48" xlink:to="loc_us-gaap_ShareBasedCompensation_7bb89445-6d21-4156-a3c7-c1053a1659a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_36530f14-9b8d-4573-87bf-806176588a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_db5f83aa-0978-40ae-94ea-fb5182c27f48" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_36530f14-9b8d-4573-87bf-806176588a72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6689d1a3-cc3e-4940-9908-0fa64be6257f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_d069b20d-94b9-4843-bdd0-98624d551b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6689d1a3-cc3e-4940-9908-0fa64be6257f" xlink:to="loc_us-gaap_ProceedsFromStockPlans_d069b20d-94b9-4843-bdd0-98624d551b86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_081bb523-769b-44ac-8416-a1e08308a872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6689d1a3-cc3e-4940-9908-0fa64be6257f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_081bb523-769b-44ac-8416-a1e08308a872" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_604f1089-4883-4fa4-83cd-1f0cf9e6d6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6689d1a3-cc3e-4940-9908-0fa64be6257f" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_604f1089-4883-4fa4-83cd-1f0cf9e6d6e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_f40248ab-2b60-494a-a26e-1f928c14c6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6689d1a3-cc3e-4940-9908-0fa64be6257f" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_f40248ab-2b60-494a-a26e-1f928c14c6cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ca972f4a-f2f0-4b4b-9598-05bd01f41466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6689d1a3-cc3e-4940-9908-0fa64be6257f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ca972f4a-f2f0-4b4b-9598-05bd01f41466" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f700f44-24a1-4136-8bed-7945f6797bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cc0a5175-2290-4de2-9b71-51e500a42a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f700f44-24a1-4136-8bed-7945f6797bb3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cc0a5175-2290-4de2-9b71-51e500a42a33" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a8c43cca-00fc-4d39-8496-a26b818ca221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_f4f4873b-8d51-4d97-af9a-03f2951fa39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a8c43cca-00fc-4d39-8496-a26b818ca221" xlink:to="loc_us-gaap_RestrictedCash_f4f4873b-8d51-4d97-af9a-03f2951fa39a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_39453f68-0fe5-4dc6-83c2-1d9e51635ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a8c43cca-00fc-4d39-8496-a26b818ca221" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_39453f68-0fe5-4dc6-83c2-1d9e51635ee2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#OtherFinancialInformationPrepaidExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_37e63436-a07d-4717-af08-04abc02e614d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_4df8b697-eb90-412c-89af-e69c4a79693a" xlink:href="exdx-20230331.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_37e63436-a07d-4717-af08-04abc02e614d" xlink:to="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_4df8b697-eb90-412c-89af-e69c4a79693a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties_77184e40-4682-42d0-8531-d664700e93a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRoyalties"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_37e63436-a07d-4717-af08-04abc02e614d" xlink:to="loc_us-gaap_PrepaidRoyalties_77184e40-4682-42d0-8531-d664700e93a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_15d67096-fb0b-460b-9fd9-118978131164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_37e63436-a07d-4717-af08-04abc02e614d" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_15d67096-fb0b-460b-9fd9-118978131164" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_3af4398d-8aca-428c-9f86-04a6a63009ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_37e63436-a07d-4717-af08-04abc02e614d" xlink:to="loc_us-gaap_OtherAssetsCurrent_3af4398d-8aca-428c-9f86-04a6a63009ed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#OtherFinancialInformationPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d70c2eda-d6fa-46df-9d04-e84a999a0542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_831f2b97-66cd-4e09-940e-d68b551753e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d70c2eda-d6fa-46df-9d04-e84a999a0542" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_831f2b97-66cd-4e09-940e-d68b551753e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_fb1aa142-571a-4c5f-a0d4-07b9e32bf8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d70c2eda-d6fa-46df-9d04-e84a999a0542" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_fb1aa142-571a-4c5f-a0d4-07b9e32bf8a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_890963e5-3320-445f-97b2-c08d7a54079d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_09028ec7-8158-44cb-9723-4a20bd165af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_890963e5-3320-445f-97b2-c08d7a54079d" xlink:to="loc_us-gaap_AccruedSalariesCurrent_09028ec7-8158-44cb-9723-4a20bd165af5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_e12421ff-0b11-4138-a9b7-78071846dfbe" xlink:href="exdx-20230331.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_890963e5-3320-445f-97b2-c08d7a54079d" xlink:to="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_e12421ff-0b11-4138-a9b7-78071846dfbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_43b37d10-798a-49fd-9ab1-665490f4d1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_890963e5-3320-445f-97b2-c08d7a54079d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_43b37d10-798a-49fd-9ab1-665490f4d1b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_f65fc284-a3b3-4846-a2e3-03dd2a127ca4" xlink:href="exdx-20230331.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_890963e5-3320-445f-97b2-c08d7a54079d" xlink:to="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_f65fc284-a3b3-4846-a2e3-03dd2a127ca4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_b8cc91ff-49ee-45a5-9dd6-5689e6fb483a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_890963e5-3320-445f-97b2-c08d7a54079d" xlink:to="loc_us-gaap_InterestPayableCurrent_b8cc91ff-49ee-45a5-9dd6-5689e6fb483a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_70ad964b-810b-4810-b99c-319faee36ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_890963e5-3320-445f-97b2-c08d7a54079d" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_70ad964b-810b-4810-b99c-319faee36ac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_43aca17c-6857-4909-b5bf-b39da469ed34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_890963e5-3320-445f-97b2-c08d7a54079d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_43aca17c-6857-4909-b5bf-b39da469ed34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_b974f1d0-c205-487b-9d91-841d6bd39d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_890963e5-3320-445f-97b2-c08d7a54079d" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_b974f1d0-c205-487b-9d91-841d6bd39d0e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#BorrowingsFutureMinimumPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_660c63c2-cbaa-4b7a-a3f9-b9d9e018e0af" xlink:href="exdx-20230331.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2189466a-4b17-40ce-bab7-49c62ca836a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_660c63c2-cbaa-4b7a-a3f9-b9d9e018e0af" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2189466a-4b17-40ce-bab7-49c62ca836a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_a21ce77e-9d20-4a3d-aeb3-7fab57114357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_660c63c2-cbaa-4b7a-a3f9-b9d9e018e0af" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_a21ce77e-9d20-4a3d-aeb3-7fab57114357" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c76ee4d0-03b1-46ab-b03e-cd047c3c3e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_660c63c2-cbaa-4b7a-a3f9-b9d9e018e0af" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c76ee4d0-03b1-46ab-b03e-cd047c3c3e12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_528fcbbb-47e7-4ff2-9193-d046931a871e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_660c63c2-cbaa-4b7a-a3f9-b9d9e018e0af" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_528fcbbb-47e7-4ff2-9193-d046931a871e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e6da6caf-f827-439b-b452-e7a1602ac585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_bd74ec98-4261-4ae8-9a97-3fe713c03024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e6da6caf-f827-439b-b452-e7a1602ac585" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_bd74ec98-4261-4ae8-9a97-3fe713c03024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_8aa27b5c-e4f6-4767-85d0-040cd6a70fe9" xlink:href="exdx-20230331.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e6da6caf-f827-439b-b452-e7a1602ac585" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_8aa27b5c-e4f6-4767-85d0-040cd6a70fe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_26eb31ff-f744-4ea4-8a45-c1f82021cfef" xlink:href="exdx-20230331.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e6da6caf-f827-439b-b452-e7a1602ac585" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_26eb31ff-f744-4ea4-8a45-c1f82021cfef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_84c4344d-bff6-49af-bcb6-7837ce6865ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3c253844-8c89-41a2-9c8c-0010ddf90137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_84c4344d-bff6-49af-bcb6-7837ce6865ad" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3c253844-8c89-41a2-9c8c-0010ddf90137" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>exdx-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:986b824d-5d9a-48e8-aa5f-764c09336517,g:f595c211-a573-4e45-813e-7a98f9aeca2c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exdx-20230331.xsd#UnauditedCondensedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="extended" id="ia7c445b895e5474cafeec87fd8369696_UnauditedCondensedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_91cc3f75-8818-4cb7-995b-7fa3e86a9852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91cc3f75-8818-4cb7-995b-7fa3e86a9852" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cd79ba0c-8580-4283-bc55-7a95ce825e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cd79ba0c-8580-4283-bc55-7a95ce825e56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9fe80d2e-ea65-48e6-b0d7-151bc208244d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_StockholdersEquity_9fe80d2e-ea65-48e6-b0d7-151bc208244d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_2e8c58c3-d6ab-4d14-bf2a-e47335f3d6de" xlink:href="exdx-20230331.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_2e8c58c3-d6ab-4d14-bf2a-e47335f3d6de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_23b312de-6856-412f-8c3c-8c2806b31097" xlink:href="exdx-20230331.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_23b312de-6856-412f-8c3c-8c2806b31097" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_08220cde-028e-4e9c-9370-67d0450f40fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_08220cde-028e-4e9c-9370-67d0450f40fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_30494856-590e-4565-bf6d-8c36d7310962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_30494856-590e-4565-bf6d-8c36d7310962" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1119900d-c86f-4a38-9fd1-309005d9f2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1119900d-c86f-4a38-9fd1-309005d9f2c7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6b89e8a9-da81-4989-987a-557ad72830dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6b89e8a9-da81-4989-987a-557ad72830dc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c8b35d70-c796-4dc0-817e-9d4f82200b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c8b35d70-c796-4dc0-817e-9d4f82200b46" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cb3e99ef-ec68-458a-858a-0c88dc538983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_NetIncomeLoss_cb3e99ef-ec68-458a-858a-0c88dc538983" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2bcf9c9d-7844-4f2a-8eec-d8d5cb4e4672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_23ea4417-7590-42f7-ac1e-e45852af1061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9552d2c3-3595-4eaf-b09f-6b1d570ad31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_91cc3f75-8818-4cb7-995b-7fa3e86a9852" xlink:to="loc_us-gaap_StatementTable_9552d2c3-3595-4eaf-b09f-6b1d570ad31b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b0469d96-e9c6-46e4-96c5-90e36496d128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9552d2c3-3595-4eaf-b09f-6b1d570ad31b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b0469d96-e9c6-46e4-96c5-90e36496d128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b0469d96-e9c6-46e4-96c5-90e36496d128_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b0469d96-e9c6-46e4-96c5-90e36496d128" xlink:to="loc_us-gaap_EquityComponentDomain_b0469d96-e9c6-46e4-96c5-90e36496d128_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b37e9760-51a8-483b-87c3-e79d03da0493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b0469d96-e9c6-46e4-96c5-90e36496d128" xlink:to="loc_us-gaap_EquityComponentDomain_b37e9760-51a8-483b-87c3-e79d03da0493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e8b748bd-37fc-45ac-ad35-5ac509328965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b37e9760-51a8-483b-87c3-e79d03da0493" xlink:to="loc_us-gaap_CommonStockMember_e8b748bd-37fc-45ac-ad35-5ac509328965" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f874c6ed-c20b-45ee-a2a6-33d63298313a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b37e9760-51a8-483b-87c3-e79d03da0493" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f874c6ed-c20b-45ee-a2a6-33d63298313a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0f7548b4-91e1-4c92-93f4-2a36b45a5428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b37e9760-51a8-483b-87c3-e79d03da0493" xlink:to="loc_us-gaap_RetainedEarningsMember_0f7548b4-91e1-4c92-93f4-2a36b45a5428" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended" id="i313342e288e94612a302f5e88ef39d46_SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5f0f8882-f792-4429-ac11-c333f4d7ba64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_006cc5c2-36c6-422a-9a11-9fdc3b1deaff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5f0f8882-f792-4429-ac11-c333f4d7ba64" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_006cc5c2-36c6-422a-9a11-9fdc3b1deaff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6020973b-9416-4df8-9046-ceee3a71bdae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5f0f8882-f792-4429-ac11-c333f4d7ba64" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6020973b-9416-4df8-9046-ceee3a71bdae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_aa086f5f-f7b6-4d0c-bdb4-2194f873e9ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6020973b-9416-4df8-9046-ceee3a71bdae" xlink:to="loc_srt_MajorCustomersAxis_aa086f5f-f7b6-4d0c-bdb4-2194f873e9ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_aa086f5f-f7b6-4d0c-bdb4-2194f873e9ba_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_aa086f5f-f7b6-4d0c-bdb4-2194f873e9ba" xlink:to="loc_srt_NameOfMajorCustomerDomain_aa086f5f-f7b6-4d0c-bdb4-2194f873e9ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a3929d56-32b7-48b9-80d5-1ae45d047d93" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_aa086f5f-f7b6-4d0c-bdb4-2194f873e9ba" xlink:to="loc_srt_NameOfMajorCustomerDomain_a3929d56-32b7-48b9-80d5-1ae45d047d93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_f29c454e-33d9-4eed-9b73-6219bd66b306" xlink:href="exdx-20230331.xsd#exdx_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a3929d56-32b7-48b9-80d5-1ae45d047d93" xlink:to="loc_exdx_MedicareMember_f29c454e-33d9-4eed-9b73-6219bd66b306" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_a5acd24d-e033-4fcf-a44d-eb7b46f77c2f" xlink:href="exdx-20230331.xsd#exdx_MedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a3929d56-32b7-48b9-80d5-1ae45d047d93" xlink:to="loc_exdx_MedicareAdvantageMember_a5acd24d-e033-4fcf-a44d-eb7b46f77c2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember_45aaffcc-6ff4-46c7-a274-ada0d90f5333" xlink:href="exdx-20230331.xsd#exdx_BlueShieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a3929d56-32b7-48b9-80d5-1ae45d047d93" xlink:to="loc_exdx_BlueShieldMember_45aaffcc-6ff4-46c7-a274-ada0d90f5333" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f5dc79c8-8d25-4c59-95dd-33f5a52b72b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6020973b-9416-4df8-9046-ceee3a71bdae" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f5dc79c8-8d25-4c59-95dd-33f5a52b72b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f5dc79c8-8d25-4c59-95dd-33f5a52b72b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f5dc79c8-8d25-4c59-95dd-33f5a52b72b7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f5dc79c8-8d25-4c59-95dd-33f5a52b72b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8cd1d5c1-9881-46a9-96a5-706eba7d478d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f5dc79c8-8d25-4c59-95dd-33f5a52b72b7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8cd1d5c1-9881-46a9-96a5-706eba7d478d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_86e737a7-2466-4618-901c-c8f9928a4349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8cd1d5c1-9881-46a9-96a5-706eba7d478d" xlink:to="loc_us-gaap_SalesRevenueNetMember_86e737a7-2466-4618-901c-c8f9928a4349" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_71fd8a39-5af7-4431-bbec-d037249eba2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8cd1d5c1-9881-46a9-96a5-706eba7d478d" xlink:to="loc_us-gaap_AccountsReceivableMember_71fd8a39-5af7-4431-bbec-d037249eba2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_51d3bb30-0738-452b-a015-0c1736c12871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6020973b-9416-4df8-9046-ceee3a71bdae" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_51d3bb30-0738-452b-a015-0c1736c12871" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_51d3bb30-0738-452b-a015-0c1736c12871_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_51d3bb30-0738-452b-a015-0c1736c12871" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_51d3bb30-0738-452b-a015-0c1736c12871_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c2a6a855-a158-401c-bac1-2cfbbc6dba46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_51d3bb30-0738-452b-a015-0c1736c12871" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c2a6a855-a158-401c-bac1-2cfbbc6dba46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_9bdd4db4-d717-4663-af9f-da11526822c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c2a6a855-a158-401c-bac1-2cfbbc6dba46" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_9bdd4db4-d717-4663-af9f-da11526822c7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="ia1d6ea035bb2472b94a80dbe217dab85_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d9a35dcd-5f53-4783-bdd7-9aa24ed88288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d9a35dcd-5f53-4783-bdd7-9aa24ed88288" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_79a0cb3b-81de-450a-8325-7e94dbd09ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_LongTermDebt_79a0cb3b-81de-450a-8325-7e94dbd09ddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_72c70a84-acce-404f-ad7b-5cb5bdefc39d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_DebtInstrumentFairValue_72c70a84-acce-404f-ad7b-5cb5bdefc39d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_60328336-75d3-4cca-90f0-0dfcfd1d9ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_RestrictedCash_60328336-75d3-4cca-90f0-0dfcfd1d9ba0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e1040586-d022-48b1-9ba9-761623bb9a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e1040586-d022-48b1-9ba9-761623bb9a4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_93757a1a-e361-4204-adbb-bc4ab1be2b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_AdvertisingExpense_93757a1a-e361-4204-adbb-bc4ab1be2b5c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_973e8503-2879-4373-a325-c73abfe11c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_CostOfRevenue_973e8503-2879-4373-a325-c73abfe11c8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4d820968-ae54-432d-b085-9244fff2c773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4d820968-ae54-432d-b085-9244fff2c773" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c96acfc7-0d2f-4ab7-81d3-25f6bba459df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c96acfc7-0d2f-4ab7-81d3-25f6bba459df" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b02a8732-3c84-46f2-8314-86f34199cbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b02a8732-3c84-46f2-8314-86f34199cbbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b02a8732-3c84-46f2-8314-86f34199cbbd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b02a8732-3c84-46f2-8314-86f34199cbbd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b02a8732-3c84-46f2-8314-86f34199cbbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c43d1471-4d2a-4e50-b2b8-8a87798d9db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b02a8732-3c84-46f2-8314-86f34199cbbd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c43d1471-4d2a-4e50-b2b8-8a87798d9db4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_6041cb37-e77d-4cea-b667-75ba0b038707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c43d1471-4d2a-4e50-b2b8-8a87798d9db4" xlink:to="loc_us-gaap_SalesRevenueNetMember_6041cb37-e77d-4cea-b667-75ba0b038707" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_edb8f72b-4883-455d-94c2-be96cfe26eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_edb8f72b-4883-455d-94c2-be96cfe26eb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_edb8f72b-4883-455d-94c2-be96cfe26eb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_edb8f72b-4883-455d-94c2-be96cfe26eb0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_edb8f72b-4883-455d-94c2-be96cfe26eb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_38354f15-9b8a-4d1f-92d4-255cf8a68b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_edb8f72b-4883-455d-94c2-be96cfe26eb0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_38354f15-9b8a-4d1f-92d4-255cf8a68b03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_72802282-deef-4745-9481-2d1e4382f507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_38354f15-9b8a-4d1f-92d4-255cf8a68b03" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_72802282-deef-4745-9481-2d1e4382f507" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_56f989e7-923d-4d95-90a0-6916aa8cd9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_38354f15-9b8a-4d1f-92d4-255cf8a68b03" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_56f989e7-923d-4d95-90a0-6916aa8cd9f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5fe9bfda-19c3-4975-9c49-bfb7238e6412" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_srt_ProductOrServiceAxis_5fe9bfda-19c3-4975-9c49-bfb7238e6412" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5fe9bfda-19c3-4975-9c49-bfb7238e6412_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5fe9bfda-19c3-4975-9c49-bfb7238e6412" xlink:to="loc_srt_ProductsAndServicesDomain_5fe9bfda-19c3-4975-9c49-bfb7238e6412_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5eddb6fe-2cb0-4850-a930-66e969ee3375" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5fe9bfda-19c3-4975-9c49-bfb7238e6412" xlink:to="loc_srt_ProductsAndServicesDomain_5eddb6fe-2cb0-4850-a930-66e969ee3375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_c511d7b0-56ad-46fa-a44c-a818545e29eb" xlink:href="exdx-20230331.xsd#exdx_AVISECTDTestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5eddb6fe-2cb0-4850-a930-66e969ee3375" xlink:to="loc_exdx_AVISECTDTestMember_c511d7b0-56ad-46fa-a44c-a818545e29eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_9780f92a-df55-4173-ac23-06ce307a5dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5eddb6fe-2cb0-4850-a930-66e969ee3375" xlink:to="loc_us-gaap_ShippingAndHandlingMember_9780f92a-df55-4173-ac23-06ce307a5dc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_a34fae01-99f1-4e99-8174-38e1e64da56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_a34fae01-99f1-4e99-8174-38e1e64da56d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_a34fae01-99f1-4e99-8174-38e1e64da56d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_a34fae01-99f1-4e99-8174-38e1e64da56d" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_a34fae01-99f1-4e99-8174-38e1e64da56d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_a9999803-e137-4177-a29a-c7ce1813c8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_a34fae01-99f1-4e99-8174-38e1e64da56d" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_a9999803-e137-4177-a29a-c7ce1813c8bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TwoMajorSuppliersMember_0b04bbde-c7f2-434c-b54c-2b70f61a29ae" xlink:href="exdx-20230331.xsd#exdx_TwoMajorSuppliersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_a9999803-e137-4177-a29a-c7ce1813c8bd" xlink:to="loc_exdx_TwoMajorSuppliersMember_0b04bbde-c7f2-434c-b54c-2b70f61a29ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d3a5e875-3940-42d5-97bb-c60704e67993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_DebtInstrumentAxis_d3a5e875-3940-42d5-97bb-c60704e67993" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d3a5e875-3940-42d5-97bb-c60704e67993_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d3a5e875-3940-42d5-97bb-c60704e67993" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d3a5e875-3940-42d5-97bb-c60704e67993_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0f9ced6a-49de-4c43-81b0-6256000fbd61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d3a5e875-3940-42d5-97bb-c60704e67993" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0f9ced6a-49de-4c43-81b0-6256000fbd61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_e7f81cea-bde0-458d-9121-c5097eb092f1" xlink:href="exdx-20230331.xsd#exdx_Term2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0f9ced6a-49de-4c43-81b0-6256000fbd61" xlink:to="loc_exdx_Term2017Member_e7f81cea-bde0-458d-9121-c5097eb092f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d44bf48-d700-445d-b456-adfbe6b56198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d44bf48-d700-445d-b456-adfbe6b56198" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d44bf48-d700-445d-b456-adfbe6b56198_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d44bf48-d700-445d-b456-adfbe6b56198" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d44bf48-d700-445d-b456-adfbe6b56198_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82c0b551-de93-4112-8e51-be47b3b7f8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d44bf48-d700-445d-b456-adfbe6b56198" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82c0b551-de93-4112-8e51-be47b3b7f8a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d758f79e-f05f-488f-a66b-d0781cff1249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82c0b551-de93-4112-8e51-be47b3b7f8a9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d758f79e-f05f-488f-a66b-d0781cff1249" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_84a93b70-7a0b-4704-bdb3-a82b171f23eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_84a93b70-7a0b-4704-bdb3-a82b171f23eb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_84a93b70-7a0b-4704-bdb3-a82b171f23eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_84a93b70-7a0b-4704-bdb3-a82b171f23eb" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_84a93b70-7a0b-4704-bdb3-a82b171f23eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e6ed4e26-8f55-4c5c-90ce-70151220a0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_84a93b70-7a0b-4704-bdb3-a82b171f23eb" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e6ed4e26-8f55-4c5c-90ce-70151220a0d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c0b64855-9989-419d-a27c-16398839ea83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e6ed4e26-8f55-4c5c-90ce-70151220a0d8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c0b64855-9989-419d-a27c-16398839ea83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f60ae44c-11d5-469f-b1bc-241adabf03e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_AwardTypeAxis_f60ae44c-11d5-469f-b1bc-241adabf03e1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f60ae44c-11d5-469f-b1bc-241adabf03e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f60ae44c-11d5-469f-b1bc-241adabf03e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f60ae44c-11d5-469f-b1bc-241adabf03e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a6272db-4f9f-4a06-b3bb-280ff4b44313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f60ae44c-11d5-469f-b1bc-241adabf03e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a6272db-4f9f-4a06-b3bb-280ff4b44313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b461167e-10d9-4226-b658-6a0bd7773146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a6272db-4f9f-4a06-b3bb-280ff4b44313" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b461167e-10d9-4226-b658-6a0bd7773146" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3659fce6-d384-4554-b297-cc8ca1669a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3659fce6-d384-4554-b297-cc8ca1669a6c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3659fce6-d384-4554-b297-cc8ca1669a6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3659fce6-d384-4554-b297-cc8ca1669a6c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3659fce6-d384-4554-b297-cc8ca1669a6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a448c170-6593-47d7-bb5a-8e4dcc1f9f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3659fce6-d384-4554-b297-cc8ca1669a6c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a448c170-6593-47d7-bb5a-8e4dcc1f9f82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherLongTermDebtMember_61d76e58-f294-455a-9be5-8468f8979b45" xlink:href="exdx-20230331.xsd#exdx_OtherLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a448c170-6593-47d7-bb5a-8e4dcc1f9f82" xlink:to="loc_exdx_OtherLongTermDebtMember_61d76e58-f294-455a-9be5-8468f8979b45" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended" id="i87a0fdf743ae48e6be76843e0af40f2c_SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_13aef40f-7711-4b28-97a2-54f18014ce1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8bfe6c9b-9d7a-42ca-bff6-4a0bef0ad6de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_13aef40f-7711-4b28-97a2-54f18014ce1a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8bfe6c9b-9d7a-42ca-bff6-4a0bef0ad6de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4d275b8b-3d92-4ac6-8425-2384a0624921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_13aef40f-7711-4b28-97a2-54f18014ce1a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4d275b8b-3d92-4ac6-8425-2384a0624921" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_8209c290-d78f-481b-ab41-5c1234364899" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4d275b8b-3d92-4ac6-8425-2384a0624921" xlink:to="loc_srt_MajorCustomersAxis_8209c290-d78f-481b-ab41-5c1234364899" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_8209c290-d78f-481b-ab41-5c1234364899_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_8209c290-d78f-481b-ab41-5c1234364899" xlink:to="loc_srt_NameOfMajorCustomerDomain_8209c290-d78f-481b-ab41-5c1234364899_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ebff17b9-05b5-45a7-874b-9b05f795a99d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_8209c290-d78f-481b-ab41-5c1234364899" xlink:to="loc_srt_NameOfMajorCustomerDomain_ebff17b9-05b5-45a7-874b-9b05f795a99d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember_74016f62-72ee-4937-b9ab-751af1973827" xlink:href="exdx-20230331.xsd#exdx_HealthcareInsurersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ebff17b9-05b5-45a7-874b-9b05f795a99d" xlink:to="loc_exdx_HealthcareInsurersMember_74016f62-72ee-4937-b9ab-751af1973827" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member_36538bfc-25f0-4782-84f3-3017bbefbd51" xlink:href="exdx-20230331.xsd#exdx_Government1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ebff17b9-05b5-45a7-874b-9b05f795a99d" xlink:to="loc_exdx_Government1Member_36538bfc-25f0-4782-84f3-3017bbefbd51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_f890254b-0e22-4eaf-a4bb-13ddfcf688ee" xlink:href="exdx-20230331.xsd#exdx_ClientMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ebff17b9-05b5-45a7-874b-9b05f795a99d" xlink:to="loc_exdx_ClientMember_f890254b-0e22-4eaf-a4bb-13ddfcf688ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember_7204b8e2-ba85-4cb4-8f81-1a174706636e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ebff17b9-05b5-45a7-874b-9b05f795a99d" xlink:to="loc_us-gaap_OtherCustomerMember_7204b8e2-ba85-4cb4-8f81-1a174706636e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended" id="i1b0276617e1144afb2d943920227da05_SummaryofSignificantAccountingPoliciesSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f86d2f27-c7da-47cb-973a-f33532302eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_025596db-a6c8-4b8e-ac9b-a7e3a7799c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f86d2f27-c7da-47cb-973a-f33532302eb9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_025596db-a6c8-4b8e-ac9b-a7e3a7799c82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5bca8ffa-2ee6-4762-a3e3-aa3354ce2286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f86d2f27-c7da-47cb-973a-f33532302eb9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5bca8ffa-2ee6-4762-a3e3-aa3354ce2286" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4c2b6faf-ae06-4191-bd6c-4d024b3c8dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5bca8ffa-2ee6-4762-a3e3-aa3354ce2286" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4c2b6faf-ae06-4191-bd6c-4d024b3c8dc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c2b6faf-ae06-4191-bd6c-4d024b3c8dc2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4c2b6faf-ae06-4191-bd6c-4d024b3c8dc2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c2b6faf-ae06-4191-bd6c-4d024b3c8dc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1a109c2-8eb3-4ede-bb7d-ba35740d0687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4c2b6faf-ae06-4191-bd6c-4d024b3c8dc2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1a109c2-8eb3-4ede-bb7d-ba35740d0687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2c383acc-1da3-4473-ba35-9316d2710877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1a109c2-8eb3-4ede-bb7d-ba35740d0687" xlink:to="loc_us-gaap_WarrantMember_2c383acc-1da3-4473-ba35-9316d2710877" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_df230f5b-3c4f-4bec-bc58-56caf912a6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1a109c2-8eb3-4ede-bb7d-ba35740d0687" xlink:to="loc_us-gaap_StockOptionMember_df230f5b-3c4f-4bec-bc58-56caf912a6a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_88c2dfff-8d35-4da0-8818-5dea5616896a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1a109c2-8eb3-4ede-bb7d-ba35740d0687" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_88c2dfff-8d35-4da0-8818-5dea5616896a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a53c34f0-a71f-4fd1-aaff-21b5dd96b4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1a109c2-8eb3-4ede-bb7d-ba35740d0687" xlink:to="loc_us-gaap_EmployeeStockMember_a53c34f0-a71f-4fd1-aaff-21b5dd96b4a8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#OtherFinancialInformationPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="extended" id="i7fbebec026ab45f2ab442cfa1bfae1b6_OtherFinancialInformationPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e273782c-2be7-4fe2-81dc-e545cbcbd013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_bbd23772-881c-4d60-9db2-6f07186064bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e273782c-2be7-4fe2-81dc-e545cbcbd013" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_bbd23772-881c-4d60-9db2-6f07186064bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_353cd937-bc07-4d56-ac19-a6d746108969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e273782c-2be7-4fe2-81dc-e545cbcbd013" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_353cd937-bc07-4d56-ac19-a6d746108969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_fb3cfac0-e292-4733-87d2-8a6889e4e636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e273782c-2be7-4fe2-81dc-e545cbcbd013" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_fb3cfac0-e292-4733-87d2-8a6889e4e636" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_46483f59-17f8-4e1c-b6a9-3f4406eb852d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e273782c-2be7-4fe2-81dc-e545cbcbd013" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_46483f59-17f8-4e1c-b6a9-3f4406eb852d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0575f6fc-6692-4016-87d1-3e597b40792c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_46483f59-17f8-4e1c-b6a9-3f4406eb852d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0575f6fc-6692-4016-87d1-3e597b40792c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0575f6fc-6692-4016-87d1-3e597b40792c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0575f6fc-6692-4016-87d1-3e597b40792c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0575f6fc-6692-4016-87d1-3e597b40792c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecaedeb2-abe7-4a3b-9872-ef6c20e80a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0575f6fc-6692-4016-87d1-3e597b40792c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecaedeb2-abe7-4a3b-9872-ef6c20e80a84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_6ab6391c-e844-4c05-80b2-fa5679f205a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecaedeb2-abe7-4a3b-9872-ef6c20e80a84" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_6ab6391c-e844-4c05-80b2-fa5679f205a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_c170d386-4be5-46ef-b06a-807fe6d73c89" xlink:href="exdx-20230331.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecaedeb2-abe7-4a3b-9872-ef6c20e80a84" xlink:to="loc_exdx_LaboratoryEquipmentMember_c170d386-4be5-46ef-b06a-807fe6d73c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_dec24912-c549-416f-98e2-85ec15bfc358" xlink:href="exdx-20230331.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecaedeb2-abe7-4a3b-9872-ef6c20e80a84" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_dec24912-c549-416f-98e2-85ec15bfc358" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_36504d41-cffe-4bed-bad4-d1fb37392e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecaedeb2-abe7-4a3b-9872-ef6c20e80a84" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_36504d41-cffe-4bed-bad4-d1fb37392e73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_696bdd5d-13e9-4303-82a9-fa492cf7aaad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecaedeb2-abe7-4a3b-9872-ef6c20e80a84" xlink:to="loc_us-gaap_ConstructionInProgressMember_696bdd5d-13e9-4303-82a9-fa492cf7aaad" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="i272e70b923d641f59ffc36f42fff46c9_BorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3e781aba-bce2-4f37-9ae1-2b8ac6fc0265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3e781aba-bce2-4f37-9ae1-2b8ac6fc0265" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_fbc5a1e0-9f18-47c1-8495-0d640deb2794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_fbc5a1e0-9f18-47c1-8495-0d640deb2794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_df6a28cd-faaa-4004-8e47-861cf9e7e30f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_df6a28cd-faaa-4004-8e47-861cf9e7e30f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_9968100a-a1e9-474f-a2fd-5aaaece8b616" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_9968100a-a1e9-474f-a2fd-5aaaece8b616" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_73c0a598-b170-4a7c-912c-3d02b8682930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_73c0a598-b170-4a7c-912c-3d02b8682930" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments_9816d80b-67f6-4baa-b081-efe99e8bca4a" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentNumberOfMonthlyInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments_9816d80b-67f6-4baa-b081-efe99e8bca4a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_4eedfbdf-2520-4188-90e3-5c1bf07235bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_4eedfbdf-2520-4188-90e3-5c1bf07235bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_68e97642-6887-4c35-853d-71e2569ee15b" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_68e97642-6887-4c35-853d-71e2569ee15b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_6ff81d64-cca5-45fa-a7ac-0db13f51fc16" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_6ff81d64-cca5-45fa-a7ac-0db13f51fc16" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_eed62277-f68c-4ad8-8025-1514ea71240e" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_eed62277-f68c-4ad8-8025-1514ea71240e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_5e7d057d-e729-48a9-ba45-94cc36e449b1" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentCovenantRevenuePerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_5e7d057d-e729-48a9-ba45-94cc36e449b1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_59d9a4d5-e59e-4d94-9bf6-c97a620bde32" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_59d9a4d5-e59e-4d94-9bf6-c97a620bde32" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_8250eeb0-f24c-4bca-8049-2ed789f49938" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_8250eeb0-f24c-4bca-8049-2ed789f49938" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_c1f68e04-3ba5-4799-9eb5-d8391594eb65" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_c1f68e04-3ba5-4799-9eb5-d8391594eb65" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_2bb240ce-b88b-4323-b98e-31d12fa3e812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_NotesPayable_2bb240ce-b88b-4323-b98e-31d12fa3e812" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_3bec8c9a-3172-4550-8a28-330c29bde64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_NotesPayableCurrent_3bec8c9a-3172-4550-8a28-330c29bde64c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_8ff53ee1-74b2-46aa-9ae7-bf6cb43334be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_LongTermNotesPayable_8ff53ee1-74b2-46aa-9ae7-bf6cb43334be" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8c658094-a9c6-4e57-b6cc-6f97a6ff48f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_DebtInstrumentTable_8c658094-a9c6-4e57-b6cc-6f97a6ff48f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c6c8d579-28e1-4f1d-86f4-6a357eb76aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8c658094-a9c6-4e57-b6cc-6f97a6ff48f6" xlink:to="loc_us-gaap_DebtInstrumentAxis_c6c8d579-28e1-4f1d-86f4-6a357eb76aa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c6c8d579-28e1-4f1d-86f4-6a357eb76aa6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c6c8d579-28e1-4f1d-86f4-6a357eb76aa6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c6c8d579-28e1-4f1d-86f4-6a357eb76aa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42216f91-c3cf-4f12-a805-842667c2f13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c6c8d579-28e1-4f1d-86f4-6a357eb76aa6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_42216f91-c3cf-4f12-a805-842667c2f13f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_edc51768-9da7-40d7-be38-6e547f93add3" xlink:href="exdx-20230331.xsd#exdx_Term2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42216f91-c3cf-4f12-a805-842667c2f13f" xlink:to="loc_exdx_Term2017Member_edc51768-9da7-40d7-be38-6e547f93add3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentNotesPayableMember_24b9d17e-bfa5-4356-b35c-9c4b700d1da2" xlink:href="exdx-20230331.xsd#exdx_EquipmentNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42216f91-c3cf-4f12-a805-842667c2f13f" xlink:to="loc_exdx_EquipmentNotesPayableMember_24b9d17e-bfa5-4356-b35c-9c4b700d1da2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d976162a-0b23-418e-a70c-30bccf120c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8c658094-a9c6-4e57-b6cc-6f97a6ff48f6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d976162a-0b23-418e-a70c-30bccf120c45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d976162a-0b23-418e-a70c-30bccf120c45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d976162a-0b23-418e-a70c-30bccf120c45" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d976162a-0b23-418e-a70c-30bccf120c45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f94cc30a-2244-4bfc-be58-5539caac5273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d976162a-0b23-418e-a70c-30bccf120c45" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f94cc30a-2244-4bfc-be58-5539caac5273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_e5469347-6242-423e-879b-b6d87eb1809b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f94cc30a-2244-4bfc-be58-5539caac5273" xlink:to="loc_us-gaap_LoansPayableMember_e5469347-6242-423e-879b-b6d87eb1809b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_81c7e59f-8fe1-4b0e-9e7f-bd8e9bf24fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f94cc30a-2244-4bfc-be58-5539caac5273" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_81c7e59f-8fe1-4b0e-9e7f-bd8e9bf24fe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_a6c49538-eb35-42ff-a1d1-978c30ba3bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8c658094-a9c6-4e57-b6cc-6f97a6ff48f6" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_a6c49538-eb35-42ff-a1d1-978c30ba3bbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_a6c49538-eb35-42ff-a1d1-978c30ba3bbd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_a6c49538-eb35-42ff-a1d1-978c30ba3bbd" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_a6c49538-eb35-42ff-a1d1-978c30ba3bbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_ac5b110f-bd51-4007-b794-a6b6ce604124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_a6c49538-eb35-42ff-a1d1-978c30ba3bbd" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_ac5b110f-bd51-4007-b794-a6b6ce604124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_fdf927a0-acda-4e40-a098-4544bcaaa4bf" xlink:href="exdx-20230331.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_ac5b110f-bd51-4007-b794-a6b6ce604124" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_fdf927a0-acda-4e40-a098-4544bcaaa4bf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#CommitmentandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesDetails" xlink:type="extended" id="i073d13f2c0854a46abe61899c6aa6d0e_CommitmentandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_3d869652-76eb-44ee-830f-5685fc4ce414" xlink:href="exdx-20230331.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_3d869652-76eb-44ee-830f-5685fc4ce414" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_6e47842f-ced3-42e1-a685-c4400c581d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_6e47842f-ced3-42e1-a685-c4400c581d1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment_d8a087e2-f1a8-4395-b234-d499875af48a" xlink:href="exdx-20230331.xsd#exdx_AdvancePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_exdx_AdvancePayment_d8a087e2-f1a8-4395-b234-d499875af48a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee_6f0bf2a3-1ee8-47bd-bc45-e71cf249ada1" xlink:href="exdx-20230331.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_exdx_CollaborationAgreementAnnualCollaborationFee_6f0bf2a3-1ee8-47bd-bc45-e71cf249ada1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses_5c06251e-fcdf-414b-851a-0ca94e3d5ca7" xlink:href="exdx-20230331.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_exdx_CollaborationAgreementCollaborationExpenses_5c06251e-fcdf-414b-851a-0ca94e3d5ca7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_fd6acf30-f5a9-4882-8f79-a1329cd868a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_fd6acf30-f5a9-4882-8f79-a1329cd868a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_a76aed1e-8594-418d-b51e-ffb5261a3ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_a76aed1e-8594-418d-b51e-ffb5261a3ad4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_da298309-9cc5-4877-a19e-6eb2cea1a5dc" xlink:href="exdx-20230331.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_da298309-9cc5-4877-a19e-6eb2cea1a5dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_24e9e46b-ab4d-4038-ac5f-45882236ec96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_us-gaap_LossContingenciesTable_24e9e46b-ab4d-4038-ac5f-45882236ec96" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_461c7b32-c363-4e5b-a02e-b18c407580ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_24e9e46b-ab4d-4038-ac5f-45882236ec96" xlink:to="loc_srt_CounterpartyNameAxis_461c7b32-c363-4e5b-a02e-b18c407580ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_461c7b32-c363-4e5b-a02e-b18c407580ef_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_461c7b32-c363-4e5b-a02e-b18c407580ef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_461c7b32-c363-4e5b-a02e-b18c407580ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2488af8-e541-4168-9133-a73c4904dcd8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_461c7b32-c363-4e5b-a02e-b18c407580ef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2488af8-e541-4168-9133-a73c4904dcd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember_1c3af7c7-c440-45b6-85fe-cac1f22aec35" xlink:href="exdx-20230331.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2488af8-e541-4168-9133-a73c4904dcd8" xlink:to="loc_exdx_PrometheusLaboratoriesIncMember_1c3af7c7-c440-45b6-85fe-cac1f22aec35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_f85b7ad4-c8c1-4907-a8b3-946577ea389f" xlink:href="exdx-20230331.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2488af8-e541-4168-9133-a73c4904dcd8" xlink:to="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_f85b7ad4-c8c1-4907-a8b3-946577ea389f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cfad3d17-5e42-4641-8349-fb74247434ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_24e9e46b-ab4d-4038-ac5f-45882236ec96" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cfad3d17-5e42-4641-8349-fb74247434ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cfad3d17-5e42-4641-8349-fb74247434ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cfad3d17-5e42-4641-8349-fb74247434ad" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cfad3d17-5e42-4641-8349-fb74247434ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e75806e1-839b-4d6c-aab3-5f473ae85bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cfad3d17-5e42-4641-8349-fb74247434ad" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e75806e1-839b-4d6c-aab3-5f473ae85bfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember_211d6922-7250-4133-ab04-3e3fd106c02f" xlink:href="exdx-20230331.xsd#exdx_AHNCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e75806e1-839b-4d6c-aab3-5f473ae85bfa" xlink:to="loc_exdx_AHNCollaborationMember_211d6922-7250-4133-ab04-3e3fd106c02f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d8ea5aac-c33b-4237-8413-0c0fc212573d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_24e9e46b-ab4d-4038-ac5f-45882236ec96" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d8ea5aac-c33b-4237-8413-0c0fc212573d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d8ea5aac-c33b-4237-8413-0c0fc212573d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d8ea5aac-c33b-4237-8413-0c0fc212573d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d8ea5aac-c33b-4237-8413-0c0fc212573d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_12c387b9-a426-4d4b-9d65-ac45fe000088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d8ea5aac-c33b-4237-8413-0c0fc212573d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_12c387b9-a426-4d4b-9d65-ac45fe000088" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_ab46b3b1-4fa7-4d7a-807a-a6141a441cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_12c387b9-a426-4d4b-9d65-ac45fe000088" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_ab46b3b1-4fa7-4d7a-807a-a6141a441cd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4e8dd51a-9d59-421b-873f-9af3ee08cd89" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_24e9e46b-ab4d-4038-ac5f-45882236ec96" xlink:to="loc_srt_RangeAxis_4e8dd51a-9d59-421b-873f-9af3ee08cd89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4e8dd51a-9d59-421b-873f-9af3ee08cd89_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4e8dd51a-9d59-421b-873f-9af3ee08cd89" xlink:to="loc_srt_RangeMember_4e8dd51a-9d59-421b-873f-9af3ee08cd89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2b20629c-d14d-4850-bfcf-a32305f38d62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4e8dd51a-9d59-421b-873f-9af3ee08cd89" xlink:to="loc_srt_RangeMember_2b20629c-d14d-4850-bfcf-a32305f38d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2c25dd5b-3dc4-42d1-8c70-394b27d43dee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2b20629c-d14d-4850-bfcf-a32305f38d62" xlink:to="loc_srt_MinimumMember_2c25dd5b-3dc4-42d1-8c70-394b27d43dee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1be8f358-fa37-40be-a415-a685b6239e2d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2b20629c-d14d-4850-bfcf-a32305f38d62" xlink:to="loc_srt_MaximumMember_1be8f358-fa37-40be-a415-a685b6239e2d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="ie71a26be9a57441ba31ad56147ddca0d_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_44d563f7-bcf1-4f43-8769-e917fe3b35c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_f7158a70-f03c-435b-8d9a-4b5240ee91a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_44d563f7-bcf1-4f43-8769-e917fe3b35c7" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_f7158a70-f03c-435b-8d9a-4b5240ee91a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_55d445fe-abda-49ac-8b26-8ee14de40dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f7158a70-f03c-435b-8d9a-4b5240ee91a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_55d445fe-abda-49ac-8b26-8ee14de40dda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_35a3cf77-5886-46cf-8875-616e3c429571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f7158a70-f03c-435b-8d9a-4b5240ee91a5" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_35a3cf77-5886-46cf-8875-616e3c429571" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_393faca6-7385-43c8-840a-a2f908a9d38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_44d563f7-bcf1-4f43-8769-e917fe3b35c7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_393faca6-7385-43c8-840a-a2f908a9d38b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_60aab6aa-7d48-45f4-993e-dd8cd18ad62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_393faca6-7385-43c8-840a-a2f908a9d38b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_60aab6aa-7d48-45f4-993e-dd8cd18ad62d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_60aab6aa-7d48-45f4-993e-dd8cd18ad62d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_60aab6aa-7d48-45f4-993e-dd8cd18ad62d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_60aab6aa-7d48-45f4-993e-dd8cd18ad62d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_78c5ea50-4662-4831-987c-2f549bb5847e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_60aab6aa-7d48-45f4-993e-dd8cd18ad62d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_78c5ea50-4662-4831-987c-2f549bb5847e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7c88a7e2-1535-4a65-b244-73963d4a05c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_78c5ea50-4662-4831-987c-2f549bb5847e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7c88a7e2-1535-4a65-b244-73963d4a05c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_414fccc0-ba19-4f1e-acfb-6645d12f3247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_393faca6-7385-43c8-840a-a2f908a9d38b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_414fccc0-ba19-4f1e-acfb-6645d12f3247" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_414fccc0-ba19-4f1e-acfb-6645d12f3247_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_414fccc0-ba19-4f1e-acfb-6645d12f3247" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_414fccc0-ba19-4f1e-acfb-6645d12f3247_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8552343-1cf8-4b01-98df-34267a3d95ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_414fccc0-ba19-4f1e-acfb-6645d12f3247" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8552343-1cf8-4b01-98df-34267a3d95ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a03c8fda-3966-4ae2-ad4c-21c7659f34f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8552343-1cf8-4b01-98df-34267a3d95ba" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a03c8fda-3966-4ae2-ad4c-21c7659f34f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b94e7c4e-6b68-4ec7-b3d1-05d4bd6f3788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8552343-1cf8-4b01-98df-34267a3d95ba" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b94e7c4e-6b68-4ec7-b3d1-05d4bd6f3788" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6fd51de1-3071-4a20-9bdd-754a8d374167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8552343-1cf8-4b01-98df-34267a3d95ba" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6fd51de1-3071-4a20-9bdd-754a8d374167" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9c3e505b-cebd-461d-b94e-56270b18e0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_393faca6-7385-43c8-840a-a2f908a9d38b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9c3e505b-cebd-461d-b94e-56270b18e0f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c3e505b-cebd-461d-b94e-56270b18e0f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9c3e505b-cebd-461d-b94e-56270b18e0f7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9c3e505b-cebd-461d-b94e-56270b18e0f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f1fc670-7885-4901-bd1b-9bdab5287043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9c3e505b-cebd-461d-b94e-56270b18e0f7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f1fc670-7885-4901-bd1b-9bdab5287043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5808cd1d-258c-435e-a6f9-549c9ec63e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f1fc670-7885-4901-bd1b-9bdab5287043" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5808cd1d-258c-435e-a6f9-549c9ec63e15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_bc64ba7d-91e1-4173-92ff-5580bb13f446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f1fc670-7885-4901-bd1b-9bdab5287043" xlink:to="loc_us-gaap_CertificatesOfDepositMember_bc64ba7d-91e1-4173-92ff-5580bb13f446" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="ie4cbc319d40c4cf7aea06909a9b74c0d_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0ec2da93-c4d1-44e5-a97f-689516a22a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7879473d-2ece-4eb9-ad4a-b0ff26ebefdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0ec2da93-c4d1-44e5-a97f-689516a22a89" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7879473d-2ece-4eb9-ad4a-b0ff26ebefdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_b301e4a8-faa3-4788-9787-a7e82d1e5715" xlink:href="exdx-20230331.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0ec2da93-c4d1-44e5-a97f-689516a22a89" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_b301e4a8-faa3-4788-9787-a7e82d1e5715" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0840f31a-197b-437f-a5de-1bb226dc0edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0ec2da93-c4d1-44e5-a97f-689516a22a89" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0840f31a-197b-437f-a5de-1bb226dc0edd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0dece2a1-9907-4c69-aec3-ad61dc43bd74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0840f31a-197b-437f-a5de-1bb226dc0edd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0dece2a1-9907-4c69-aec3-ad61dc43bd74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0dece2a1-9907-4c69-aec3-ad61dc43bd74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0dece2a1-9907-4c69-aec3-ad61dc43bd74" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0dece2a1-9907-4c69-aec3-ad61dc43bd74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4f50b2ad-f70f-43f9-b048-87e37ec90c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0dece2a1-9907-4c69-aec3-ad61dc43bd74" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4f50b2ad-f70f-43f9-b048-87e37ec90c65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CowenEquityDistributionAgreementMember_5e3fcb1f-e41e-477d-9487-a0e0d29ddbdb" xlink:href="exdx-20230331.xsd#exdx_CowenEquityDistributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4f50b2ad-f70f-43f9-b048-87e37ec90c65" xlink:to="loc_exdx_CowenEquityDistributionAgreementMember_5e3fcb1f-e41e-477d-9487-a0e0d29ddbdb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#StockholdersEquityScheduleofOutstandingWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails" xlink:type="extended" id="i6d359e76bc244dceb599ff6e6f0c7855_StockholdersEquityScheduleofOutstandingWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_feec8c20-3b93-4c3d-a7d1-1734ee215823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f0f79da3-644f-4bed-a142-d34b587d52ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_feec8c20-3b93-4c3d-a7d1-1734ee215823" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f0f79da3-644f-4bed-a142-d34b587d52ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_af13d023-36d0-4387-8945-568b482ecd98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_feec8c20-3b93-4c3d-a7d1-1734ee215823" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_af13d023-36d0-4387-8945-568b482ecd98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e5d18721-a287-44f6-a882-4aeb71b1cedd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_feec8c20-3b93-4c3d-a7d1-1734ee215823" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e5d18721-a287-44f6-a882-4aeb71b1cedd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_506ffed9-6777-4ed7-9a5d-0d0843e4f2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e5d18721-a287-44f6-a882-4aeb71b1cedd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_506ffed9-6777-4ed7-9a5d-0d0843e4f2b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_506ffed9-6777-4ed7-9a5d-0d0843e4f2b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_506ffed9-6777-4ed7-9a5d-0d0843e4f2b2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_506ffed9-6777-4ed7-9a5d-0d0843e4f2b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a7b71fb8-f426-47df-885d-91d6cd4883b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_506ffed9-6777-4ed7-9a5d-0d0843e4f2b2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a7b71fb8-f426-47df-885d-91d6cd4883b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_e0639830-4c3d-410b-9126-f42112d69b36" xlink:href="exdx-20230331.xsd#exdx_ExpirationJan192026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a7b71fb8-f426-47df-885d-91d6cd4883b7" xlink:to="loc_exdx_ExpirationJan192026Member_e0639830-4c3d-410b-9126-f42112d69b36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_ce489b40-24b6-4e90-95e4-d6a95640a3b2" xlink:href="exdx-20230331.xsd#exdx_ExpirationMar312026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a7b71fb8-f426-47df-885d-91d6cd4883b7" xlink:to="loc_exdx_ExpirationMar312026Member_ce489b40-24b6-4e90-95e4-d6a95640a3b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_bceaa312-3c06-4eab-bf56-0a1b044e4246" xlink:href="exdx-20230331.xsd#exdx_ExpirationApr12026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a7b71fb8-f426-47df-885d-91d6cd4883b7" xlink:to="loc_exdx_ExpirationApr12026Member_bceaa312-3c06-4eab-bf56-0a1b044e4246" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member_08925b93-a110-443f-bd95-0e087089e29e" xlink:href="exdx-20230331.xsd#exdx_ExpirationSep72024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a7b71fb8-f426-47df-885d-91d6cd4883b7" xlink:to="loc_exdx_ExpirationSep72024Member_08925b93-a110-443f-bd95-0e087089e29e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_0a991178-efc6-448e-8d1e-4077bb27a714" xlink:href="exdx-20230331.xsd#exdx_ExpirationDec72025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a7b71fb8-f426-47df-885d-91d6cd4883b7" xlink:to="loc_exdx_ExpirationDec72025Member_0a991178-efc6-448e-8d1e-4077bb27a714" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember_03c39d15-5034-4aa9-b7c2-e414d1effd55" xlink:href="exdx-20230331.xsd#exdx_NoExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a7b71fb8-f426-47df-885d-91d6cd4883b7" xlink:to="loc_exdx_NoExpirationMember_03c39d15-5034-4aa9-b7c2-e414d1effd55" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#StockOptionPlanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended" id="if0a4f88e337b4d3ab4ac089677d11589_StockOptionPlanNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7e1267f3-2823-4e6e-bc1d-bc2c0083e870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7e1267f3-2823-4e6e-bc1d-bc2c0083e870" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6d8cc33a-9857-40c2-a351-716c10be86a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6d8cc33a-9857-40c2-a351-716c10be86a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_fd4e2331-f478-4998-9f7c-738cc23944a4" xlink:href="exdx-20230331.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_fd4e2331-f478-4998-9f7c-738cc23944a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1f21b4bb-0e72-46c2-8c78-f54f1e997da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1f21b4bb-0e72-46c2-8c78-f54f1e997da7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ef524766-f54e-424f-b76c-8f4b30849c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ef524766-f54e-424f-b76c-8f4b30849c01" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1f1f0244-c22e-4f72-8b34-f0277d69fee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1f1f0244-c22e-4f72-8b34-f0277d69fee9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c202406c-340a-42bf-bcbe-af0aa0f3fae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c202406c-340a-42bf-bcbe-af0aa0f3fae1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1cfd2f41-fd5e-4d2d-bb60-9c3ff576772a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1cfd2f41-fd5e-4d2d-bb60-9c3ff576772a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_1f138d9a-3bea-40cd-9462-96adf55f30c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_1f138d9a-3bea-40cd-9462-96adf55f30c7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019a3cd8-0474-48b4-92a6-4003dde5c049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019a3cd8-0474-48b4-92a6-4003dde5c049" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_19512f00-e117-4867-9885-59199ae20cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_19512f00-e117-4867-9885-59199ae20cb4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f087d9e3-cf6c-4f7d-8b18-fbd6726d4620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f087d9e3-cf6c-4f7d-8b18-fbd6726d4620" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9c50518b-b5f5-4658-abb7-08fffdf8af8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f087d9e3-cf6c-4f7d-8b18-fbd6726d4620" xlink:to="loc_us-gaap_PlanNameAxis_9c50518b-b5f5-4658-abb7-08fffdf8af8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9c50518b-b5f5-4658-abb7-08fffdf8af8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9c50518b-b5f5-4658-abb7-08fffdf8af8f" xlink:to="loc_us-gaap_PlanNameDomain_9c50518b-b5f5-4658-abb7-08fffdf8af8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_31ba29ec-fdf6-460c-b36b-894ecb467deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9c50518b-b5f5-4658-abb7-08fffdf8af8f" xlink:to="loc_us-gaap_PlanNameDomain_31ba29ec-fdf6-460c-b36b-894ecb467deb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_d84fca49-8455-4853-a39a-d5d7c942acaa" xlink:href="exdx-20230331.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_31ba29ec-fdf6-460c-b36b-894ecb467deb" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_d84fca49-8455-4853-a39a-d5d7c942acaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e4ec3afc-74f7-41e6-8489-38f652a9f77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f087d9e3-cf6c-4f7d-8b18-fbd6726d4620" xlink:to="loc_us-gaap_AwardTypeAxis_e4ec3afc-74f7-41e6-8489-38f652a9f77b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e4ec3afc-74f7-41e6-8489-38f652a9f77b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e4ec3afc-74f7-41e6-8489-38f652a9f77b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e4ec3afc-74f7-41e6-8489-38f652a9f77b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c71e36d-c5b6-4964-abeb-ee2e8e39ba6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e4ec3afc-74f7-41e6-8489-38f652a9f77b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c71e36d-c5b6-4964-abeb-ee2e8e39ba6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_baa1fd1e-904c-4b99-b000-53250b5b1000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c71e36d-c5b6-4964-abeb-ee2e8e39ba6f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_baa1fd1e-904c-4b99-b000-53250b5b1000" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a65ee7a7-01c3-4c40-af5d-aebd2601a800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c71e36d-c5b6-4964-abeb-ee2e8e39ba6f" xlink:to="loc_us-gaap_EmployeeStockMember_a65ee7a7-01c3-4c40-af5d-aebd2601a800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c2d1519d-14a4-4239-9c69-227cd7f00ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c71e36d-c5b6-4964-abeb-ee2e8e39ba6f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c2d1519d-14a4-4239-9c69-227cd7f00ec4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended" id="ic7732695e0f546e894b11af40f419ef4_StockOptionPlanStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a434bd2b-be50-4c19-8344-e18d786fb408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a434bd2b-be50-4c19-8344-e18d786fb408" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_407d0025-714a-42a0-b2cb-2803b625d5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a434bd2b-be50-4c19-8344-e18d786fb408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_407d0025-714a-42a0-b2cb-2803b625d5c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1ca4d751-712c-4e67-9be7-d0c583ffc9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a434bd2b-be50-4c19-8344-e18d786fb408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1ca4d751-712c-4e67-9be7-d0c583ffc9ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_184edcae-5b06-4061-91eb-c868dd956233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a434bd2b-be50-4c19-8344-e18d786fb408" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_184edcae-5b06-4061-91eb-c868dd956233" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_42a2e296-1448-450d-aeb5-6e56a124ef6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a434bd2b-be50-4c19-8344-e18d786fb408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_42a2e296-1448-450d-aeb5-6e56a124ef6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4826294a-542f-4177-9613-2820d3f7a9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a434bd2b-be50-4c19-8344-e18d786fb408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4826294a-542f-4177-9613-2820d3f7a9fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cbfa1ba6-10f5-4aab-94be-6f4bc7a62acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_09337d91-807a-431a-a996-1eb6c29bb3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_09337d91-807a-431a-a996-1eb6c29bb3f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_6db6defb-a4cc-466c-aaff-278a0157e68d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_6db6defb-a4cc-466c-aaff-278a0157e68d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0db1200-d407-44cc-b35e-092eaf1f0536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0db1200-d407-44cc-b35e-092eaf1f0536" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9b19b6b2-1e96-4c06-a495-068b9bfa6686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0db1200-d407-44cc-b35e-092eaf1f0536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9b19b6b2-1e96-4c06-a495-068b9bfa6686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c9243b1f-0474-4cf5-978b-8213db9898fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0db1200-d407-44cc-b35e-092eaf1f0536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c9243b1f-0474-4cf5-978b-8213db9898fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ad5ef4fa-cb7e-4070-a9e9-456a67b413da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0db1200-d407-44cc-b35e-092eaf1f0536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ad5ef4fa-cb7e-4070-a9e9-456a67b413da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fe237048-d2ed-43a0-af58-0959bff32ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0db1200-d407-44cc-b35e-092eaf1f0536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fe237048-d2ed-43a0-af58-0959bff32ea3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ea1503e5-837f-451e-8c15-36b289190f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0db1200-d407-44cc-b35e-092eaf1f0536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ea1503e5-837f-451e-8c15-36b289190f73" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ff8dddea-4a0a-4d3d-b8fe-6c495d8da0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_88748565-dcb3-4077-986c-b57537d17cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_88748565-dcb3-4077-986c-b57537d17cca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_72a81d93-5f65-4310-995d-8a4392b05bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_72a81d93-5f65-4310-995d-8a4392b05bf6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ec28912-2119-4c76-a12b-0ebe96bc9d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ec28912-2119-4c76-a12b-0ebe96bc9d77" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9e5d18c9-4738-4f4f-98f4-e67217e66455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ec28912-2119-4c76-a12b-0ebe96bc9d77" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9e5d18c9-4738-4f4f-98f4-e67217e66455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_57281464-5aea-4fd7-b7e7-a9c1ec16f059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ec28912-2119-4c76-a12b-0ebe96bc9d77" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_57281464-5aea-4fd7-b7e7-a9c1ec16f059" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_24dec232-8bf6-45cd-8c92-18a1725776e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ec28912-2119-4c76-a12b-0ebe96bc9d77" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_24dec232-8bf6-45cd-8c92-18a1725776e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7cafdfd2-740c-451c-b2c8-b09db63ab767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ec28912-2119-4c76-a12b-0ebe96bc9d77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7cafdfd2-740c-451c-b2c8-b09db63ab767" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4d0cec4d-1734-47eb-90c5-32f8a2c8809f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ec28912-2119-4c76-a12b-0ebe96bc9d77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4d0cec4d-1734-47eb-90c5-32f8a2c8809f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_06977080-99bf-4781-be8d-a4d71d888150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ec28912-2119-4c76-a12b-0ebe96bc9d77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_06977080-99bf-4781-be8d-a4d71d888150" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_510d7025-08f8-4fda-93ac-18229c6c8b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_510d7025-08f8-4fda-93ac-18229c6c8b51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1861049e-a4fa-40a8-b761-e355fcd93c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_510d7025-08f8-4fda-93ac-18229c6c8b51" xlink:to="loc_us-gaap_AwardTypeAxis_1861049e-a4fa-40a8-b761-e355fcd93c93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1861049e-a4fa-40a8-b761-e355fcd93c93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1861049e-a4fa-40a8-b761-e355fcd93c93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1861049e-a4fa-40a8-b761-e355fcd93c93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd30b680-fd14-4332-81a4-eda712774ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1861049e-a4fa-40a8-b761-e355fcd93c93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd30b680-fd14-4332-81a4-eda712774ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a9289d06-5178-496c-954a-70cec2afcfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd30b680-fd14-4332-81a4-eda712774ba0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a9289d06-5178-496c-954a-70cec2afcfc9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#StockOptionPlanRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="extended" id="i2081420f1880495ca72c97897f3c2e66_StockOptionPlanRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_717c7a98-56c6-4bab-94c9-2afc3b768e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15d8bbc2-6e36-446d-aa15-72f263e54447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_717c7a98-56c6-4bab-94c9-2afc3b768e4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15d8bbc2-6e36-446d-aa15-72f263e54447" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bfdc707a-2e7c-40d0-b620-2db952df6a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15d8bbc2-6e36-446d-aa15-72f263e54447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bfdc707a-2e7c-40d0-b620-2db952df6a72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b08fe588-938e-46d6-b5df-9d0cd487f29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15d8bbc2-6e36-446d-aa15-72f263e54447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b08fe588-938e-46d6-b5df-9d0cd487f29a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_460fba65-cdca-4d24-89d3-cc32a58d5175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15d8bbc2-6e36-446d-aa15-72f263e54447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_460fba65-cdca-4d24-89d3-cc32a58d5175" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c819b56-4cae-4610-8f1c-7df1832cb9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15d8bbc2-6e36-446d-aa15-72f263e54447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c819b56-4cae-4610-8f1c-7df1832cb9bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dbda030a-8407-4743-90a5-cf4f68cb8544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_31fed3d7-884d-4da7-bdc5-33f12b5f2f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_717c7a98-56c6-4bab-94c9-2afc3b768e4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_31fed3d7-884d-4da7-bdc5-33f12b5f2f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_976ff32e-4d98-4457-bd68-4c51513b216d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_31fed3d7-884d-4da7-bdc5-33f12b5f2f39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_976ff32e-4d98-4457-bd68-4c51513b216d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_756fac27-6285-40ef-8e40-06dc33e71cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_31fed3d7-884d-4da7-bdc5-33f12b5f2f39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_756fac27-6285-40ef-8e40-06dc33e71cdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3386b24d-78ef-4392-8526-d4efd03849eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_31fed3d7-884d-4da7-bdc5-33f12b5f2f39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3386b24d-78ef-4392-8526-d4efd03849eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e6b30c58-6b0d-4646-9e3b-30cc63aedf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_31fed3d7-884d-4da7-bdc5-33f12b5f2f39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e6b30c58-6b0d-4646-9e3b-30cc63aedf2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2aedcc59-4b38-4d3e-aee7-c3086153efa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_cfd4f9f8-167f-4ef6-98e3-76b62d6f9db1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_717c7a98-56c6-4bab-94c9-2afc3b768e4e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_cfd4f9f8-167f-4ef6-98e3-76b62d6f9db1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2cfa236e-91f8-4cf4-ac58-97ac22d64f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_cfd4f9f8-167f-4ef6-98e3-76b62d6f9db1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2cfa236e-91f8-4cf4-ac58-97ac22d64f53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f672f9ef-4036-42d9-872e-66105596ae20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_717c7a98-56c6-4bab-94c9-2afc3b768e4e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f672f9ef-4036-42d9-872e-66105596ae20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4a7cfabb-c63d-4ffd-8dde-751605ddcd85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f672f9ef-4036-42d9-872e-66105596ae20" xlink:to="loc_us-gaap_AwardTypeAxis_4a7cfabb-c63d-4ffd-8dde-751605ddcd85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a7cfabb-c63d-4ffd-8dde-751605ddcd85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4a7cfabb-c63d-4ffd-8dde-751605ddcd85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a7cfabb-c63d-4ffd-8dde-751605ddcd85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e169a8c-5cb7-4c7d-bd20-7d34312c85b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4a7cfabb-c63d-4ffd-8dde-751605ddcd85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e169a8c-5cb7-4c7d-bd20-7d34312c85b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f2e3726b-0ab2-422d-b3b8-9bde705df939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e169a8c-5cb7-4c7d-bd20-7d34312c85b5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f2e3726b-0ab2-422d-b3b8-9bde705df939" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended" id="i3133b1ba385547d99606d38647a0abb3_StockOptionPlanStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40881ab1-2f7b-4af8-b334-45871c3dd56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0fb3374d-8a09-4973-b4d0-a4085ec10e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40881ab1-2f7b-4af8-b334-45871c3dd56a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0fb3374d-8a09-4973-b4d0-a4085ec10e90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6aaf1e25-4985-44ab-95c4-5c2d45553cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40881ab1-2f7b-4af8-b334-45871c3dd56a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6aaf1e25-4985-44ab-95c4-5c2d45553cf6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_585ffd9e-79d2-4021-9457-18bf4327dcce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6aaf1e25-4985-44ab-95c4-5c2d45553cf6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_585ffd9e-79d2-4021-9457-18bf4327dcce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_585ffd9e-79d2-4021-9457-18bf4327dcce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_585ffd9e-79d2-4021-9457-18bf4327dcce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_585ffd9e-79d2-4021-9457-18bf4327dcce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3b535443-b491-49fd-9b12-2bee4ebc4b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_585ffd9e-79d2-4021-9457-18bf4327dcce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3b535443-b491-49fd-9b12-2bee4ebc4b33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_cd0a6b86-5be0-419c-ac87-e918596dc8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3b535443-b491-49fd-9b12-2bee4ebc4b33" xlink:to="loc_us-gaap_CostOfSalesMember_cd0a6b86-5be0-419c-ac87-e918596dc8e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6cd593e2-8515-4331-b281-e1bad0f20133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3b535443-b491-49fd-9b12-2bee4ebc4b33" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6cd593e2-8515-4331-b281-e1bad0f20133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d96cd97e-1fff-442c-b5bb-ad866545575f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3b535443-b491-49fd-9b12-2bee4ebc4b33" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d96cd97e-1fff-442c-b5bb-ad866545575f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SubsequentEventsDetails" xlink:type="extended" id="id4cfa9d5b88944549e7bf642b47a6bfd_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_0b259fc1-9adc-4b93-b838-4349cb61c4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7e8c58cb-fed8-481e-a93b-6222868d03a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0b259fc1-9adc-4b93-b838-4349cb61c4a7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7e8c58cb-fed8-481e-a93b-6222868d03a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_181d3cc0-f7d7-4b57-aa47-096c6bc04cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0b259fc1-9adc-4b93-b838-4349cb61c4a7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_181d3cc0-f7d7-4b57-aa47-096c6bc04cbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_acf0c38d-966d-4fcf-b83c-ade5b067b667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0b259fc1-9adc-4b93-b838-4349cb61c4a7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_acf0c38d-966d-4fcf-b83c-ade5b067b667" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_d8809e2e-54a4-4fe6-a6cf-0fa72bf1f4aa" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0b259fc1-9adc-4b93-b838-4349cb61c4a7" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_d8809e2e-54a4-4fe6-a6cf-0fa72bf1f4aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_98657f9c-f5e5-4da2-8271-ddbcbab5c7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0b259fc1-9adc-4b93-b838-4349cb61c4a7" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_98657f9c-f5e5-4da2-8271-ddbcbab5c7ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_1d533c86-9a99-459d-84f4-b6e955571879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0b259fc1-9adc-4b93-b838-4349cb61c4a7" xlink:to="loc_us-gaap_SubsequentEventTable_1d533c86-9a99-459d-84f4-b6e955571879" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8d2dacb5-5b11-42d7-a286-d9b05a82c2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1d533c86-9a99-459d-84f4-b6e955571879" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8d2dacb5-5b11-42d7-a286-d9b05a82c2a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8d2dacb5-5b11-42d7-a286-d9b05a82c2a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8d2dacb5-5b11-42d7-a286-d9b05a82c2a5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8d2dacb5-5b11-42d7-a286-d9b05a82c2a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_187f4c09-a245-44f0-80b2-a52746388b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8d2dacb5-5b11-42d7-a286-d9b05a82c2a5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_187f4c09-a245-44f0-80b2-a52746388b75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b2a1e6f4-e3b7-43c8-882e-a770aea9fdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_187f4c09-a245-44f0-80b2-a52746388b75" xlink:to="loc_us-gaap_SubsequentEventMember_b2a1e6f4-e3b7-43c8-882e-a770aea9fdcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_59ea8d62-c77d-4749-8233-44ef8d2d4b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1d533c86-9a99-459d-84f4-b6e955571879" xlink:to="loc_us-gaap_DebtInstrumentAxis_59ea8d62-c77d-4749-8233-44ef8d2d4b6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_59ea8d62-c77d-4749-8233-44ef8d2d4b6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_59ea8d62-c77d-4749-8233-44ef8d2d4b6a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_59ea8d62-c77d-4749-8233-44ef8d2d4b6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1ff78162-e99f-4067-8435-6d31c8739c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_59ea8d62-c77d-4749-8233-44ef8d2d4b6a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1ff78162-e99f-4067-8435-6d31c8739c38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_a3095b77-cd7f-40b4-ad68-c209a5a648cc" xlink:href="exdx-20230331.xsd#exdx_Term2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ff78162-e99f-4067-8435-6d31c8739c38" xlink:to="loc_exdx_Term2017Member_a3095b77-cd7f-40b4-ad68-c209a5a648cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_dbb86046-b1be-4324-bf06-127b79435b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1d533c86-9a99-459d-84f4-b6e955571879" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_dbb86046-b1be-4324-bf06-127b79435b1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_dbb86046-b1be-4324-bf06-127b79435b1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_dbb86046-b1be-4324-bf06-127b79435b1e" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_dbb86046-b1be-4324-bf06-127b79435b1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_d0915995-9793-4221-b361-e69046951190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_dbb86046-b1be-4324-bf06-127b79435b1e" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_d0915995-9793-4221-b361-e69046951190" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_a0f0b3c5-131c-438f-9abc-46b36730d076" xlink:href="exdx-20230331.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_d0915995-9793-4221-b361-e69046951190" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_a0f0b3c5-131c-438f-9abc-46b36730d076" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5b817bb2-f5fe-4329-869f-c33f8172ebc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1d533c86-9a99-459d-84f4-b6e955571879" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5b817bb2-f5fe-4329-869f-c33f8172ebc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5b817bb2-f5fe-4329-869f-c33f8172ebc7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5b817bb2-f5fe-4329-869f-c33f8172ebc7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5b817bb2-f5fe-4329-869f-c33f8172ebc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6a445b4f-187e-415c-827b-e8da2dd6837c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5b817bb2-f5fe-4329-869f-c33f8172ebc7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6a445b4f-187e-415c-827b-e8da2dd6837c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_b2e46303-0022-4c40-ad17-389cfd37b879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6a445b4f-187e-415c-827b-e8da2dd6837c" xlink:to="loc_us-gaap_LoansPayableMember_b2e46303-0022-4c40-ad17-389cfd37b879" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_0f5cff86-8818-4a73-bd1e-8e3f13fbd541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1d533c86-9a99-459d-84f4-b6e955571879" xlink:to="loc_us-gaap_VariableRateAxis_0f5cff86-8818-4a73-bd1e-8e3f13fbd541" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0f5cff86-8818-4a73-bd1e-8e3f13fbd541_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_0f5cff86-8818-4a73-bd1e-8e3f13fbd541" xlink:to="loc_us-gaap_VariableRateDomain_0f5cff86-8818-4a73-bd1e-8e3f13fbd541_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4eabd90e-c2a8-4557-ac07-fadd05e7aee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_0f5cff86-8818-4a73-bd1e-8e3f13fbd541" xlink:to="loc_us-gaap_VariableRateDomain_4eabd90e-c2a8-4557-ac07-fadd05e7aee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_5944bd22-dc65-4a4f-921a-9a2e24563e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4eabd90e-c2a8-4557-ac07-fadd05e7aee1" xlink:to="loc_us-gaap_PrimeRateMember_5944bd22-dc65-4a4f-921a-9a2e24563e94" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>exdx-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:986b824d-5d9a-48e8-aa5f-764c09336517,g:f595c211-a573-4e45-813e-7a98f9aeca2c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1ae788c-1576-4d38-81e1-5f19b3b6f21b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_8154e93c-57b9-4dc6-a91f-ec1d9a60fe43_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7152322d-f3fb-4bf4-9dbb-6cfdb7d25646_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_01d0969c-6aeb-4412-a985-a98dbacda043_terseLabel_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_label_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund [Member]</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_documentation_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:href="exdx-20230331.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:to="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_50b85450-1116-4487-ae21-5ec3ba17682e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_014edaae-9072-42fe-aecd-7189c37c451a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments_e64774b9-ecc7-4e88-9b8e-ab1131b7cc2c_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of monthly installments</link:label>
    <link:label id="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments_label_en-US" xlink:label="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Monthly Installments</link:label>
    <link:label id="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Monthly Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentNumberOfMonthlyInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:to="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_bf34dad0-3045-41bf-a5f6-2ad9b928eab5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_22abe44b-f7a5-46a9-9a38-9c3c31095a9f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_803baa50-3e7c-4b9b-b123-6e338b9812df_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_272cd05a-0b15-45b1-9610-15b0edb7cf4b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d63e247f-7a84-4566-bb65-1f5c36ccbf60_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f81edab8-215d-49db-a3a0-3e0f753eba3e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_cea7b890-215d-415d-8a4f-4cff1e8fece4_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_BlueShieldMember_922e6331-c339-4cd7-8c7a-eb02caf703a4_terseLabel_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield</link:label>
    <link:label id="lab_exdx_BlueShieldMember_label_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield [Member]</link:label>
    <link:label id="lab_exdx_BlueShieldMember_documentation_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember" xlink:href="exdx-20230331.xsd#exdx_BlueShieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_BlueShieldMember" xlink:to="lab_exdx_BlueShieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_970bf24a-5a0f-49eb-b4fe-cc1604dd05e2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d21a5431-47e8-4f06-9f4d-09589264b756_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9072bfcb-484b-413d-8bb0-6d7039570871_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_2eae9486-c465-4722-8a23-290f0cde9176_terseLabel_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty obligation, percent of net sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_label_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_documentation_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:href="exdx-20230331.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:to="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5879683c-191f-49d5-870a-40d787d94472_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_2688858d-d95a-45c6-be58-daca2c24c77a_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_97f53251-da75-42ab-b5ef-e26198c4873e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e41ff6c2-1da7-41fc-a0ef-291f9be89365_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5f47e1c2-10c9-4d0e-b0b7-eface086bebe_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_aa034139-6ab8-4814-911a-f2230efec1f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0aeb87e8-7fe0-4d88-bcbd-8cd8aae2f053_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_555368ae-8118-4f80-88d5-746ceac5f9df_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8387b55c-4c4c-4ad5-b710-2356b03079ad_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_0e5102f2-10d9-46c6-91f4-08af479ed3c2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_142604be-9ee9-4374-8d0b-e223a58ee7d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_6093d1e9-b7ad-4694-b764-e4b1a2ad296a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_232f9817-7f36-4e6d-9590-b9009f67a24d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash items:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_8ac9ef2e-e552-4d3c-995a-158a9032998d_terseLabel_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued purchases of goods and services</link:label>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_label_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase, Goods and Services, Current</link:label>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase, Goods and Services, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:href="exdx-20230331.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:to="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_36691afb-cd24-4706-b17e-59f54e620aa0_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_268fe06e-f4f6-49bd-a2b2-6bc681d14969_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_abc47329-6ba4-4f7e-8a5d-c17fd8c946b0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_42d9258a-77ba-49bd-8417-b7f9f09362ab_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_248b3e1d-8ec9-4388-b952-48f064ea398d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_51aebf42-c0d5-4bc8-9068-4200060d59a2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9d7e58ac-e829-4d6a-a26f-8244c49014e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_090499f2-dcb6-4431-a8ce-dd848fb38a99_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5ce1d3c2-9cab-4df2-9cb8-a7674598245e_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_1b1a7efc-1c98-497c-acf2-459fd7fb7a1c_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, paid in-kind loans issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_label_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:to="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_494d4581-d4f3-462a-acad-eaebd8ce0899_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationSep72024Member_33b87cc9-d6c2-4954-ae46-60eb79100eaf_terseLabel_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration September 7, 2024</link:label>
    <link:label id="lab_exdx_ExpirationSep72024Member_label_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Sep 7, 2024 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationSep72024Member_documentation_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Sep 7, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member" xlink:href="exdx-20230331.xsd#exdx_ExpirationSep72024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationSep72024Member" xlink:to="lab_exdx_ExpirationSep72024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49c38d44-4d76-44b5-831e-07e3cd855941_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e47f0a11-04a9-4168-be0e-062b8a891a49_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9e75ed63-a809-4a0f-ba3b-e4bb09a50e3e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c2fe75ff-49df-4c81-9a65-90ee66db0803_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_4f34661f-4f6d-4efa-9186-4417a970a36b_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_fbfac7fd-cef7-403a-8908-2c7fee6e8dc5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3b9922f9-4acc-4952-a5ad-79944198ea39_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationMar312026Member_799e3bb1-a6fc-40e4-84bb-0e94581aa4c9_terseLabel_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration March 31, 2026</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_label_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Mar 31, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Mar 31, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member" xlink:href="exdx-20230331.xsd#exdx_ExpirationMar312026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationMar312026Member" xlink:to="lab_exdx_ExpirationMar312026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_47ab8033-2668-4f31-817f-4d70a11a9684_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings-non-current portion, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_ad8f9581-64f9-4f84-b732-226b523f86d1_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings-non-current portion, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_5565b414-83b9-466b-b975-b2c779907464_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposit, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0bd7d183-3359-4d3e-8b13-f0bab60155b0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25e5653d-5781-4393-8b8f-e864eb94b044_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_aad147df-c893-4877-87e9-a39d987e6008_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_b0ef3fe8-33da-4298-8fd6-0956c78df4c2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2b540243-447c-434b-be9a-1648bce2082e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4957b653-6a44-49ab-bef5-7ea383963473_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_346a3123-78f6-4b6e-a7ec-2a749147c8d8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_44dc8c6b-d806-421f-8db2-51f7c41b603b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_edd915fc-e61a-4c0e-916d-1c0286890196_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareMember_c108463f-ba75-4fc8-8d57-433ce21e837a_terseLabel_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_exdx_MedicareMember_label_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_exdx_MedicareMember_documentation_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember" xlink:href="exdx-20230331.xsd#exdx_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareMember" xlink:to="lab_exdx_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5c4507d2-26a8-4258-b454-eaa17c2ab7b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9e9db972-02a5-484f-9d6c-bb38d248dcd0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_4ca77126-d74a-46de-b20f-76cb3bb1eb26_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_37994266-efcd-465e-a060-d1e93a3ff55d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7ee34c36-23dd-433d-811d-6b6d1252f9db_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December&#160;31, 2022 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_714eb295-0bd9-4469-b82e-7fc850b56e05_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, March 31, 2023 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_07ac427e-ba93-44cd-af14-2a2a94e2f5f1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9d95e265-0fbb-471a-9d30-f4c3b3faeb15_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_4528653a-5dbb-49c0-808c-ffd8b7a16762_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_8ef49802-dd58-4b94-8dd7-3f20c06bfd81_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationDec72025Member_69301e6d-9703-4b24-b826-05427d7b5b98_terseLabel_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration December 7, 2025</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_label_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Dec 7, 2025 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_documentation_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Dec 7, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member" xlink:href="exdx-20230331.xsd#exdx_ExpirationDec72025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationDec72025Member" xlink:to="lab_exdx_ExpirationDec72025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5c8466f7-08e8-4b84-ab00-48be9b0707de_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_adbeee75-8701-40bc-9df6-fcdf78a1799b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_8f237e7c-7e2a-4502-88e4-ebecb2e7fbe3_negatedLabel_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_label_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_documentation_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:href="exdx-20230331.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:to="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_76578bb0-5f5f-49d3-a943-ddc67a14945f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_7def542b-b3f9-40d5-9d24-0899951f7cfb_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ca7ecfbf-2314-4a83-b729-cfe60c445df6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_32d4ed8b-e4ef-4d85-86c9-a8d321eb989a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_4e7d4526-41dd-4497-8b30-7a39fcb1cecb_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_ba5fc130-2f41-4879-b339-1a8ed37e4237_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b6e62aec-0fbf-4eda-8aa1-e0f2570aa94b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a803da8e-b611-4017-b592-b98c5a6f43c7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4c3179b2-8852-479d-a0ca-bb8691f2e464_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_009a58cd-00f8-41a7-a5cf-de120fd8b38b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_c9855b2d-d51d-4d92-8ceb-3514b6de123f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings-current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_ad5cb363-4699-410f-815b-a1218fba9acd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Borrowings-current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c17a96cd-cd68-4b6a-8bec-7b81615aaa48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f3a2d5e-9eae-4981-a6c9-786c88baf23c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_065c56e0-debc-49e7-8c45-9acdeb6f75f7_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b58aad9a-fee7-468e-9dc1-1d88b7b0ac16_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9bd01ce6-8143-477a-82b6-d1f11b8591e0_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_00a9dcd3-2b89-4eca-a1cf-47323d70075f_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b9b94178-d00b-4882-b6f9-3ddf7acceb52_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_07197654-030d-4011-a0de-08ab53f689fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7cd17de-a402-4b21-9b58-5ad670a4ea0d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7613ecca-982b-4e89-b6c4-f5de45df2b4f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, cost not yet recognized, remaining weighted average vesting period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_9fa5b19f-1510-412e-af25-e6983761e811_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock issued under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_eeb74136-0933-4337-a45e-0b48a9770d3e_terseLabel_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories</link:label>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_label_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories, Inc. [Member]</link:label>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_documentation_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember" xlink:href="exdx-20230331.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrometheusLaboratoriesIncMember" xlink:to="lab_exdx_PrometheusLaboratoriesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_99523fa8-32e8-4bea-a7fd-fafb87efa2fe_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_60f2e791-8c75-4c5d-8efe-cc804bedfc8b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_60b3739d-b3d6-40a0-bb95-36243a639eac_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_0c76cf0e-6b01-42e2-9ab6-3b32d5119f70_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk</link:label>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_86cefbf5-5834-4d06-9443-43d9cf4ae510_terseLabel_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Award Plan</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_label_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Award Plan, 2019 [Member]</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_documentation_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Award Plan, 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member" xlink:href="exdx-20230331.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncentiveAwardPlan2019Member" xlink:to="lab_exdx_IncentiveAwardPlan2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cdbdc963-5449-4e03-b24e-86a17926d9ab_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ca6b51ea-acd8-45bb-a048-503bb1a80d90_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_6abe47fe-fdf3-4735-a486-190e2ef1ac0c_negatedLabel_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_label_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_documentation_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:href="exdx-20230331.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:to="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_94621fc4-0468-4ed0-88ec-9ea5d86e201c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c0ccb5a9-2fed-431d-8877-1c3ebd2dcde4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b4d82eb4-850d-4e83-b8da-abcae3fad0cb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5ca790d6-21fa-4e00-8d99-bd4616f0252d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3634a30f-df25-4ef4-9917-6ebdc7766fe4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a0590b8b-6890-49cc-8ddb-169e989585ca_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4cec7dcc-36ff-481f-9b1d-51cb507d0b57_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_7375aed1-5bc2-4f95-adf1-0e898fe6a405_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, paid in-kind, interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_label_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:to="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_9c7cbeb9-5a5c-4004-b76d-6846ffe2d539_terseLabel_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock from vested restricted stock units and payment of employees' taxes (in shares)</link:label>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_label_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares</link:label>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_documentation_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:href="exdx-20230331.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:to="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_dface7bc-b518-4667-b3a5-300ef01ecae0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b29ee1a5-281a-4765-b5b5-29058eff6a07_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_f23095cc-0c42-406c-8983-84dcd445f9ec_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6c9e2528-28e0-4501-b61c-b8ab90a206c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d62d4bcd-2ac8-417f-b311-2f20109f5a05_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_d0da950a-1a93-48c0-b4e2-79674433f47a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_39ebbb06-b26a-40e2-8c13-c3de2d94624f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, March 31, 2022 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_13f51119-0b9d-48fc-8f1d-1188aaee9f58_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_de6b2636-87ac-4c35-a612-c82951c44b2c_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refund liability</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_023bc163-69d5-45a7-be09-53ff6b3e1f49_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_23ee6a9d-c978-4e9e-8943-bde58c54f2b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_325a2d73-2091-46a6-844f-98aafc995044_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_7fdf8984-e603-4aaf-9349-22c7ec3a63eb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_a03415ae-3f7c-44a7-bad8-b7ea8fbb0522_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_ed51f102-33aa-4e55-9b0c-76b3dc15115f_terseLabel_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid maintenance and insurance contracts</link:label>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_label_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Maintenance and Insurance Contracts</link:label>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_documentation_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Maintenance and Insurance Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:href="exdx-20230331.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:to="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_72dbe6a3-cffc-41ab-9de8-7582f3d7f2fe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, fee incurred upon payment of final installment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_a3b503da-9605-4873-9511-de6bb89daf67_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_c0e716ff-6d08-4e00-8936-d074073d7840_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9c38eb03-2e46-4e0f-bb09-6e1496d10fec_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_c77211ab-ec1a-4d09-ba3d-b0346b0bc550_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a1f3fb30-66f6-422b-b2d5-fa666842c4f3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ae0927b2-d219-4503-b83d-094d0a04baf6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_98ba919c-2958-49c6-9bd9-97cb85c9207e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_1247f0b2-db17-4ccd-ad16-ca8ffc053b5e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_a2dcc24f-2b7a-4f46-9924-ab0dad8e1d6c_terseLabel_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, collaboration expenses</link:label>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_label_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Collaboration Expenses</link:label>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_documentation_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Collaboration Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses" xlink:href="exdx-20230331.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CollaborationAgreementCollaborationExpenses" xlink:to="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_513cbfde-c253-4b6b-b31f-1c372793e457_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6c20123c-4b1f-4c04-afb8-2e7fb33ade84_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_057b35dc-a010-4d2f-83b6-5833d9c4a5a2_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_58bc5591-a7a0-457a-a504-83c1396486b5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f83847c4-de78-4126-a8fc-4deec576fa11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards canceled, Weighted-Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_HealthcareInsurersMember_9d463ab7-98c2-4c08-b8aa-51cd976a414e_terseLabel_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_exdx_HealthcareInsurersMember_label_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Insurers [Member]</link:label>
    <link:label id="lab_exdx_HealthcareInsurersMember_documentation_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Insurers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember" xlink:href="exdx-20230331.xsd#exdx_HealthcareInsurersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_HealthcareInsurersMember" xlink:to="lab_exdx_HealthcareInsurersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8bf91c2a-d6d8-455a-9396-a3ca64403b07_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_11a20d5b-c1b3-40e8-949e-5eb22dd8982e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_02c44422-8de3-4678-9db5-9868c4da326e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_03bfbfbc-1840-4f65-a860-86a9efcfaef8_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_384741eb-cf6e-4c92-8f31-6cbae1a44c16_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2497baf3-a389-4c86-a854-4cc777f21417_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_fde68fe5-188c-46df-966e-0da4087a69d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee payroll deduction percentage</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0ff64fa3-2e31-4e8e-ba19-c07129507ba4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-cash Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3b370825-6d9c-4e63-b96c-025d2638fda9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares that remain available for future awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_54a9a5eb-b1dc-4ad6-a5d7-e6cac03e6fe2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_86005e7f-7800-4f5e-8a1f-f28546471c9e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5f17d0a8-ed0c-458b-9c1a-bfaa04f4e1e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards released, Weighted-Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_bd9aef51-d742-444f-b818-fe41900ae49c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_f2f6e714-221d-4173-ab5a-16ba050c5cb0_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_873c7ce8-c691-4735-9e81-45b89ee72804_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture&#160;and&#160;fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b29367a6-e4d9-459f-bd15-78dbb896adf0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_ea8660d8-4884-4eaa-b8c2-50094b814cad_terseLabel_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock warrants (in shares)</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_label_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_documentation_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:href="exdx-20230331.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:to="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b64c7922-e1e9-4529-b749-ebc80c611c26_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_86356865-9ee2-4d4a-81e3-73847107ab3e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_a5fa2a68-0a33-492a-adc4-49179cc8d122_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_15c1ac04-c106-4169-b66e-c0c2f90a79f2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_06ee3b5a-22a6-43bc-a83c-a92ab16b8dac_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7474790f-ddef-42c6-8879-3cb0ba3dba3c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_59cdcd4e-9d44-451e-932e-186c7176f3ca_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_33fac52a-2881-4762-895f-ddb4dce8032c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_e37cee7b-dc47-45ea-824b-d1dc1e422cd7_terseLabel_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:href="exdx-20230331.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:to="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_032b625f-584f-45ec-b9f2-51eed04bc5c4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_a5810a6c-3142-4574-b099-39d116fff03b_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a493b826-8ca6-4c3f-a002-2b264224f4d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_0a6fe2c7-df08-4e88-b171-bd3ba3ab838e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f7af1361-617a-4add-8b1b-109a3c41d0aa_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_717e80fc-ec6f-446d-888d-8dd68008ec73_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_f92fed92-29db-49a2-bbac-4c1ce48b7d12_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0fcaedef-6771-406e-83f9-0439878b95d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cf5dd77e-a81f-4ab5-9ea6-c2d938c9cde5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2022 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a41eb4ee-2adc-460d-a72a-6136482c64b3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, March 31, 2023 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_832c0e03-f96e-4853-a0c7-6eb808f56e28_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_16639056-8019-4eeb-9236-f552068644af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_a7e5737d-e6f6-4395-8354-b772db3a8a3c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_7bff6ac0-94fe-4e6f-af72-7a00ad37e67c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_167b044e-0fc0-49c0-9c15-b1d21b47cb52_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d09ad771-ab48-4fdf-b6df-f0ef35ec7302_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d1ef45e7-2d92-4fbe-aca3-29ec64cdf9e9_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_61d0f7da-ce4f-49fe-9a98-37f8608742e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, March 31, 2022 (in shares), Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_67e9106f-9be4-4e7c-8693-8eb6126bc11a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c674e8f0-4d7f-4808-8ff6-cf070e200621_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_313317ed-f1e9-45b9-9a22-0e76b0a60abc_terseLabel_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegheny Health Network Research Institute</link:label>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_label_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegheny Health Network Research Institute [Member]</link:label>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_documentation_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegheny Health Network Research Institute</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:href="exdx-20230331.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:to="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6832b6ce-b316-483e-bb0a-03ac5698e91a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f5bc94af-8b61-45d2-8ed0-de30dfb06da3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_12a0e4d9-8ee8-4c28-9627-9a254ac441aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e6072b42-7c29-4e2d-b4c0-25471ffebf96_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements and Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_da764d57-db4e-4377-9c2a-0447e719ee7d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c37ab7be-e5e4-407c-8392-ac2490c24d6e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a5ba5b13-3861-4262-a3fc-43edb689d632_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_11889966-bf54-4e96-a287-5315faf65db5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_62443166-bfb0-45be-b19e-83fe7972d310_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_f38249cd-c6da-499c-9355-816c42236fd9_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Term2017Member_196e2307-10a8-4883-bc7f-3a4f489aca68_terseLabel_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Term loan</link:label>
    <link:label id="lab_exdx_Term2017Member_label_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term 2017 [Member]</link:label>
    <link:label id="lab_exdx_Term2017Member_documentation_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member" xlink:href="exdx-20230331.xsd#exdx_Term2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Term2017Member" xlink:to="lab_exdx_Term2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d1a17a5f-7248-4ad0-915e-463e94a7d09d_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1c226204-5d87-4392-ac18-dfa60cc7ea36_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_78ff235f-611e-46b6-8615-8ec3ab40c9b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60a8401d-6b88-4296-9fc7-f9985ea4f9d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_a5978665-423c-4f57-a530-2350befc24f4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4a81f630-7821-4a7e-81af-c5efadb4f8be_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_d26fbb9c-2261-4411-9b0e-cd8502caed92_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a9225bb1-b385-4292-bb42-c50e3fd6c054_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used to compute net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_37f65e48-f77e-4a3c-967b-2787f0f7b049_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_b46d2caa-2e8d-4705-bee7-8bbe4d0d41d3_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, covenant, number of days to cure covenant if performance measure is not met</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:to="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_394858f7-9ac7-4d8d-b792-e0d4ab481214_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_75f5d431-babb-4fd1-a9a4-36e7cfb6a120_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, current</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_ecc958f0-0135-4154-97b3-d08197de0716_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_05c137e4-331b-4700-a906-7b78e307568d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 200,000,000 shares authorized as of March&#160;31, 2023 and December 31, 2022; 16,827,014 and 16,549,984 shares issued and outstanding as of March&#160;31, 2023 and December 31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_dc75c4b9-103c-45f8-869a-8d79080c09d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e2b5c0ac-102b-4b8a-b8d7-09518fc3d038_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted, Weighted-Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_65d6d935-dd8c-4a59-b16a-6ba4d56ddc31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a6c1dace-a99c-4f14-9cdf-d0b62576e04d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_28fba062-32d6-495f-b02e-03e39bed4277_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_fffd6ce4-5cb0-4b6f-b7fa-b00a1ffe48db_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_e4ade959-7a0f-45aa-9644-93d795194b70_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_865d5e0c-cde0-4944-b571-630545081c85_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22661965-1ed4-4756-ad06-bdcb010ff65d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_07dab09f-8ccc-4192-be19-d26fe7906590_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_edd1291a-c94c-4973-ad4e-e0a3d06e2365_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c16aa0fb-82e2-4f09-a81d-997ff294f04c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e5d1a927-d765-4830-8c18-f187db83e60f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_be0e715e-76e3-4658-8e13-39a579075fb6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_54af31b0-738f-479a-a97f-1b25f18e37d9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_fc6eec3a-75b5-4d1c-bc9c-419495f32ec5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_348a300c-363b-4822-8437-768b85302ba3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_1403bfa3-177b-4477-962b-5a676da1f8ac_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, due in year one</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_544af2a0-235f-4c85-bb10-6e5c2cd36786_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred, but not paid, in connection with capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_266cc07d-6440-4b74-8610-b3e471d74000_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_605b1032-cc3e-439e-93ba-b47d6459eb61_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_a46ca8f5-521c-4ded-81f8-5846ccaf6425_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease obligations, current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AHNCollaborationMember_dd4c8208-eee3-4047-891d-489de964b169_terseLabel_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHN Collaboration</link:label>
    <link:label id="lab_exdx_AHNCollaborationMember_label_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHN Collaboration [Member]</link:label>
    <link:label id="lab_exdx_AHNCollaborationMember_documentation_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHN Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember" xlink:href="exdx-20230331.xsd#exdx_AHNCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AHNCollaborationMember" xlink:to="lab_exdx_AHNCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cd94ef43-19a4-4c4c-9dad-64869bda8d56_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b1efa3e-29f0-496f-b46e-6426c4b3da98_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ac190f1d-01fe-4116-b9fb-7857967edaed_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_a957beeb-e272-427b-a9af-e323a33cfd5b_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_23c4caa4-a5b9-4f80-ac16-2a0b54d0f45e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_17443c71-aeea-4516-a251-03743337213e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidRoyalties_79ec2970-e1b9-446e-9424-7ebd5e4dddfd_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid product royalties</link:label>
    <link:label id="lab_us-gaap_PrepaidRoyalties_label_en-US" xlink:label="lab_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRoyalties" xlink:to="lab_us-gaap_PrepaidRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_be576fcc-b831-4d2b-942a-77805c0fc047_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_363c0884-069a-4710-ad0a-54b78da1b283_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCustomerMember_07bdbec4-c49a-4387-962f-8ea611fb84ed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherCustomerMember_label_en-US" xlink:label="lab_us-gaap_OtherCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCustomerMember" xlink:to="lab_us-gaap_OtherCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_e78cc804-22c7-4245-bc16-169c4d00724f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_51f5de7e-6dae-4a3b-8676-d639d2ab7f88_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan covenant, minimum unrestricted cash balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:to="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_a7468f69-83d3-4e1a-a40f-abac14f52e56_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payment on note payable obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_a221fa9a-9008-4740-87d6-a5b11e10f78f_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, due in second year</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_22df798b-e6c8-4756-9139-677da8d0a84f_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_9592d366-0631-401f-a848-badd3d33e759_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_757545f4-f16f-49f7-a23b-c3fe5ce6d059_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2022 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1de5eea9-167a-4b47-9f02-7a7e059354e3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, March 31, 2023 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9d0937e3-7398-4b8e-8125-91a2d194d78a_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_cfd84486-5684-4099-92de-ce7f97c57286_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_389dcc17-1559-45af-a79a-94b577c0359f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TwoMajorSuppliersMember_3f3cb3a8-796b-445c-a299-d5bdaf40a9c4_terseLabel_en-US" xlink:label="lab_exdx_TwoMajorSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Major Suppliers</link:label>
    <link:label id="lab_exdx_TwoMajorSuppliersMember_label_en-US" xlink:label="lab_exdx_TwoMajorSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Major Suppliers [Member]</link:label>
    <link:label id="lab_exdx_TwoMajorSuppliersMember_documentation_en-US" xlink:label="lab_exdx_TwoMajorSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Major Suppliers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TwoMajorSuppliersMember" xlink:href="exdx-20230331.xsd#exdx_TwoMajorSuppliersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TwoMajorSuppliersMember" xlink:to="lab_exdx_TwoMajorSuppliersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Government1Member_afd45560-f499-4070-9b27-236128ac7042_terseLabel_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government</link:label>
    <link:label id="lab_exdx_Government1Member_label_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government1 [Member]</link:label>
    <link:label id="lab_exdx_Government1Member_documentation_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member" xlink:href="exdx-20230331.xsd#exdx_Government1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Government1Member" xlink:to="lab_exdx_Government1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_a6efb32e-5942-4f15-8de1-6e972dffe221_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7eb901b4-0576-45a5-986c-732dae14af21_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9a6c4a71-e269-4e29-b988-01168ea97ac8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d596bbe0-ca39-4c14-996a-b2fd86cfd885_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6fadb6f9-43b2-411a-9817-5e6c757d35b8_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_8110b9a8-1dbe-49fd-8877-c186b292caac_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_6d91f780-67c0-4a3d-9a23-65779473ef4c_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total borrowings, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations_e0a13d95-0eed-4878-88a3-6433e0647411_terseLabel_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment purchased under notes payable obligations</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations_label_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Purchased Under Notes Payable Obligations</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations_documentation_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Purchased Under Notes Payable Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:href="exdx-20230331.xsd#exdx_EquipmentPurchasedUnderNotesPayableObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:to="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_3fa45fe6-7036-4b2d-962c-72c02b160d9b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_daec620c-1350-44dc-83f2-6d72d60d672d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_0701d326-038e-47e5-bd7c-d903aae78e5d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_134ccd39-19af-4efd-957c-b52c928dd1d2_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_610e49ba-f41e-4343-a269-7e0a38061ca0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_db9c7002-afb5-4c7e-a316-ac0202b09c0f_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_3c06f5d2-68cc-4438-a2ab-8b2f923dfd3c_terseLabel_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_label_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:href="exdx-20230331.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:to="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5c02f2f6-9833-498c-96c1-60cd2d2f3b17_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c87cf108-0149-43ad-b044-6c6c5d4b5346_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_84e18823-0ee4-4d58-bc25-3e00b6fe430b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_790044e9-06ea-4f6f-a183-c2fe8cbab7dc_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3dcf49b6-5232-4764-bd1f-326b40b36f7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_65a9c4db-4ad5-4998-be62-694425e98066_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fdd74fa9-57d8-4731-a072-e0a918058cf8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_5ca3a8ee-7b2f-432b-83cb-d28effb43bd3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_23d32bbb-a6c7-4ecb-a46a-b5ae43b9fd37_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling Costs</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_935bd2a2-c20c-449d-9f23-1dde57965817_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8c49d98c-4da3-417a-809d-78070303e245_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3c02b6bc-3c88-4d66-895e-95f516da79d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_0784bcc1-075f-43ea-ab08-381376f78b7b_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_a2ca84ec-b0e2-4154-9b8a-45cc4db63197_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ee8b2a8f-bc27-4b71-9890-983e0711b123_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareAdvantageMember_7f615dd3-a3c5-4caf-98a4-8ace99606428_verboseLabel_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_label_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_documentation_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember" xlink:href="exdx-20230331.xsd#exdx_MedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareAdvantageMember" xlink:to="lab_exdx_MedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_dd42d552-8506-49e9-acaf-3adae7bd7d20_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_54ae8020-30a5-4477-867f-d8079d3f20b3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2d1c7aa2-1be0-4bb1-8d89-f50b9d93097b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_abc994ef-7b1e-4682-a0ab-e4e00b12b9c4_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, covenant, revenue performance period</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Revenue Performance Period</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Revenue Performance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentCovenantRevenuePerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:to="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_7c4cbd3b-e5e8-4a23-8565-7b0c11b8bdca_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_afbf9c39-293c-433f-8229-15d582ed3477_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, prepayment premium percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_label_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:to="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_07c71077-6ef3-4a54-ac55-71c46779eb5d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_ff73658e-44a0-4304-ac9b-04ea160b75de_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ff9cbfb5-e267-4c6a-b2e6-ae814b817e3b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_92a19bdc-b894-439b-9bc6-958d72208dd1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1545c050-5363-4884-b276-fd940dca2872_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_8f0cfef1-4079-4265-9f7f-84f4b4ea7c67_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum royalty commitment</link:label>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_label_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7ba112f5-2ad5-4325-a986-3a54fbd736a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0e9910b2-132d-4b94-bef3-d8365a52ee43_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_309175cc-812c-49c6-870f-f743f209c197_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6ad6306-3162-420d-bd0c-760e70a93cd7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f09a1fcf-9f4e-4209-86d4-a3067bb443f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdvancePayment_968f55b3-72d0-41bb-8005-6270c562e588_terseLabel_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance royalties payment</link:label>
    <link:label id="lab_exdx_AdvancePayment_label_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payment</link:label>
    <link:label id="lab_exdx_AdvancePayment_documentation_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment" xlink:href="exdx-20230331.xsd#exdx_AdvancePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdvancePayment" xlink:to="lab_exdx_AdvancePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d241fac7-d1f2-4080-989b-a199a9b6adaa_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (remaining)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ced7c681-4bd6-4eaf-9f6b-a719be09350b_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_d0a54da0-1b1c-42c6-acde-6688add08bf1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_620ed16b-6e31-4fe2-b155-88e229387d34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_5f156e8c-5803-4fa0-948b-cfc0469afa54_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_NonCashLeaseExpense_b50c0c0b-26b3-48c9-ae8e-55ab2cb2a789_terseLabel_en-US" xlink:label="lab_exdx_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exdx_NonCashLeaseExpense_label_en-US" xlink:label="lab_exdx_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:label id="lab_exdx_NonCashLeaseExpense_documentation_en-US" xlink:label="lab_exdx_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NonCashLeaseExpense" xlink:href="exdx-20230331.xsd#exdx_NonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_NonCashLeaseExpense" xlink:to="lab_exdx_NonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_0c382f62-f791-4eaf-856d-7bc49f23e7cb_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_fa5d02a2-394b-46bd-a47b-1369c9fe78b8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6b441ce4-494f-4e8e-b690-d38a1e02354e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used to compute net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_61f14ee3-20bf-45f6-a602-6078e56287ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised, March 31, 2022 (in shares), Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AVISECTDTestMember_7c393adc-9955-4e0c-96e1-206fd5563ae1_terseLabel_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_label_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test [Member]</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_documentation_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember" xlink:href="exdx-20230331.xsd#exdx_AVISECTDTestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AVISECTDTestMember" xlink:to="lab_exdx_AVISECTDTestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_fda74799-2202-41d8-a6d2-94ef0c61f1d1_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_e54e5c85-8173-4bab-9e34-fd7fa96f158e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 5)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b5d0ada4-f3f5-43d0-af36-c03ec05a97dd_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19ea47f8-731b-4113-bc3f-53b3c53cbe7e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2022, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_84346313-d773-4199-9f44-0a74c6c98332_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, March 31, 2023, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_e747a1ef-a34e-4f3f-9d94-fbfe716f76be_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_ef2f6d03-b1f2-44e1-9e63-3781d380e40d_terseLabel_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember" xlink:href="exdx-20230331.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LaboratoryEquipmentMember" xlink:to="lab_exdx_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_81edf832-4d2b-4478-9f66-c18c19c2a6ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_b497a0b2-da4f-4c20-8f0c-d798750d08d0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding as of March&#160;31, 2023 and December 31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationJan192026Member_85405c31-cf50-4289-9eed-7dd6700f286b_terseLabel_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration January 19, 2026</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_label_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Jan 19, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Jan 19, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member" xlink:href="exdx-20230331.xsd#exdx_ExpirationJan192026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationJan192026Member" xlink:to="lab_exdx_ExpirationJan192026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e5e8b584-39cc-4837-82a4-8ba3b0beb5dd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_245854c9-d813-46de-9809-e6d0a3296beb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_cfa87629-d62e-4e0d-be3f-f8bfbac04b33_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_ecd1cfef-1ba9-42f8-b3af-0c052b0da909_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OtherLongTermDebtMember_6be17fe0-8e68-4306-bc51-d67768ecc5b8_terseLabel_en-US" xlink:label="lab_exdx_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt</link:label>
    <link:label id="lab_exdx_OtherLongTermDebtMember_label_en-US" xlink:label="lab_exdx_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt [Member]</link:label>
    <link:label id="lab_exdx_OtherLongTermDebtMember_documentation_en-US" xlink:label="lab_exdx_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherLongTermDebtMember" xlink:href="exdx-20230331.xsd#exdx_OtherLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OtherLongTermDebtMember" xlink:to="lab_exdx_OtherLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_99656910-15dc-4df1-ac73-f078cf131783_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d54212d8-9d42-4f82-af2e-9ae20ee1177b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_EquipmentNotesPayableMember_7d442225-466a-41ce-ba03-f4551c5782c5_terseLabel_en-US" xlink:label="lab_exdx_EquipmentNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Notes Payable</link:label>
    <link:label id="lab_exdx_EquipmentNotesPayableMember_label_en-US" xlink:label="lab_exdx_EquipmentNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Notes Payable [Member]</link:label>
    <link:label id="lab_exdx_EquipmentNotesPayableMember_documentation_en-US" xlink:label="lab_exdx_EquipmentNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentNotesPayableMember" xlink:href="exdx-20230331.xsd#exdx_EquipmentNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_EquipmentNotesPayableMember" xlink:to="lab_exdx_EquipmentNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_1baf7d8c-1949-4406-8fec-24c2f50ebd24_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, annual reduction in prepayment penalty percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_label_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage, Annual Reduction</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage, Annual Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:to="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_5a745db0-0c85-404e-91a5-73fa8e394293_terseLabel_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical study activity</link:label>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_label_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Clinical Study, Current</link:label>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Clinical Study, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:href="exdx-20230331.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:to="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d179c7da-d559-4ef9-9ccd-3fd54ba184d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of taxes withheld on vested restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_073430e3-4cf8-40ec-8e44-654cec5a1ea9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_672fe398-e253-4b54-a9a3-685fc14fb536_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_74729a68-df7c-4a59-b524-2a58e7bac6bd_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan covenant, increase to interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:to="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_bfbfcc7d-0005-4bf6-b04a-bb954e66096e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_NoExpirationMember_580375eb-16c3-4574-a7df-27d6b7dcc9d7_terseLabel_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No expiration</link:label>
    <link:label id="lab_exdx_NoExpirationMember_label_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No expiration [Member]</link:label>
    <link:label id="lab_exdx_NoExpirationMember_documentation_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember" xlink:href="exdx-20230331.xsd#exdx_NoExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_NoExpirationMember" xlink:to="lab_exdx_NoExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5297d13e-490f-46f0-b8fe-9e173162113a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClientMember_a8679e3a-73fa-48e3-af6e-0bc90e04fc28_terseLabel_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client</link:label>
    <link:label id="lab_exdx_ClientMember_label_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client [Member]</link:label>
    <link:label id="lab_exdx_ClientMember_documentation_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember" xlink:href="exdx-20230331.xsd#exdx_ClientMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClientMember" xlink:to="lab_exdx_ClientMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5cc9a2c4-e074-4014-bf56-11892a4da3e1_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_88199c4a-4d9b-458a-a983-bffb1630874c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0c3eb248-3b16-4fb6-ae53-ea3333fc5c45_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9bccd991-2e47-4fa1-9566-ef03e16da963_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c7bbe867-ef94-4f12-8b1c-58c9096798ad_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_546b1a24-4491-4af8-b7e5-5147966a86ae_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_07d56eee-6e15-40c8-a57b-3baa1abfd23a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_d53c0e2a-3b99-477d-9e05-53e3aa41bfa1_terseLabel_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in purchase commitments</link:label>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_label_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Annual Increase In Commitment, Percentage</link:label>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_documentation_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Annual Increase In Commitment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:href="exdx-20230331.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:to="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_58e23a36-f46c-40fa-99a8-1ebb6f47bb3d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic&#160;testing&#160;supplies</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_e64177c5-8954-4ebd-9849-e6e5a1c6c454_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_adf8fccb-3c70-4d0b-ae48-4b5878ad08e0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, noncurrent</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_03f6d063-bdf5-4b3e-b683-471e8406921a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_31e46451-f378-4e10-ac3c-127fc54934ca_totalLabel_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_label_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_documentation_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:href="exdx-20230331.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:to="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_108fdf2a-3e2a-4db0-ae28-8ecb598417c1_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_51aed942-35d3-459d-9dd4-ad6a79d8da64_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_140250c2-6bfd-4e8c-9ae3-6796229fc10d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, March 31, 2022 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_1bedc37a-66c5-4511-a755-7dd28d884b1b_terseLabel_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration fee</link:label>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_label_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Annual Collaboration Fee</link:label>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_documentation_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Annual Collaboration Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:href="exdx-20230331.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:to="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract" xlink:href="exdx-20230331.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OtherFinancialInformationAbstract" xlink:to="lab_exdx_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a521248f-6040-4ac6-8fdb-1aa8b4e44cf9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_5b5d217a-a660-4b82-992c-dc6771b2337c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_099ac081-88e1-4d65-802b-0695994e5ae4_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e7d4d5be-85d9-46f5-b38a-668b62447499_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_448d291a-1caa-4068-a389-0944760674b9_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e92f10c6-75f6-4cf6-b569-c5a1bfd79386_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a29ed847-29c0-4c74-b330-6fc5e05d96ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_2e8e6df3-7a1f-4202-8b3f-bf8196d94bb9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_614a5edc-e3f0-4e5c-aaa5-f7c6b799be27_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4c86bc1d-f6ee-4e9a-a848-eaba871dbc12_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_6e64b53d-9cab-4cce-b47d-a59c97722382_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CowenEquityDistributionAgreementMember_60ca30e4-e782-4cfd-95f1-9705aa6e6eba_terseLabel_en-US" xlink:label="lab_exdx_CowenEquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen Equity Distribution Agreement</link:label>
    <link:label id="lab_exdx_CowenEquityDistributionAgreementMember_label_en-US" xlink:label="lab_exdx_CowenEquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen Equity Distribution Agreement [Member]</link:label>
    <link:label id="lab_exdx_CowenEquityDistributionAgreementMember_documentation_en-US" xlink:label="lab_exdx_CowenEquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen Equity Distribution Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CowenEquityDistributionAgreementMember" xlink:href="exdx-20230331.xsd#exdx_CowenEquityDistributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CowenEquityDistributionAgreementMember" xlink:to="lab_exdx_CowenEquityDistributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_97a25c0a-6844-4794-be4c-35f8cf52e470_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_ac30632a-1290-4fa7-b79c-b36bf1811ada_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_7c6a719d-83e7-4878-9a07-3658cd5875f0_terseLabel_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized, percentage</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_label_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_documentation_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:href="exdx-20230331.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:to="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_46e3b74c-2375-42c8-9d81-3fdc11acb9f3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7a0329c7-414e-4740-a1fb-809ee6b1afcc_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_8571d644-46df-49b1-89ae-1a974dfbb995_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid in-kind note</link:label>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_label_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment in Kind (PIK) Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:to="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationApr12026Member_d5339c6a-3929-46ad-82ff-f7b34a76c493_terseLabel_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration April 1, 2026</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_label_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Apr 1, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Apr 1, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member" xlink:href="exdx-20230331.xsd#exdx_ExpirationApr12026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationApr12026Member" xlink:to="lab_exdx_ExpirationApr12026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a558bead-d7bf-4a29-92f1-93ec878f22b0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_dd9d1b70-2be1-4c18-9d7e-6191be7128b7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_aaa6ead2-1642-4e84-9240-415db579cb3a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_3afdf2f5-7d23-4480-9bea-d0496cc1bcfa_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3ca49b78-d1f7-4743-82ac-cddf3f51c99d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96fe205b-2e24-45df-8c2f-09274cefbbf9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_2c272bcd-5436-4c7e-9757-83f69e1f2f75_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risk and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7889c1f8-f7a3-46b7-b61c-a31c00997155_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_46e7d6ca-e408-4128-963b-0bbcfbee823f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_d569e597-69ad-4362-8b13-91a77bcba871_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_e1d6b940-b0d3-4e50-94d2-ea0439bd3dcf_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6e156090-52f2-4d36-a56f-3f73d318f92c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_bf6ff652-ade3-441d-b1fc-40ebd96ef86b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_65c17fff-08d6-4c57-84b8-8a1996b77ebb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_30ebb8a3-60bb-4c71-824c-d2332a92c768_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising and Marketing Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_ec385cc5-fba2-40f4-9bd1-44f2e66e328c_negatedTerseLabel_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock from vested restricted stock units</link:label>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_label_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Value</link:label>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_documentation_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:href="exdx-20230331.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:to="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_2500eacd-02c6-459a-8f4d-f1b5c69e709a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_ae4cc23c-7e4a-4183-9da4-5c9cbcbe5102_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_40387f2d-71a7-4fbb-8089-6b01553f94b4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_025e8f1c-418d-46ea-b9ec-987efda319c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_795444d4-5fa2-4f3a-8c67-c153b03ea03e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_2620a7ed-2581-4432-814c-063a8d04c243_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued to purchase redeemable convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_b6b8a6aa-6082-4b99-ad92-9de5d1a3fa8d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_826fbae1-9e1e-4946-b640-996a872b40a6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_92ed3dc0-3712-4f09-b044-aab580a45f0e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_c3ce74de-c1e0-4b85-a977-87a859b308e8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_d43c764f-8979-45df-a512-2cc9b5378ac3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_581fdb2d-1d07-4bdd-a289-ee1d5ffc8305_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>exdx-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:986b824d-5d9a-48e8-aa5f-764c09336517,g:f595c211-a573-4e45-813e-7a98f9aeca2c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/Cover" xlink:type="simple" xlink:href="exdx-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_aeb424ee-29d5-41fe-a95d-af5dee8d2b51" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_DocumentType_aeb424ee-29d5-41fe-a95d-af5dee8d2b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_81febd88-59e1-497b-b470-eb309bda93e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_DocumentQuarterlyReport_81febd88-59e1-497b-b470-eb309bda93e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2d2305dd-2ce5-489c-b1c7-0a48ed18fc20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_DocumentPeriodEndDate_2d2305dd-2ce5-489c-b1c7-0a48ed18fc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c932c704-048b-412f-8f41-7140ceed9ded" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_DocumentTransitionReport_c932c704-048b-412f-8f41-7140ceed9ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_cfd1c411-31a5-46e8-9186-e489661b1078" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntityFileNumber_cfd1c411-31a5-46e8-9186-e489661b1078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_566099a0-2cbc-4afc-9cab-a8d4ed12c12c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntityRegistrantName_566099a0-2cbc-4afc-9cab-a8d4ed12c12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4420ddd1-0fda-4620-b376-f45adcf4aca6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4420ddd1-0fda-4620-b376-f45adcf4aca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_71a53279-bbad-4065-afd6-c285cd9cb23f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntityTaxIdentificationNumber_71a53279-bbad-4065-afd6-c285cd9cb23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d5490932-8971-4c6a-8dd2-1969950d2e44" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntityAddressAddressLine1_d5490932-8971-4c6a-8dd2-1969950d2e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5efa431d-e538-481d-a064-bb2a947a8676" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntityAddressCityOrTown_5efa431d-e538-481d-a064-bb2a947a8676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ee5e1958-571f-437c-b419-6df3ffb75f06" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntityAddressStateOrProvince_ee5e1958-571f-437c-b419-6df3ffb75f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_89c7a9ce-bd55-4b12-8487-438580ff5e17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntityAddressPostalZipCode_89c7a9ce-bd55-4b12-8487-438580ff5e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3047da12-8d9f-44f0-bef4-0840936f6968" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_CityAreaCode_3047da12-8d9f-44f0-bef4-0840936f6968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_34f3c44d-cc8e-41f0-92d3-4e42f0454138" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_LocalPhoneNumber_34f3c44d-cc8e-41f0-92d3-4e42f0454138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1333063a-a42e-48f8-ac4f-d01f1e8d07c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_Security12bTitle_1333063a-a42e-48f8-ac4f-d01f1e8d07c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fae57bce-7f4f-4f86-912f-791331128da7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_TradingSymbol_fae57bce-7f4f-4f86-912f-791331128da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2a282e60-ed3c-4165-ae97-9df51d5da086" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_SecurityExchangeName_2a282e60-ed3c-4165-ae97-9df51d5da086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_adbdcb67-60bb-4a34-851d-c9fc63d5c9ed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntityCurrentReportingStatus_adbdcb67-60bb-4a34-851d-c9fc63d5c9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0276e75f-d076-4a00-aeaa-c42ebf1206a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntityInteractiveDataCurrent_0276e75f-d076-4a00-aeaa-c42ebf1206a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0baa9423-8e0f-4fdd-9c61-e2d8152b8128" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntityFilerCategory_0baa9423-8e0f-4fdd-9c61-e2d8152b8128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b268176c-b052-4cdb-95d8-add56a9b9ab8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntitySmallBusiness_b268176c-b052-4cdb-95d8-add56a9b9ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_62d529e8-d9ee-4a74-8310-cbcc8796829d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntityEmergingGrowthCompany_62d529e8-d9ee-4a74-8310-cbcc8796829d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_88445761-762b-4fee-a4b8-97ad6f9ea49c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntityExTransitionPeriod_88445761-762b-4fee-a4b8-97ad6f9ea49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_7564a90d-9633-44c1-865b-d94ca9eb64ba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntityShellCompany_7564a90d-9633-44c1-865b-d94ca9eb64ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bcf046cb-35d1-4f29-b8cf-84d651860173" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bcf046cb-35d1-4f29-b8cf-84d651860173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d7cb16ed-565b-44a1-9d38-0a0df1d2b1fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_EntityCentralIndexKey_d7cb16ed-565b-44a1-9d38-0a0df1d2b1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_77f63d71-5207-40ad-b7d3-32513d361ef7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_CurrentFiscalYearEndDate_77f63d71-5207-40ad-b7d3-32513d361ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b7c53aa5-5988-4624-8951-093dc1a7897e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_DocumentFiscalYearFocus_b7c53aa5-5988-4624-8951-093dc1a7897e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f3853a0c-63bc-4953-b1a5-477872953a70" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f3853a0c-63bc-4953-b1a5-477872953a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_301c232a-0b00-48bc-8e6f-4ba949f63356" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8263356e-6e19-403e-86bf-77303583fabb" xlink:to="loc_dei_AmendmentFlag_301c232a-0b00-48bc-8e6f-4ba949f63356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedBalanceSheets" xlink:type="simple" xlink:href="exdx-20230331.xsd#UnauditedCondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_477f8d01-8737-4cdf-81cb-984252d7a2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ae653632-e6f0-45c1-894c-cdad41d549b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_477f8d01-8737-4cdf-81cb-984252d7a2c1" xlink:to="loc_us-gaap_AssetsAbstract_ae653632-e6f0-45c1-894c-cdad41d549b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1964ac43-607c-4f1d-9ec9-4721eacdbd61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ae653632-e6f0-45c1-894c-cdad41d549b0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1964ac43-607c-4f1d-9ec9-4721eacdbd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_48ba101a-0640-4084-a3fd-99efad7a6dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1964ac43-607c-4f1d-9ec9-4721eacdbd61" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_48ba101a-0640-4084-a3fd-99efad7a6dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_19fa6251-1a52-4137-bd2f-6c4e930585b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1964ac43-607c-4f1d-9ec9-4721eacdbd61" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_19fa6251-1a52-4137-bd2f-6c4e930585b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_b7b3e1a6-3c4c-4dfa-b2a4-df219d7d8743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1964ac43-607c-4f1d-9ec9-4721eacdbd61" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_b7b3e1a6-3c4c-4dfa-b2a4-df219d7d8743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5b8c3f2f-714a-46ef-bb15-b9de44c8ce0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1964ac43-607c-4f1d-9ec9-4721eacdbd61" xlink:to="loc_us-gaap_AssetsCurrent_5b8c3f2f-714a-46ef-bb15-b9de44c8ce0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_868a7a82-04d0-4f9b-8a72-3b04061e26c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ae653632-e6f0-45c1-894c-cdad41d549b0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_868a7a82-04d0-4f9b-8a72-3b04061e26c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ee6801ef-7dde-48ea-bac5-8a727b10c58a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ae653632-e6f0-45c1-894c-cdad41d549b0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ee6801ef-7dde-48ea-bac5-8a727b10c58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1e499025-b5c8-49c8-9422-6fd1a184057f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ae653632-e6f0-45c1-894c-cdad41d549b0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1e499025-b5c8-49c8-9422-6fd1a184057f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8a8b3f50-c236-4cf1-b6fe-038945f501e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ae653632-e6f0-45c1-894c-cdad41d549b0" xlink:to="loc_us-gaap_Assets_8a8b3f50-c236-4cf1-b6fe-038945f501e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36f3cc7e-e531-4e98-bfa1-370fc34ebdeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_477f8d01-8737-4cdf-81cb-984252d7a2c1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36f3cc7e-e531-4e98-bfa1-370fc34ebdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_05514570-2ca9-4d43-8151-6c7a835f60bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36f3cc7e-e531-4e98-bfa1-370fc34ebdeb" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_05514570-2ca9-4d43-8151-6c7a835f60bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_636e1266-461a-458b-97b0-ddda3b655ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_05514570-2ca9-4d43-8151-6c7a835f60bf" xlink:to="loc_us-gaap_AccountsPayableCurrent_636e1266-461a-458b-97b0-ddda3b655ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_21bedfed-06ea-4e92-87e2-4fa8cc331bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_05514570-2ca9-4d43-8151-6c7a835f60bf" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_21bedfed-06ea-4e92-87e2-4fa8cc331bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_beb66e28-d7c3-460a-83de-4ec9fca26882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_05514570-2ca9-4d43-8151-6c7a835f60bf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_beb66e28-d7c3-460a-83de-4ec9fca26882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_734c03ff-7d20-4473-b772-1695e0485e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_05514570-2ca9-4d43-8151-6c7a835f60bf" xlink:to="loc_us-gaap_LongTermDebtCurrent_734c03ff-7d20-4473-b772-1695e0485e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_86a1c4d4-0f5b-479e-9d36-b359bd65c5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_05514570-2ca9-4d43-8151-6c7a835f60bf" xlink:to="loc_us-gaap_LiabilitiesCurrent_86a1c4d4-0f5b-479e-9d36-b359bd65c5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_71d42db1-147d-4231-bf83-6bf1726cdfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36f3cc7e-e531-4e98-bfa1-370fc34ebdeb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_71d42db1-147d-4231-bf83-6bf1726cdfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_514dee9f-5f33-4170-a4f1-1e410f01abc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36f3cc7e-e531-4e98-bfa1-370fc34ebdeb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_514dee9f-5f33-4170-a4f1-1e410f01abc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_607d4375-e9b7-47e7-b93f-db4c50084c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36f3cc7e-e531-4e98-bfa1-370fc34ebdeb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_607d4375-e9b7-47e7-b93f-db4c50084c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9f25972f-86d0-443b-b570-fe20bd77c19e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36f3cc7e-e531-4e98-bfa1-370fc34ebdeb" xlink:to="loc_us-gaap_Liabilities_9f25972f-86d0-443b-b570-fe20bd77c19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a6301a34-9d25-44df-8c76-b5b0e6f32c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36f3cc7e-e531-4e98-bfa1-370fc34ebdeb" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a6301a34-9d25-44df-8c76-b5b0e6f32c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_c42a3603-fedc-4548-a951-abcdac64b56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36f3cc7e-e531-4e98-bfa1-370fc34ebdeb" xlink:to="loc_us-gaap_StockholdersEquityAbstract_c42a3603-fedc-4548-a951-abcdac64b56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_72e17902-d167-497a-bc6d-6ab8dc94d8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c42a3603-fedc-4548-a951-abcdac64b56e" xlink:to="loc_us-gaap_PreferredStockValue_72e17902-d167-497a-bc6d-6ab8dc94d8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_634489c2-bdc9-4c6a-90a6-bf9c6d0530cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c42a3603-fedc-4548-a951-abcdac64b56e" xlink:to="loc_us-gaap_CommonStockValue_634489c2-bdc9-4c6a-90a6-bf9c6d0530cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e60b5814-bca1-441c-af32-3f3ef99850d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c42a3603-fedc-4548-a951-abcdac64b56e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e60b5814-bca1-441c-af32-3f3ef99850d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6dd41aa1-f4e3-482d-982f-5a9fcd9615ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c42a3603-fedc-4548-a951-abcdac64b56e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6dd41aa1-f4e3-482d-982f-5a9fcd9615ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8b498de0-1fff-4775-89f0-ec65894a49be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c42a3603-fedc-4548-a951-abcdac64b56e" xlink:to="loc_us-gaap_StockholdersEquity_8b498de0-1fff-4775-89f0-ec65894a49be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae05f2b6-70fa-4dfd-af1e-cf88a3ab38ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36f3cc7e-e531-4e98-bfa1-370fc34ebdeb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae05f2b6-70fa-4dfd-af1e-cf88a3ab38ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exdx-20230331.xsd#UnauditedCondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3629f9c1-d38d-404d-bda4-49afb310e480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e7c1e269-2b54-447c-8b7b-512a0522eaad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3629f9c1-d38d-404d-bda4-49afb310e480" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e7c1e269-2b54-447c-8b7b-512a0522eaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b5d1d268-6cf2-4e49-b241-38d115b9c6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e7c1e269-2b54-447c-8b7b-512a0522eaad" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b5d1d268-6cf2-4e49-b241-38d115b9c6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9cd61cd0-a914-4681-abc6-3d92834c72df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e7c1e269-2b54-447c-8b7b-512a0522eaad" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9cd61cd0-a914-4681-abc6-3d92834c72df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_b9926e31-bd32-4b32-b154-c02dd6f4cc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e7c1e269-2b54-447c-8b7b-512a0522eaad" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_b9926e31-bd32-4b32-b154-c02dd6f4cc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_87eeb31d-aded-4319-89b9-7a1bd806a90e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e7c1e269-2b54-447c-8b7b-512a0522eaad" xlink:to="loc_us-gaap_PreferredStockSharesIssued_87eeb31d-aded-4319-89b9-7a1bd806a90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8d3bee0a-672d-4f09-b157-2244c59ab471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3629f9c1-d38d-404d-bda4-49afb310e480" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8d3bee0a-672d-4f09-b157-2244c59ab471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1dbd6116-9cc0-427a-be17-734256b956a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8d3bee0a-672d-4f09-b157-2244c59ab471" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1dbd6116-9cc0-427a-be17-734256b956a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_bd7d9842-bad1-4588-94ee-2185d50b8294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8d3bee0a-672d-4f09-b157-2244c59ab471" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_bd7d9842-bad1-4588-94ee-2185d50b8294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cf46c864-39c3-4580-8ee3-f416f9c77516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8d3bee0a-672d-4f09-b157-2244c59ab471" xlink:to="loc_us-gaap_CommonStockSharesIssued_cf46c864-39c3-4580-8ee3-f416f9c77516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0da85920-e265-4304-8049-e00ea3d1c02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8d3bee0a-672d-4f09-b157-2244c59ab471" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0da85920-e265-4304-8049-e00ea3d1c02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="simple" xlink:href="exdx-20230331.xsd#UnauditedCondensedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8a02069e-2486-4733-808c-6d01903eca5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2012e678-a79e-4a2e-ae2e-871ccd9145be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a02069e-2486-4733-808c-6d01903eca5f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2012e678-a79e-4a2e-ae2e-871ccd9145be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_c3bd7fc7-70f8-4df4-9acf-d3d4aecd0e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a02069e-2486-4733-808c-6d01903eca5f" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_c3bd7fc7-70f8-4df4-9acf-d3d4aecd0e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_60acc8cc-0c3e-432c-ace7-6fcb69a70820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c3bd7fc7-70f8-4df4-9acf-d3d4aecd0e8e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_60acc8cc-0c3e-432c-ace7-6fcb69a70820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e6eec1cf-48cc-491f-966e-82826b866dca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c3bd7fc7-70f8-4df4-9acf-d3d4aecd0e8e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e6eec1cf-48cc-491f-966e-82826b866dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e28d5ceb-da2a-4f56-9a36-05929888ad3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c3bd7fc7-70f8-4df4-9acf-d3d4aecd0e8e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e28d5ceb-da2a-4f56-9a36-05929888ad3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_941d451d-1635-471c-a259-c3a46213e30e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c3bd7fc7-70f8-4df4-9acf-d3d4aecd0e8e" xlink:to="loc_us-gaap_CostsAndExpenses_941d451d-1635-471c-a259-c3a46213e30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0fb10fa4-859b-4cac-9b61-ad098fd18ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a02069e-2486-4733-808c-6d01903eca5f" xlink:to="loc_us-gaap_OperatingIncomeLoss_0fb10fa4-859b-4cac-9b61-ad098fd18ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8374e624-cd3d-4467-be88-31107a3672e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a02069e-2486-4733-808c-6d01903eca5f" xlink:to="loc_us-gaap_InterestExpense_8374e624-cd3d-4467-be88-31107a3672e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_77f7e643-5e94-4da1-a62c-24a172e184b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a02069e-2486-4733-808c-6d01903eca5f" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_77f7e643-5e94-4da1-a62c-24a172e184b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5febab1a-0258-4bc5-9130-bf8a400708da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a02069e-2486-4733-808c-6d01903eca5f" xlink:to="loc_us-gaap_NetIncomeLoss_5febab1a-0258-4bc5-9130-bf8a400708da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f05ee688-953e-476b-b1c1-3d586d3ec22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a02069e-2486-4733-808c-6d01903eca5f" xlink:to="loc_us-gaap_EarningsPerShareBasic_f05ee688-953e-476b-b1c1-3d586d3ec22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_93f1b557-cb71-49f3-bafb-a786d714ba51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a02069e-2486-4733-808c-6d01903eca5f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_93f1b557-cb71-49f3-bafb-a786d714ba51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_500a8b0b-0031-40b1-9e87-9f637f224c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a02069e-2486-4733-808c-6d01903eca5f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_500a8b0b-0031-40b1-9e87-9f637f224c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b9e8fbd0-60df-4e3e-8350-d7b83477720c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a02069e-2486-4733-808c-6d01903eca5f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b9e8fbd0-60df-4e3e-8350-d7b83477720c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exdx-20230331.xsd#UnauditedCondensedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_11079782-16e5-4681-b7e3-8a8190ff5df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9552d2c3-3595-4eaf-b09f-6b1d570ad31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_11079782-16e5-4681-b7e3-8a8190ff5df8" xlink:to="loc_us-gaap_StatementTable_9552d2c3-3595-4eaf-b09f-6b1d570ad31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b0469d96-e9c6-46e4-96c5-90e36496d128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9552d2c3-3595-4eaf-b09f-6b1d570ad31b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b0469d96-e9c6-46e4-96c5-90e36496d128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b37e9760-51a8-483b-87c3-e79d03da0493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b0469d96-e9c6-46e4-96c5-90e36496d128" xlink:to="loc_us-gaap_EquityComponentDomain_b37e9760-51a8-483b-87c3-e79d03da0493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e8b748bd-37fc-45ac-ad35-5ac509328965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b37e9760-51a8-483b-87c3-e79d03da0493" xlink:to="loc_us-gaap_CommonStockMember_e8b748bd-37fc-45ac-ad35-5ac509328965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f874c6ed-c20b-45ee-a2a6-33d63298313a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b37e9760-51a8-483b-87c3-e79d03da0493" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f874c6ed-c20b-45ee-a2a6-33d63298313a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0f7548b4-91e1-4c92-93f4-2a36b45a5428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b37e9760-51a8-483b-87c3-e79d03da0493" xlink:to="loc_us-gaap_RetainedEarningsMember_0f7548b4-91e1-4c92-93f4-2a36b45a5428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_91cc3f75-8818-4cb7-995b-7fa3e86a9852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9552d2c3-3595-4eaf-b09f-6b1d570ad31b" xlink:to="loc_us-gaap_StatementLineItems_91cc3f75-8818-4cb7-995b-7fa3e86a9852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91cc3f75-8818-4cb7-995b-7fa3e86a9852" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cd79ba0c-8580-4283-bc55-7a95ce825e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cd79ba0c-8580-4283-bc55-7a95ce825e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9fe80d2e-ea65-48e6-b0d7-151bc208244d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_StockholdersEquity_9fe80d2e-ea65-48e6-b0d7-151bc208244d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_2e8c58c3-d6ab-4d14-bf2a-e47335f3d6de" xlink:href="exdx-20230331.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_2e8c58c3-d6ab-4d14-bf2a-e47335f3d6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_23b312de-6856-412f-8c3c-8c2806b31097" xlink:href="exdx-20230331.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_23b312de-6856-412f-8c3c-8c2806b31097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_08220cde-028e-4e9c-9370-67d0450f40fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_08220cde-028e-4e9c-9370-67d0450f40fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_30494856-590e-4565-bf6d-8c36d7310962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_30494856-590e-4565-bf6d-8c36d7310962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1119900d-c86f-4a38-9fd1-309005d9f2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1119900d-c86f-4a38-9fd1-309005d9f2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6b89e8a9-da81-4989-987a-557ad72830dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6b89e8a9-da81-4989-987a-557ad72830dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c8b35d70-c796-4dc0-817e-9d4f82200b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c8b35d70-c796-4dc0-817e-9d4f82200b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cb3e99ef-ec68-458a-858a-0c88dc538983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_NetIncomeLoss_cb3e99ef-ec68-458a-858a-0c88dc538983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2bcf9c9d-7844-4f2a-8eec-d8d5cb4e4672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2bcf9c9d-7844-4f2a-8eec-d8d5cb4e4672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_23ea4417-7590-42f7-ac1e-e45852af1061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bee9cc99-b243-4d37-b98f-3c6059d1e9e8" xlink:to="loc_us-gaap_StockholdersEquity_23ea4417-7590-42f7-ac1e-e45852af1061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20230331.xsd#UnauditedCondensedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_85c93a4e-5522-4ba2-ad68-81cca7667710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_d22da458-74fc-40b1-a444-b35bcc8c2d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_85c93a4e-5522-4ba2-ad68-81cca7667710" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_d22da458-74fc-40b1-a444-b35bcc8c2d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2462eb97-0da9-4012-a136-7500ae75ce84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_d22da458-74fc-40b1-a444-b35bcc8c2d4d" xlink:to="loc_us-gaap_NetIncomeLoss_2462eb97-0da9-4012-a136-7500ae75ce84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a6238fc3-2117-4218-a40d-edd131e39339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_d22da458-74fc-40b1-a444-b35bcc8c2d4d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a6238fc3-2117-4218-a40d-edd131e39339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_23370207-7882-4e8a-89f2-bb0053e9c095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a6238fc3-2117-4218-a40d-edd131e39339" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_23370207-7882-4e8a-89f2-bb0053e9c095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a8e5ad65-88f5-4e98-abcd-9cff39d05bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a6238fc3-2117-4218-a40d-edd131e39339" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a8e5ad65-88f5-4e98-abcd-9cff39d05bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_1de798b5-b55f-40a1-b182-266782dd3b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a6238fc3-2117-4218-a40d-edd131e39339" xlink:to="loc_us-gaap_PaidInKindInterest_1de798b5-b55f-40a1-b182-266782dd3b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_cc8ae0f0-3d72-493c-8d70-e38b42fff86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a6238fc3-2117-4218-a40d-edd131e39339" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_cc8ae0f0-3d72-493c-8d70-e38b42fff86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NonCashLeaseExpense_48550bfc-3473-484a-a191-53e5b2ef3515" xlink:href="exdx-20230331.xsd#exdx_NonCashLeaseExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a6238fc3-2117-4218-a40d-edd131e39339" xlink:to="loc_exdx_NonCashLeaseExpense_48550bfc-3473-484a-a191-53e5b2ef3515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c07f4878-d681-4dbb-910c-59c77469bf35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a6238fc3-2117-4218-a40d-edd131e39339" xlink:to="loc_us-gaap_ShareBasedCompensation_c07f4878-d681-4dbb-910c-59c77469bf35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25fc1356-9c81-4db9-9729-2a030b89d42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a6238fc3-2117-4218-a40d-edd131e39339" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25fc1356-9c81-4db9-9729-2a030b89d42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7d9d9d00-8d3e-49a7-baa6-7f3b690f6962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25fc1356-9c81-4db9-9729-2a030b89d42e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7d9d9d00-8d3e-49a7-baa6-7f3b690f6962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_6bb5f624-175b-4fa1-8aed-f8eaca7dca42" xlink:href="exdx-20230331.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25fc1356-9c81-4db9-9729-2a030b89d42e" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_6bb5f624-175b-4fa1-8aed-f8eaca7dca42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_bc3c5ba3-2cf2-4425-9cf2-aca009780fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25fc1356-9c81-4db9-9729-2a030b89d42e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_bc3c5ba3-2cf2-4425-9cf2-aca009780fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b45b724c-9c00-4b41-bd66-99a7ea112fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25fc1356-9c81-4db9-9729-2a030b89d42e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b45b724c-9c00-4b41-bd66-99a7ea112fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9720e90d-c8a1-4c39-bc4b-1c2925d14e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25fc1356-9c81-4db9-9729-2a030b89d42e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9720e90d-c8a1-4c39-bc4b-1c2925d14e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1e21dbbf-4dad-406f-a27e-9a112f5b55b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_25fc1356-9c81-4db9-9729-2a030b89d42e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1e21dbbf-4dad-406f-a27e-9a112f5b55b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33a2c968-f8e9-44d5-af72-16d5ae10244f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_d22da458-74fc-40b1-a444-b35bcc8c2d4d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33a2c968-f8e9-44d5-af72-16d5ae10244f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_43ad2bfd-a92d-4f72-bf56-a30ea07ea669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_85c93a4e-5522-4ba2-ad68-81cca7667710" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_43ad2bfd-a92d-4f72-bf56-a30ea07ea669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e781b144-e80d-4540-97a4-8d2a756c4adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_43ad2bfd-a92d-4f72-bf56-a30ea07ea669" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e781b144-e80d-4540-97a4-8d2a756c4adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a2bbee56-6159-4c29-b82c-93611c83dfd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_43ad2bfd-a92d-4f72-bf56-a30ea07ea669" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a2bbee56-6159-4c29-b82c-93611c83dfd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9d043b4e-d7ba-44ba-9d47-9cde50aec22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_85c93a4e-5522-4ba2-ad68-81cca7667710" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9d043b4e-d7ba-44ba-9d47-9cde50aec22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_22e36e33-df2d-4df7-963e-b0534c775d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9d043b4e-d7ba-44ba-9d47-9cde50aec22f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_22e36e33-df2d-4df7-963e-b0534c775d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9112526a-0fd4-4027-8b6f-2c14aaf813db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9d043b4e-d7ba-44ba-9d47-9cde50aec22f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9112526a-0fd4-4027-8b6f-2c14aaf813db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_03402558-63a1-461e-bbc7-3c0d671a24f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9d043b4e-d7ba-44ba-9d47-9cde50aec22f" xlink:to="loc_us-gaap_ProceedsFromStockPlans_03402558-63a1-461e-bbc7-3c0d671a24f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_464f5be1-bc0f-45f5-b5a5-8cfd92dac4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9d043b4e-d7ba-44ba-9d47-9cde50aec22f" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_464f5be1-bc0f-45f5-b5a5-8cfd92dac4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_6b83dae7-9657-4d0c-b503-8c19715c4d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9d043b4e-d7ba-44ba-9d47-9cde50aec22f" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_6b83dae7-9657-4d0c-b503-8c19715c4d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e3aa5f03-74db-48f7-ba4f-339a8c1c5756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9d043b4e-d7ba-44ba-9d47-9cde50aec22f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e3aa5f03-74db-48f7-ba4f-339a8c1c5756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3581b5c0-cf6c-4852-b15f-b9478a57f892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_85c93a4e-5522-4ba2-ad68-81cca7667710" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3581b5c0-cf6c-4852-b15f-b9478a57f892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54bd8e55-7665-40a5-a2af-18400e84ec67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_85c93a4e-5522-4ba2-ad68-81cca7667710" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54bd8e55-7665-40a5-a2af-18400e84ec67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14ad3145-10b8-4dcc-a372-34b187b99c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_85c93a4e-5522-4ba2-ad68-81cca7667710" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14ad3145-10b8-4dcc-a372-34b187b99c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b9d05a01-1edf-41ba-893c-1ade936e7732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_85c93a4e-5522-4ba2-ad68-81cca7667710" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b9d05a01-1edf-41ba-893c-1ade936e7732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_89b852b4-0f8a-41bb-87a4-bbb060f07a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b9d05a01-1edf-41ba-893c-1ade936e7732" xlink:to="loc_us-gaap_InterestPaidNet_89b852b4-0f8a-41bb-87a4-bbb060f07a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_23f0f208-ae12-46dc-9f93-34dfcb8e50bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_85c93a4e-5522-4ba2-ad68-81cca7667710" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_23f0f208-ae12-46dc-9f93-34dfcb8e50bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations_740d1baa-03b1-4a3e-b16a-c888c5653fb0" xlink:href="exdx-20230331.xsd#exdx_EquipmentPurchasedUnderNotesPayableObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_23f0f208-ae12-46dc-9f93-34dfcb8e50bc" xlink:to="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations_740d1baa-03b1-4a3e-b16a-c888c5653fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_186eb035-f4ab-41b0-bbd8-a64c6d2f6048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_23f0f208-ae12-46dc-9f93-34dfcb8e50bc" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_186eb035-f4ab-41b0-bbd8-a64c6d2f6048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Organization" xlink:type="simple" xlink:href="exdx-20230331.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_52e2b668-01cc-4c4b-a198-24997c2eba7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_85091419-eddc-43b5-90f3-129aa350d777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_52e2b668-01cc-4c4b-a198-24997c2eba7f" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_85091419-eddc-43b5-90f3-129aa350d777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exdx-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0c59d0db-9cf8-4a07-90c7-557416907b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_97f15baa-1e96-4540-b4d2-9e5b60abfe46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c59d0db-9cf8-4a07-90c7-557416907b04" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_97f15baa-1e96-4540-b4d2-9e5b60abfe46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="exdx-20230331.xsd#OtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_f31bc1d6-fb96-4e0f-bb51-e40fc0daf18c" xlink:href="exdx-20230331.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_b40729da-278f-45fa-bf9c-cf60eb74da8a" xlink:href="exdx-20230331.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_f31bc1d6-fb96-4e0f-bb51-e40fc0daf18c" xlink:to="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_b40729da-278f-45fa-bf9c-cf60eb74da8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Borrowings" xlink:type="simple" xlink:href="exdx-20230331.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_79269627-db89-4676-92f6-4b875f2dbc21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_86296e9c-285e-434a-b929-836fd526d2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_79269627-db89-4676-92f6-4b875f2dbc21" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_86296e9c-285e-434a-b929-836fd526d2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="exdx-20230331.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_03e7334d-2adb-4331-94a9-4b005a783ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_21e34f96-08b3-4058-a3db-d8140b2bcf79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_03e7334d-2adb-4331-94a9-4b005a783ae1" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_21e34f96-08b3-4058-a3db-d8140b2bcf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exdx-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0c818f81-9374-4544-9c66-7cb7dcb08c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_53151781-47e1-4477-9c1d-f263530e650b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0c818f81-9374-4544-9c66-7cb7dcb08c46" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_53151781-47e1-4477-9c1d-f263530e650b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquity" xlink:type="simple" xlink:href="exdx-20230331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4b274979-33de-4a77-8050-5611cac1787f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f69a15f6-aafb-4bbc-acc2-069538ad4fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4b274979-33de-4a77-8050-5611cac1787f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f69a15f6-aafb-4bbc-acc2-069538ad4fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlan" xlink:type="simple" xlink:href="exdx-20230331.xsd#StockOptionPlan"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2bd4238c-d210-45c0-8b96-40a05bebd23a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7738e692-ceb6-4ade-bd07-70a26493c6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2bd4238c-d210-45c0-8b96-40a05bebd23a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7738e692-ceb6-4ade-bd07-70a26493c6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SubsequentEvents" xlink:type="simple" xlink:href="exdx-20230331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9d0867dc-24b0-40c1-931b-b332ea07d06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_c05055c9-3617-4d1a-9027-16d4b2c4baf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9d0867dc-24b0-40c1-931b-b332ea07d06d" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_c05055c9-3617-4d1a-9027-16d4b2c4baf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exdx-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9b21509a-5487-4946-8b5b-efceb5c4c918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_b22fc5a0-7325-4224-8ea3-1591cd92dfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b21509a-5487-4946-8b5b-efceb5c4c918" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_b22fc5a0-7325-4224-8ea3-1591cd92dfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e68199b3-9db7-4f1c-bfe8-b0cf9c1485a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b21509a-5487-4946-8b5b-efceb5c4c918" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e68199b3-9db7-4f1c-bfe8-b0cf9c1485a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3267317b-f285-46de-b275-2ad8c3b9d0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b21509a-5487-4946-8b5b-efceb5c4c918" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3267317b-f285-46de-b275-2ad8c3b9d0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_dc357321-b67e-4cb3-9922-44130c960d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b21509a-5487-4946-8b5b-efceb5c4c918" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_dc357321-b67e-4cb3-9922-44130c960d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_ff2f6b51-0e7d-40d6-8888-5cb3ad6fa498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b21509a-5487-4946-8b5b-efceb5c4c918" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_ff2f6b51-0e7d-40d6-8888-5cb3ad6fa498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8573d48e-315e-49f7-9ae0-8e21069224f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b21509a-5487-4946-8b5b-efceb5c4c918" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8573d48e-315e-49f7-9ae0-8e21069224f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_3ca0d891-3006-4bd0-a87d-165a18a70bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b21509a-5487-4946-8b5b-efceb5c4c918" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_3ca0d891-3006-4bd0-a87d-165a18a70bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_736625dc-913b-4ee7-9ca4-036bb4f725dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b21509a-5487-4946-8b5b-efceb5c4c918" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_736625dc-913b-4ee7-9ca4-036bb4f725dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_999e2589-8f97-426e-8220-b9956ecebc22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b21509a-5487-4946-8b5b-efceb5c4c918" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_999e2589-8f97-426e-8220-b9956ecebc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_d56b8271-4dc8-417c-8c5f-e8ab47fdc586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b21509a-5487-4946-8b5b-efceb5c4c918" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_d56b8271-4dc8-417c-8c5f-e8ab47fdc586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_da3deabd-5ae7-43c4-baed-ddc9035eb4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b21509a-5487-4946-8b5b-efceb5c4c918" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_da3deabd-5ae7-43c4-baed-ddc9035eb4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8c9cae40-8da7-4dd9-8005-2fe2e55c5af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b21509a-5487-4946-8b5b-efceb5c4c918" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8c9cae40-8da7-4dd9-8005-2fe2e55c5af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4d9f5539-996b-40d2-a103-2c6cc6a09bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b21509a-5487-4946-8b5b-efceb5c4c918" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4d9f5539-996b-40d2-a103-2c6cc6a09bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exdx-20230331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7bcee6cd-c62a-469b-a2a5-293a5e9b4937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_418c453d-ce16-4ce0-a63a-cb3a25baa22e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7bcee6cd-c62a-469b-a2a5-293a5e9b4937" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_418c453d-ce16-4ce0-a63a-cb3a25baa22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_58b44f5d-7a2f-48a3-9110-fe13b86b6bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7bcee6cd-c62a-469b-a2a5-293a5e9b4937" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_58b44f5d-7a2f-48a3-9110-fe13b86b6bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_2e7a2bb6-898b-4546-91a9-190347025bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7bcee6cd-c62a-469b-a2a5-293a5e9b4937" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_2e7a2bb6-898b-4546-91a9-190347025bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5ab39c2e-8a4d-4c5a-bd65-8945e5e379a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7bcee6cd-c62a-469b-a2a5-293a5e9b4937" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5ab39c2e-8a4d-4c5a-bd65-8945e5e379a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_528d7ce4-a7b9-4943-b861-95ca1b01dff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7bcee6cd-c62a-469b-a2a5-293a5e9b4937" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_528d7ce4-a7b9-4943-b861-95ca1b01dff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="exdx-20230331.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_42672244-bf70-4c2f-b338-a9288a9e583a" xlink:href="exdx-20230331.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_8bd15745-5b9e-4eb1-8227-ec54ef3fcf35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_42672244-bf70-4c2f-b338-a9288a9e583a" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_8bd15745-5b9e-4eb1-8227-ec54ef3fcf35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5a617c2b-8542-4e87-b0e1-525f8515c81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_42672244-bf70-4c2f-b338-a9288a9e583a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5a617c2b-8542-4e87-b0e1-525f8515c81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a9dba247-efaa-43ef-9180-347fbb636722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_42672244-bf70-4c2f-b338-a9288a9e583a" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a9dba247-efaa-43ef-9180-347fbb636722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsTables" xlink:type="simple" xlink:href="exdx-20230331.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c70f62f6-1417-4276-89b1-952d4c1877e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_722b539f-4ed0-4a5b-9355-10ce938996da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c70f62f6-1417-4276-89b1-952d4c1877e4" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_722b539f-4ed0-4a5b-9355-10ce938996da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exdx-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d7152250-4819-4773-9599-5824f493180b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a036173e-a82d-4c1c-96b7-612e56621a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d7152250-4819-4773-9599-5824f493180b" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a036173e-a82d-4c1c-96b7-612e56621a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="exdx-20230331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b708046f-59f7-44b4-a422-e2732a870460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_75b289c6-6b7d-403e-8e06-221879c8fe61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b708046f-59f7-44b4-a422-e2732a870460" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_75b289c6-6b7d-403e-8e06-221879c8fe61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="simple" xlink:href="exdx-20230331.xsd#StockOptionPlanTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f36f366-1955-462f-8347-f68f8ec53b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e3ae39b7-5482-451b-a59a-4fbc4864b3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f36f366-1955-462f-8347-f68f8ec53b9b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e3ae39b7-5482-451b-a59a-4fbc4864b3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1227f11f-eefc-47c6-b3be-032f754b46c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f36f366-1955-462f-8347-f68f8ec53b9b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1227f11f-eefc-47c6-b3be-032f754b46c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8b16381b-fbfa-4dfd-aefd-c6b7fac66907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f36f366-1955-462f-8347-f68f8ec53b9b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8b16381b-fbfa-4dfd-aefd-c6b7fac66907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bafcd95-5184-482f-ba5d-f37a04b0b20d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_613b6d27-8d7b-4f2b-9666-c479cad179c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bafcd95-5184-482f-ba5d-f37a04b0b20d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_613b6d27-8d7b-4f2b-9666-c479cad179c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0d87ab9-3eb0-444c-bcee-66875e75fdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bafcd95-5184-482f-ba5d-f37a04b0b20d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d0d87ab9-3eb0-444c-bcee-66875e75fdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_51e7357e-6711-4be6-a0f5-0d2625a4f0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6020973b-9416-4df8-9046-ceee3a71bdae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_51e7357e-6711-4be6-a0f5-0d2625a4f0b7" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6020973b-9416-4df8-9046-ceee3a71bdae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_aa086f5f-f7b6-4d0c-bdb4-2194f873e9ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6020973b-9416-4df8-9046-ceee3a71bdae" xlink:to="loc_srt_MajorCustomersAxis_aa086f5f-f7b6-4d0c-bdb4-2194f873e9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a3929d56-32b7-48b9-80d5-1ae45d047d93" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_aa086f5f-f7b6-4d0c-bdb4-2194f873e9ba" xlink:to="loc_srt_NameOfMajorCustomerDomain_a3929d56-32b7-48b9-80d5-1ae45d047d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_f29c454e-33d9-4eed-9b73-6219bd66b306" xlink:href="exdx-20230331.xsd#exdx_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a3929d56-32b7-48b9-80d5-1ae45d047d93" xlink:to="loc_exdx_MedicareMember_f29c454e-33d9-4eed-9b73-6219bd66b306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_a5acd24d-e033-4fcf-a44d-eb7b46f77c2f" xlink:href="exdx-20230331.xsd#exdx_MedicareAdvantageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a3929d56-32b7-48b9-80d5-1ae45d047d93" xlink:to="loc_exdx_MedicareAdvantageMember_a5acd24d-e033-4fcf-a44d-eb7b46f77c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember_45aaffcc-6ff4-46c7-a274-ada0d90f5333" xlink:href="exdx-20230331.xsd#exdx_BlueShieldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a3929d56-32b7-48b9-80d5-1ae45d047d93" xlink:to="loc_exdx_BlueShieldMember_45aaffcc-6ff4-46c7-a274-ada0d90f5333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f5dc79c8-8d25-4c59-95dd-33f5a52b72b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6020973b-9416-4df8-9046-ceee3a71bdae" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f5dc79c8-8d25-4c59-95dd-33f5a52b72b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8cd1d5c1-9881-46a9-96a5-706eba7d478d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f5dc79c8-8d25-4c59-95dd-33f5a52b72b7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8cd1d5c1-9881-46a9-96a5-706eba7d478d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_86e737a7-2466-4618-901c-c8f9928a4349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8cd1d5c1-9881-46a9-96a5-706eba7d478d" xlink:to="loc_us-gaap_SalesRevenueNetMember_86e737a7-2466-4618-901c-c8f9928a4349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_71fd8a39-5af7-4431-bbec-d037249eba2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8cd1d5c1-9881-46a9-96a5-706eba7d478d" xlink:to="loc_us-gaap_AccountsReceivableMember_71fd8a39-5af7-4431-bbec-d037249eba2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_51d3bb30-0738-452b-a015-0c1736c12871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6020973b-9416-4df8-9046-ceee3a71bdae" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_51d3bb30-0738-452b-a015-0c1736c12871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c2a6a855-a158-401c-bac1-2cfbbc6dba46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_51d3bb30-0738-452b-a015-0c1736c12871" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c2a6a855-a158-401c-bac1-2cfbbc6dba46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_9bdd4db4-d717-4663-af9f-da11526822c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c2a6a855-a158-401c-bac1-2cfbbc6dba46" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_9bdd4db4-d717-4663-af9f-da11526822c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5f0f8882-f792-4429-ac11-c333f4d7ba64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6020973b-9416-4df8-9046-ceee3a71bdae" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5f0f8882-f792-4429-ac11-c333f4d7ba64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_006cc5c2-36c6-422a-9a11-9fdc3b1deaff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5f0f8882-f792-4429-ac11-c333f4d7ba64" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_006cc5c2-36c6-422a-9a11-9fdc3b1deaff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_81d44765-1903-43ec-9b3d-a4e3ebaefa34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_81d44765-1903-43ec-9b3d-a4e3ebaefa34" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b02a8732-3c84-46f2-8314-86f34199cbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b02a8732-3c84-46f2-8314-86f34199cbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c43d1471-4d2a-4e50-b2b8-8a87798d9db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b02a8732-3c84-46f2-8314-86f34199cbbd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c43d1471-4d2a-4e50-b2b8-8a87798d9db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_6041cb37-e77d-4cea-b667-75ba0b038707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c43d1471-4d2a-4e50-b2b8-8a87798d9db4" xlink:to="loc_us-gaap_SalesRevenueNetMember_6041cb37-e77d-4cea-b667-75ba0b038707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_edb8f72b-4883-455d-94c2-be96cfe26eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_edb8f72b-4883-455d-94c2-be96cfe26eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_38354f15-9b8a-4d1f-92d4-255cf8a68b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_edb8f72b-4883-455d-94c2-be96cfe26eb0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_38354f15-9b8a-4d1f-92d4-255cf8a68b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_72802282-deef-4745-9481-2d1e4382f507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_38354f15-9b8a-4d1f-92d4-255cf8a68b03" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_72802282-deef-4745-9481-2d1e4382f507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_56f989e7-923d-4d95-90a0-6916aa8cd9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_38354f15-9b8a-4d1f-92d4-255cf8a68b03" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_56f989e7-923d-4d95-90a0-6916aa8cd9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5fe9bfda-19c3-4975-9c49-bfb7238e6412" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_srt_ProductOrServiceAxis_5fe9bfda-19c3-4975-9c49-bfb7238e6412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5eddb6fe-2cb0-4850-a930-66e969ee3375" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5fe9bfda-19c3-4975-9c49-bfb7238e6412" xlink:to="loc_srt_ProductsAndServicesDomain_5eddb6fe-2cb0-4850-a930-66e969ee3375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_c511d7b0-56ad-46fa-a44c-a818545e29eb" xlink:href="exdx-20230331.xsd#exdx_AVISECTDTestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5eddb6fe-2cb0-4850-a930-66e969ee3375" xlink:to="loc_exdx_AVISECTDTestMember_c511d7b0-56ad-46fa-a44c-a818545e29eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_9780f92a-df55-4173-ac23-06ce307a5dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5eddb6fe-2cb0-4850-a930-66e969ee3375" xlink:to="loc_us-gaap_ShippingAndHandlingMember_9780f92a-df55-4173-ac23-06ce307a5dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_a34fae01-99f1-4e99-8174-38e1e64da56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_a34fae01-99f1-4e99-8174-38e1e64da56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_a9999803-e137-4177-a29a-c7ce1813c8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_a34fae01-99f1-4e99-8174-38e1e64da56d" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_a9999803-e137-4177-a29a-c7ce1813c8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TwoMajorSuppliersMember_0b04bbde-c7f2-434c-b54c-2b70f61a29ae" xlink:href="exdx-20230331.xsd#exdx_TwoMajorSuppliersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_a9999803-e137-4177-a29a-c7ce1813c8bd" xlink:to="loc_exdx_TwoMajorSuppliersMember_0b04bbde-c7f2-434c-b54c-2b70f61a29ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d3a5e875-3940-42d5-97bb-c60704e67993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_DebtInstrumentAxis_d3a5e875-3940-42d5-97bb-c60704e67993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0f9ced6a-49de-4c43-81b0-6256000fbd61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d3a5e875-3940-42d5-97bb-c60704e67993" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0f9ced6a-49de-4c43-81b0-6256000fbd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_e7f81cea-bde0-458d-9121-c5097eb092f1" xlink:href="exdx-20230331.xsd#exdx_Term2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0f9ced6a-49de-4c43-81b0-6256000fbd61" xlink:to="loc_exdx_Term2017Member_e7f81cea-bde0-458d-9121-c5097eb092f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d44bf48-d700-445d-b456-adfbe6b56198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d44bf48-d700-445d-b456-adfbe6b56198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82c0b551-de93-4112-8e51-be47b3b7f8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d44bf48-d700-445d-b456-adfbe6b56198" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82c0b551-de93-4112-8e51-be47b3b7f8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d758f79e-f05f-488f-a66b-d0781cff1249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82c0b551-de93-4112-8e51-be47b3b7f8a9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d758f79e-f05f-488f-a66b-d0781cff1249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_84a93b70-7a0b-4704-bdb3-a82b171f23eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_84a93b70-7a0b-4704-bdb3-a82b171f23eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e6ed4e26-8f55-4c5c-90ce-70151220a0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_84a93b70-7a0b-4704-bdb3-a82b171f23eb" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e6ed4e26-8f55-4c5c-90ce-70151220a0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c0b64855-9989-419d-a27c-16398839ea83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e6ed4e26-8f55-4c5c-90ce-70151220a0d8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c0b64855-9989-419d-a27c-16398839ea83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f60ae44c-11d5-469f-b1bc-241adabf03e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_AwardTypeAxis_f60ae44c-11d5-469f-b1bc-241adabf03e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a6272db-4f9f-4a06-b3bb-280ff4b44313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f60ae44c-11d5-469f-b1bc-241adabf03e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a6272db-4f9f-4a06-b3bb-280ff4b44313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b461167e-10d9-4226-b658-6a0bd7773146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a6272db-4f9f-4a06-b3bb-280ff4b44313" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b461167e-10d9-4226-b658-6a0bd7773146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3659fce6-d384-4554-b297-cc8ca1669a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3659fce6-d384-4554-b297-cc8ca1669a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a448c170-6593-47d7-bb5a-8e4dcc1f9f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3659fce6-d384-4554-b297-cc8ca1669a6c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a448c170-6593-47d7-bb5a-8e4dcc1f9f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherLongTermDebtMember_61d76e58-f294-455a-9be5-8468f8979b45" xlink:href="exdx-20230331.xsd#exdx_OtherLongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a448c170-6593-47d7-bb5a-8e4dcc1f9f82" xlink:to="loc_exdx_OtherLongTermDebtMember_61d76e58-f294-455a-9be5-8468f8979b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_308d5424-636f-499c-a33e-86d74a331786" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d9a35dcd-5f53-4783-bdd7-9aa24ed88288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d9a35dcd-5f53-4783-bdd7-9aa24ed88288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_79a0cb3b-81de-450a-8325-7e94dbd09ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_LongTermDebt_79a0cb3b-81de-450a-8325-7e94dbd09ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_72c70a84-acce-404f-ad7b-5cb5bdefc39d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_DebtInstrumentFairValue_72c70a84-acce-404f-ad7b-5cb5bdefc39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_60328336-75d3-4cca-90f0-0dfcfd1d9ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_RestrictedCash_60328336-75d3-4cca-90f0-0dfcfd1d9ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e1040586-d022-48b1-9ba9-761623bb9a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e1040586-d022-48b1-9ba9-761623bb9a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_93757a1a-e361-4204-adbb-bc4ab1be2b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_AdvertisingExpense_93757a1a-e361-4204-adbb-bc4ab1be2b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_973e8503-2879-4373-a325-c73abfe11c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_CostOfRevenue_973e8503-2879-4373-a325-c73abfe11c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4d820968-ae54-432d-b085-9244fff2c773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4d820968-ae54-432d-b085-9244fff2c773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c96acfc7-0d2f-4ab7-81d3-25f6bba459df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_70508833-4851-49ea-a162-72d9000c5ec7" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c96acfc7-0d2f-4ab7-81d3-25f6bba459df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_eea5fff5-4078-4509-81be-81565821958a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4d275b8b-3d92-4ac6-8425-2384a0624921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eea5fff5-4078-4509-81be-81565821958a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4d275b8b-3d92-4ac6-8425-2384a0624921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_8209c290-d78f-481b-ab41-5c1234364899" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4d275b8b-3d92-4ac6-8425-2384a0624921" xlink:to="loc_srt_MajorCustomersAxis_8209c290-d78f-481b-ab41-5c1234364899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ebff17b9-05b5-45a7-874b-9b05f795a99d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_8209c290-d78f-481b-ab41-5c1234364899" xlink:to="loc_srt_NameOfMajorCustomerDomain_ebff17b9-05b5-45a7-874b-9b05f795a99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember_74016f62-72ee-4937-b9ab-751af1973827" xlink:href="exdx-20230331.xsd#exdx_HealthcareInsurersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ebff17b9-05b5-45a7-874b-9b05f795a99d" xlink:to="loc_exdx_HealthcareInsurersMember_74016f62-72ee-4937-b9ab-751af1973827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member_36538bfc-25f0-4782-84f3-3017bbefbd51" xlink:href="exdx-20230331.xsd#exdx_Government1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ebff17b9-05b5-45a7-874b-9b05f795a99d" xlink:to="loc_exdx_Government1Member_36538bfc-25f0-4782-84f3-3017bbefbd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_f890254b-0e22-4eaf-a4bb-13ddfcf688ee" xlink:href="exdx-20230331.xsd#exdx_ClientMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ebff17b9-05b5-45a7-874b-9b05f795a99d" xlink:to="loc_exdx_ClientMember_f890254b-0e22-4eaf-a4bb-13ddfcf688ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember_7204b8e2-ba85-4cb4-8f81-1a174706636e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCustomerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ebff17b9-05b5-45a7-874b-9b05f795a99d" xlink:to="loc_us-gaap_OtherCustomerMember_7204b8e2-ba85-4cb4-8f81-1a174706636e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_13aef40f-7711-4b28-97a2-54f18014ce1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4d275b8b-3d92-4ac6-8425-2384a0624921" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_13aef40f-7711-4b28-97a2-54f18014ce1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8bfe6c9b-9d7a-42ca-bff6-4a0bef0ad6de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_13aef40f-7711-4b28-97a2-54f18014ce1a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8bfe6c9b-9d7a-42ca-bff6-4a0bef0ad6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_76696a6e-34ba-45ae-8e49-740f329fe23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4c54c5fd-e5eb-428c-809d-1a91caa4d6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76696a6e-34ba-45ae-8e49-740f329fe23f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4c54c5fd-e5eb-428c-809d-1a91caa4d6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_5fc52098-804f-43b1-9edd-6e3007d4201d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76696a6e-34ba-45ae-8e49-740f329fe23f" xlink:to="loc_us-gaap_RestrictedCash_5fc52098-804f-43b1-9edd-6e3007d4201d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78efcaa9-aa34-4022-8516-889747e90f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76696a6e-34ba-45ae-8e49-740f329fe23f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78efcaa9-aa34-4022-8516-889747e90f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6ed2de37-579e-4f89-99a8-cb2f7b7340cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5bca8ffa-2ee6-4762-a3e3-aa3354ce2286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ed2de37-579e-4f89-99a8-cb2f7b7340cd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5bca8ffa-2ee6-4762-a3e3-aa3354ce2286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4c2b6faf-ae06-4191-bd6c-4d024b3c8dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5bca8ffa-2ee6-4762-a3e3-aa3354ce2286" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4c2b6faf-ae06-4191-bd6c-4d024b3c8dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1a109c2-8eb3-4ede-bb7d-ba35740d0687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4c2b6faf-ae06-4191-bd6c-4d024b3c8dc2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1a109c2-8eb3-4ede-bb7d-ba35740d0687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2c383acc-1da3-4473-ba35-9316d2710877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1a109c2-8eb3-4ede-bb7d-ba35740d0687" xlink:to="loc_us-gaap_WarrantMember_2c383acc-1da3-4473-ba35-9316d2710877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_df230f5b-3c4f-4bec-bc58-56caf912a6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1a109c2-8eb3-4ede-bb7d-ba35740d0687" xlink:to="loc_us-gaap_StockOptionMember_df230f5b-3c4f-4bec-bc58-56caf912a6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_88c2dfff-8d35-4da0-8818-5dea5616896a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1a109c2-8eb3-4ede-bb7d-ba35740d0687" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_88c2dfff-8d35-4da0-8818-5dea5616896a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a53c34f0-a71f-4fd1-aaff-21b5dd96b4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e1a109c2-8eb3-4ede-bb7d-ba35740d0687" xlink:to="loc_us-gaap_EmployeeStockMember_a53c34f0-a71f-4fd1-aaff-21b5dd96b4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f86d2f27-c7da-47cb-973a-f33532302eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5bca8ffa-2ee6-4762-a3e3-aa3354ce2286" xlink:to="loc_us-gaap_ClassOfStockLineItems_f86d2f27-c7da-47cb-973a-f33532302eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_025596db-a6c8-4b8e-ac9b-a7e3a7799c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f86d2f27-c7da-47cb-973a-f33532302eb9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_025596db-a6c8-4b8e-ac9b-a7e3a7799c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#OtherFinancialInformationPrepaidExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_1b4c22b3-8f15-4866-8024-885e6e67ebca" xlink:href="exdx-20230331.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e3ec94e4-bfbf-4fd3-b442-7645e07e820a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_1b4c22b3-8f15-4866-8024-885e6e67ebca" xlink:to="loc_us-gaap_OtherAssetsCurrent_e3ec94e4-bfbf-4fd3-b442-7645e07e820a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties_17abe91e-8966-491e-862d-260a7c2d4d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_1b4c22b3-8f15-4866-8024-885e6e67ebca" xlink:to="loc_us-gaap_PrepaidRoyalties_17abe91e-8966-491e-862d-260a7c2d4d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_225c0965-d19b-44e0-bdd2-aba2601e35f7" xlink:href="exdx-20230331.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_1b4c22b3-8f15-4866-8024-885e6e67ebca" xlink:to="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_225c0965-d19b-44e0-bdd2-aba2601e35f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_c192df68-eefc-4f3e-ab98-44c88be8acb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_1b4c22b3-8f15-4866-8024-885e6e67ebca" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_c192df68-eefc-4f3e-ab98-44c88be8acb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b482fcb8-2148-4d19-b955-f8885a1b11ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_1b4c22b3-8f15-4866-8024-885e6e67ebca" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b482fcb8-2148-4d19-b955-f8885a1b11ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#OtherFinancialInformationPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_cc7c02cf-a932-47f0-a807-5a0314654280" xlink:href="exdx-20230331.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_46483f59-17f8-4e1c-b6a9-3f4406eb852d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_cc7c02cf-a932-47f0-a807-5a0314654280" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_46483f59-17f8-4e1c-b6a9-3f4406eb852d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0575f6fc-6692-4016-87d1-3e597b40792c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_46483f59-17f8-4e1c-b6a9-3f4406eb852d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0575f6fc-6692-4016-87d1-3e597b40792c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecaedeb2-abe7-4a3b-9872-ef6c20e80a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0575f6fc-6692-4016-87d1-3e597b40792c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecaedeb2-abe7-4a3b-9872-ef6c20e80a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_6ab6391c-e844-4c05-80b2-fa5679f205a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecaedeb2-abe7-4a3b-9872-ef6c20e80a84" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_6ab6391c-e844-4c05-80b2-fa5679f205a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_c170d386-4be5-46ef-b06a-807fe6d73c89" xlink:href="exdx-20230331.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecaedeb2-abe7-4a3b-9872-ef6c20e80a84" xlink:to="loc_exdx_LaboratoryEquipmentMember_c170d386-4be5-46ef-b06a-807fe6d73c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_dec24912-c549-416f-98e2-85ec15bfc358" xlink:href="exdx-20230331.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecaedeb2-abe7-4a3b-9872-ef6c20e80a84" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_dec24912-c549-416f-98e2-85ec15bfc358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_36504d41-cffe-4bed-bad4-d1fb37392e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecaedeb2-abe7-4a3b-9872-ef6c20e80a84" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_36504d41-cffe-4bed-bad4-d1fb37392e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_696bdd5d-13e9-4303-82a9-fa492cf7aaad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecaedeb2-abe7-4a3b-9872-ef6c20e80a84" xlink:to="loc_us-gaap_ConstructionInProgressMember_696bdd5d-13e9-4303-82a9-fa492cf7aaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e273782c-2be7-4fe2-81dc-e545cbcbd013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_46483f59-17f8-4e1c-b6a9-3f4406eb852d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e273782c-2be7-4fe2-81dc-e545cbcbd013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_bbd23772-881c-4d60-9db2-6f07186064bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e273782c-2be7-4fe2-81dc-e545cbcbd013" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_bbd23772-881c-4d60-9db2-6f07186064bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_353cd937-bc07-4d56-ac19-a6d746108969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e273782c-2be7-4fe2-81dc-e545cbcbd013" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_353cd937-bc07-4d56-ac19-a6d746108969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_fb3cfac0-e292-4733-87d2-8a6889e4e636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e273782c-2be7-4fe2-81dc-e545cbcbd013" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_fb3cfac0-e292-4733-87d2-8a6889e4e636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_2cc907a5-0097-4a4f-935e-810600cf3024" xlink:href="exdx-20230331.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f90a09fb-3d37-4022-b0f6-e1b1745d4ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_2cc907a5-0097-4a4f-935e-810600cf3024" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f90a09fb-3d37-4022-b0f6-e1b1745d4ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_5b5f3b40-e9c7-404b-99c3-e4fb71d1ee90" xlink:href="exdx-20230331.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_ad41cbe5-7faa-423a-8705-7e57e748c271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_5b5f3b40-e9c7-404b-99c3-e4fb71d1ee90" xlink:to="loc_us-gaap_AccruedSalariesCurrent_ad41cbe5-7faa-423a-8705-7e57e748c271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_424d89a6-186e-4c25-9323-f0349708c5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_5b5f3b40-e9c7-404b-99c3-e4fb71d1ee90" xlink:to="loc_us-gaap_InterestPayableCurrent_424d89a6-186e-4c25-9323-f0349708c5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_c23bdff9-a16b-4abb-8732-2268f05f84ad" xlink:href="exdx-20230331.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_5b5f3b40-e9c7-404b-99c3-e4fb71d1ee90" xlink:to="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_c23bdff9-a16b-4abb-8732-2268f05f84ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_950e7347-4c4c-42dc-be06-e26da8a7fbdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_5b5f3b40-e9c7-404b-99c3-e4fb71d1ee90" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_950e7347-4c4c-42dc-be06-e26da8a7fbdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_cd4edd77-1d55-4119-b12c-e004cfb9f889" xlink:href="exdx-20230331.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_5b5f3b40-e9c7-404b-99c3-e4fb71d1ee90" xlink:to="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_cd4edd77-1d55-4119-b12c-e004cfb9f889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_ee98b784-8586-49af-b0b9-87b29f322da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_5b5f3b40-e9c7-404b-99c3-e4fb71d1ee90" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_ee98b784-8586-49af-b0b9-87b29f322da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_39e07c00-cd93-4dc8-acdf-145dad96ea79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_5b5f3b40-e9c7-404b-99c3-e4fb71d1ee90" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_39e07c00-cd93-4dc8-acdf-145dad96ea79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_68299527-80d3-433e-a80a-d1af13fa727b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_5b5f3b40-e9c7-404b-99c3-e4fb71d1ee90" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_68299527-80d3-433e-a80a-d1af13fa727b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_56112021-50fa-4c8c-8711-e2df9e2bdd8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_5b5f3b40-e9c7-404b-99c3-e4fb71d1ee90" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_56112021-50fa-4c8c-8711-e2df9e2bdd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ea1b554b-0963-468e-b09b-bd47b84c9dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8c658094-a9c6-4e57-b6cc-6f97a6ff48f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ea1b554b-0963-468e-b09b-bd47b84c9dd1" xlink:to="loc_us-gaap_DebtInstrumentTable_8c658094-a9c6-4e57-b6cc-6f97a6ff48f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c6c8d579-28e1-4f1d-86f4-6a357eb76aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8c658094-a9c6-4e57-b6cc-6f97a6ff48f6" xlink:to="loc_us-gaap_DebtInstrumentAxis_c6c8d579-28e1-4f1d-86f4-6a357eb76aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42216f91-c3cf-4f12-a805-842667c2f13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c6c8d579-28e1-4f1d-86f4-6a357eb76aa6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_42216f91-c3cf-4f12-a805-842667c2f13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_edc51768-9da7-40d7-be38-6e547f93add3" xlink:href="exdx-20230331.xsd#exdx_Term2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42216f91-c3cf-4f12-a805-842667c2f13f" xlink:to="loc_exdx_Term2017Member_edc51768-9da7-40d7-be38-6e547f93add3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentNotesPayableMember_24b9d17e-bfa5-4356-b35c-9c4b700d1da2" xlink:href="exdx-20230331.xsd#exdx_EquipmentNotesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42216f91-c3cf-4f12-a805-842667c2f13f" xlink:to="loc_exdx_EquipmentNotesPayableMember_24b9d17e-bfa5-4356-b35c-9c4b700d1da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d976162a-0b23-418e-a70c-30bccf120c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8c658094-a9c6-4e57-b6cc-6f97a6ff48f6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d976162a-0b23-418e-a70c-30bccf120c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f94cc30a-2244-4bfc-be58-5539caac5273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d976162a-0b23-418e-a70c-30bccf120c45" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f94cc30a-2244-4bfc-be58-5539caac5273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_e5469347-6242-423e-879b-b6d87eb1809b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f94cc30a-2244-4bfc-be58-5539caac5273" xlink:to="loc_us-gaap_LoansPayableMember_e5469347-6242-423e-879b-b6d87eb1809b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_81c7e59f-8fe1-4b0e-9e7f-bd8e9bf24fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f94cc30a-2244-4bfc-be58-5539caac5273" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_81c7e59f-8fe1-4b0e-9e7f-bd8e9bf24fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_a6c49538-eb35-42ff-a1d1-978c30ba3bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8c658094-a9c6-4e57-b6cc-6f97a6ff48f6" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_a6c49538-eb35-42ff-a1d1-978c30ba3bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_ac5b110f-bd51-4007-b794-a6b6ce604124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_a6c49538-eb35-42ff-a1d1-978c30ba3bbd" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_ac5b110f-bd51-4007-b794-a6b6ce604124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_fdf927a0-acda-4e40-a098-4544bcaaa4bf" xlink:href="exdx-20230331.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_ac5b110f-bd51-4007-b794-a6b6ce604124" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_fdf927a0-acda-4e40-a098-4544bcaaa4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8c658094-a9c6-4e57-b6cc-6f97a6ff48f6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3e781aba-bce2-4f37-9ae1-2b8ac6fc0265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3e781aba-bce2-4f37-9ae1-2b8ac6fc0265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_fbc5a1e0-9f18-47c1-8495-0d640deb2794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_fbc5a1e0-9f18-47c1-8495-0d640deb2794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_df6a28cd-faaa-4004-8e47-861cf9e7e30f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_df6a28cd-faaa-4004-8e47-861cf9e7e30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_9968100a-a1e9-474f-a2fd-5aaaece8b616" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_9968100a-a1e9-474f-a2fd-5aaaece8b616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_73c0a598-b170-4a7c-912c-3d02b8682930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_73c0a598-b170-4a7c-912c-3d02b8682930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments_9816d80b-67f6-4baa-b081-efe99e8bca4a" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentNumberOfMonthlyInstallments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments_9816d80b-67f6-4baa-b081-efe99e8bca4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_4eedfbdf-2520-4188-90e3-5c1bf07235bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_4eedfbdf-2520-4188-90e3-5c1bf07235bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_68e97642-6887-4c35-853d-71e2569ee15b" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_68e97642-6887-4c35-853d-71e2569ee15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_6ff81d64-cca5-45fa-a7ac-0db13f51fc16" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_6ff81d64-cca5-45fa-a7ac-0db13f51fc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_eed62277-f68c-4ad8-8025-1514ea71240e" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_eed62277-f68c-4ad8-8025-1514ea71240e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_5e7d057d-e729-48a9-ba45-94cc36e449b1" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentCovenantRevenuePerformancePeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_5e7d057d-e729-48a9-ba45-94cc36e449b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_59d9a4d5-e59e-4d94-9bf6-c97a620bde32" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_59d9a4d5-e59e-4d94-9bf6-c97a620bde32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_8250eeb0-f24c-4bca-8049-2ed789f49938" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_8250eeb0-f24c-4bca-8049-2ed789f49938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_c1f68e04-3ba5-4799-9eb5-d8391594eb65" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_c1f68e04-3ba5-4799-9eb5-d8391594eb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_2bb240ce-b88b-4323-b98e-31d12fa3e812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_NotesPayable_2bb240ce-b88b-4323-b98e-31d12fa3e812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_3bec8c9a-3172-4550-8a28-330c29bde64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_NotesPayableCurrent_3bec8c9a-3172-4550-8a28-330c29bde64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_8ff53ee1-74b2-46aa-9ae7-bf6cb43334be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a9997a5-e7e1-4563-8934-a59aad40aa17" xlink:to="loc_us-gaap_LongTermNotesPayable_8ff53ee1-74b2-46aa-9ae7-bf6cb43334be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#BorrowingsFutureMinimumPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1fc0a104-d50b-4b2c-a276-3e1eba4da05e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d92d25ae-b155-469f-b698-85bf32e46883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1fc0a104-d50b-4b2c-a276-3e1eba4da05e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d92d25ae-b155-469f-b698-85bf32e46883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f23e5560-3a8f-477e-bc5f-68b9da25e877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1fc0a104-d50b-4b2c-a276-3e1eba4da05e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f23e5560-3a8f-477e-bc5f-68b9da25e877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_57c97d08-28e0-410e-9526-65f7939fd42a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1fc0a104-d50b-4b2c-a276-3e1eba4da05e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_57c97d08-28e0-410e-9526-65f7939fd42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_fbb75670-36fe-4f0e-96fc-17fe3f92b8df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1fc0a104-d50b-4b2c-a276-3e1eba4da05e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_fbb75670-36fe-4f0e-96fc-17fe3f92b8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_289d0788-65f0-44b5-aa5e-92400af2a79e" xlink:href="exdx-20230331.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1fc0a104-d50b-4b2c-a276-3e1eba4da05e" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_289d0788-65f0-44b5-aa5e-92400af2a79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6dda0503-bb81-4245-96c8-d35d8eecdb51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1fc0a104-d50b-4b2c-a276-3e1eba4da05e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6dda0503-bb81-4245-96c8-d35d8eecdb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_1eecc932-c13b-4edc-932e-a027bbda4be5" xlink:href="exdx-20230331.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1fc0a104-d50b-4b2c-a276-3e1eba4da05e" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_1eecc932-c13b-4edc-932e-a027bbda4be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f3f68011-00e1-44d0-a0c0-39a1db0f16fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1fc0a104-d50b-4b2c-a276-3e1eba4da05e" xlink:to="loc_us-gaap_LongTermDebt_f3f68011-00e1-44d0-a0c0-39a1db0f16fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_3bab03b8-ac76-4806-86b9-7b560f9e6b20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1fc0a104-d50b-4b2c-a276-3e1eba4da05e" xlink:to="loc_us-gaap_LongTermDebtCurrent_3bab03b8-ac76-4806-86b9-7b560f9e6b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a27ba562-e513-460c-aee6-3c144a1ffbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1fc0a104-d50b-4b2c-a276-3e1eba4da05e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a27ba562-e513-460c-aee6-3c144a1ffbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#CommitmentandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_55dbf2a5-8ce3-4ecd-a5e5-9ead42c3b202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_24e9e46b-ab4d-4038-ac5f-45882236ec96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_55dbf2a5-8ce3-4ecd-a5e5-9ead42c3b202" xlink:to="loc_us-gaap_LossContingenciesTable_24e9e46b-ab4d-4038-ac5f-45882236ec96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_461c7b32-c363-4e5b-a02e-b18c407580ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_24e9e46b-ab4d-4038-ac5f-45882236ec96" xlink:to="loc_srt_CounterpartyNameAxis_461c7b32-c363-4e5b-a02e-b18c407580ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2488af8-e541-4168-9133-a73c4904dcd8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_461c7b32-c363-4e5b-a02e-b18c407580ef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2488af8-e541-4168-9133-a73c4904dcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember_1c3af7c7-c440-45b6-85fe-cac1f22aec35" xlink:href="exdx-20230331.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2488af8-e541-4168-9133-a73c4904dcd8" xlink:to="loc_exdx_PrometheusLaboratoriesIncMember_1c3af7c7-c440-45b6-85fe-cac1f22aec35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_f85b7ad4-c8c1-4907-a8b3-946577ea389f" xlink:href="exdx-20230331.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2488af8-e541-4168-9133-a73c4904dcd8" xlink:to="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_f85b7ad4-c8c1-4907-a8b3-946577ea389f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cfad3d17-5e42-4641-8349-fb74247434ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_24e9e46b-ab4d-4038-ac5f-45882236ec96" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cfad3d17-5e42-4641-8349-fb74247434ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e75806e1-839b-4d6c-aab3-5f473ae85bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cfad3d17-5e42-4641-8349-fb74247434ad" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e75806e1-839b-4d6c-aab3-5f473ae85bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember_211d6922-7250-4133-ab04-3e3fd106c02f" xlink:href="exdx-20230331.xsd#exdx_AHNCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e75806e1-839b-4d6c-aab3-5f473ae85bfa" xlink:to="loc_exdx_AHNCollaborationMember_211d6922-7250-4133-ab04-3e3fd106c02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d8ea5aac-c33b-4237-8413-0c0fc212573d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_24e9e46b-ab4d-4038-ac5f-45882236ec96" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d8ea5aac-c33b-4237-8413-0c0fc212573d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_12c387b9-a426-4d4b-9d65-ac45fe000088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d8ea5aac-c33b-4237-8413-0c0fc212573d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_12c387b9-a426-4d4b-9d65-ac45fe000088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_ab46b3b1-4fa7-4d7a-807a-a6141a441cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_12c387b9-a426-4d4b-9d65-ac45fe000088" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_ab46b3b1-4fa7-4d7a-807a-a6141a441cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4e8dd51a-9d59-421b-873f-9af3ee08cd89" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_24e9e46b-ab4d-4038-ac5f-45882236ec96" xlink:to="loc_srt_RangeAxis_4e8dd51a-9d59-421b-873f-9af3ee08cd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2b20629c-d14d-4850-bfcf-a32305f38d62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4e8dd51a-9d59-421b-873f-9af3ee08cd89" xlink:to="loc_srt_RangeMember_2b20629c-d14d-4850-bfcf-a32305f38d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2c25dd5b-3dc4-42d1-8c70-394b27d43dee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2b20629c-d14d-4850-bfcf-a32305f38d62" xlink:to="loc_srt_MinimumMember_2c25dd5b-3dc4-42d1-8c70-394b27d43dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1be8f358-fa37-40be-a415-a685b6239e2d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2b20629c-d14d-4850-bfcf-a32305f38d62" xlink:to="loc_srt_MaximumMember_1be8f358-fa37-40be-a415-a685b6239e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_24e9e46b-ab4d-4038-ac5f-45882236ec96" xlink:to="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_3d869652-76eb-44ee-830f-5685fc4ce414" xlink:href="exdx-20230331.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_3d869652-76eb-44ee-830f-5685fc4ce414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_6e47842f-ced3-42e1-a685-c4400c581d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_6e47842f-ced3-42e1-a685-c4400c581d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment_d8a087e2-f1a8-4395-b234-d499875af48a" xlink:href="exdx-20230331.xsd#exdx_AdvancePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_exdx_AdvancePayment_d8a087e2-f1a8-4395-b234-d499875af48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee_6f0bf2a3-1ee8-47bd-bc45-e71cf249ada1" xlink:href="exdx-20230331.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_exdx_CollaborationAgreementAnnualCollaborationFee_6f0bf2a3-1ee8-47bd-bc45-e71cf249ada1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses_5c06251e-fcdf-414b-851a-0ca94e3d5ca7" xlink:href="exdx-20230331.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_exdx_CollaborationAgreementCollaborationExpenses_5c06251e-fcdf-414b-851a-0ca94e3d5ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_fd6acf30-f5a9-4882-8f79-a1329cd868a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_fd6acf30-f5a9-4882-8f79-a1329cd868a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_a76aed1e-8594-418d-b51e-ffb5261a3ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_a76aed1e-8594-418d-b51e-ffb5261a3ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_da298309-9cc5-4877-a19e-6eb2cea1a5dc" xlink:href="exdx-20230331.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5cc1ef25-80e5-429e-b51e-f3ed483a09f4" xlink:to="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_da298309-9cc5-4877-a19e-6eb2cea1a5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4e231451-22d1-419a-9dba-310280bef966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_393faca6-7385-43c8-840a-a2f908a9d38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4e231451-22d1-419a-9dba-310280bef966" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_393faca6-7385-43c8-840a-a2f908a9d38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_60aab6aa-7d48-45f4-993e-dd8cd18ad62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_393faca6-7385-43c8-840a-a2f908a9d38b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_60aab6aa-7d48-45f4-993e-dd8cd18ad62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_78c5ea50-4662-4831-987c-2f549bb5847e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_60aab6aa-7d48-45f4-993e-dd8cd18ad62d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_78c5ea50-4662-4831-987c-2f549bb5847e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7c88a7e2-1535-4a65-b244-73963d4a05c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_78c5ea50-4662-4831-987c-2f549bb5847e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7c88a7e2-1535-4a65-b244-73963d4a05c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_414fccc0-ba19-4f1e-acfb-6645d12f3247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_393faca6-7385-43c8-840a-a2f908a9d38b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_414fccc0-ba19-4f1e-acfb-6645d12f3247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8552343-1cf8-4b01-98df-34267a3d95ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_414fccc0-ba19-4f1e-acfb-6645d12f3247" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8552343-1cf8-4b01-98df-34267a3d95ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a03c8fda-3966-4ae2-ad4c-21c7659f34f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8552343-1cf8-4b01-98df-34267a3d95ba" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a03c8fda-3966-4ae2-ad4c-21c7659f34f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b94e7c4e-6b68-4ec7-b3d1-05d4bd6f3788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8552343-1cf8-4b01-98df-34267a3d95ba" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b94e7c4e-6b68-4ec7-b3d1-05d4bd6f3788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6fd51de1-3071-4a20-9bdd-754a8d374167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8552343-1cf8-4b01-98df-34267a3d95ba" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6fd51de1-3071-4a20-9bdd-754a8d374167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9c3e505b-cebd-461d-b94e-56270b18e0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_393faca6-7385-43c8-840a-a2f908a9d38b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9c3e505b-cebd-461d-b94e-56270b18e0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f1fc670-7885-4901-bd1b-9bdab5287043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9c3e505b-cebd-461d-b94e-56270b18e0f7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f1fc670-7885-4901-bd1b-9bdab5287043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5808cd1d-258c-435e-a6f9-549c9ec63e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f1fc670-7885-4901-bd1b-9bdab5287043" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5808cd1d-258c-435e-a6f9-549c9ec63e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_bc64ba7d-91e1-4173-92ff-5580bb13f446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f1fc670-7885-4901-bd1b-9bdab5287043" xlink:to="loc_us-gaap_CertificatesOfDepositMember_bc64ba7d-91e1-4173-92ff-5580bb13f446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_44d563f7-bcf1-4f43-8769-e917fe3b35c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_393faca6-7385-43c8-840a-a2f908a9d38b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_44d563f7-bcf1-4f43-8769-e917fe3b35c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_f7158a70-f03c-435b-8d9a-4b5240ee91a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_44d563f7-bcf1-4f43-8769-e917fe3b35c7" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_f7158a70-f03c-435b-8d9a-4b5240ee91a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_55d445fe-abda-49ac-8b26-8ee14de40dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f7158a70-f03c-435b-8d9a-4b5240ee91a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_55d445fe-abda-49ac-8b26-8ee14de40dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_35a3cf77-5886-46cf-8875-616e3c429571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f7158a70-f03c-435b-8d9a-4b5240ee91a5" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_35a3cf77-5886-46cf-8875-616e3c429571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_79a4aa33-6c3c-44cd-b906-86b8055f517c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0840f31a-197b-437f-a5de-1bb226dc0edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_79a4aa33-6c3c-44cd-b906-86b8055f517c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0840f31a-197b-437f-a5de-1bb226dc0edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0dece2a1-9907-4c69-aec3-ad61dc43bd74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0840f31a-197b-437f-a5de-1bb226dc0edd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0dece2a1-9907-4c69-aec3-ad61dc43bd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4f50b2ad-f70f-43f9-b048-87e37ec90c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0dece2a1-9907-4c69-aec3-ad61dc43bd74" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4f50b2ad-f70f-43f9-b048-87e37ec90c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CowenEquityDistributionAgreementMember_5e3fcb1f-e41e-477d-9487-a0e0d29ddbdb" xlink:href="exdx-20230331.xsd#exdx_CowenEquityDistributionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4f50b2ad-f70f-43f9-b048-87e37ec90c65" xlink:to="loc_exdx_CowenEquityDistributionAgreementMember_5e3fcb1f-e41e-477d-9487-a0e0d29ddbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0ec2da93-c4d1-44e5-a97f-689516a22a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0840f31a-197b-437f-a5de-1bb226dc0edd" xlink:to="loc_us-gaap_ClassOfStockLineItems_0ec2da93-c4d1-44e5-a97f-689516a22a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7879473d-2ece-4eb9-ad4a-b0ff26ebefdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0ec2da93-c4d1-44e5-a97f-689516a22a89" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7879473d-2ece-4eb9-ad4a-b0ff26ebefdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_b301e4a8-faa3-4788-9787-a7e82d1e5715" xlink:href="exdx-20230331.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0ec2da93-c4d1-44e5-a97f-689516a22a89" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_b301e4a8-faa3-4788-9787-a7e82d1e5715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#StockholdersEquityScheduleofOutstandingWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_143a3d77-5226-42bc-9198-b15db388adde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e5d18721-a287-44f6-a882-4aeb71b1cedd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_143a3d77-5226-42bc-9198-b15db388adde" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e5d18721-a287-44f6-a882-4aeb71b1cedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_506ffed9-6777-4ed7-9a5d-0d0843e4f2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e5d18721-a287-44f6-a882-4aeb71b1cedd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_506ffed9-6777-4ed7-9a5d-0d0843e4f2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a7b71fb8-f426-47df-885d-91d6cd4883b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_506ffed9-6777-4ed7-9a5d-0d0843e4f2b2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a7b71fb8-f426-47df-885d-91d6cd4883b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_e0639830-4c3d-410b-9126-f42112d69b36" xlink:href="exdx-20230331.xsd#exdx_ExpirationJan192026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a7b71fb8-f426-47df-885d-91d6cd4883b7" xlink:to="loc_exdx_ExpirationJan192026Member_e0639830-4c3d-410b-9126-f42112d69b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_ce489b40-24b6-4e90-95e4-d6a95640a3b2" xlink:href="exdx-20230331.xsd#exdx_ExpirationMar312026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a7b71fb8-f426-47df-885d-91d6cd4883b7" xlink:to="loc_exdx_ExpirationMar312026Member_ce489b40-24b6-4e90-95e4-d6a95640a3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_bceaa312-3c06-4eab-bf56-0a1b044e4246" xlink:href="exdx-20230331.xsd#exdx_ExpirationApr12026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a7b71fb8-f426-47df-885d-91d6cd4883b7" xlink:to="loc_exdx_ExpirationApr12026Member_bceaa312-3c06-4eab-bf56-0a1b044e4246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member_08925b93-a110-443f-bd95-0e087089e29e" xlink:href="exdx-20230331.xsd#exdx_ExpirationSep72024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a7b71fb8-f426-47df-885d-91d6cd4883b7" xlink:to="loc_exdx_ExpirationSep72024Member_08925b93-a110-443f-bd95-0e087089e29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_0a991178-efc6-448e-8d1e-4077bb27a714" xlink:href="exdx-20230331.xsd#exdx_ExpirationDec72025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a7b71fb8-f426-47df-885d-91d6cd4883b7" xlink:to="loc_exdx_ExpirationDec72025Member_0a991178-efc6-448e-8d1e-4077bb27a714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember_03c39d15-5034-4aa9-b7c2-e414d1effd55" xlink:href="exdx-20230331.xsd#exdx_NoExpirationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a7b71fb8-f426-47df-885d-91d6cd4883b7" xlink:to="loc_exdx_NoExpirationMember_03c39d15-5034-4aa9-b7c2-e414d1effd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_feec8c20-3b93-4c3d-a7d1-1734ee215823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e5d18721-a287-44f6-a882-4aeb71b1cedd" xlink:to="loc_us-gaap_ClassOfStockLineItems_feec8c20-3b93-4c3d-a7d1-1734ee215823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f0f79da3-644f-4bed-a142-d34b587d52ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_feec8c20-3b93-4c3d-a7d1-1734ee215823" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f0f79da3-644f-4bed-a142-d34b587d52ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_af13d023-36d0-4387-8945-568b482ecd98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_feec8c20-3b93-4c3d-a7d1-1734ee215823" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_af13d023-36d0-4387-8945-568b482ecd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#StockOptionPlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ba34455-60fc-441c-ad3a-eef7e5541275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f087d9e3-cf6c-4f7d-8b18-fbd6726d4620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ba34455-60fc-441c-ad3a-eef7e5541275" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f087d9e3-cf6c-4f7d-8b18-fbd6726d4620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9c50518b-b5f5-4658-abb7-08fffdf8af8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f087d9e3-cf6c-4f7d-8b18-fbd6726d4620" xlink:to="loc_us-gaap_PlanNameAxis_9c50518b-b5f5-4658-abb7-08fffdf8af8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_31ba29ec-fdf6-460c-b36b-894ecb467deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9c50518b-b5f5-4658-abb7-08fffdf8af8f" xlink:to="loc_us-gaap_PlanNameDomain_31ba29ec-fdf6-460c-b36b-894ecb467deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_d84fca49-8455-4853-a39a-d5d7c942acaa" xlink:href="exdx-20230331.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_31ba29ec-fdf6-460c-b36b-894ecb467deb" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_d84fca49-8455-4853-a39a-d5d7c942acaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e4ec3afc-74f7-41e6-8489-38f652a9f77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f087d9e3-cf6c-4f7d-8b18-fbd6726d4620" xlink:to="loc_us-gaap_AwardTypeAxis_e4ec3afc-74f7-41e6-8489-38f652a9f77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c71e36d-c5b6-4964-abeb-ee2e8e39ba6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e4ec3afc-74f7-41e6-8489-38f652a9f77b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c71e36d-c5b6-4964-abeb-ee2e8e39ba6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_baa1fd1e-904c-4b99-b000-53250b5b1000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c71e36d-c5b6-4964-abeb-ee2e8e39ba6f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_baa1fd1e-904c-4b99-b000-53250b5b1000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a65ee7a7-01c3-4c40-af5d-aebd2601a800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c71e36d-c5b6-4964-abeb-ee2e8e39ba6f" xlink:to="loc_us-gaap_EmployeeStockMember_a65ee7a7-01c3-4c40-af5d-aebd2601a800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c2d1519d-14a4-4239-9c69-227cd7f00ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c71e36d-c5b6-4964-abeb-ee2e8e39ba6f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c2d1519d-14a4-4239-9c69-227cd7f00ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f087d9e3-cf6c-4f7d-8b18-fbd6726d4620" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7e1267f3-2823-4e6e-bc1d-bc2c0083e870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7e1267f3-2823-4e6e-bc1d-bc2c0083e870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6d8cc33a-9857-40c2-a351-716c10be86a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6d8cc33a-9857-40c2-a351-716c10be86a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_fd4e2331-f478-4998-9f7c-738cc23944a4" xlink:href="exdx-20230331.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_fd4e2331-f478-4998-9f7c-738cc23944a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1f21b4bb-0e72-46c2-8c78-f54f1e997da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1f21b4bb-0e72-46c2-8c78-f54f1e997da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ef524766-f54e-424f-b76c-8f4b30849c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_ef524766-f54e-424f-b76c-8f4b30849c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1f1f0244-c22e-4f72-8b34-f0277d69fee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1f1f0244-c22e-4f72-8b34-f0277d69fee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c202406c-340a-42bf-bcbe-af0aa0f3fae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c202406c-340a-42bf-bcbe-af0aa0f3fae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1cfd2f41-fd5e-4d2d-bb60-9c3ff576772a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1cfd2f41-fd5e-4d2d-bb60-9c3ff576772a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_1f138d9a-3bea-40cd-9462-96adf55f30c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_1f138d9a-3bea-40cd-9462-96adf55f30c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019a3cd8-0474-48b4-92a6-4003dde5c049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019a3cd8-0474-48b4-92a6-4003dde5c049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_19512f00-e117-4867-9885-59199ae20cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3bf548b-89cf-4974-9051-7fda5e15c78a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_19512f00-e117-4867-9885-59199ae20cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_665c534d-fff1-4cf8-bc90-d90503e38069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_510d7025-08f8-4fda-93ac-18229c6c8b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_665c534d-fff1-4cf8-bc90-d90503e38069" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_510d7025-08f8-4fda-93ac-18229c6c8b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1861049e-a4fa-40a8-b761-e355fcd93c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_510d7025-08f8-4fda-93ac-18229c6c8b51" xlink:to="loc_us-gaap_AwardTypeAxis_1861049e-a4fa-40a8-b761-e355fcd93c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd30b680-fd14-4332-81a4-eda712774ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1861049e-a4fa-40a8-b761-e355fcd93c93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd30b680-fd14-4332-81a4-eda712774ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a9289d06-5178-496c-954a-70cec2afcfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd30b680-fd14-4332-81a4-eda712774ba0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a9289d06-5178-496c-954a-70cec2afcfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_510d7025-08f8-4fda-93ac-18229c6c8b51" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a434bd2b-be50-4c19-8344-e18d786fb408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a434bd2b-be50-4c19-8344-e18d786fb408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_407d0025-714a-42a0-b2cb-2803b625d5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a434bd2b-be50-4c19-8344-e18d786fb408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_407d0025-714a-42a0-b2cb-2803b625d5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1ca4d751-712c-4e67-9be7-d0c583ffc9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a434bd2b-be50-4c19-8344-e18d786fb408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1ca4d751-712c-4e67-9be7-d0c583ffc9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_184edcae-5b06-4061-91eb-c868dd956233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a434bd2b-be50-4c19-8344-e18d786fb408" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_184edcae-5b06-4061-91eb-c868dd956233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_42a2e296-1448-450d-aeb5-6e56a124ef6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a434bd2b-be50-4c19-8344-e18d786fb408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_42a2e296-1448-450d-aeb5-6e56a124ef6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4826294a-542f-4177-9613-2820d3f7a9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a434bd2b-be50-4c19-8344-e18d786fb408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4826294a-542f-4177-9613-2820d3f7a9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cbfa1ba6-10f5-4aab-94be-6f4bc7a62acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a434bd2b-be50-4c19-8344-e18d786fb408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cbfa1ba6-10f5-4aab-94be-6f4bc7a62acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_09337d91-807a-431a-a996-1eb6c29bb3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_09337d91-807a-431a-a996-1eb6c29bb3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_6db6defb-a4cc-466c-aaff-278a0157e68d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_6db6defb-a4cc-466c-aaff-278a0157e68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0db1200-d407-44cc-b35e-092eaf1f0536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0db1200-d407-44cc-b35e-092eaf1f0536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9b19b6b2-1e96-4c06-a495-068b9bfa6686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0db1200-d407-44cc-b35e-092eaf1f0536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9b19b6b2-1e96-4c06-a495-068b9bfa6686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c9243b1f-0474-4cf5-978b-8213db9898fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0db1200-d407-44cc-b35e-092eaf1f0536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c9243b1f-0474-4cf5-978b-8213db9898fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ad5ef4fa-cb7e-4070-a9e9-456a67b413da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0db1200-d407-44cc-b35e-092eaf1f0536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ad5ef4fa-cb7e-4070-a9e9-456a67b413da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fe237048-d2ed-43a0-af58-0959bff32ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0db1200-d407-44cc-b35e-092eaf1f0536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fe237048-d2ed-43a0-af58-0959bff32ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ea1503e5-837f-451e-8c15-36b289190f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0db1200-d407-44cc-b35e-092eaf1f0536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ea1503e5-837f-451e-8c15-36b289190f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ff8dddea-4a0a-4d3d-b8fe-6c495d8da0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0db1200-d407-44cc-b35e-092eaf1f0536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ff8dddea-4a0a-4d3d-b8fe-6c495d8da0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_88748565-dcb3-4077-986c-b57537d17cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_88748565-dcb3-4077-986c-b57537d17cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_72a81d93-5f65-4310-995d-8a4392b05bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_72a81d93-5f65-4310-995d-8a4392b05bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ec28912-2119-4c76-a12b-0ebe96bc9d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c95baf9-bb79-4349-8c96-5e53ca215d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ec28912-2119-4c76-a12b-0ebe96bc9d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9e5d18c9-4738-4f4f-98f4-e67217e66455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ec28912-2119-4c76-a12b-0ebe96bc9d77" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9e5d18c9-4738-4f4f-98f4-e67217e66455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_57281464-5aea-4fd7-b7e7-a9c1ec16f059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ec28912-2119-4c76-a12b-0ebe96bc9d77" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_57281464-5aea-4fd7-b7e7-a9c1ec16f059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_24dec232-8bf6-45cd-8c92-18a1725776e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ec28912-2119-4c76-a12b-0ebe96bc9d77" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_24dec232-8bf6-45cd-8c92-18a1725776e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7cafdfd2-740c-451c-b2c8-b09db63ab767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ec28912-2119-4c76-a12b-0ebe96bc9d77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7cafdfd2-740c-451c-b2c8-b09db63ab767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4d0cec4d-1734-47eb-90c5-32f8a2c8809f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ec28912-2119-4c76-a12b-0ebe96bc9d77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4d0cec4d-1734-47eb-90c5-32f8a2c8809f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_06977080-99bf-4781-be8d-a4d71d888150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ec28912-2119-4c76-a12b-0ebe96bc9d77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_06977080-99bf-4781-be8d-a4d71d888150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#StockOptionPlanRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43c9eb2d-db4a-432d-8e48-a8a523a76882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f672f9ef-4036-42d9-872e-66105596ae20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43c9eb2d-db4a-432d-8e48-a8a523a76882" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f672f9ef-4036-42d9-872e-66105596ae20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4a7cfabb-c63d-4ffd-8dde-751605ddcd85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f672f9ef-4036-42d9-872e-66105596ae20" xlink:to="loc_us-gaap_AwardTypeAxis_4a7cfabb-c63d-4ffd-8dde-751605ddcd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e169a8c-5cb7-4c7d-bd20-7d34312c85b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4a7cfabb-c63d-4ffd-8dde-751605ddcd85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e169a8c-5cb7-4c7d-bd20-7d34312c85b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f2e3726b-0ab2-422d-b3b8-9bde705df939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e169a8c-5cb7-4c7d-bd20-7d34312c85b5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f2e3726b-0ab2-422d-b3b8-9bde705df939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_717c7a98-56c6-4bab-94c9-2afc3b768e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f672f9ef-4036-42d9-872e-66105596ae20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_717c7a98-56c6-4bab-94c9-2afc3b768e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15d8bbc2-6e36-446d-aa15-72f263e54447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_717c7a98-56c6-4bab-94c9-2afc3b768e4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15d8bbc2-6e36-446d-aa15-72f263e54447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bfdc707a-2e7c-40d0-b620-2db952df6a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15d8bbc2-6e36-446d-aa15-72f263e54447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bfdc707a-2e7c-40d0-b620-2db952df6a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b08fe588-938e-46d6-b5df-9d0cd487f29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15d8bbc2-6e36-446d-aa15-72f263e54447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b08fe588-938e-46d6-b5df-9d0cd487f29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_460fba65-cdca-4d24-89d3-cc32a58d5175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15d8bbc2-6e36-446d-aa15-72f263e54447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_460fba65-cdca-4d24-89d3-cc32a58d5175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c819b56-4cae-4610-8f1c-7df1832cb9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15d8bbc2-6e36-446d-aa15-72f263e54447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c819b56-4cae-4610-8f1c-7df1832cb9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dbda030a-8407-4743-90a5-cf4f68cb8544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15d8bbc2-6e36-446d-aa15-72f263e54447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dbda030a-8407-4743-90a5-cf4f68cb8544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_31fed3d7-884d-4da7-bdc5-33f12b5f2f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_717c7a98-56c6-4bab-94c9-2afc3b768e4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_31fed3d7-884d-4da7-bdc5-33f12b5f2f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_976ff32e-4d98-4457-bd68-4c51513b216d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_31fed3d7-884d-4da7-bdc5-33f12b5f2f39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_976ff32e-4d98-4457-bd68-4c51513b216d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_756fac27-6285-40ef-8e40-06dc33e71cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_31fed3d7-884d-4da7-bdc5-33f12b5f2f39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_756fac27-6285-40ef-8e40-06dc33e71cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3386b24d-78ef-4392-8526-d4efd03849eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_31fed3d7-884d-4da7-bdc5-33f12b5f2f39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3386b24d-78ef-4392-8526-d4efd03849eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e6b30c58-6b0d-4646-9e3b-30cc63aedf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_31fed3d7-884d-4da7-bdc5-33f12b5f2f39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e6b30c58-6b0d-4646-9e3b-30cc63aedf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2aedcc59-4b38-4d3e-aee7-c3086153efa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_31fed3d7-884d-4da7-bdc5-33f12b5f2f39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2aedcc59-4b38-4d3e-aee7-c3086153efa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_cfd4f9f8-167f-4ef6-98e3-76b62d6f9db1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_717c7a98-56c6-4bab-94c9-2afc3b768e4e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_cfd4f9f8-167f-4ef6-98e3-76b62d6f9db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2cfa236e-91f8-4cf4-ac58-97ac22d64f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_cfd4f9f8-167f-4ef6-98e3-76b62d6f9db1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2cfa236e-91f8-4cf4-ac58-97ac22d64f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ece9b65d-a546-46ec-8588-352b6af27f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6aaf1e25-4985-44ab-95c4-5c2d45553cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ece9b65d-a546-46ec-8588-352b6af27f1d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6aaf1e25-4985-44ab-95c4-5c2d45553cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_585ffd9e-79d2-4021-9457-18bf4327dcce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6aaf1e25-4985-44ab-95c4-5c2d45553cf6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_585ffd9e-79d2-4021-9457-18bf4327dcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3b535443-b491-49fd-9b12-2bee4ebc4b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_585ffd9e-79d2-4021-9457-18bf4327dcce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3b535443-b491-49fd-9b12-2bee4ebc4b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_cd0a6b86-5be0-419c-ac87-e918596dc8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3b535443-b491-49fd-9b12-2bee4ebc4b33" xlink:to="loc_us-gaap_CostOfSalesMember_cd0a6b86-5be0-419c-ac87-e918596dc8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6cd593e2-8515-4331-b281-e1bad0f20133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3b535443-b491-49fd-9b12-2bee4ebc4b33" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6cd593e2-8515-4331-b281-e1bad0f20133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d96cd97e-1fff-442c-b5bb-ad866545575f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3b535443-b491-49fd-9b12-2bee4ebc4b33" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d96cd97e-1fff-442c-b5bb-ad866545575f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40881ab1-2f7b-4af8-b334-45871c3dd56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6aaf1e25-4985-44ab-95c4-5c2d45553cf6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40881ab1-2f7b-4af8-b334-45871c3dd56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0fb3374d-8a09-4973-b4d0-a4085ec10e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40881ab1-2f7b-4af8-b334-45871c3dd56a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0fb3374d-8a09-4973-b4d0-a4085ec10e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="exdx-20230331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_a99ae7db-bcf0-43a4-afe4-715e606fd555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_1d533c86-9a99-459d-84f4-b6e955571879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_a99ae7db-bcf0-43a4-afe4-715e606fd555" xlink:to="loc_us-gaap_SubsequentEventTable_1d533c86-9a99-459d-84f4-b6e955571879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8d2dacb5-5b11-42d7-a286-d9b05a82c2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1d533c86-9a99-459d-84f4-b6e955571879" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8d2dacb5-5b11-42d7-a286-d9b05a82c2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_187f4c09-a245-44f0-80b2-a52746388b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8d2dacb5-5b11-42d7-a286-d9b05a82c2a5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_187f4c09-a245-44f0-80b2-a52746388b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b2a1e6f4-e3b7-43c8-882e-a770aea9fdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_187f4c09-a245-44f0-80b2-a52746388b75" xlink:to="loc_us-gaap_SubsequentEventMember_b2a1e6f4-e3b7-43c8-882e-a770aea9fdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_59ea8d62-c77d-4749-8233-44ef8d2d4b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1d533c86-9a99-459d-84f4-b6e955571879" xlink:to="loc_us-gaap_DebtInstrumentAxis_59ea8d62-c77d-4749-8233-44ef8d2d4b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1ff78162-e99f-4067-8435-6d31c8739c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_59ea8d62-c77d-4749-8233-44ef8d2d4b6a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1ff78162-e99f-4067-8435-6d31c8739c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_a3095b77-cd7f-40b4-ad68-c209a5a648cc" xlink:href="exdx-20230331.xsd#exdx_Term2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ff78162-e99f-4067-8435-6d31c8739c38" xlink:to="loc_exdx_Term2017Member_a3095b77-cd7f-40b4-ad68-c209a5a648cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_dbb86046-b1be-4324-bf06-127b79435b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1d533c86-9a99-459d-84f4-b6e955571879" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_dbb86046-b1be-4324-bf06-127b79435b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_d0915995-9793-4221-b361-e69046951190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_dbb86046-b1be-4324-bf06-127b79435b1e" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_d0915995-9793-4221-b361-e69046951190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_a0f0b3c5-131c-438f-9abc-46b36730d076" xlink:href="exdx-20230331.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_d0915995-9793-4221-b361-e69046951190" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_a0f0b3c5-131c-438f-9abc-46b36730d076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5b817bb2-f5fe-4329-869f-c33f8172ebc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1d533c86-9a99-459d-84f4-b6e955571879" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5b817bb2-f5fe-4329-869f-c33f8172ebc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6a445b4f-187e-415c-827b-e8da2dd6837c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5b817bb2-f5fe-4329-869f-c33f8172ebc7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6a445b4f-187e-415c-827b-e8da2dd6837c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_b2e46303-0022-4c40-ad17-389cfd37b879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6a445b4f-187e-415c-827b-e8da2dd6837c" xlink:to="loc_us-gaap_LoansPayableMember_b2e46303-0022-4c40-ad17-389cfd37b879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_0f5cff86-8818-4a73-bd1e-8e3f13fbd541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1d533c86-9a99-459d-84f4-b6e955571879" xlink:to="loc_us-gaap_VariableRateAxis_0f5cff86-8818-4a73-bd1e-8e3f13fbd541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4eabd90e-c2a8-4557-ac07-fadd05e7aee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_0f5cff86-8818-4a73-bd1e-8e3f13fbd541" xlink:to="loc_us-gaap_VariableRateDomain_4eabd90e-c2a8-4557-ac07-fadd05e7aee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_5944bd22-dc65-4a4f-921a-9a2e24563e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4eabd90e-c2a8-4557-ac07-fadd05e7aee1" xlink:to="loc_us-gaap_PrimeRateMember_5944bd22-dc65-4a4f-921a-9a2e24563e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_0b259fc1-9adc-4b93-b838-4349cb61c4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1d533c86-9a99-459d-84f4-b6e955571879" xlink:to="loc_us-gaap_SubsequentEventLineItems_0b259fc1-9adc-4b93-b838-4349cb61c4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7e8c58cb-fed8-481e-a93b-6222868d03a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0b259fc1-9adc-4b93-b838-4349cb61c4a7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7e8c58cb-fed8-481e-a93b-6222868d03a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_181d3cc0-f7d7-4b57-aa47-096c6bc04cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0b259fc1-9adc-4b93-b838-4349cb61c4a7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_181d3cc0-f7d7-4b57-aa47-096c6bc04cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_acf0c38d-966d-4fcf-b83c-ade5b067b667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0b259fc1-9adc-4b93-b838-4349cb61c4a7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_acf0c38d-966d-4fcf-b83c-ade5b067b667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_d8809e2e-54a4-4fe6-a6cf-0fa72bf1f4aa" xlink:href="exdx-20230331.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0b259fc1-9adc-4b93-b838-4349cb61c4a7" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_d8809e2e-54a4-4fe6-a6cf-0fa72bf1f4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_98657f9c-f5e5-4da2-8271-ddbcbab5c7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0b259fc1-9adc-4b93-b838-4349cb61c4a7" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_98657f9c-f5e5-4da2-8271-ddbcbab5c7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880932999456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 11, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXAGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-0434866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1261 Liberty Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vista,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">560-1501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,825,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001274737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880930648128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 52,184<span></span>
</td>
<td class="nump">$ 62,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">9,303<span></span>
</td>
<td class="nump">6,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,229<span></span>
</td>
<td class="nump">4,143<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">65,716<span></span>
</td>
<td class="nump">72,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">8,264<span></span>
</td>
<td class="nump">8,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">4,651<span></span>
</td>
<td class="nump">4,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">603<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">79,234<span></span>
</td>
<td class="nump">86,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,878<span></span>
</td>
<td class="nump">3,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">6,064<span></span>
</td>
<td class="nump">5,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,072<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Borrowings-current portion</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,268<span></span>
</td>
<td class="nump">9,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="nump">29,092<span></span>
</td>
<td class="nump">28,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">4,211<span></span>
</td>
<td class="nump">4,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">726<span></span>
</td>
<td class="nump">867<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">43,297<span></span>
</td>
<td class="nump">43,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding as of March&#160;31, 2023 and December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized as of March&#160;31, 2023 and December 31, 2022; 16,827,014 and 16,549,984 shares issued and outstanding as of March&#160;31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">299,135<span></span>
</td>
<td class="nump">297,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(263,215)<span></span>
</td>
<td class="num">(255,527)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">35,937<span></span>
</td>
<td class="nump">42,460<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 79,234<span></span>
</td>
<td class="nump">$ 86,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880932914096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">16,827,014<span></span>
</td>
<td class="nump">16,549,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">16,827,014<span></span>
</td>
<td class="nump">16,549,984<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880928118960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 11,230<span></span>
</td>
<td class="nump">$ 10,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of revenue</a></td>
<td class="nump">5,926<span></span>
</td>
<td class="nump">5,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">11,884<span></span>
</td>
<td class="nump">12,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1,126<span></span>
</td>
<td class="nump">2,104<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">18,936<span></span>
</td>
<td class="nump">20,073<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(7,706)<span></span>
</td>
<td class="num">(9,679)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(638)<span></span>
</td>
<td class="num">(598)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,688)<span></span>
</td>
<td class="num">$ (10,272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used to compute net loss per share, basic (in shares)</a></td>
<td class="nump">17,526,763<span></span>
</td>
<td class="nump">16,992,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used to compute net loss per share, diluted (in shares)</a></td>
<td class="nump">17,526,763<span></span>
</td>
<td class="nump">16,992,391<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880931436320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,164,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 84,936<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 293,060<span></span>
</td>
<td class="num">$ (208,140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares', window );">Issuance of stock from vested restricted stock units and payment of employees' taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue', window );">Issuance of stock from vested restricted stock units</a></td>
<td class="num">(115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under Employee Stock Purchase Plan</a></td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,272)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,231,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 76,156<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">294,552<span></span>
</td>
<td class="num">(218,412)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">16,549,984<span></span>
</td>
<td class="nump">16,549,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 42,460<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">297,970<span></span>
</td>
<td class="num">(255,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares', window );">Issuance of stock from vested restricted stock units and payment of employees' taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue', window );">Issuance of stock from vested restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under Employee Stock Purchase Plan</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,688)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,688)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">16,827,014<span></span>
</td>
<td class="nump">16,827,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 35,937<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 299,135<span></span>
</td>
<td class="num">$ (263,215)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880932043792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,688)<span></span>
</td>
<td class="num">$ (10,272)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">553<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">986<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(3,226)<span></span>
</td>
<td class="num">(1,257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(86)<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(79)<span></span>
</td>
<td class="num">(273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(250)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,320)<span></span>
</td>
<td class="nump">579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">893<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(9,749)<span></span>
</td>
<td class="num">(8,574)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(396)<span></span>
</td>
<td class="num">(1,087)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(396)<span></span>
</td>
<td class="num">(1,087)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of taxes withheld on vested restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from common stock issued under Employee Stock Purchase Plan</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance lease obligations</a></td>
<td class="num">(189)<span></span>
</td>
<td class="num">(146)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payment on note payable obligations</a></td>
<td class="num">(52)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(10,207)<span></span>
</td>
<td class="num">(9,691)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">62,591<span></span>
</td>
<td class="nump">99,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">52,384<span></span>
</td>
<td class="nump">89,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_EquipmentPurchasedUnderNotesPayableObligations', window );">Equipment purchased under notes payable obligations</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Costs incurred, but not paid, in connection with capital expenditures</a></td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">$ 1,672<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_EquipmentPurchasedUnderNotesPayableObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equipment Purchased Under Notes Payable Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_EquipmentPurchasedUnderNotesPayableObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Expense and Current Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139881021459216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exagen Inc. (the Company) is a commercial-stage diagnostics company dedicated to helping patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. As of March&#160;31, 2023, the Company had cash and cash equivalents of $52.2 million and had an accumulated deficit of $263.2 million. Since inception, the Company has financed its operations primarily through a combination of equity financings, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880933658640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed balance sheet as of March&#160;31, 2023, condensed statements of operations, stockholders' equity and cash flows for the three months ended March&#160;31, 2023 and the related footnote disclosures are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. These unaudited condensed financial statements and related footnote disclosures should be read in conjunction with the Company&#8217;s audited financial statements for the year ended December 31, 2022, included in its Annual Report on Form 10-K filed with the SEC on March 20, 2023. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all normal adjustments, necessary for the fair presentation of the Company's financial position as of March&#160;31, 2023 and its results of operations for the periods presented. The results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the recoverability of its long-lived assets and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable, Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, approximately 87% and 84%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on key suppliers for certain laboratory materials. For the three months ended March&#160;31, 2023 and 2022, approximately 97% and 95%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,394&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature, which are determined to be a Level 1 measurement (see Note 6). The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for the same or similar issues. As of March&#160;31, 2023, the 2017 Term Loan (as defined below) had a carrying value of $28.4&#160;million and a fair value of $27.1&#160;million. As of December 31, 2022, the 2017 Term Loan had a carrying value of $28.3&#160;million and a fair value of $26.9&#160;million The estimated fair value of the 2017 Term Loan, was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The recorded value of the Company's other long-term borrowing was $0.7&#160;million and approximated its fair value as of March&#160;31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an arrangement with a financial institution with which it has an existing banking relationship, whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a certificate of deposit with this financial institution as collateral for the balances borrowed on these cards ($0.2 million at March&#160;31, 2023 and December 31, 2022). The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,384&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Long-lived Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, we combine our intangible assets and other long-lived assets, into groupings, a determination which we principally make on the basis of whether the assets are specific to a particular test we offer or technology we are developing. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Management&#8217;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. </span></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.) and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the three months ended March&#160;31, 2023 and 2022 was a $0.3&#160;million net revenue increase and a $0.2&#160;million net revenue decrease, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#8217;s balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue an allowance for credit losses against our accounts receivable based on management&#8217;s current estimate of amounts that will not be collected. Management&#8217;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was zero as of March&#160;31, 2023. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.3 million for the three months ended March&#160;31, 2023 and 2022, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $0.7 million and $0.6 million for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on that date. The Company's restricted stock units generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of restricted stock units is subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three months ended March&#160;31, 2023 and 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding, as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.414%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.915%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,002,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">878,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,937,005&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,296,651&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Segment Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which requires the measurement of expected credit losses (based on historical experience, current conditions and reasonable forecasts) for financial instruments (such as accounts receivable) held at the reporting date which are carried at amortized cost. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Codification Improvements to Topic 326, Financing Instruments-Credit Losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which included an amendment of the effective date for nonpublic entities. For emerging growth companies, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted this pronouncement on January 1, 2023. The adoption did not have an impact on its condensed financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for smaller reporting companies as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2023. The adoption did not have an impact on its condensed financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139881021616464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock', window );">Other Financial Information</a></td>
<td class="text">Other Financial Information<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,321&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,197&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the three months ended March&#160;31, 2023 and 2022 was approximately $0.6 million and $0.3 million, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Other Current Liabilities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Refund liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880933281600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Term Loan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), as amended, pursuant to which the Company borrowed $25.0&#160;million. As of March&#160;31, 2023, no additional amounts remained available to borrow under the 2017 Term Loan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company executed the Second Amendment to the Loan and Security Agreement (the 2017 Loan Amendment) and, as further described in Note 9, on April 28, 2023, the Company and Innovatus entered into </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Third Loan Amendment to the 2017 Term Loan (Third Loan Amendment). The interest rate on all borrowings under the 2017 Loan Amendment was 8.0%, of which 2.0% was paid in-kind in the form of additional term loans (PIK Loans) until December of 2024, after which interest was scheduled to accrue at an annual rate of 8.0%. The Company estimated the effective interest rate of this loan to be approximately 8.5%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the 2017 Loan Amendment was to be repaid in twenty-four equal monthly installments commencing in December 2024. Upon repayment of the final installment under the 2017 Loan Amendment, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of the Loan Amendment using the effective interest method. For each of the three months ended March&#160;31, 2023 and 2022, the Company issued PIK Loans totaling $0.1 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Loan Amendment required a prepayment premium of 2% of the aggregate outstanding principal and decreased by 1% on each of November 1, 2023 and 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Loan Amendment is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the 2017 Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis. The consequences of failing to achieve the performance covenant were eligible to be cured if, within sixty days of failing to achieve the performance covenant, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The 2017 Loan Amendment requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative covenants provide, among other things, that without the prior consent of Innovatus, subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company was in compliance with all covenants of the 2017 Loan Amendment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an event of default in any of the 2017 Loan Amendment covenants, the repayment of the 2017 Loan Amendment may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the 2017 Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the 2017 Loan Amendment due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2022 Equipment Notes Payable</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2022, the Company purchased laboratory equipment using notes payable. At March&#160;31, 2023, the total notes payable balance related to this financed equipment was $1.0 million, with $0.3 million classified within borrowings-current portion and $0.7 million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. The financed equipment is subject to a 5.28% effective interest rate and will mature on October 1, 2026.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Future Minimum Payments on the Outstanding Borrowings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, future minimum aggregate payments, including interest, for outstanding borrowings under the 2017 Loan Amendment are as follows (in thousands):</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,774)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Borrowings-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880931471840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related liabilities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the medical diagnostics division of Royalty Pharma Collection Trust (Royalty Pharma) (formerly known as Cypress Bioscience, Inc.) in 2010, the Company has ongoing royalty payment obligations of 2.5% on net sales of products which incorporate certain acquired technologies. Future royalties payable under these arrangements are limited to the lesser of (i) an aggregate of $1.2 million (including an upfront payment of $0.1 million) and (ii) the total royalties earned through January 1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements, individual license agreements generally provide for ongoing royalty payments ranging from 1.5% to 7.0% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when earned and recorded in costs of revenue in the accompanying condensed statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Obligations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a master research collaboration agreement with Allegheny Health Network Research Institute (AHN), pursuant to which the Company is required to pay AHN a collaboration fee of $0.4 million for each year during the initial term of the agreement. Collaboration expenses under the master research collaboration agreement were $0.1 million for each of the three months ended March&#160;31, 2023 and 2022. Collaboration expenses under the AHN collaboration are included in research and development expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supply Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $6.9 million and $8.0 million for the years ending December 31, 2023 and 2024, respectively, with a 15% annual increase thereafter for unconditional minimum purchase commitments through the year ending December 31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including for subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities. The Company does not believe the outcome of any such matters will have a material effect on its financial position or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880933078512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificate of deposit, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,146&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,146&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificate of deposit, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The fair value of the Company's money market funds is based on quoted market prices.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880933157568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At The Market Sales Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 15, 2022, the Company entered into a sales agreement (the Sales Agreement) with Cowen and Company, LLC (the Sales Agent), pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $50.0&#160;million. The Company is not obligated to </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">sell any shares of Company common stock in the offering. As of March&#160;31, 2023, the Company has not sold any shares of its common stock pursuant to the Sales Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Outstanding Warrants</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following equity classified warrants to purchase common stock were outstanding as of March&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237,169</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,086</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,951</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214,059</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, no warrants to purchase common stock were exercised.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880933128000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Option Plan</a></td>
<td class="text">Stock Option Plan<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Incentive Award Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally four years from the date of grant or, for grants to new hires, date of hire. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) 4% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board of Directors. As of March&#160;31, 2023, 1,851,836 shares of common stock remained available for future awards under the 2019 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, the Board of Directors adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the lesser of (i) 1% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board of Directors. As of March&#160;31, 2023, 508,608 shares of common stock remained available for issuance under the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company's 2019 Plan is set forth below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.894%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(93,335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(277,805)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019,076&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019,076&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.97</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,742&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.64</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no stock options granted in the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The aggregate intrinsic value of options exercised during the three months ended March 31, 2023 was $0.2 million. There were no options exercised during the three months ended March 31, 2022. As of March&#160;31, 2023, total unrecognized compensation cost related to option awards was $1.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 0.82&#160;years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(113,720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66,903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494,085&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, all of the outstanding restricted stock units were unvested. The fair value of restricted stock units vested in each of the three months ended March 31, 2023 and 2022 was $0.3 million. The weighted average grant date fair value for restricted stock units granted in the three months ended March 31, 2023 and 2022 was $2.30 and $8.72, respectively. As of March&#160;31, 2023, total unrecognized compensation cost related to restricted stock units was $6.2 million, which is expected to be recognized over a remaining weighted-average vesting period of 3.5 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statements of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880933149280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 28, 2023, the Company and Innovatus entered into the Third Loan Amendment.  Pursuant to the Third Loan Amendment, the Company prepaid $10.0&#160;million of principal (Prepayment) and amended the 2017 Term Loan by, among other things:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">waiving the Prepayment Fee (as defined in the 2017 Term Loan, as amended) with respect to the Prepayment;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">revising the interest rate to the sum (the Basic Rate) of (a) the greater of The Wall Street Journal prime rate (the Prime Rate) or 8.0%, plus (b) 2.0%, of which 1.5% will be payable in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until April 1, 2026;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">extending the interest-only period through March 2026 and the maturity date to December 31, 2026;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">decreasing the specified levels of revenue, as measured on the last day of each quarter on a rolling twelve-month basis, that the Company must achieve to satisfy the related financial covenants (the Revenue Covenant) in the 2017 Term Loan;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">removing the obligation to comply with the Revenue Covenant during any fiscal quarter if the Company maintains a minimum aggregate cash balance equal to fifty percent of the aggregate principal amount of the loan at all times during such quarter;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">providing the Company with a cure period in the event it breaches certain covenants; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">revising the definition of &#8220;Permitted Indebtedness&#8221; to permit the Company to broaden the limits on the Company&#8217;s ability to incur capitalized lease obligations, finance lease obligations, purchase money indebtedness or equipment financings without Innovatus&#8217;s prior written consent.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880928144736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risk and Uncertainties</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature, which are determined to be a Level 1 measurement (see Note 6). The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for the same or similar issues. As of March&#160;31, 2023, the 2017 Term Loan (as defined below) had a carrying value of $28.4&#160;million and a fair value of $27.1&#160;million. As of December 31, 2022, the 2017 Term Loan had a carrying value of $28.3&#160;million and a fair value of $26.9&#160;million The estimated fair value of the 2017 Term Loan, was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The recorded value of the Company's other long-term borrowing was $0.7&#160;million and approximated its fair value as of March&#160;31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-lived Assets</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Long-lived Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, we combine our intangible assets and other long-lived assets, into groupings, a determination which we principally make on the basis of whether the assets are specific to a particular test we offer or technology we are developing. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A </span></div>long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Management&#8217;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:16pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.) and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the three months ended March&#160;31, 2023 and 2022 was a $0.3&#160;million net revenue increase and a $0.2&#160;million net revenue decrease, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#8217;s balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory </span></div>supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Marketing Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.3 million for the three months ended March&#160;31, 2023 and 2022, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $0.7 million and $0.6 million for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on that date. The Company's restricted stock units generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of restricted stock units is subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three months ended March&#160;31, 2023 and 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding, as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Segment Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements and Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which requires the measurement of expected credit losses (based on historical experience, current conditions and reasonable forecasts) for financial instruments (such as accounts receivable) held at the reporting date which are carried at amortized cost. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Codification Improvements to Topic 326, Financing Instruments-Credit Losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which included an amendment of the effective date for nonpublic entities. For emerging growth companies, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted this pronouncement on January 1, 2023. The adoption did not have an impact on its condensed financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for smaller reporting companies as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2023. The adoption did not have an impact on its condensed financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880926989152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</a></td>
<td class="text">For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable, Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,394&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,384&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,384&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.414%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.915%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,002,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">878,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,937,005&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,296,651&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880934194768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">Prepaid expenses and other current assets consist of the following (in thousands):<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,321&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,197&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Refund liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880933232992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</a></td>
<td class="text">As of March&#160;31, 2023, future minimum aggregate payments, including interest, for outstanding borrowings under the 2017 Loan Amendment are as follows (in thousands):<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,774)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Borrowings-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880933191392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</a></td>
<td class="text">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificate of deposit, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,146&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,146&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificate of deposit, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880933313248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following equity classified warrants to purchase common stock were outstanding as of March&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237,169</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,086</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,951</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214,059</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880930990592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text">Stock option activity under the Company's 2019 Plan is set forth below:<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.894%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(93,335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(277,805)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019,076&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019,076&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.97</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,742&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.64</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(113,720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66,903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494,085&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Non-cash Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statements of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880928159280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 52,184<span></span>
</td>
<td class="nump">$ 62,391<span></span>
</td>
<td class="nump">$ 89,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (263,215)<span></span>
</td>
<td class="num">$ (255,527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880930989184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue by Major Payers (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareMember', window );">Medicare | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareMember', window );">Medicare | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember', window );">Medicare Advantage | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember', window );">Medicare Advantage | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_BlueShieldMember', window );">Blue Shield | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_BlueShieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_BlueShieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880931299824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 29,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized in previous periods</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=exdx_OtherLongTermDebtMember', window );">Other Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instrument</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 28,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instrument</a></td>
<td class="nump">27,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Product Concentration Risk | AVISE CTD Test</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Supplier Concentration Risk | Two Major Suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=exdx_OtherLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=exdx_OtherLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_Term2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exdx_AVISECTDTestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exdx_AVISECTDTestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=exdx_TwoMajorSuppliersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=exdx_TwoMajorSuppliersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880928122768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 11,230<span></span>
</td>
<td class="nump">$ 10,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_HealthcareInsurersMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">4,215<span></span>
</td>
<td class="nump">6,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_Government1Member', window );">Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">4,426<span></span>
</td>
<td class="nump">2,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_ClientMember', window );">Client</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">2,407<span></span>
</td>
<td class="nump">1,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">$ 260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_HealthcareInsurersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_HealthcareInsurersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_Government1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_Government1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_ClientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_ClientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=us-gaap_OtherCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880930999088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 52,184<span></span>
</td>
<td class="nump">$ 62,391<span></span>
</td>
<td class="nump">$ 89,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">$ 52,384<span></span>
</td>
<td class="nump">$ 62,591<span></span>
</td>
<td class="nump">$ 89,851<span></span>
</td>
<td class="nump">$ 99,542<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880931375376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">2,937,005<span></span>
</td>
<td class="nump">3,296,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">409,108<span></span>
</td>
<td class="nump">409,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">1,019,076<span></span>
</td>
<td class="nump">2,002,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">1,494,085<span></span>
</td>
<td class="nump">878,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">14,736<span></span>
</td>
<td class="nump">6,929<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880932916352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Prepaid Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Diagnostic&#160;testing&#160;supplies</a></td>
<td class="nump">$ 1,736<span></span>
</td>
<td class="nump">$ 1,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRoyalties', window );">Prepaid product royalties</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_PrepaidMaintenanceAndInsuranceContracts', window );">Prepaid maintenance and insurance contracts</a></td>
<td class="nump">2,210<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses and other current assets</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 4,229<span></span>
</td>
<td class="nump">$ 4,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidMaintenanceAndInsuranceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Maintenance and Insurance Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidMaintenanceAndInsuranceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880931528912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">$ 13,934<span></span>
</td>
<td class="nump">$ 13,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(5,670)<span></span>
</td>
<td class="num">(5,124)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">8,264<span></span>
</td>
<td class="nump">8,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture&#160;and&#160;fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">5,209<span></span>
</td>
<td class="nump">5,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">1,548<span></span>
</td>
<td class="nump">1,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">5,223<span></span>
</td>
<td class="nump">5,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">$ 1,856<span></span>
</td>
<td class="nump">$ 1,382<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880933062864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880930990016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</a></td>
<td class="nump">$ 3,662<span></span>
</td>
<td class="nump">$ 2,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_AccruedPurchaseGoodsAndServicesCurrent', window );">Accrued purchases of goods and services</a></td>
<td class="nump">665<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_AccruedLiabilitiesClinicalStudyCurrent', window );">Accrued clinical study activity</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligations, current portion</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Refund liability</a></td>
<td class="nump">445<span></span>
</td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 6,064<span></span>
</td>
<td class="nump">$ 5,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedLiabilitiesClinicalStudyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Clinical Study, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedLiabilitiesClinicalStudyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedPurchaseGoodsAndServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Purchase, Goods and Services, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedPurchaseGoodsAndServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880931027040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Loan payable | Innovatus Life Sciences Lending Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Term loan borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Term loan, interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentStatedInterestRatePaidInKind', window );">Term loan, paid in-kind, interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Term loan, effective interest rate</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentNumberOfMonthlyInstallments', window );">Number of monthly installments | installment</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Term loan, fee incurred upon payment of final installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentPrepaymentPremiumPercentage', window );">Term loan, prepayment premium percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction', window );">Term loan, annual reduction in prepayment penalty percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantRevenuePerformancePeriod', window );">Term loan, covenant, revenue performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet', window );">Term loan, covenant, number of days to cure covenant if performance measure is not met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance', window );">Term loan covenant, minimum unrestricted cash balance</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease', window );">Term loan covenant, increase to interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Paid in-kind note | Innovatus Life Sciences Lending Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentPaidInKindLoansIssued', window );">Term loan, paid in-kind loans issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_EquipmentNotesPayableMember', window );">Equipment Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Term loan, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.28%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantRevenuePerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Revenue Performance Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantRevenuePerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentNumberOfMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Monthly Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentNumberOfMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPaidInKindLoansIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Paid In Kind Loans Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPaidInKindLoansIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPrepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPrepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium Percentage, Annual Reduction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentStatedInterestRatePaidInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Stated Interest Rate, Paid In-Kind</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentStatedInterestRatePaidInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_Term2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_EquipmentNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_EquipmentNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880931380880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Future Minimum Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2023 (remaining)</a></td>
<td class="nump">$ 1,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">3,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">16,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">15,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_LongTermDebtIncludingUndiscountedInterest', window );">Total</a></td>
<td class="nump">36,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="num">(145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_LongTermDebtUndiscountedInterestAmount', window );">Interest</a></td>
<td class="num">(6,774)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="nump">29,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Borrowings-current portion</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">$ (190)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="nump">$ 29,092<span></span>
</td>
<td class="nump">$ 28,778<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtIncludingUndiscountedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Including Undiscounted Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtIncludingUndiscountedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtUndiscountedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Undiscounted Interest Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtUndiscountedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880931697168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase obligation, due in year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Purchase obligation, due in second year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage', window );">Annual increase in purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Licensing Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Licensing Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember', window );">AHN Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_CollaborationAgreementCollaborationExpenses', window );">Collaboration agreement, collaboration expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember', window );">Prometheus Laboratories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Future minimum royalty commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_AdvancePayment', window );">Advance royalties payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember', window );">Prometheus Laboratories | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember', window );">Allegheny Health Network Research Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_CollaborationAgreementAnnualCollaborationFee', window );">Collaboration fee</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdvancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdvancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CollaborationAgreementAnnualCollaborationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Annual Collaboration Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CollaborationAgreementAnnualCollaborationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CollaborationAgreementCollaborationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Collaboration Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CollaborationAgreementCollaborationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Annual Increase In Commitment, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RoyaltyObligationPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Percentage of Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RoyaltyObligationPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880930704512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 50,146<span></span>
</td>
<td class="nump">$ 59,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">20,146<span></span>
</td>
<td class="nump">29,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificate of deposit, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">50,146<span></span>
</td>
<td class="nump">59,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1 | Money market funds, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">20,146<span></span>
</td>
<td class="nump">29,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1 | Certificate of deposit, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2 | Money market funds, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2 | Certificate of deposit, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Money market funds, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Certificate of deposit, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139881102174416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=exdx_CowenEquityDistributionAgreementMember', window );">Cowen Equity Distribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=exdx_CowenEquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=exdx_CowenEquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880931089200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Outstanding Warrants (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">1,214,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member', window );">Warrant expiration January 19, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">237,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member', window );">Warrant expiration March 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">67,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member', window );">Warrant expiration April 1, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member', window );">Warrant expiration September 7, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">83,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member', window );">Warrant expiration December 7, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">20,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember', window );">No expiration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">804,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880930965760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock options, unrecognized compensation cost</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">9 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage', window );">Shares authorized, percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares that remain available for future awards (in shares)</a></td>
<td class="nump">508,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee payroll deduction percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock options, unrecognized compensation cost</a></td>
<td class="nump">$ 6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate intrinsic value, vested</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awards granted, Weighted-Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="nump">$ 8.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member', window );">2019 Incentive Award Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage', window );">Shares authorized, percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares that remain available for future awards (in shares)</a></td>
<td class="nump">1,851,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880927478800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock Option Activity (Details) - Stock options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, December 31, 2022 (in shares)</a></td>
<td class="nump">1,421,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(93,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(31,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(277,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, March 31, 2023 (in shares)</a></td>
<td class="nump">1,019,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,421,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, March 31, 2022 (in shares)</a></td>
<td class="nump">1,019,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options exercisable, March 31, 2022 (in shares)</a></td>
<td class="nump">804,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, December 31, 2022, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 12.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">14.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">17.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, March 31, 2023, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">12.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, March 31, 2022 (in shares), Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">12.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options exercised, March 31, 2022 (in shares), Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 12.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880928036896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Restricted Stock Units (Details) - Restricted stock units - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, December 31, 2022 (in shares)</a></td>
<td class="nump">1,036,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="nump">638,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Awards released (in shares)</a></td>
<td class="num">(113,720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Awards canceled (in shares)</a></td>
<td class="num">(66,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, March 31, 2023 (in shares)</a></td>
<td class="nump">1,494,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, December&#160;31, 2022 (in dollars per share)</a></td>
<td class="nump">$ 7.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awards granted, Weighted-Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">2.30<span></span>
</td>
<td class="nump">$ 8.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Awards released, Weighted-Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">11.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Awards canceled, Weighted-Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">11.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, March 31, 2023 (in dollars per share)</a></td>
<td class="nump">$ 4.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 3,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880932858160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 986<span></span>
</td>
<td class="nump">$ 1,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Costs of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">831<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139880928082208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - 2017 Term loan - Innovatus Life Sciences Lending Fund - Loan payable - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Term loan borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Term loan, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentStatedInterestRatePaidInKind', window );">Term loan, paid in-kind, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Term loan, interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentStatedInterestRatePaidInKind', window );">Term loan, paid in-kind, interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payment for Debt Extinguishment or Debt Prepayment Cost</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentStatedInterestRatePaidInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Stated Interest Rate, Paid In-Kind</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentStatedInterestRatePaidInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_Term2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>exdx-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:exdx="http://www.exagen.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exdx-20230331.xsd" xlink:type="simple"/>
    <context id="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icbe60ad4860843a2ab64b5cd330ef707_I20230511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2023-05-11</instant>
        </period>
    </context>
    <context id="i7dbf9a0fcf934366948459c15f4770d1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6bb6db3028e64addadc73284bff78b54_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia0649efcb68545c6b7b9b7ec6425a6bf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0705a248fabf483b8d91cb9179b97e90_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2fe0be00ef494161bd0549b671f2fe9b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i62b1db4c0c1d4c9f841e4594fe97bc2a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if71859fd80494dddb569b483b53c0f5b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8b09d1c772d642c2be65db1440589466_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i84709c32e10840689d3198791460cf9b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0c57b87359174c8ba8490118ae86e8ea_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i90a82a0082294a76aa4b428dfc020494_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f0a7eb3bdd5459aac214c6226b676a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if296323417ca4b029d7a11232e87aad2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i140c8595c10a41eeb48e5be8f884c4cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c10b316a5a146458ede9d5dc729ac84_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1b616351de9643b99134e16eafc041e6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9bc0bf262ca04963b27d2f261ce272bd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if2395d65c2f04e0c82d354b532c429b4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i72308a08a4614029a1a34e29777d8a6b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia408b342e58a47b4b9fab75709a394d2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic10d09e997d04be59819eb9f739c540e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icde0546e33bc4e4dbdee35365b9dbeec_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i53feb630091f4619a5126ec58f43ca87_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icd65ad1f84754ac2be24f4c994f8f3cd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia6abda9f9e6d446892e7c0f30b5d60d3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib670f4a2e3f647279e6c9c81af57ffc1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ife65d382ae2a47219439e25b9543c648_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4838d54052ca4b00a39f1c6ae8f5cfd5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibdb3a7f4fb2b4a099c8ab9a2651f42d9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1d88ab7784214d388b2b50fb5bb4c7b3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia2a4f1732f624b489e8f50c6d6b4e485_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iecd13c786620474fa63cd266b54a3b74_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i309af3d1bef54a83aaa50e2c61f71a24_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i90730eb7530d4cc89a0fc5a794ff71a1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iae6ce9aaec2a446c9c116ff73b70f8b3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id6a670771b95429a8cb648b92575b810_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i35095a09a8d844129623d819fcf1cacb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i705da3eb6365425bb71d37b40211def3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i939a0caa5e764269961b35c18b4916a0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i30fc00a42642408badd375838de42222_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8df9a05d543b42d696a2487ba38b7424_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if846aeeb8f314bd9a6bf240c914de52a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3f88c29ff5974403bff253575a02defd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6610d7c73b1f4958b659b907335a85a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9c3e2b7da46c423383b2883aad5f1fba_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">exdx:OtherLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia543ba88573a4f76b3f29f77c2c449a3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i96b7c50405024efea4bb7ce5ef47adb3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i895d656b22474a18a403f1fd341b6467_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6b4f7177650b41ea9633024d9953c438_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3d8153a1b8c047f5ba1ab683df79cb7f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i30edb0fc3f0c427ab5994bec9d4cb64a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iafc6e1b4e06e45fcb9b81908405af3e3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i19225060b0864579b9f675d97dd4b83b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i574ca98624ca4a4b9e2538fbfee1fab3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i32c2432d847f4430ba1a0adb828fc7e5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7cb9b15bd3534c7b959fafc69dd136ca_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iad556f0486564986b0fe232198d50b00_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea90a46da8b0473b81bd14734a0e680a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie8b419bb6ccf44b485236b67f0570541_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifffe2a329326445ebf186d1dbfc97983_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6dbff6a1aa00481ca92a92d62756b86b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c7b49c0d49e41acb5a83a3b738931e7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iecd2c1906e2f4109b2230036ad76ebce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ice0b71e76bbd4e2e84837c2eba278fff_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idf0198dc6d684b77b81f517d3508fe26_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i94ecd2ce87e1410596492d2b66fe3d3d_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="ibb33abf78bcd4170a8b0655f9f35138a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i859e111840c844b0912ab35300e78234_I20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="i0d50b70a9daa46a5b489435a77934c85_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="iabe905c72ff84d589835e599cc035ca4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0a372fdfdb7a4826a6cbffa763f05288_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2a7f825dbe7d4f5c828334d605f13e10_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i66d0781c430544b080c8b6a0138f9b6e_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="i0bf8defbc1fa44d882189373b2849672_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia5c76f81d9cd409eb1b8a90d4fe48c57_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4931e73aebd8406f8a9334dd51dbbc52_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3350c67771f646c6b53fca4a8f67d638_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib3e0014fc8a94ef0953febf2e7cf24ad_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:AlleghenyHealthNetworkResearchInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i0e499e7ea6aa4310baa5eca3da4d604b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6d3bd6c4fe2242cf87f21e0213354a26_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if4fc1eac300c43b6a7327014b06ddfa9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i523c8d55aeb0417e85e726ce80798a7c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ieff95e26dba14d95a8f3cd8ee4182372_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3f4ffb1c43554f1a90dfd599025b8c9e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9625bbb62da645d980dedf056fae0d11_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i173e25ca60a14e9eb6d2a3839cd12de8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i626b7154acb34ccaafa6ab945abf40c9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie210aad638e548c4870de1627ee59314_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id41f690f8baf4faba442062c5cd09d97_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3981775f29d04856b8989e7532c82c09_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i15ae8bd4f38347fb8cd1eda4e1828338_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9d9435b79cd7491eaf962b33022de57f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie7a2e37140ea4e5d964b371b5b2e678e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifdbc12a0fd3349cea91fc35053c905ac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a4807b9a98e45a1ba7d94b95b6cf1db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id2057c462f3f407fac03e7ed09fbf60b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c407749d2e847a7803b2c710bcc16b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i75e67690fd9847e1aaece1d7ff577378_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69fb565bd3a94c019700911026c93178_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3aff556ef6e84baa8337afc2d1b6be3c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i90e1b44e5ed44cc28aa97c0d68594467_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4f4f95f45fbb40f4a140c25ba96bc721_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie9b6627751494aab9971b2c3202d9569_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b6b812b1a86449d836330f0d3b625bb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie95865dfdf5b4540b73e69eb6e14d14b_D20220915-20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:CowenEquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="i5ff0d03d717e4fe3bc16e2a5c900dc45_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic3de710b92f4485e825c6c2d1c6fb10a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2912cd445faf49c38783149855c13b6d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie36f5616d2e44e80a9e03af14c0045a4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationSep72024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i02a6a7e72b5342cfb6df8c09e1146039_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0885affce6b54cc8bb7d28029c8146fa_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia4840a5daec942e9baf60b20b64f05d2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9f4d0fe871b84f4bbc6b2e49f7ca8aa6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i35ee5d15536b446d8e71cf4f2712b1ad_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6cd5e724cdb246d89edfa68105eaed87_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i55497019afe7489891af1088e9d0a6da_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1acc384230fc42e6a9d187464e747867_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i385f1d93cdab453180c8c50401ec671d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia1400e06e8cb4cce8e16afdae774fbd6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i59cad19a4f2e4767b2e7f56240d61b72_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic458c78631fa444ea666b52d5645ae1d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic58dee38f10d467fbc953d0b8e7713b1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i23da898f496444b2a82b5eefd3e7d4f2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7f1e21f8e6db4d83b4cb8e0ef40e4ebe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie60dda0bce3a4221b4328da9ade954c1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5e8041ed528a46088f0c79a375de1fae_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0587f1e7aef2471cb273055cd67d1cb1_D20230428-20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-28</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="ib55a36a6d42741f28786ba980d9e68d7_D20230428-20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-28</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="i7e4dbcbbf1954393ba5599909a82c6ed_I20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>exdx:segment</measure>
    </unit>
    <unit id="installment">
        <measure>exdx:installment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80L2ZyYWc6MWNjNzNlNmI2ZTc1NDkwYjliODIxZDU3NDRiZGVlYzQvdGFibGU6NTk0Y2FlNzY0NzRlNGJmNWI5NzEwY2NjZGFhMDg0MTMvdGFibGVyYW5nZTo1OTRjYWU3NjQ3NGU0YmY1Yjk3MTBjY2NkYWEwODQxM18zLTEtMS0xLTYyNDU1_c976eea4-9008-421c-a6c2-6a7c26e6d0e8">0001274737</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80L2ZyYWc6MWNjNzNlNmI2ZTc1NDkwYjliODIxZDU3NDRiZGVlYzQvdGFibGU6NTk0Y2FlNzY0NzRlNGJmNWI5NzEwY2NjZGFhMDg0MTMvdGFibGVyYW5nZTo1OTRjYWU3NjQ3NGU0YmY1Yjk3MTBjY2NkYWEwODQxM180LTEtMS0xLTYyNDU1_b01c11e1-0541-4645-9c01-eda7fc2a0a61">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80L2ZyYWc6MWNjNzNlNmI2ZTc1NDkwYjliODIxZDU3NDRiZGVlYzQvdGFibGU6NTk0Y2FlNzY0NzRlNGJmNWI5NzEwY2NjZGFhMDg0MTMvdGFibGVyYW5nZTo1OTRjYWU3NjQ3NGU0YmY1Yjk3MTBjY2NkYWEwODQxM181LTEtMS0xLTYyNDU1_fe2a64a3-3b93-4a20-a72c-c99f6d19d248">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80L2ZyYWc6MWNjNzNlNmI2ZTc1NDkwYjliODIxZDU3NDRiZGVlYzQvdGFibGU6NTk0Y2FlNzY0NzRlNGJmNWI5NzEwY2NjZGFhMDg0MTMvdGFibGVyYW5nZTo1OTRjYWU3NjQ3NGU0YmY1Yjk3MTBjY2NkYWEwODQxM182LTEtMS0xLTYyNDU1_d3a1d039-2965-4f22-bebc-4c9a28f825cb">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80L2ZyYWc6MWNjNzNlNmI2ZTc1NDkwYjliODIxZDU3NDRiZGVlYzQvdGFibGU6NTk0Y2FlNzY0NzRlNGJmNWI5NzEwY2NjZGFhMDg0MTMvdGFibGVyYW5nZTo1OTRjYWU3NjQ3NGU0YmY1Yjk3MTBjY2NkYWEwODQxM183LTEtMS0xLTYyNDU1_e6fef1d0-ea13-43c3-a6ea-40771a718829">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGV4dHJlZ2lvbjphY2RhOTIyMjQyMmI0N2I3YmZkMDhhMThkMDA0ZjA1OF84NA_01fe438c-8745-4052-9013-368725c3d8f4">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6Y2IxZTA4N2UzMWEwNDU0Y2E3ZjRkMWMyMWM3NTZhZTUvdGFibGVyYW5nZTpjYjFlMDg3ZTMxYTA0NTRjYTdmNGQxYzIxYzc1NmFlNV8wLTAtMS0xLTYyNDU1_f4ce9aa2-df7b-4442-963a-095158c35b98">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6Y2IxZTA4N2UzMWEwNDU0Y2E3ZjRkMWMyMWM3NTZhZTUvdGFibGVyYW5nZTpjYjFlMDg3ZTMxYTA0NTRjYTdmNGQxYzIxYzc1NmFlNV8xLTAtMS0xLTYyNDU1L3RleHRyZWdpb246MjRhMmQ5MmZjYWQ5NGM1MTg1MzNkNzE1MDU5OGU4MzhfMzY_e1b667e2-816a-4e8c-8313-158b99ac34b3">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6Y2IxZTA4N2UzMWEwNDU0Y2E3ZjRkMWMyMWM3NTZhZTUvdGFibGVyYW5nZTpjYjFlMDg3ZTMxYTA0NTRjYTdmNGQxYzIxYzc1NmFlNV8yLTAtMS0xLTYyNDU1_e3954413-b3ed-486c-9f70-57cb2f11e1f1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGV4dHJlZ2lvbjphY2RhOTIyMjQyMmI0N2I3YmZkMDhhMThkMDA0ZjA1OF8xMjk_6734e76b-e13c-444d-89df-d702c4da5e9d">001-39049</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGV4dHJlZ2lvbjphY2RhOTIyMjQyMmI0N2I3YmZkMDhhMThkMDA0ZjA1OF8xMzM_c7128671-43b4-43ad-9d4b-41290321996a">EXAGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZWE4ODdhODlkM2NlNGM1ZmJmODMxYTlmMDlhMzBkMjYvdGFibGVyYW5nZTplYTg4N2E4OWQzY2U0YzVmYmY4MzFhOWYwOWEzMGQyNl8wLTAtMS0xLTYyNDU1_57c349cc-53e4-44ee-8eeb-e92848336d27">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZWE4ODdhODlkM2NlNGM1ZmJmODMxYTlmMDlhMzBkMjYvdGFibGVyYW5nZTplYTg4N2E4OWQzY2U0YzVmYmY4MzFhOWYwOWEzMGQyNl8wLTYtMS0xLTYyNDU1_4665655a-223c-4e51-86a5-0d058aeab607">20-0434866</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZWE4ODdhODlkM2NlNGM1ZmJmODMxYTlmMDlhMzBkMjYvdGFibGVyYW5nZTplYTg4N2E4OWQzY2U0YzVmYmY4MzFhOWYwOWEzMGQyNl8zLTEtMS0xLTYyNDU1_aba4e774-1508-44fa-95e3-6747cd7f9187">1261 Liberty Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZWE4ODdhODlkM2NlNGM1ZmJmODMxYTlmMDlhMzBkMjYvdGFibGVyYW5nZTplYTg4N2E4OWQzY2U0YzVmYmY4MzFhOWYwOWEzMGQyNl80LTEtMS0xLTYyNDU1_1f20471f-64d4-4ee4-aec7-a98fe683755f">Vista,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZWE4ODdhODlkM2NlNGM1ZmJmODMxYTlmMDlhMzBkMjYvdGFibGVyYW5nZTplYTg4N2E4OWQzY2U0YzVmYmY4MzFhOWYwOWEzMGQyNl80LTItMS0xLTYyNDU1_c910d055-ff1b-4304-b1d4-a44975a628a5">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZWE4ODdhODlkM2NlNGM1ZmJmODMxYTlmMDlhMzBkMjYvdGFibGVyYW5nZTplYTg4N2E4OWQzY2U0YzVmYmY4MzFhOWYwOWEzMGQyNl80LTYtMS0xLTYyNDU1_88bfb1b4-b6e8-4f40-a53e-779c98caa7d3">92081</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6M2RkODIzYjMwZDYyNGQ3MTg1OWFhZTAyOGNmZTQ0MGUvdGFibGVyYW5nZTozZGQ4MjNiMzBkNjI0ZDcxODU5YWFlMDI4Y2ZlNDQwZV8wLTAtMS0xLTYyNDU1_0b9fe69e-00dd-435e-9722-3c80534d310f">(760)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6M2RkODIzYjMwZDYyNGQ3MTg1OWFhZTAyOGNmZTQ0MGUvdGFibGVyYW5nZTozZGQ4MjNiMzBkNjI0ZDcxODU5YWFlMDI4Y2ZlNDQwZV8wLTEtMS0xLTYyNDU1_6b096c8d-0878-407c-893d-c711a9e7bda4">560-1501</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6Y2ZlNjc4OTFjZDkyNDgzNjhiYjRjZTIxMzJmOGM1MmEvdGFibGVyYW5nZTpjZmU2Nzg5MWNkOTI0ODM2OGJiNGNlMjEzMmY4YzUyYV8xLTAtMS0xLTYyNDU1_2b1f161e-75ee-4e18-8d06-851e5d144529">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6Y2ZlNjc4OTFjZDkyNDgzNjhiYjRjZTIxMzJmOGM1MmEvdGFibGVyYW5nZTpjZmU2Nzg5MWNkOTI0ODM2OGJiNGNlMjEzMmY4YzUyYV8xLTItMS0xLTYyNDU1_68c32927-4466-4fcc-af56-737385d0751d">XGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6Y2ZlNjc4OTFjZDkyNDgzNjhiYjRjZTIxMzJmOGM1MmEvdGFibGVyYW5nZTpjZmU2Nzg5MWNkOTI0ODM2OGJiNGNlMjEzMmY4YzUyYV8xLTQtMS0xLTYyNDU1_9b6eb524-ce73-42b0-b644-6e2823d42e93">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGV4dHJlZ2lvbjphY2RhOTIyMjQyMmI0N2I3YmZkMDhhMThkMDA0ZjA1OF81OTk_f881ff18-454d-4609-9959-8c546ac8af7e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGV4dHJlZ2lvbjphY2RhOTIyMjQyMmI0N2I3YmZkMDhhMThkMDA0ZjA1OF85MDE_3cfeb529-2287-44c0-ad5c-85a46f1ff9cb">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZDg1YTA2OTA5MWE1NDZhOGI5NmU3MzQwYzVlNGYxZTgvdGFibGVyYW5nZTpkODVhMDY5MDkxYTU0NmE4Yjk2ZTczNDBjNWU0ZjFlOF8yLTAtMS0xLTYyNDU1_70aab985-0034-4550-98f3-04dea7d7be13">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZDg1YTA2OTA5MWE1NDZhOGI5NmU3MzQwYzVlNGYxZTgvdGFibGVyYW5nZTpkODVhMDY5MDkxYTU0NmE4Yjk2ZTczNDBjNWU0ZjFlOF8yLTQtMS0xLTYyNDU1_ca72eac2-cb32-457a-8e62-91732b589773">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGFibGU6ZDg1YTA2OTA5MWE1NDZhOGI5NmU3MzQwYzVlNGYxZTgvdGFibGVyYW5nZTpkODVhMDY5MDkxYTU0NmE4Yjk2ZTczNDBjNWU0ZjFlOF80LTQtMS0xLTYyNDU1_32f02cfe-50a2-4087-8179-9c724424003c">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGV4dHJlZ2lvbjphY2RhOTIyMjQyMmI0N2I3YmZkMDhhMThkMDA0ZjA1OF8xNTM0_9f2a14d5-23db-4617-b2b7-e1f96e9f0339">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGV4dHJlZ2lvbjphY2RhOTIyMjQyMmI0N2I3YmZkMDhhMThkMDA0ZjA1OF8xNzQz_8c15bfa0-455c-4786-a3b3-3b11e09c4d67">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="icbe60ad4860843a2ab64b5cd330ef707_I20230511"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xL2ZyYWc6YWNkYTkyMjI0MjJiNDdiN2JmZDA4YTE4ZDAwNGYwNTgvdGV4dHJlZ2lvbjphY2RhOTIyMjQyMmI0N2I3YmZkMDhhMThkMDA0ZjA1OF8xNzQx_1dc19de1-071e-48df-a9b7-b5557e15ab3c"
      unitRef="shares">16825696</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfNC00LTEtMS02MjQ1NQ_3a417c74-6d96-4459-b96a-a9b4d66e43ef"
      unitRef="usd">52184000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfNC02LTEtMS02MjQ1NQ_dc14c98a-a45f-46fd-ba82-4e73ec98f059"
      unitRef="usd">62391000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfNi00LTEtMS02MjQ1NQ_82c534e5-7e01-48fd-8184-31f4abc9b565"
      unitRef="usd">9303000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfNi02LTEtMS02MjQ1NQ_943c27d0-df87-409c-8f90-d474febfc361"
      unitRef="usd">6077000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfNy00LTEtMS02MjQ1NQ_7c2c36d6-7840-4c31-85fc-9445b96f9de0"
      unitRef="usd">4229000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfNy02LTEtMS02MjQ1NQ_6466e42a-101a-48b4-a03b-7d8d78646187"
      unitRef="usd">4143000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AssetsCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfOC00LTEtMS02MjQ1NQ_07ef5c99-6788-415b-87a1-308c3ad5596b"
      unitRef="usd">65716000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfOC02LTEtMS02MjQ1NQ_cb78c76b-81cd-4982-b6d8-fc14ceccf365"
      unitRef="usd">72611000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfOS00LTEtMS02MjQ1NQ_126233d6-e885-4864-ac5e-1687fbbe7545"
      unitRef="usd">8264000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfOS02LTEtMS02MjQ1NQ_c18f4f91-79e4-4f02-911a-4f9503feef68"
      unitRef="usd">8197000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTAtNC0xLTEtNjI0NTU_8b48a7aa-a1eb-49e3-a289-fc67fbcf73d4"
      unitRef="usd">4651000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTAtNi0xLTEtNjI0NTU_9280ced3-e5fb-4b09-97eb-437367861d4c"
      unitRef="usd">4885000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTItNC0xLTEtNjI0NTU_60b00b68-c741-4514-9fc0-24d7a4f425cd"
      unitRef="usd">603000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTItNi0xLTEtNjI0NTU_9b1a09e7-cf03-4ec7-8f7d-9af1a331caca"
      unitRef="usd">528000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTMtNC0xLTEtNjI0NTU_f2d1782e-0a5c-4912-ba22-ff98405d9c29"
      unitRef="usd">79234000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTMtNi0xLTEtNjI0NTU_e31f7561-d08b-4be6-8f7a-6848818b096f"
      unitRef="usd">86221000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTYtNC0xLTEtNjI0NTU_8ee0abad-4b74-4761-a39c-92f5f7f59ce7"
      unitRef="usd">1878000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTYtNi0xLTEtNjI0NTU_1c4e82b1-b60c-4397-88ae-b8db55c2aae3"
      unitRef="usd">3046000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTUtMi0xLTEtOTQ1NTU_dad4bf9d-4c52-49b7-ad97-46bbe6a40815"
      unitRef="usd">6064000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTUtNC0xLTEtOTQ1NTU_852202a2-3f4f-47b0-bdb7-152f6fe35ccd"
      unitRef="usd">5347000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTctNC0xLTEtNjI0NTU_5353ce4f-7318-4645-a5cd-0cb2a6858e6c"
      unitRef="usd">1072000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTctNi0xLTEtNjI0NTU_37e679c7-c62e-4d67-9939-c07939172014"
      unitRef="usd">1040000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTctMi0xLTEtODM1NDM_47680adb-fc85-45de-8e5b-7c2b9cf61967"
      unitRef="usd">254000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTctNC0xLTEtODM1NzI_1f28ede4-d620-4fbb-acbb-771b816a0616"
      unitRef="usd">190000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTktNC0xLTEtNjI0NTU_00566448-68f7-4e8e-8401-254f100de540"
      unitRef="usd">9268000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMTktNi0xLTEtNjI0NTU_484c9c12-f16a-4608-8764-24f8d35e326d"
      unitRef="usd">9623000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjAtNC0xLTEtNjI0NTU_46c62a5b-187a-4b52-97a6-839c49c2f682"
      unitRef="usd">29092000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjAtNi0xLTEtNjI0NTU_8ee9c369-7cdf-43aa-ae69-2d0fb7e15ee1"
      unitRef="usd">28778000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjItNC0xLTEtNjI0NTU_1579a40e-ecc2-4934-bba3-7285ab946a8b"
      unitRef="usd">4211000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjItNi0xLTEtNjI0NTU_d4f4be57-5fc6-4b02-a68f-7f5068259a38"
      unitRef="usd">4493000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjQtNC0xLTEtNjI0NTU_dd9ca9e3-3f8a-441c-87a2-a4e98207724d"
      unitRef="usd">726000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjQtNi0xLTEtNjI0NTU_2accc5ee-c8c9-4b49-94da-9dde811b52a6"
      unitRef="usd">867000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjUtNC0xLTEtNjI0NTU_13d07a4a-91e9-451d-9344-c09a12e498de"
      unitRef="usd">43297000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjUtNi0xLTEtNjI0NTU_e1c01228-2a04-4b52-8b39-d2a67c9268ac"
      unitRef="usd">43761000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjYtNC0xLTEtNjI0NTU_cf34c3bf-ad05-4b01-88bb-0e1213b5b749"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjYtNi0xLTEtNjI0NTU_8350e157-92ae-4c32-a5df-4a1659640ed5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoyNDRlOTU1MjQwYWQ0MzY3YTJjYWE5YjgwNjVhYWZlN18yMQ_1bc260b8-461a-4eb0-bfb0-d486c8e78697"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoyNDRlOTU1MjQwYWQ0MzY3YTJjYWE5YjgwNjVhYWZlN18yMQ_ad4ba43d-9e0b-46ad-b9bc-a8421333dd55"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoyNDRlOTU1MjQwYWQ0MzY3YTJjYWE5YjgwNjVhYWZlN18zNQ_8f120046-fd65-4d03-88cd-bd5c421872fd"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoyNDRlOTU1MjQwYWQ0MzY3YTJjYWE5YjgwNjVhYWZlN18zNQ_a5b1051b-1851-4085-ac8c-a49cb0ae7d4e"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoyNDRlOTU1MjQwYWQ0MzY3YTJjYWE5YjgwNjVhYWZlN181Nw_490a2754-d14f-4fe8-b217-8c5eb9949763"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoyNDRlOTU1MjQwYWQ0MzY3YTJjYWE5YjgwNjVhYWZlN181Nw_540f5aa8-de82-4cb5-847e-25716d84117d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoyNDRlOTU1MjQwYWQ0MzY3YTJjYWE5YjgwNjVhYWZlN181Nw_553bc712-f377-4648-88bb-5c22bb65e360"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoyNDRlOTU1MjQwYWQ0MzY3YTJjYWE5YjgwNjVhYWZlN181Nw_e2290cb2-9794-490d-b35e-1c7999ba1ee7"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktNC0xLTEtNjI0NTU_fc3cd102-8180-4659-a341-d4a4476d4934"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMjktNi0xLTEtNjI0NTU_32ff3baa-d07a-466c-86fc-92ba923898f3"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoxNzBhNDBiODY0YWI0ODJlOTEzMDQ5N2QyOWVjMjI5ZV8xOA_67018913-40c1-45d0-b545-e0a259ce40e4"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoxNzBhNDBiODY0YWI0ODJlOTEzMDQ5N2QyOWVjMjI5ZV8xOA_8466aef3-b433-4fd3-b99c-77a83497f812"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoxNzBhNDBiODY0YWI0ODJlOTEzMDQ5N2QyOWVjMjI5ZV8zMg_392f0fb6-61f5-4601-b3f6-fe4655bda954"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoxNzBhNDBiODY0YWI0ODJlOTEzMDQ5N2QyOWVjMjI5ZV8zMg_c82ef24c-7da3-4aca-8eac-f63c35bcd886"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoxNzBhNDBiODY0YWI0ODJlOTEzMDQ5N2QyOWVjMjI5ZV83MA_6c686b2c-57e7-4f8a-8a87-dbaf282cc3dc"
      unitRef="shares">16827014</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoxNzBhNDBiODY0YWI0ODJlOTEzMDQ5N2QyOWVjMjI5ZV83MA_911031f9-62c8-4fd6-90f4-044bea48cbb6"
      unitRef="shares">16827014</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoxNzBhNDBiODY0YWI0ODJlOTEzMDQ5N2QyOWVjMjI5ZV83Nw_364467e7-8b9d-4e19-8a28-6b9b478dd679"
      unitRef="shares">16549984</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtMC0xLTEtNjI0NTUvdGV4dHJlZ2lvbjoxNzBhNDBiODY0YWI0ODJlOTEzMDQ5N2QyOWVjMjI5ZV83Nw_91e36345-134e-4142-a599-027d3e6419d5"
      unitRef="shares">16549984</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtNC0xLTEtNjI0NTU_d900a5cf-4fbc-4f01-bd91-f9e8c2e97aef"
      unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzAtNi0xLTEtNjI0NTU_77a1db73-8295-44a6-9cbf-4679110756fb"
      unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzEtNC0xLTEtNjI0NTU_cb261bcb-a858-477c-b689-2018c5e70c96"
      unitRef="usd">299135000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzEtNi0xLTEtNjI0NTU_0a1c7edb-d191-42dc-9302-f8299d253cb4"
      unitRef="usd">297970000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzItNC0xLTEtNjI0NTU_aa39eb3b-1244-483d-9814-6b8ccbdd46aa"
      unitRef="usd">-263215000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzItNi0xLTEtNjI0NTU_44064e48-b220-4da3-a54c-a64223b4f102"
      unitRef="usd">-255527000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzMtNC0xLTEtNjI0NTU_a57a31b2-e257-47d9-9ffe-da8a77c5a28c"
      unitRef="usd">35937000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzMtNi0xLTEtNjI0NTU_cdf23ecf-e94e-4208-be3c-6aeabbe5352d"
      unitRef="usd">42460000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzQtNC0xLTEtNjI0NTU_a14e5adf-ee12-4486-8edd-410b5d61fdec"
      unitRef="usd">79234000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xNi9mcmFnOmU4ZTQ5Nzk5ODU4MTRjMDBhNzA2NzI3MzgyM2Q2YzAyL3RhYmxlOjE0ZmVmZTgxNTE0MDQyNDNhYzQzN2ViMDE5NDA1OWIwL3RhYmxlcmFuZ2U6MTRmZWZlODE1MTQwNDI0M2FjNDM3ZWIwMTk0MDU5YjBfMzQtNi0xLTEtNjI0NTU_5deb3ae9-bfc0-4674-965d-bb699f707a51"
      unitRef="usd">86221000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMy0yLTEtMS02MjQ1NQ_24f9e664-0e6c-4693-905c-db949f8f923a"
      unitRef="usd">11230000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMy00LTEtMS02MjQ1NQ_712ee752-7ebc-432b-90f2-16bdc7976ea7"
      unitRef="usd">10394000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfNS0yLTEtMS02MjQ1NQ_dc5b054b-9b56-4a63-a23b-e06b4b190a87"
      unitRef="usd">5926000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfNS00LTEtMS02MjQ1NQ_ec507c8f-8b1d-4f5c-8dcf-78d44c52ed21"
      unitRef="usd">5817000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfNi0yLTEtMS02MjQ1NQ_fa093adb-50e9-4f65-9aa8-2e8e333d29d8"
      unitRef="usd">11884000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfNi00LTEtMS02MjQ1NQ_e13c29fa-cab6-4438-908c-0110a396b90c"
      unitRef="usd">12152000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfNy0yLTEtMS02MjQ1NQ_3bc6bcf3-229a-44b6-a256-e780acfef81c"
      unitRef="usd">1126000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfNy00LTEtMS02MjQ1NQ_52f4db0b-c111-477d-b9da-88e4c80ed4c2"
      unitRef="usd">2104000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTAtMi0xLTEtNjI0NTU_aab69174-46ee-460f-b8ea-2f787d751a21"
      unitRef="usd">18936000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTAtNC0xLTEtNjI0NTU_5bcaed4e-ee35-4a51-9538-8f3315fef84c"
      unitRef="usd">20073000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTEtMi0xLTEtNjI0NTU_7d3a2050-7264-4005-8b15-00e9cf60949a"
      unitRef="usd">-7706000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTEtNC0xLTEtNjI0NTU_14639a4b-50c6-40a0-95d1-93cb7c8c8ee4"
      unitRef="usd">-9679000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTItMi0xLTEtNjI0NTU_8823b4c7-a026-4955-94c0-86f3d9d08ff5"
      unitRef="usd">638000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTItNC0xLTEtNjI0NTU_b884cd61-3e40-4ab6-929c-141a085749c2"
      unitRef="usd">598000</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTQtMi0xLTEtNjI0NTU_4ba05424-4141-4024-bb11-75b012427dcd"
      unitRef="usd">656000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTQtNC0xLTEtNjI0NTU_93cf6875-caf1-4830-ba72-ef1144ce63b9"
      unitRef="usd">5000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTctMi0xLTEtNjI0NTU_b696de95-e71c-4752-bd25-036b062882b5"
      unitRef="usd">-7688000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMTctNC0xLTEtNjI0NTU_1515e9ff-0c07-4da7-9326-04da4a2f53c0"
      unitRef="usd">-10272000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMjEtMi0xLTEtNjI0NTU_596efe73-2ae9-4536-8056-76bb9ea938fb"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMjEtMi0xLTEtNjI0NTU_5f00201c-980b-4341-a1ba-035b3d961078"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMjEtNC0xLTEtNjI0NTU_311c1d57-4d55-4df4-8bc5-450c2122e9fe"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMjEtNC0xLTEtNjI0NTU_c9e77a11-df29-4e22-b7a1-f979990e74b2"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMjItMi0xLTEtNjI0NTU_8fae21c5-8ae7-4d7b-858b-782182b1d259"
      unitRef="shares">17526763</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMjItMi0xLTEtNjI0NTU_cdfc05a0-fb79-41e0-b6fd-7248bd20656d"
      unitRef="shares">17526763</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMjItNC0xLTEtNjI0NTU_ee45ba83-44ed-4cf4-af43-a5a15aa7d279"
      unitRef="shares">16992391</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8xOS9mcmFnOjk5MzQ0YWJkY2ZjZDRhY2M5MTY2YmI0YzYzM2RkMDI2L3RhYmxlOjg1NzgxYzYyNGJhYzRhYWQ5ODFhYTJhYTk2ZWFhNjJmL3RhYmxlcmFuZ2U6ODU3ODFjNjI0YmFjNGFhZDk4MWFhMmFhOTZlYWE2MmZfMjItNC0xLTEtNjI0NTU_fe102ac8-36b1-4fa6-9169-c1870c254a53"
      unitRef="shares">16992391</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6bb6db3028e64addadc73284bff78b54_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfMi0yLTEtMS02MjQ1NQ_2fd33906-fb65-4c4c-9889-20e498ffdc0c"
      unitRef="shares">16549984</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6bb6db3028e64addadc73284bff78b54_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfMi00LTEtMS02MjQ1NQ_b292dada-8738-4c61-a182-afdbbf81aa15"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia0649efcb68545c6b7b9b7ec6425a6bf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfMi02LTEtMS02MjQ1NQ_36fe6760-c332-4e6d-a1c2-849c488364fa"
      unitRef="usd">297970000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0705a248fabf483b8d91cb9179b97e90_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfMi04LTEtMS02MjQ1NQ_d50a3690-fe2b-402c-974c-d44b746e17f6"
      unitRef="usd">-255527000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfMi0xMC0xLTEtNjI0NTU_95381946-b735-4f93-9d3d-bcae03c5f976"
      unitRef="usd">42460000</us-gaap:StockholdersEquity>
    <exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares
      contextRef="i2fe0be00ef494161bd0549b671f2fe9b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfMy0yLTEtMS02MjQ1NQ_03fcc488-2831-428d-afd0-33e55a17e3d5"
      unitRef="shares">113378</exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares>
    <exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue
      contextRef="i62b1db4c0c1d4c9f841e4594fe97bc2a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfMy02LTEtMS02MjQ1NQ_c07f88a8-239a-4b5e-92b3-81a8dc0cc054"
      unitRef="usd">0</exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue>
    <exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfMy0xMC0xLTEtNjI0NTU_45751978-fbee-47da-af66-6757a952f6e6"
      unitRef="usd">0</exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i2fe0be00ef494161bd0549b671f2fe9b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNC0yLTEtMS02MjQ1NQ_d71804d2-407c-4fee-9699-e2ff5a7bff7c"
      unitRef="shares">70317</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i62b1db4c0c1d4c9f841e4594fe97bc2a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNC02LTEtMS02MjQ1NQ_8297010e-97db-4cd4-807f-a48092f32721"
      unitRef="usd">152000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNC0xMC0xLTEtNjI0NTU_fa9bfa4e-4a39-446b-8786-a72bfb97bac6"
      unitRef="usd">152000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2fe0be00ef494161bd0549b671f2fe9b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNS0yLTEtMS05MjA2Mw_0d14843b-881a-468d-a8bd-9cdc31ecde0b"
      unitRef="shares">93335</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i62b1db4c0c1d4c9f841e4594fe97bc2a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNS02LTEtMS05MjA3OQ_efc7efc2-ab38-4c43-a0ad-5d7bb8ea9970"
      unitRef="usd">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNS0xMC0xLTEtOTIwOTU_9d81c411-f1da-4ec8-b96b-c2938a237735"
      unitRef="usd">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i62b1db4c0c1d4c9f841e4594fe97bc2a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNS02LTEtMS02MjQ1NQ_8892e54b-894e-46a3-bf80-409f92284527"
      unitRef="usd">986000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNS0xMC0xLTEtNjI0NTU_0138b4b8-91dc-49e6-809a-f5a1623b17dc"
      unitRef="usd">986000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="if71859fd80494dddb569b483b53c0f5b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNi04LTEtMS02MjQ1NQ_1cddeeb3-4c2f-4dfb-b352-be7ba22b7b47"
      unitRef="usd">-7688000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNi0xMC0xLTEtNjI0NTU_00c4b5de-dee2-480d-b327-7523a095b37d"
      unitRef="usd">-7688000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8b09d1c772d642c2be65db1440589466_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNy0yLTEtMS02MjQ1NQ_5b168387-b354-4f44-9d87-85f3c85283de"
      unitRef="shares">16827014</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8b09d1c772d642c2be65db1440589466_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNy00LTEtMS02MjQ1NQ_365dc866-c087-4a54-a834-51829768475b"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i84709c32e10840689d3198791460cf9b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNy02LTEtMS02MjQ1NQ_78c1c6f7-139d-496a-bb00-86ad75569e49"
      unitRef="usd">299135000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0c57b87359174c8ba8490118ae86e8ea_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNy04LTEtMS02MjQ1NQ_a7ee5ce3-7ab7-46f0-b06d-4630c59db674"
      unitRef="usd">-263215000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOjgzNDU1NjdhYzdiNzQ3YmRiZTBmZTg4ZmIxMWViMzIwL3RhYmxlcmFuZ2U6ODM0NTU2N2FjN2I3NDdiZGJlMGZlODhmYjExZWIzMjBfNy0xMC0xLTEtNjI0NTU_03b7cf81-9fa4-4431-8bc0-8b7d845db212"
      unitRef="usd">35937000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i90a82a0082294a76aa4b428dfc020494_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfMi0yLTEtMS02MjQ1NQ_123ea122-95b0-4b63-b487-2319c92b4dd2"
      unitRef="shares">16164994</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i90a82a0082294a76aa4b428dfc020494_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfMi00LTEtMS02MjQ1NQ_700007f4-db2c-44be-870f-62ad4769ae04"
      unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2f0a7eb3bdd5459aac214c6226b676a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfMi02LTEtMS02MjQ1NQ_b8af2fa6-cb04-469c-9e66-f7691c673785"
      unitRef="usd">293060000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if296323417ca4b029d7a11232e87aad2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfMi04LTEtMS02MjQ1NQ_32c4b3e4-1145-4318-996d-1d957c2a28f4"
      unitRef="usd">-208140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i140c8595c10a41eeb48e5be8f884c4cb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfMi0xMC0xLTEtNjI0NTU_9a5c1afd-21d3-4c5d-be88-1e1c04a9d6ac"
      unitRef="usd">84936000</us-gaap:StockholdersEquity>
    <exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares
      contextRef="i9c10b316a5a146458ede9d5dc729ac84_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNC0yLTEtMS02MjQ1NQ_076a1fb7-163a-4577-8847-111e10e1f1a7"
      unitRef="shares">30523</exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares>
    <exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue
      contextRef="i1b616351de9643b99134e16eafc041e6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNC02LTEtMS02MjQ1NQ_8c6ef092-15b4-4475-9cc4-68fc8bbdadc0"
      unitRef="usd">115000</exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue>
    <exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNC0xMC0xLTEtNjI0NTU_317e386a-d365-4ffc-8f7c-7ff51406ab0f"
      unitRef="usd">115000</exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i9c10b316a5a146458ede9d5dc729ac84_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNS0yLTEtMS02MjQ1NQ_09e0bf3f-3273-44ee-be60-186132f77fe2"
      unitRef="shares">35681</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i1b616351de9643b99134e16eafc041e6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNS02LTEtMS02MjQ1NQ_4209870e-c8ce-4ca7-bbf7-ec39b1e86c87"
      unitRef="usd">231000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNS0xMC0xLTEtNjI0NTU_32623267-57ba-4680-ae47-ef5e28700873"
      unitRef="usd">231000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1b616351de9643b99134e16eafc041e6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNi02LTEtMS02MjQ1NQ_c12e5cc2-e640-4954-aaaf-7e2bdb7d33f0"
      unitRef="usd">1376000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNi0xMC0xLTEtNjI0NTU_959e8760-6f06-4dd9-9342-9bbab0c19c02"
      unitRef="usd">1376000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i9bc0bf262ca04963b27d2f261ce272bd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNy04LTEtMS02MjQ1NQ_da29cef7-66b1-4b24-bbf1-e3c1b60fa14e"
      unitRef="usd">-10272000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfNy0xMC0xLTEtNjI0NTU_80e72399-8dc6-4130-ac24-e3f8010c8cb1"
      unitRef="usd">-10272000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if2395d65c2f04e0c82d354b532c429b4_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfOC0yLTEtMS02MjQ1NQ_1f3a592e-ecb5-4b40-aa9a-0904794dc11f"
      unitRef="shares">16231198</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if2395d65c2f04e0c82d354b532c429b4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfOC00LTEtMS02MjQ1NQ_911c72aa-48b0-47f1-adc8-3edb5e1215c4"
      unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i72308a08a4614029a1a34e29777d8a6b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfOC02LTEtMS02MjQ1NQ_2d0d33f8-bbcb-4860-b8f6-e39cdb2042a3"
      unitRef="usd">294552000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia408b342e58a47b4b9fab75709a394d2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfOC04LTEtMS02MjQ1NQ_a31d4bd5-b36c-4a62-b7fc-00b0e7015b90"
      unitRef="usd">-218412000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic10d09e997d04be59819eb9f739c540e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yMi9mcmFnOjg3NzhhMjI4YjFkYjQ2YWI4MTMyY2IwMDAxMTYxNWRjL3RhYmxlOmU4OTExMWZlMDFmODRiNTNhZmI3OWZjNzJhNjIwYWQ4L3RhYmxlcmFuZ2U6ZTg5MTExZmUwMWY4NGI1M2FmYjc5ZmM3MmE2MjBhZDhfOC0xMC0xLTEtNjI0NTU_ce793b86-774a-4947-97a9-6630f428e467"
      unitRef="usd">76156000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNC02LTEtMS02MjQ1NQ_76879320-3f6f-4774-941e-a8aa71bae434"
      unitRef="usd">-7688000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNC04LTEtMS02MjQ1NQ_99054852-a743-40d4-a20d-47a03791bc45"
      unitRef="usd">-10272000</us-gaap:NetIncomeLoss>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNi02LTEtMS02MjQ1NQ_55afb10a-056e-400e-b7b3-77dabb6bc3be"
      unitRef="usd">553000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNi04LTEtMS02MjQ1NQ_f4f5c889-2f41-40d2-9443-98afe4579b53"
      unitRef="usd">283000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNy02LTEtMS02MjQ1NQ_29b904be-9362-4c71-8cff-71ee1efbccb3"
      unitRef="usd">42000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNy04LTEtMS02MjQ1NQ_46207261-cee8-4e22-979e-e44e630e98ae"
      unitRef="usd">38000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:PaidInKindInterest
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfOC02LTEtMS02MjQ1NQ_b02aeebc-58e7-4b04-ae0b-9cd9be34e2e9"
      unitRef="usd">137000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfOC04LTEtMS02MjQ1NQ_c59f3cd3-d8f6-4a62-b6a8-dfbd18864537"
      unitRef="usd">135000</us-gaap:PaidInKindInterest>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTEtNi0xLTEtNjI0NTU_5d3f36b1-eae5-491e-82c7-e5f041dae054"
      unitRef="usd">-55000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTEtOC0xLTEtNjI0NTU_4d8453cd-3180-4e55-879a-a975fe881cd0"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <exdx:NonCashLeaseExpense
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTItNi0xLTEtNjI0NTU_faddf3e3-6260-44d3-ab60-73966b46642d"
      unitRef="usd">234000</exdx:NonCashLeaseExpense>
    <exdx:NonCashLeaseExpense
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTItOC0xLTEtNjI0NTU_804e4d01-a245-4d2d-9f14-c2cceef968fe"
      unitRef="usd">219000</exdx:NonCashLeaseExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTMtNi0xLTEtNjI0NTU_415e83c9-b39e-440e-9cb0-22439a6de2bf"
      unitRef="usd">986000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTMtOC0xLTEtNjI0NTU_71b3c020-150f-4d53-885f-0c2fcaf2da26"
      unitRef="usd">1376000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTYtNi0xLTEtNjI0NTU_4f1d0cd3-ea89-48f8-81fe-60ef1b03c791"
      unitRef="usd">3226000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTYtOC0xLTEtNjI0NTU_75cbadbe-284a-4c9b-b471-4a89ebab87b2"
      unitRef="usd">1257000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTctNi0xLTEtNjI0NTU_1ecb7c03-0594-486d-9db4-c496a9fd298f"
      unitRef="usd">86000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTctOC0xLTEtNjI0NTU_aca8c456-6fd6-45b3-9f8a-4527159c0199"
      unitRef="usd">-664000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTgtNi0xLTEtNjI0NTU_17ac98b8-62d5-4497-967c-acd793d4d8bc"
      unitRef="usd">79000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTgtOC0xLTEtNjI0NTU_4b939fc5-8009-481a-bd40-be8f99b5e7e4"
      unitRef="usd">273000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTktNi0xLTEtNjI0NTU_16c1a1dc-38db-4a69-acb4-a1b5349a6923"
      unitRef="usd">-250000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMTktOC0xLTEtNjI0NTU_24ee1132-bf7f-47e2-9976-b2c7a5f69a02"
      unitRef="usd">-155000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMjAtNi0xLTEtNjI0NTU_bc8e9e18-ab6e-4a66-bb1e-4faf5a3494cd"
      unitRef="usd">-1320000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMjAtOC0xLTEtNjI0NTU_bbc76f10-7a14-4a9e-9790-39268dc6c424"
      unitRef="usd">579000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMjEtNi0xLTEtNjI0NTU_fb4f69c3-bde5-468d-aac4-5d4b6c7896d2"
      unitRef="usd">893000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMjEtOC0xLTEtNjI0NTU_66ea471c-ea3b-43de-ba38-2298b4265498"
      unitRef="usd">89000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMjMtNi0xLTEtNjI0NTU_79ab3cc7-208d-43f2-a122-8afc6a61f611"
      unitRef="usd">-9749000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMjMtOC0xLTEtNjI0NTU_306b7ad0-5d1d-4487-afde-6a39c6c484c4"
      unitRef="usd">-8574000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMjUtNi0xLTEtNjI0NTU_32c543cc-56cb-4972-a2cd-c417cc5cdfb6"
      unitRef="usd">396000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMjUtOC0xLTEtNjI0NTU_25be1937-6a2d-4505-9ac8-cf42ab463d5f"
      unitRef="usd">1087000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzAtNi0xLTEtNjI0NTU_47d290c3-12db-42a3-afbd-4f5906c8e025"
      unitRef="usd">-396000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzAtOC0xLTEtNjI0NTU_31cc5e2c-e235-4614-b40a-04d245ef2964"
      unitRef="usd">-1087000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzItNi0xLTEtNjI0NTU_f27026da-e446-45e8-849c-4fc5110b3601"
      unitRef="usd">27000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzItOC0xLTEtNjI0NTU_49f94cd7-583e-4261-a3ec-70375aa361a7"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzMtNi0xLTEtNjI0NTU_12b55a24-9e1b-4f15-8567-b3674fb495d6"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzMtOC0xLTEtNjI0NTU_ec074650-eb8c-433c-8195-4ed10708ac4a"
      unitRef="usd">115000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzQtNi0xLTEtNjI0NTU_b64f9a81-a072-4b6b-b9a5-56e6dd2c152b"
      unitRef="usd">152000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzQtOC0xLTEtNjI0NTU_22021a77-d631-4d7d-a8a6-16049a78370c"
      unitRef="usd">231000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzYtNi0xLTEtNjI0NTU_7d10f480-93ab-48f0-8544-f6afbf8a2760"
      unitRef="usd">189000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzYtOC0xLTEtNjI0NTU_bfa4c8c0-8052-46c6-9d27-7053e18073d6"
      unitRef="usd">146000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzItMi0xLTEtOTIxNDQ_d8e80abb-45b8-47ba-873b-48dfa32952b5"
      unitRef="usd">52000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfMzItNC0xLTEtOTIxNTI_2a90ff40-b1c9-423b-b717-7127e9be2714"
      unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNDctNi0xLTEtNjI0NTU_6411fbbd-8179-49c9-98b7-d8c956d913f4"
      unitRef="usd">-62000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNDctOC0xLTEtNjI0NTU_daeac3ea-34e9-4e04-a046-ab791414b449"
      unitRef="usd">-30000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNDgtNi0xLTEtNjI0NTU_d4480f64-cdb7-44b1-a1f6-2dc0e9b91de3"
      unitRef="usd">-10207000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNDgtOC0xLTEtNjI0NTU_5a059f36-ed50-4266-a7e3-721990901b12"
      unitRef="usd">-9691000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNDktNi0xLTEtNjI0NTU_b5f873f1-438a-41b0-82ff-410cdd0f9311"
      unitRef="usd">62591000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i140c8595c10a41eeb48e5be8f884c4cb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNDktOC0xLTEtNjI0NTU_3686ec82-97cf-4d54-b029-8d728c2a481f"
      unitRef="usd">99542000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNTAtNi0xLTEtNjI0NTU_07e70cb4-d2b4-4f08-acf4-95a19e230da9"
      unitRef="usd">52384000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic10d09e997d04be59819eb9f739c540e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNTAtOC0xLTEtNjI0NTU_08004eb1-dd68-4987-8327-33b87c09d58e"
      unitRef="usd">89851000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNTItNi0xLTEtNjI0NTU_53c7f705-bc93-404e-bd2b-6d0de21a6dc0"
      unitRef="usd">449000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNTItOC0xLTEtNjI0NTU_efa184bd-2fe5-4989-872e-8f0645b8b295"
      unitRef="usd">424000</us-gaap:InterestPaidNet>
    <exdx:EquipmentPurchasedUnderNotesPayableObligations
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNDQtMi0xLTEtOTIxNzA_dbb3017b-77dd-4f23-a784-f9b33974383d"
      unitRef="usd">250000</exdx:EquipmentPurchasedUnderNotesPayableObligations>
    <exdx:EquipmentPurchasedUnderNotesPayableObligations
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNDQtNC0xLTEtOTIxNzg_1a7a6424-7114-4871-9e71-ea39d518f0a3"
      unitRef="usd">0</exdx:EquipmentPurchasedUnderNotesPayableObligations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNTctNi0xLTEtNjI0NTU_fb04ac37-f598-4595-9518-8aff1479b25a"
      unitRef="usd">199000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8yNS9mcmFnOmMxYjRmMDMyNDEwNzQxYWJiOTAwYWY4NDYxYmY1YTRlL3RhYmxlOjA4ZGJmOTJlZjg2ZTRiMzA4ZGFiOTY1ZTBmMzkyYzY1L3RhYmxlcmFuZ2U6MDhkYmY5MmVmODZlNGIzMDhkYWI5NjVlMGYzOTJjNjVfNTctOC0xLTEtNjI0NTU_9971440f-449a-4f2d-8dae-d6aa8ec9ded7"
      unitRef="usd">1672000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zMS9mcmFnOmQyYTNmZjJlZjQwYjRmOTk5NjRmMjJiZjdjNzNmODU3L3RleHRyZWdpb246ZDJhM2ZmMmVmNDBiNGY5OTk2NGYyMmJmN2M3M2Y4NTdfMjIwNA_abccf801-9662-430f-9814-56a84899579f">Organization&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Exagen Inc. (the Company) is a commercial-stage diagnostics company dedicated to helping patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. As of March&#160;31, 2023, the Company had cash and cash equivalents of $52.2 million and had an accumulated deficit of $263.2 million. Since inception, the Company has financed its operations primarily through a combination of equity financings, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zMS9mcmFnOmQyYTNmZjJlZjQwYjRmOTk5NjRmMjJiZjdjNzNmODU3L3RleHRyZWdpb246ZDJhM2ZmMmVmNDBiNGY5OTk2NGYyMmJmN2M3M2Y4NTdfNjIx_ad088d16-1074-40ae-91bf-59458b5900d2"
      unitRef="usd">52200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zMS9mcmFnOmQyYTNmZjJlZjQwYjRmOTk5NjRmMjJiZjdjNzNmODU3L3RleHRyZWdpb246ZDJhM2ZmMmVmNDBiNGY5OTk2NGYyMmJmN2M3M2Y4NTdfNjU4_0c524b98-ba7e-419c-9559-ef35b2bc36d1"
      unitRef="usd">-263200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMzg0ODI5MDc4Mjg2MQ_2d306f19-96ae-4952-8d2e-d3c427f64086">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim condensed balance sheet as of March&#160;31, 2023, condensed statements of operations, stockholders' equity and cash flows for the three months ended March&#160;31, 2023 and the related footnote disclosures are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. These unaudited condensed financial statements and related footnote disclosures should be read in conjunction with the Company&#x2019;s audited financial statements for the year ended December 31, 2022, included in its Annual Report on Form 10-K filed with the SEC on March 20, 2023. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all normal adjustments, necessary for the fair presentation of the Company's financial position as of March&#160;31, 2023 and its results of operations for the periods presented. The results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the recoverability of its long-lived assets and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023 and 2022, approximately 87% and 84%, respectively, of the Company's revenue was related to the AVISE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; CTD test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is dependent on key suppliers for certain laboratory materials. For the three months ended March&#160;31, 2023 and 2022, approximately 97% and 95%, respectively, of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Client(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes hospitals, other laboratories, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes patient self-pay&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature, which are determined to be a Level 1 measurement (see Note 6). The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for the same or similar issues. As of March&#160;31, 2023, the 2017 Term Loan (as defined below) had a carrying value of $28.4&#160;million and a fair value of $27.1&#160;million. As of December 31, 2022, the 2017 Term Loan had a carrying value of $28.3&#160;million and a fair value of $26.9&#160;million The estimated fair value of the 2017 Term Loan, was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The recorded value of the Company's other long-term borrowing was $0.7&#160;million and approximated its fair value as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an arrangement with a financial institution with which it has an existing banking relationship, whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a certificate of deposit with this financial institution as collateral for the balances borrowed on these cards ($0.2 million at March&#160;31, 2023 and December 31, 2022). The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, we combine our intangible assets and other long-lived assets, into groupings, a determination which we principally make on the basis of whether the assets are specific to a particular test we offer or technology we are developing. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#x2019;s carrying amount. Management&#x2019;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#x2019;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.) and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the three months ended March&#160;31, 2023 and 2022 was a $0.3&#160;million net revenue increase and a $0.2&#160;million net revenue decrease, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue an allowance for credit losses against our accounts receivable based on management&#x2019;s current estimate of amounts that will not be collected. Management&#x2019;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was zero as of March&#160;31, 2023. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.3 million for the three months ended March&#160;31, 2023 and 2022, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $0.7 million and $0.6 million for the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on that date. The Company's restricted stock units generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of restricted stock units is subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three months ended March&#160;31, 2023 and 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding, as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.915%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,019,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,002,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,494,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;878,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,937,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,296,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which requires the measurement of expected credit losses (based on historical experience, current conditions and reasonable forecasts) for financial instruments (such as accounts receivable) held at the reporting date which are carried at amortized cost. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Codification Improvements to Topic 326, Financing Instruments-Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which included an amendment of the effective date for nonpublic entities. For emerging growth companies, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted this pronouncement on January 1, 2023. The adoption did not have an impact on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for smaller reporting companies as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2023. The adoption did not have an impact on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMzU_5174cccb-ed3d-443c-b950-676e83213e80">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMTk_1de624e0-70ca-430a-a92d-9eb04e9d95dd">For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icde0546e33bc4e4dbdee35365b9dbeec_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjJjYWI5ZTk2MGMwMTQ5YmNiZDI5OTE4NTRkOTJmZWQyL3RhYmxlcmFuZ2U6MmNhYjllOTYwYzAxNDliY2JkMjk5MTg1NGQ5MmZlZDJfNC0yLTEtMS02MjQ1NQ_65ce9377-542a-4b75-af63-01ff653560ca"
      unitRef="number">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i53feb630091f4619a5126ec58f43ca87_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjJjYWI5ZTk2MGMwMTQ5YmNiZDI5OTE4NTRkOTJmZWQyL3RhYmxlcmFuZ2U6MmNhYjllOTYwYzAxNDliY2JkMjk5MTg1NGQ5MmZlZDJfNC00LTEtMS02MjQ1NQ_8de8415e-09da-4ff3-90f9-f72fb835974e"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icd65ad1f84754ac2be24f4c994f8f3cd_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjJjYWI5ZTk2MGMwMTQ5YmNiZDI5OTE4NTRkOTJmZWQyL3RhYmxlcmFuZ2U6MmNhYjllOTYwYzAxNDliY2JkMjk5MTg1NGQ5MmZlZDJfNS0yLTEtMS02MjQ1NQ_25a53e0c-2de3-4306-b1a5-3e15d5ed8c1d"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia6abda9f9e6d446892e7c0f30b5d60d3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjJjYWI5ZTk2MGMwMTQ5YmNiZDI5OTE4NTRkOTJmZWQyL3RhYmxlcmFuZ2U6MmNhYjllOTYwYzAxNDliY2JkMjk5MTg1NGQ5MmZlZDJfNS00LTEtMS02MjQ1NQ_bcf448dc-5b9f-4596-a2af-ae7a0835770a"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib670f4a2e3f647279e6c9c81af57ffc1_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjJjYWI5ZTk2MGMwMTQ5YmNiZDI5OTE4NTRkOTJmZWQyL3RhYmxlcmFuZ2U6MmNhYjllOTYwYzAxNDliY2JkMjk5MTg1NGQ5MmZlZDJfNS00LTEtMS05NTE2NQ_abb70f7b-fb9a-4a5c-94b0-f562df58b1e6"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ife65d382ae2a47219439e25b9543c648_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjcwMTVjMDRlNGM1OTQ3YzRhNDVkZjViM2EzMTg5ZDE2L3RhYmxlcmFuZ2U6NzAxNWMwNGU0YzU5NDdjNGE0NWRmNWIzYTMxODlkMTZfMy00LTEtMS02MjQ1NQ_56e1982e-78db-417a-a59b-249bbc10ef50"
      unitRef="number">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4838d54052ca4b00a39f1c6ae8f5cfd5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjcwMTVjMDRlNGM1OTQ3YzRhNDVkZjViM2EzMTg5ZDE2L3RhYmxlcmFuZ2U6NzAxNWMwNGU0YzU5NDdjNGE0NWRmNWIzYTMxODlkMTZfMy02LTEtMS02MjQ1NQ_2a5c74fd-9913-4a83-bfd5-654c0a21fce1"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibdb3a7f4fb2b4a099c8ab9a2651f42d9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjcwMTVjMDRlNGM1OTQ3YzRhNDVkZjViM2EzMTg5ZDE2L3RhYmxlcmFuZ2U6NzAxNWMwNGU0YzU5NDdjNGE0NWRmNWIzYTMxODlkMTZfNC00LTEtMS02MjQ1NQ_5025e048-c36e-4a56-88f6-84d263414181"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1d88ab7784214d388b2b50fb5bb4c7b3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjcwMTVjMDRlNGM1OTQ3YzRhNDVkZjViM2EzMTg5ZDE2L3RhYmxlcmFuZ2U6NzAxNWMwNGU0YzU5NDdjNGE0NWRmNWIzYTMxODlkMTZfNC02LTEtMS02MjQ1NQ_6d7f330b-90d5-4116-9a5e-b08003736da0"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia2a4f1732f624b489e8f50c6d6b4e485_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMzM5Mw_72181471-7b9d-4866-8a93-13206d379a64"
      unitRef="number">0.87</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iecd13c786620474fa63cd266b54a3b74_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMzQwMA_fff9aad0-530f-4ce1-b8b8-6aae1886d0d2"
      unitRef="number">0.84</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i309af3d1bef54a83aaa50e2c61f71a24_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMzc0NA_b0460719-507b-483e-8ff2-677063bf27c4"
      unitRef="number">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i90730eb7530d4cc89a0fc5a794ff71a1_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMzc1MQ_970d0d58-109e-4c84-b64b-02c8ef6cba4f"
      unitRef="number">0.95</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMzE_07a69a22-90ea-418a-ade5-1784d726a4e6">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Client(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes hospitals, other laboratories, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes patient self-pay&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae6ce9aaec2a446c9c116ff73b70f8b3_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfMy0yLTEtMS02MjQ1NQ_89f13d62-4faf-4916-970e-fa83fcbb66c6"
      unitRef="usd">4215000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6a670771b95429a8cb648b92575b810_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfMy00LTEtMS02MjQ1NQ_e642ff03-6053-4f8b-8761-89d81b583871"
      unitRef="usd">6423000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35095a09a8d844129623d819fcf1cacb_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfNC0yLTEtMS02MjQ1NQ_344a0718-ca46-45af-9bef-ebdac88dcab4"
      unitRef="usd">4426000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i705da3eb6365425bb71d37b40211def3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfNC00LTEtMS02MjQ1NQ_b0c84455-5504-45c7-b8f7-2f387b920b83"
      unitRef="usd">2120000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i939a0caa5e764269961b35c18b4916a0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfNS0yLTEtMS02MjQ1NQ_7f213c7d-8985-431b-9f64-f3f6a42474f4"
      unitRef="usd">2407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30fc00a42642408badd375838de42222_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfNS00LTEtMS02MjQ1NQ_2d7e8aa1-a4ec-4197-b369-119db3a68fdd"
      unitRef="usd">1591000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8df9a05d543b42d696a2487ba38b7424_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfNi0yLTEtMS02MjQ1NQ_84efffcd-b217-4ed1-84e7-38c84192008f"
      unitRef="usd">182000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if846aeeb8f314bd9a6bf240c914de52a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfNi00LTEtMS02MjQ1NQ_9c9e55fa-dde6-4568-a355-a3866c400c94"
      unitRef="usd">260000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfOC0yLTEtMS02MjQ1NQ_eca8c0f2-88ef-452b-8e2f-b1ec85b344da"
      unitRef="usd">11230000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjIzNWVjODkyOGI5ZjQxMjg4MGQ4NThlYmQ2ZWI1YjM2L3RhYmxlcmFuZ2U6MjM1ZWM4OTI4YjlmNDEyODgwZDg1OGViZDZlYjViMzZfOC00LTEtMS02MjQ1NQ_db76a802-ba0d-4da7-97c3-8fb6ca932f4c"
      unitRef="usd">10394000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMjA_e485ad8a-cdf3-4860-9759-903dae87cb41">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature, which are determined to be a Level 1 measurement (see Note 6). The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for the same or similar issues. As of March&#160;31, 2023, the 2017 Term Loan (as defined below) had a carrying value of $28.4&#160;million and a fair value of $27.1&#160;million. As of December 31, 2022, the 2017 Term Loan had a carrying value of $28.3&#160;million and a fair value of $26.9&#160;million The estimated fair value of the 2017 Term Loan, was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The recorded value of the Company's other long-term borrowing was $0.7&#160;million and approximated its fair value as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i3f88c29ff5974403bff253575a02defd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTA5OTUxMTcyNDU0Mg_20d631ae-0d7c-4818-98c6-7cc0a65730e0"
      unitRef="usd">28400000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i3f88c29ff5974403bff253575a02defd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTA5OTUxMTcyNDU2Ng_74904591-e331-4b74-be4f-2b564ce3a806"
      unitRef="usd">27100000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:LongTermDebt
      contextRef="i6610d7c73b1f4958b659b907335a85a0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfNTQ5NzU1OTE1NjYy_1d1fc955-f397-4aba-b02d-6c067035fea0"
      unitRef="usd">28300000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i6610d7c73b1f4958b659b907335a85a0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfNTQ5NzU1OTE1Njc3_82b1c028-bf95-4be5-a825-f82480f6aa5f"
      unitRef="usd">26900000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i9c3e2b7da46c423383b2883aad5f1fba_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfODI0NjMzNzMwOTk1Mg_65f86aea-022f-42e9-a8d5-6d64d0182f85"
      unitRef="usd">700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMTE_de61e24f-3d6d-46da-9c3a-61f34aca7d01">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCash
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfNjQyNA_8e03799b-d8ab-4ba8-b993-7b2fcb2ed26f"
      unitRef="usd">200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfNjQyNA_c8e374c3-e5fe-481d-93b0-c8f4b1d9a7b8"
      unitRef="usd">200000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyNDE_e90c5084-6ddf-442c-8d70-26952f29995f">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyNDE_fa9ca9f3-d8fd-41a4-9689-7fb02cd1ea56">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOmRiMzg5OTk4MDYyNDRlMjhhMDhiM2ZmYTViY2U1M2UwL3RhYmxlcmFuZ2U6ZGIzODk5OTgwNjI0NGUyOGEwOGIzZmZhNWJjZTUzZTBfMS0yLTEtMS02MjQ1NQ_7ce558b0-164d-4cc5-a5e4-76e9e44990f5"
      unitRef="usd">52184000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic10d09e997d04be59819eb9f739c540e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOmRiMzg5OTk4MDYyNDRlMjhhMDhiM2ZmYTViY2U1M2UwL3RhYmxlcmFuZ2U6ZGIzODk5OTgwNjI0NGUyOGEwOGIzZmZhNWJjZTUzZTBfMS00LTEtMS02MjQ1NQ_b21d2fab-eaee-4c4a-854f-c74422c7663c"
      unitRef="usd">89751000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOmRiMzg5OTk4MDYyNDRlMjhhMDhiM2ZmYTViY2U1M2UwL3RhYmxlcmFuZ2U6ZGIzODk5OTgwNjI0NGUyOGEwOGIzZmZhNWJjZTUzZTBfMi0yLTEtMS02MjQ1NQ_516c5a49-ba5d-4aad-affc-fa16daf65dcb"
      unitRef="usd">200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ic10d09e997d04be59819eb9f739c540e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOmRiMzg5OTk4MDYyNDRlMjhhMDhiM2ZmYTViY2U1M2UwL3RhYmxlcmFuZ2U6ZGIzODk5OTgwNjI0NGUyOGEwOGIzZmZhNWJjZTUzZTBfMi00LTEtMS02MjQ1NQ_430f3341-54a7-411a-a49b-77f86658e746"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOmRiMzg5OTk4MDYyNDRlMjhhMDhiM2ZmYTViY2U1M2UwL3RhYmxlcmFuZ2U6ZGIzODk5OTgwNjI0NGUyOGEwOGIzZmZhNWJjZTUzZTBfMy0yLTEtMS02MjQ1NQ_bcf52d7f-8790-4bcf-8f04-1ac095d90f2d"
      unitRef="usd">52384000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic10d09e997d04be59819eb9f739c540e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOmRiMzg5OTk4MDYyNDRlMjhhMDhiM2ZmYTViY2U1M2UwL3RhYmxlcmFuZ2U6ZGIzODk5OTgwNjI0NGUyOGEwOGIzZmZhNWJjZTUzZTBfMy00LTEtMS02MjQ1NQ_76350cfd-5cfd-4d67-9d64-f59fbb9f7467"
      unitRef="usd">89851000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfODI0NjMzNzMwNjg1NA_20a09e88-1d08-4b8f-8a25-d89d2b8f1383">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, we combine our intangible assets and other long-lived assets, into groupings, a determination which we principally make on the basis of whether the assets are specific to a particular test we offer or technology we are developing. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A &lt;/span&gt;&lt;/div&gt;long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#x2019;s carrying amount. Management&#x2019;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#x2019;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMzA_db5ab1ad-2358-48c7-8db4-ab107fefacd4">&lt;div style="margin-top:16pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.) and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the three months ended March&#160;31, 2023 and 2022 was a $0.3&#160;million net revenue increase and a $0.2&#160;million net revenue decrease, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTA1NzA_49f10fd2-2340-4088-8448-0b6f92e6ec89"
      unitRef="usd">300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfNTQ5NzU1OTE1NzM5_33f3defa-0e7e-42ae-ada8-2ea2222b1c1e"
      unitRef="usd">200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMzc_618038ba-7527-4f8d-86ce-9e066897095d">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory &lt;/span&gt;&lt;/div&gt;supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMzY_4a3ee2df-671c-4e1d-ac7a-eced0d96d979">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.3 million for the three months ended March&#160;31, 2023 and 2022, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTY0NDQ_9e6bb6da-deec-4cd4-9977-94bee9d5e29a"
      unitRef="usd">300000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTY0NDQ_f676c897-98cc-4c41-b135-106fa304a67d"
      unitRef="usd">300000</us-gaap:AdvertisingExpense>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMzM_9fc7a61b-480d-4b48-949c-ce8066a01f56">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $0.7 million and $0.6 million for the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:CostOfRevenue
      contextRef="ia543ba88573a4f76b3f29f77c2c449a3_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTY5MDc_fdd29bb6-2d12-4ab0-b78a-b1b541290575"
      unitRef="usd">700000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i96b7c50405024efea4bb7ce5ef47adb3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTY5MTQ_cf832224-80b3-4b32-a082-23673e1d7150"
      unitRef="usd">600000</us-gaap:CostOfRevenue>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMzg0ODI5MDc5MTg3NQ_7db580f9-78d5-4cf2-b867-cb94562d3fab">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on that date. The Company's restricted stock units generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of restricted stock units is subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTA5OTUxMTcyMjAyOA_010f9ac1-b3dd-45c2-8c22-19782714d276">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMTI_16b2ca11-366a-46d0-b2ce-727ba020c01a">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMzQ_ca246fee-d460-49ac-a781-e23e62a58522">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three months ended March&#160;31, 2023 and 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding, as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyMzI_ee168a3e-fbd1-4bdc-8651-127f80609081">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.915%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,019,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,002,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,494,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;878,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,937,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,296,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i895d656b22474a18a403f1fd341b6467_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfNC0yLTEtMS02MjQ1NQ_fdf9248f-d40c-4e80-b7e1-7abbd73fb366"
      unitRef="shares">409108</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6b4f7177650b41ea9633024d9953c438_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfNC00LTEtMS02MjQ1NQ_b58ec35c-b491-482d-919a-4d7f673fb84c"
      unitRef="shares">409108</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3d8153a1b8c047f5ba1ab683df79cb7f_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfNS0yLTEtMS02MjQ1NQ_c0f36c98-17ed-4d48-a54c-fc639653fec4"
      unitRef="shares">1019076</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i30edb0fc3f0c427ab5994bec9d4cb64a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfNS00LTEtMS02MjQ1NQ_8c2778c4-8c75-4911-9a00-913745d81c1e"
      unitRef="shares">2002039</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iafc6e1b4e06e45fcb9b81908405af3e3_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfNi0yLTEtMS02MjQ1NQ_45b10744-2821-4b24-ac09-770b5e4e1891"
      unitRef="shares">1494085</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i19225060b0864579b9f675d97dd4b83b_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfNi00LTEtMS02MjQ1NQ_628d91ca-0987-4d80-93d7-2ee9ba9075d6"
      unitRef="shares">878575</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i574ca98624ca4a4b9e2538fbfee1fab3_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfNy0yLTEtMS02MjQ1NQ_195af2e6-9f34-406b-adaa-95110224b0c0"
      unitRef="shares">14736</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i32c2432d847f4430ba1a0adb828fc7e5_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfNy00LTEtMS02MjQ1NQ_834f9d6e-92ea-4d62-95e0-5a67d67c21bc"
      unitRef="shares">6929</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfOC0yLTEtMS02MjQ1NQ_a7363291-b58a-4d44-b488-1c317331ac0c"
      unitRef="shares">2937005</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RhYmxlOjkzODc2NWI0MmI2ZTQyOTFhOTVkODIxODlkMDVhMGE0L3RhYmxlcmFuZ2U6OTM4NzY1YjQyYjZlNDI5MWE5NWQ4MjE4OWQwNWEwYTRfOC00LTEtMS02MjQ1NQ_2aabe2e6-e3a8-4a46-bd32-5e012d1e1b71"
      unitRef="shares">3296651</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMzg0ODI5MDc5MTg3Ng_501cb53c-e8ba-4175-bc8d-7666db01244d">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMTA5OTUxMTcyMjQwMQ_e29ee4b2-65b2-4fe9-a9da-e9cf6fb9f7b4"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF8zNy9mcmFnOmEzYWY4ZjFiMzc0ZjQzNThhOTUzZmQyNzU2OTFhMGM1L3RleHRyZWdpb246YTNhZjhmMWIzNzRmNDM1OGE5NTNmZDI3NTY5MWEwYzVfMjQyNDM_adfb8433-da9c-49f2-9914-6b6a7af1fa9a">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which requires the measurement of expected credit losses (based on historical experience, current conditions and reasonable forecasts) for financial instruments (such as accounts receivable) held at the reporting date which are carried at amortized cost. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Codification Improvements to Topic 326, Financing Instruments-Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which included an amendment of the effective date for nonpublic entities. For emerging growth companies, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted this pronouncement on January 1, 2023. The adoption did not have an impact on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for smaller reporting companies as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2023. The adoption did not have an impact on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RleHRyZWdpb246YmMyMDA0YzczMzZmNDQ0ZDg5NTZlMDc2ZjJlOTQwZTJfNjM0_3cea36fb-7a41-4111-aa6b-ea3ba18410f9">Other Financial Information&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid product royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid maintenance and insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for the three months ended March&#160;31, 2023 and 2022 was approximately $0.6 million and $0.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued purchases of goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued clinical study activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease obligations, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Refund liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RleHRyZWdpb246YmMyMDA0YzczMzZmNDQ0ZDg5NTZlMDc2ZjJlOTQwZTJfNjMz_0136b12f-1ce6-42ea-9b42-c35dd8409f5e">Prepaid expenses and other current assets consist of the following (in thousands):&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid product royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid maintenance and insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:OtherAssetsCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfMS0yLTEtMS02MjQ1NQ_12cd5620-b143-4daf-a9ee-05b545245b89"
      unitRef="usd">1736000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfMS00LTEtMS02MjQ1NQ_d8f96640-2013-4dff-b17f-aff97d335c6e"
      unitRef="usd">1795000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidRoyalties
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfMi0yLTEtMS02MjQ1NQ_f2a02867-d061-4aeb-88fe-4ab3ba44c48f"
      unitRef="usd">39000</us-gaap:PrepaidRoyalties>
    <us-gaap:PrepaidRoyalties
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfMi00LTEtMS02MjQ1NQ_093475a3-2575-4552-899c-10a3ce1030d1"
      unitRef="usd">40000</us-gaap:PrepaidRoyalties>
    <exdx:PrepaidMaintenanceAndInsuranceContracts
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfMy0yLTEtMS02MjQ1NQ_5b94b35a-e302-4168-921b-146ab4e65348"
      unitRef="usd">2210000</exdx:PrepaidMaintenanceAndInsuranceContracts>
    <exdx:PrepaidMaintenanceAndInsuranceContracts
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfMy00LTEtMS02MjQ1NQ_0f64976d-4a27-4aba-a0d1-6eed8f82c286"
      unitRef="usd">2072000</exdx:PrepaidMaintenanceAndInsuranceContracts>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfNC0yLTEtMS02MjQ1NQ_444bcb1c-5a9c-4264-a134-b24e53be931d"
      unitRef="usd">244000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfNC00LTEtMS02MjQ1NQ_b5182a83-e5e4-4b9b-8f4d-2520368ed973"
      unitRef="usd">236000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfNS0yLTEtMS02MjQ1NQ_073cc288-2353-47fa-b77b-a8545c3373b7"
      unitRef="usd">4229000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjdhNWNiMGJkZDA3NzQwZmFiZmEyNzJlZTc4Y2QyZmI5L3RhYmxlcmFuZ2U6N2E1Y2IwYmRkMDc3NDBmYWJmYTI3MmVlNzhjZDJmYjlfNS00LTEtMS02MjQ1NQ_ccffad4b-cf26-409b-9482-be8fa7709955"
      unitRef="usd">4143000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RleHRyZWdpb246YmMyMDA0YzczMzZmNDQ0ZDg5NTZlMDc2ZjJlOTQwZTJfNjI5_5e0a8a53-d115-4c72-8ab4-5f739ede2bff">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i7cb9b15bd3534c7b959fafc69dd136ca_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfMS0yLTEtMS02MjQ1NQ_c8956c39-af30-44c0-94a8-16917768dc1a"
      unitRef="usd">98000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="iad556f0486564986b0fe232198d50b00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfMS00LTEtMS02MjQ1NQ_3dfca3cf-988d-4b72-aaa4-9d48f25d4113"
      unitRef="usd">98000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="iea90a46da8b0473b81bd14734a0e680a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfMi0yLTEtMS02MjQ1NQ_23308afa-a144-4713-96e8-1b3d7f13e937"
      unitRef="usd">5209000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ie8b419bb6ccf44b485236b67f0570541_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfMi00LTEtMS02MjQ1NQ_0459c961-b7c4-4be8-9521-e2c2e1bc0131"
      unitRef="usd">5136000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ifffe2a329326445ebf186d1dbfc97983_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfMy0yLTEtMS02MjQ1NQ_c1715f4f-444c-4c85-83c0-ffd0d8527318"
      unitRef="usd">1548000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i6dbff6a1aa00481ca92a92d62756b86b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfMy00LTEtMS02MjQ1NQ_0888d49f-7445-4ba8-94bd-f8316eec41fd"
      unitRef="usd">1482000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i0c7b49c0d49e41acb5a83a3b738931e7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfNC0yLTEtMS02MjQ1NQ_3cff8bf4-630a-42b5-beed-6c6b930b341a"
      unitRef="usd">5223000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="iecd2c1906e2f4109b2230036ad76ebce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfNC00LTEtMS02MjQ1NQ_715b584b-dc5c-4b72-9708-d6406faca870"
      unitRef="usd">5223000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ice0b71e76bbd4e2e84837c2eba278fff_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfNS0yLTEtMS02MjQ1NQ_e1a286cc-b012-4e97-9bde-0b15dd5df99f"
      unitRef="usd">1856000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="idf0198dc6d684b77b81f517d3508fe26_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfNS00LTEtMS02MjQ1NQ_7348e68a-d183-478e-9896-97ac72f063d0"
      unitRef="usd">1382000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfNi0yLTEtMS02MjQ1NQ_01104ced-68f5-4355-be67-1754f93f8be3"
      unitRef="usd">13934000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfNi00LTEtMS02MjQ1NQ_a4818ecd-eef2-4bb8-8672-51b8c58c965a"
      unitRef="usd">13321000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfNy0yLTEtMS02MjQ1NQ_19c7f1ed-4bc7-4bbf-8121-c9b332f6a666"
      unitRef="usd">5670000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfNy00LTEtMS02MjQ1NQ_f39e70d1-feb4-484d-9693-a2965b92b16c"
      unitRef="usd">5124000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfOC0yLTEtMS02MjQ1NQ_4efc0ae9-17e3-473f-a0a5-b3fd6d55984b"
      unitRef="usd">8264000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOmI4NjA3ODQyN2UyOTQzMDJhNWM2ZjFmMDQ4MzcyZmM3L3RhYmxlcmFuZ2U6Yjg2MDc4NDI3ZTI5NDMwMmE1YzZmMWYwNDgzNzJmYzdfOC00LTEtMS02MjQ1NQ_875e4f91-501b-49f8-8399-4e966f7bfd3c"
      unitRef="usd">8197000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RleHRyZWdpb246YmMyMDA0YzczMzZmNDQ0ZDg5NTZlMDc2ZjJlOTQwZTJfMzgx_8426ec7a-f111-4db9-8eb6-5f2bc553b455"
      unitRef="usd">600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RleHRyZWdpb246YmMyMDA0YzczMzZmNDQ0ZDg5NTZlMDc2ZjJlOTQwZTJfMzk2_4f93575b-29c9-4201-805e-162f0e492112"
      unitRef="usd">300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RleHRyZWdpb246YmMyMDA0YzczMzZmNDQ0ZDg5NTZlMDc2ZjJlOTQwZTJfNjM1_7553bf4f-1585-4d46-acbb-b512c72400b9">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued purchases of goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued clinical study activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease obligations, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Refund liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfMS0yLTEtMS02MjQ1NQ_59063371-5959-4ca4-8aa6-25b4baf9a5ba"
      unitRef="usd">3662000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfMS00LTEtMS02MjQ1NQ_cfa4939c-c4d0-48e6-8318-db4697d03360"
      unitRef="usd">2355000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfMi0yLTEtMS02MjQ1NQ_8eb31791-ed6b-453b-bb85-35643e7d94eb"
      unitRef="usd">142000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfMi00LTEtMS02MjQ1NQ_3977797a-50a0-4311-8732-f4ed92a0e71d"
      unitRef="usd">142000</us-gaap:InterestPayableCurrent>
    <exdx:AccruedPurchaseGoodsAndServicesCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfMy0yLTEtMS02MjQ1NQ_c1206a88-2f88-4fee-a6cd-66452dfdd835"
      unitRef="usd">665000</exdx:AccruedPurchaseGoodsAndServicesCurrent>
    <exdx:AccruedPurchaseGoodsAndServicesCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfMy00LTEtMS02MjQ1NQ_03088f66-9b50-4500-b0ab-be7bbd353a40"
      unitRef="usd">803000</exdx:AccruedPurchaseGoodsAndServicesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfNC0yLTEtMS02MjQ1NQ_bac58e8b-ea13-4522-a2ca-c5737d58354b"
      unitRef="usd">114000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfNC00LTEtMS02MjQ1NQ_3e0a274f-e322-417f-a453-495d3726dd96"
      unitRef="usd">514000</us-gaap:AccruedRoyaltiesCurrent>
    <exdx:AccruedLiabilitiesClinicalStudyCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfNS0yLTEtMS02MjQ1NQ_4375638d-6708-42b7-afb3-e4b0d7862163"
      unitRef="usd">160000</exdx:AccruedLiabilitiesClinicalStudyCurrent>
    <exdx:AccruedLiabilitiesClinicalStudyCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfNS00LTEtMS02MjQ1NQ_4223b0b2-3ca5-4b70-a814-26aefd58d310"
      unitRef="usd">162000</exdx:AccruedLiabilitiesClinicalStudyCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfNi0yLTEtMS02MjQ1NQ_2af93341-82c9-4775-90cc-6ed729bb87ea"
      unitRef="usd">650000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfNi00LTEtMS02MjQ1NQ_9386be3e-f276-4576-b05c-2786b0612e42"
      unitRef="usd">700000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfNy0yLTEtMS02MjQ1NQ_efca9642-968e-41a8-b2bc-03625de0cb20"
      unitRef="usd">445000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfNy00LTEtMS02MjQ1NQ_dd7b882f-ace6-4f9a-99c3-c4cbe0e9563a"
      unitRef="usd">445000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfOC0yLTEtMS02MjQ1NQ_701166d8-be70-41d0-aeb5-d9e5abe2065b"
      unitRef="usd">226000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfOC00LTEtMS02MjQ1NQ_712c2822-f7fe-465b-9da0-066c2625b64a"
      unitRef="usd">226000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfOS0yLTEtMS02MjQ1NQ_a444fd81-a535-4762-be18-4cd20d3247bd"
      unitRef="usd">6064000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i19a0ad082dff4b1a84ff370e3c67dfd6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80MC9mcmFnOmJjMjAwNGM3MzM2ZjQ0NGQ4OTU2ZTA3NmYyZTk0MGUyL3RhYmxlOjU3NzY2ZDk0ZGRiZjRhNjFhMTU2MmYzNTBhZjg0MDhiL3RhYmxlcmFuZ2U6NTc3NjZkOTRkZGJmNGE2MWExNTYyZjM1MGFmODQwOGJfOS00LTEtMS02MjQ1NQ_39422b22-d2b9-44ac-b6ba-d1018d16b937"
      unitRef="usd">5347000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNTEyMQ_e54c26e8-fb35-444c-ae54-4214076fa03c">Borrowings&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), as amended, pursuant to which the Company borrowed $25.0&#160;million. As of March&#160;31, 2023, no additional amounts remained available to borrow under the 2017 Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Company executed the Second Amendment to the Loan and Security Agreement (the 2017 Loan Amendment) and, as further described in Note 9, on April 28, 2023, the Company and Innovatus entered into &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Third Loan Amendment to the 2017 Term Loan (Third Loan Amendment). The interest rate on all borrowings under the 2017 Loan Amendment was 8.0%, of which 2.0% was paid in-kind in the form of additional term loans (PIK Loans) until December of 2024, after which interest was scheduled to accrue at an annual rate of 8.0%. The Company estimated the effective interest rate of this loan to be approximately 8.5%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the 2017 Loan Amendment was to be repaid in twenty-four equal monthly installments commencing in December 2024. Upon repayment of the final installment under the 2017 Loan Amendment, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of the Loan Amendment using the effective interest method. For each of the three months ended March&#160;31, 2023 and 2022, the Company issued PIK Loans totaling $0.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2017 Loan Amendment required a prepayment premium of 2% of the aggregate outstanding principal and decreased by 1% on each of November 1, 2023 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2017 Loan Amendment is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the 2017 Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis. The consequences of failing to achieve the performance covenant were eligible to be cured if, within sixty days of failing to achieve the performance covenant, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The 2017 Loan Amendment requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The negative covenants provide, among other things, that without the prior consent of Innovatus, subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the Company was in compliance with all covenants of the 2017 Loan Amendment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon an event of default in any of the 2017 Loan Amendment covenants, the repayment of the 2017 Loan Amendment may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the 2017 Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the 2017 Loan Amendment due beyond twelve months of the balance sheet date as non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;2022 Equipment Notes Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2022, the Company purchased laboratory equipment using notes payable. At March&#160;31, 2023, the total notes payable balance related to this financed equipment was $1.0 million, with $0.3 million classified within borrowings-current portion and $0.7 million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. The financed equipment is subject to a 5.28% effective interest rate and will mature on October 1, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Future Minimum Payments on the Outstanding Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, future minimum aggregate payments, including interest, for outstanding borrowings under the 2017 Loan Amendment are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Borrowings-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Borrowings-non-current portion, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i94ecd2ce87e1410596492d2b66fe3d3d_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMzg0ODI5MDcwMzE4Ng_c47a92af-8bcc-48ec-aa78-d7691a99b18f"
      unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="ibb33abf78bcd4170a8b0655f9f35138a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNTA0_5ce73c5b-bf0a-431e-a69f-d81fcbe473aa"
      unitRef="usd">0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i859e111840c844b0912ab35300e78234_I20211130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNzcw_15a13a0c-bcfc-4115-9239-3d08eaa746c3"
      unitRef="number">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <exdx:DebtInstrumentStatedInterestRatePaidInKind
      contextRef="i859e111840c844b0912ab35300e78234_I20211130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNzgz_09086fb4-a83c-4cda-8fb0-c8722e79aabb"
      unitRef="number">0.020</exdx:DebtInstrumentStatedInterestRatePaidInKind>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i859e111840c844b0912ab35300e78234_I20211130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfOTI1_15a13a0c-bcfc-4115-9239-3d08eaa746c3"
      unitRef="number">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i859e111840c844b0912ab35300e78234_I20211130"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMTAxNg_bc669abb-6a55-406f-9c4e-9a12fb3f1c4e"
      unitRef="number">0.085</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <exdx:DebtInstrumentNumberOfMonthlyInstallments
      contextRef="i0d50b70a9daa46a5b489435a77934c85_D20211101-20211130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMTIxMw_e6a3c17e-ab47-46d0-a9a7-24086530c501"
      unitRef="installment">24</exdx:DebtInstrumentNumberOfMonthlyInstallments>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="ibb33abf78bcd4170a8b0655f9f35138a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMTM5NQ_effe2b99-7616-4c81-b479-e86a557fcef3"
      unitRef="usd">1000000</us-gaap:DebtInstrumentFeeAmount>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="iabe905c72ff84d589835e599cc035ca4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMTYxNw_c9002b87-c07e-4b92-bed6-72bf32c32391"
      unitRef="usd">100000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="i0a372fdfdb7a4826a6cbffa763f05288_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMTYxNw_fbcafa32-66c3-4a15-aa3f-23cb7b566328"
      unitRef="usd">100000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="i859e111840c844b0912ab35300e78234_I20211130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMTc2Ng_98350ec2-786d-428f-bfb7-39e3d0a86cc1"
      unitRef="number">0.02</exdx:DebtInstrumentPrepaymentPremiumPercentage>
    <exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction
      contextRef="i859e111840c844b0912ab35300e78234_I20211130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMzg0ODI5MDcwMzE3Ng_a93d0bee-6644-40ac-a33a-928f722c2014"
      unitRef="number">0.01</exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction>
    <exdx:DebtInstrumentCovenantRevenuePerformancePeriod
      contextRef="i2a7f825dbe7d4f5c828334d605f13e10_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNTExNw_fdbffeca-56f5-4eb8-82fa-0f7070a8fb60">P12M</exdx:DebtInstrumentCovenantRevenuePerformancePeriod>
    <exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet
      contextRef="i2a7f825dbe7d4f5c828334d605f13e10_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMjc3Mg_4702625b-6335-42e1-8fcd-8d2926f9dd16">P60D</exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet>
    <exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance
      contextRef="i859e111840c844b0912ab35300e78234_I20211130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMzEzNA_3037b4c9-0321-41bb-9ef6-7180360c5335"
      unitRef="usd">2000000.0</exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance>
    <exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease
      contextRef="ibb33abf78bcd4170a8b0655f9f35138a_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMzg0ODI5MDcwMzE4MA_ce23c00d-595f-4473-a58d-7cfaea9f9d08"
      unitRef="number">0.040</exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease>
    <us-gaap:NotesPayable
      contextRef="i66d0781c430544b080c8b6a0138f9b6e_I20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNTQ5NzU1ODI5MjI2_e71bd09e-b4d4-407f-be0c-ed2c0264d3f4"
      unitRef="usd">1000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="i66d0781c430544b080c8b6a0138f9b6e_I20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNTQ5NzU1ODI5MjE2_0d3b6f76-7762-432c-b668-17f012fd1941"
      unitRef="usd">300000</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="i66d0781c430544b080c8b6a0138f9b6e_I20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNTQ5NzU1ODI5MjIx_95d315a3-5726-4a3d-b17b-d299b580cfcc"
      unitRef="usd">700000</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i66d0781c430544b080c8b6a0138f9b6e_I20220531"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfMzg0ODI5MDcxMjM2Ng_2f511c84-ed23-4b1f-b1d5-f694dfbc8338"
      unitRef="number">0.0528</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RleHRyZWdpb246ZTMwMTM5ZjE5YjdlNDAxMmExMjZkYmZhODhhN2EyMjdfNTExOA_d07cf69e-7706-4d9c-be6a-5ce639b0a680">As of March&#160;31, 2023, future minimum aggregate payments, including interest, for outstanding borrowings under the 2017 Loan Amendment are as follows (in thousands):&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Borrowings-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Borrowings-non-current portion, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfMS0yLTEtMS02MjQ1NQ_274e50e9-204d-40ae-851d-e9116d102424"
      unitRef="usd">1498000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfMi0yLTEtMS02MjQ1NQ_e16ecb0f-1059-4d8b-96e1-86d74efb3d47"
      unitRef="usd">3279000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfMy0yLTEtMS02MjQ1NQ_4594dfab-3453-452b-a687-3d44f9abdd80"
      unitRef="usd">16451000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfNC0yLTEtMS02MjQ1NQ_33d0897a-36c6-4d18-95ce-e5e12364f3cd"
      unitRef="usd">15037000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <exdx:LongTermDebtIncludingUndiscountedInterest
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfNS0yLTEtMS02MjQ1NQ_6bf16c9d-77cd-47ee-96fb-0a071caefa33"
      unitRef="usd">36265000</exdx:LongTermDebtIncludingUndiscountedInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfNy0yLTEtMS02MjQ1NQ_b0cbd55a-f3ab-4931-afcb-c57cbb379c17"
      unitRef="usd">145000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <exdx:LongTermDebtUndiscountedInterestAmount
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfOC0yLTEtMS02MjQ1NQ_9b9bdef1-9880-498d-8130-0030fd81b4aa"
      unitRef="usd">6774000</exdx:LongTermDebtUndiscountedInterestAmount>
    <us-gaap:LongTermDebt
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfOS0yLTEtMS02MjQ1NQ_121a58e3-8fc7-4257-907d-3a53635c2d1a"
      unitRef="usd">29346000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfMTAtMi0xLTEtOTQwNjk_dabb464c-c4a3-48c9-8ee5-fbaa991429bb"
      unitRef="usd">254000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80My9mcmFnOmUzMDEzOWYxOWI3ZTQwMTJhMTI2ZGJmYTg4YTdhMjI3L3RhYmxlOmM4YTgxMDVkOWZjNTRhMTlhNjJkNjhjYzYzMTgwMjZiL3RhYmxlcmFuZ2U6YzhhODEwNWQ5ZmM1NGExOWE2MmQ2OGNjNjMxODAyNmJfMTEtMi0xLTEtOTQwODk_f3305bdb-1d95-4f43-b490-730c2e96ca9f"
      unitRef="usd">29092000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfNDgwNg_a629edda-b91f-4ada-8d46-223d1fcc6e8e">Commitments and Contingencies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition-related liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of the medical diagnostics division of Royalty Pharma Collection Trust (Royalty Pharma) (formerly known as Cypress Bioscience, Inc.) in 2010, the Company has ongoing royalty payment obligations of 2.5% on net sales of products which incorporate certain acquired technologies. Future royalties payable under these arrangements are limited to the lesser of (i) an aggregate of $1.2 million (including an upfront payment of $0.1 million) and (ii) the total royalties earned through January 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements, individual license agreements generally provide for ongoing royalty payments ranging from 1.5% to 7.0% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when earned and recorded in costs of revenue in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into a master research collaboration agreement with Allegheny Health Network Research Institute (AHN), pursuant to which the Company is required to pay AHN a collaboration fee of $0.4 million for each year during the initial term of the agreement. Collaboration expenses under the master research collaboration agreement were $0.1 million for each of the three months ended March&#160;31, 2023 and 2022. Collaboration expenses under the AHN collaboration are included in research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $6.9 million and $8.0 million for the years ending December 31, 2023 and 2024, respectively, with a 15% annual increase thereafter for unconditional minimum purchase commitments through the year ending December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including for subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities. The Company does not believe the outcome of any such matters will have a material effect on its financial position or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i0bf8defbc1fa44d882189373b2849672_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfNTc0_67d721fa-57bc-4971-943c-49a9b3b419b2"
      unitRef="number">0.025</exdx:RoyaltyObligationPercentageOfSales>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="ia5c76f81d9cd409eb1b8a90d4fe48c57_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfNzUw_c0b207a3-b9cf-4582-8058-4caddeff2a7f"
      unitRef="usd">1200000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <exdx:AdvancePayment
      contextRef="ia5c76f81d9cd409eb1b8a90d4fe48c57_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfNzk0_ff033fad-2d17-4c38-8bc2-a0877d2d43e5"
      unitRef="usd">100000</exdx:AdvancePayment>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i4931e73aebd8406f8a9334dd51dbbc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfMTEzNA_8e674312-4561-4708-973d-bdb474beaa50"
      unitRef="number">0.015</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i3350c67771f646c6b53fca4a8f67d638_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfMTE0MA_f6dd1f3a-fef8-484e-b98f-912e3c05afcb"
      unitRef="number">0.070</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:CollaborationAgreementAnnualCollaborationFee
      contextRef="ib3e0014fc8a94ef0953febf2e7cf24ad_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfMzE5NA_cd244628-7418-4bbd-ab98-aa20fe835bcb"
      unitRef="usd">400000</exdx:CollaborationAgreementAnnualCollaborationFee>
    <exdx:CollaborationAgreementCollaborationExpenses
      contextRef="i0e499e7ea6aa4310baa5eca3da4d604b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfMzMzOQ_19d4ca72-883e-452c-8ba0-2c06b03ad5da"
      unitRef="usd">100000</exdx:CollaborationAgreementCollaborationExpenses>
    <exdx:CollaborationAgreementCollaborationExpenses
      contextRef="i6d3bd6c4fe2242cf87f21e0213354a26_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfMzMzOQ_a8907979-13d4-46c9-8c7e-0a3c80303529"
      unitRef="usd">100000</exdx:CollaborationAgreementCollaborationExpenses>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="i140c8595c10a41eeb48e5be8f884c4cb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfNTQ5NzU1ODE5OTc1_4705e57c-5b12-4a77-b513-2b5aa0e24b60"
      unitRef="usd">6900000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="i140c8595c10a41eeb48e5be8f884c4cb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfNTQ5NzU1ODE5OTc5_4f64ee13-edf7-4b4e-97dd-c42899504f1c"
      unitRef="usd">8000000.0</us-gaap:PurchaseObligationDueInSecondYear>
    <exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage
      contextRef="i140c8595c10a41eeb48e5be8f884c4cb_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF80OS9mcmFnOjYwZDA2ZDIyZTQ1YzRhNjk4YmU5OTdjNTQ5N2U2MTg3L3RleHRyZWdpb246NjBkMDZkMjJlNDVjNGE2OThiZTk5N2M1NDk3ZTYxODdfNTQ5NzU1ODE5Njk3_c4281fd3-8a50-417e-a5d4-6da7c6642931"
      unitRef="number">0.15</exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RleHRyZWdpb246NmVlN2VkYmFlZTRiNGU5NDk1M2NhN2ExNDgzYjI4NjZfMjk4_d65762f7-896d-4d32-96c2-e6e7719dd12e">Fair Value Measurements&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certificate of deposit, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certificate of deposit, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The fair value of the Company's money market funds is based on quoted market prices.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RleHRyZWdpb246NmVlN2VkYmFlZTRiNGU5NDk1M2NhN2ExNDgzYjI4NjZfMjk5_4278ee79-e0bc-4e78-8082-b6f4c37a9eee">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certificate of deposit, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certificate of deposit, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if4fc1eac300c43b6a7327014b06ddfa9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfMy0yLTEtMS02MjQ1NQ_2b9857b8-f09a-4d71-8c4f-91db4f56f67d"
      unitRef="usd">20146000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i523c8d55aeb0417e85e726ce80798a7c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfMy00LTEtMS02MjQ1NQ_61e94137-647f-4447-8a47-66aaa3968dc5"
      unitRef="usd">20146000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ieff95e26dba14d95a8f3cd8ee4182372_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfMy02LTEtMS02MjQ1NQ_8978af1a-0fd3-4539-914e-22d87cc41fc9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3f4ffb1c43554f1a90dfd599025b8c9e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfMy04LTEtMS02MjQ1NQ_0496ae14-7eaf-4bac-bb79-2f0007b07f95"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9625bbb62da645d980dedf056fae0d11_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfNC0yLTEtMS04NDY0Mw_57c3f799-2247-4bdc-bcf3-19bf2e5070b8"
      unitRef="usd">30000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i173e25ca60a14e9eb6d2a3839cd12de8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfNC00LTEtMS04NDY1NQ_bc543fd4-c87d-4746-b24e-762457ddd441"
      unitRef="usd">30000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i626b7154acb34ccaafa6ab945abf40c9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfNC02LTEtMS04NDY3MQ_3821ec67-4e73-4572-a919-e75f3f364670"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie210aad638e548c4870de1627ee59314_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfNC04LTEtMS04NDY4Mw_1b425607-5b01-4412-8245-520ac617cbaa"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id41f690f8baf4faba442062c5cd09d97_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfNS0yLTEtMS04NDY0Mw_6ff77b86-40ba-4e03-98b2-d35949091f1d"
      unitRef="usd">50146000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3981775f29d04856b8989e7532c82c09_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfNS00LTEtMS04NDY1NQ_5a6a1fbc-a80b-483a-8419-937e7c9ef7b8"
      unitRef="usd">50146000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i15ae8bd4f38347fb8cd1eda4e1828338_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfNS02LTEtMS04NDY3MQ_a30fa08a-3381-4b19-b6d9-afdfb48d9526"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9d9435b79cd7491eaf962b33022de57f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOjdjYTNjMjcxNmNkZTQ0OTE4MGYzZjUzY2Y3MWU2YmVlL3RhYmxlcmFuZ2U6N2NhM2MyNzE2Y2RlNDQ5MTgwZjNmNTNjZjcxZTZiZWVfNS04LTEtMS04NDY4Mw_a399bddd-0863-4eba-8a34-f4802eec4bf3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie7a2e37140ea4e5d964b371b5b2e678e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfMy0yLTEtMS02MjQ1NQ_d0da806a-bad7-471c-a68a-916598759b31"
      unitRef="usd">29438000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifdbc12a0fd3349cea91fc35053c905ac_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfMy00LTEtMS02MjQ1NQ_ce443928-8f84-4d04-8667-48a7c83cd27b"
      unitRef="usd">29438000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8a4807b9a98e45a1ba7d94b95b6cf1db_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfMy02LTEtMS02MjQ1NQ_c1c885de-29ef-48e4-ad16-4e755bcf74b3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id2057c462f3f407fac03e7ed09fbf60b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfMy04LTEtMS02MjQ1NQ_bf05d1b5-b2be-4da3-aa24-f15eea749d4b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0c407749d2e847a7803b2c710bcc16b8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfNC0yLTEtMS04NDY5Mw_a0dd6e87-2e03-409b-a6eb-b13a1289639b"
      unitRef="usd">30100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i75e67690fd9847e1aaece1d7ff577378_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfNC00LTEtMS04NDY5Mw_83d0b3dc-f75e-422f-bf35-3df2a4b97802"
      unitRef="usd">30100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i69fb565bd3a94c019700911026c93178_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfNC02LTEtMS04NDY5Mw_d1fd616a-b3e6-4023-ab0f-8582f166cbfe"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3aff556ef6e84baa8337afc2d1b6be3c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfNC04LTEtMS04NDY5Mw_fb4ea5c9-b4bf-4b80-990e-bdc9a904f287"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i90e1b44e5ed44cc28aa97c0d68594467_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfNS0yLTEtMS02MjQ1NQ_61df3664-667f-4b21-bd2d-dd48c85debc4"
      unitRef="usd">59538000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4f4f95f45fbb40f4a140c25ba96bc721_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfNS00LTEtMS02MjQ1NQ_99c0363c-0f46-49e3-914d-bb99ea17e7e2"
      unitRef="usd">59538000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie9b6627751494aab9971b2c3202d9569_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfNS02LTEtMS02MjQ1NQ_e3c44a6a-8f35-47f6-a9a0-887d312571ad"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1b6b812b1a86449d836330f0d3b625bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81Mi9mcmFnOjZlZTdlZGJhZWU0YjRlOTQ5NTNjYTdhMTQ4M2IyODY2L3RhYmxlOmJlMGNkMjViNWNjMTRjOTVhNmU5ZGQxNjE1ZDg2NmZlL3RhYmxlcmFuZ2U6YmUwY2QyNWI1Y2MxNGM5NWE2ZTlkZDE2MTVkODY2ZmVfNS04LTEtMS02MjQ1NQ_7caf9d86-e080-4f7d-8ccd-eacfb2ca6872"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RleHRyZWdpb246YjAyYzFhZTY2Y2E2NDQ5MThkNTJmYmJhODgyNDc5YzdfMzIxMg_3e50efa3-9233-4ca6-8bf3-1e2d8658e7ce">Stockholders' Equity&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;At The Market Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On September 15, 2022, the Company entered into a sales agreement (the Sales Agreement) with Cowen and Company, LLC (the Sales Agent), pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $50.0&#160;million. The Company is not obligated to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;sell any shares of Company common stock in the offering. As of March&#160;31, 2023, the Company has not sold any shares of its common stock pursuant to the Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Outstanding Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following equity classified warrants to purchase common stock were outstanding as of March&#160;31, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237,169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,086&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;804,951&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,214,059&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, no warrants to purchase common stock were exercised.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ie95865dfdf5b4540b73e69eb6e14d14b_D20220915-20220915"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RleHRyZWdpb246YjAyYzFhZTY2Y2E2NDQ5MThkNTJmYmJhODgyNDc5YzdfMzg0ODI5MDcwNjgxOQ_9251a328-d84a-4157-824b-517e1afc25d8"
      unitRef="usd">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RleHRyZWdpb246YjAyYzFhZTY2Y2E2NDQ5MThkNTJmYmJhODgyNDc5YzdfMzIxMA_609ed75a-4aff-41ff-8aac-fda07d8026fe">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following equity classified warrants to purchase common stock were outstanding as of March&#160;31, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237,169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,086&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;804,951&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,214,059&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i5ff0d03d717e4fe3bc16e2a5c900dc45_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfMS0xLTEtMS02MjQ1NQ_d26e15bb-7cae-4dd4-9449-d5546933b979"
      unitRef="shares">237169</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i5ff0d03d717e4fe3bc16e2a5c900dc45_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfMS0zLTEtMS02MjQ1NQ_2122d619-8cc6-4a94-96fe-c0c741523405"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic3de710b92f4485e825c6c2d1c6fb10a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfMi0xLTEtMS02MjQ1NQ_0d7f4386-a8e4-4f93-beca-209b4a460b16"
      unitRef="shares">67086</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic3de710b92f4485e825c6c2d1c6fb10a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfMi0zLTEtMS02MjQ1NQ_755af79a-b4bf-458e-a841-84ecf074846e"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2912cd445faf49c38783149855c13b6d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfMy0xLTEtMS02MjQ1NQ_390dd613-17d4-4655-b685-4ab12c05f991"
      unitRef="shares">131</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i2912cd445faf49c38783149855c13b6d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfMy0zLTEtMS02MjQ1NQ_9f644ee3-a674-41da-90d9-a35d8805f866"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie36f5616d2e44e80a9e03af14c0045a4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfNC0xLTEtMS02MjQ1NQ_42dac7ae-0ce6-4498-b1a1-01d3b76259a0"
      unitRef="shares">83778</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie36f5616d2e44e80a9e03af14c0045a4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfNC0zLTEtMS02MjQ1NQ_6965e544-2cff-4dba-9d83-02da1aa8d6d0"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i02a6a7e72b5342cfb6df8c09e1146039_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfNS0xLTEtMS02MjQ1NQ_0c70400b-b50d-47fb-bcb9-c5964f8bf9ea"
      unitRef="shares">20944</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i02a6a7e72b5342cfb6df8c09e1146039_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfNS0zLTEtMS02MjQ1NQ_d2f2fc73-3646-4dbf-820f-51c77deef940"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i0885affce6b54cc8bb7d28029c8146fa_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfNi0xLTEtMS02MjQ1NQ_b3dc552c-4b4e-4205-bd52-e43418b35459"
      unitRef="shares">804951</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i0885affce6b54cc8bb7d28029c8146fa_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfNi0zLTEtMS02MjQ1NQ_35fcb231-b263-4db9-9326-37277dafa5a1"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i7dbf9a0fcf934366948459c15f4770d1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RhYmxlOjZmNmJlYzE2YTI0NjQ0YzE4Y2NlMzAxMWE4YzRiNWQwL3RhYmxlcmFuZ2U6NmY2YmVjMTZhMjQ2NDRjMThjY2UzMDExYThjNGI1ZDBfNy0xLTEtMS02MjQ1NQ_56746254-5979-4ba9-b6d5-da0621025565"
      unitRef="shares">1214059</us-gaap:ClassOfWarrantOrRightOutstanding>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81NS9mcmFnOmIwMmMxYWU2NmNhNjQ0OTE4ZDUyZmJiYTg4MjQ3OWM3L3RleHRyZWdpb246YjAyYzFhZTY2Y2E2NDQ5MThkNTJmYmJhODgyNDc5YzdfMzE1OA_870bd7e6-706e-4a6b-a3d7-25affb9f0a52"
      unitRef="shares">0</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMjk1Ng_425309de-feba-488a-adb5-4b9031c3aa1b">Stock Option Plan&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Incentive Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally four years from the date of grant or, for grants to new hires, date of hire. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) 4% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board of Directors. As of March&#160;31, 2023, 1,851,836 shares of common stock remained available for future awards under the 2019 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2019, the Board of Directors adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the lesser of (i) 1% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Board of Directors. As of March&#160;31, 2023, 508,608 shares of common stock remained available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(93,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(277,805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,019,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,019,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;804,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;There were no stock options granted in the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The aggregate intrinsic value of options exercised during the three months ended March 31, 2023 was $0.2 million. There were no options exercised during the three months ended March 31, 2022. As of March&#160;31, 2023, total unrecognized compensation cost related to option awards was $1.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 0.82&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,036,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;638,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(113,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66,903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,494,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, all of the outstanding restricted stock units were unvested. The fair value of restricted stock units vested in each of the three months ended March 31, 2023 and 2022 was $0.3 million. The weighted average grant date fair value for restricted stock units granted in the three months ended March 31, 2023 and 2022 was $2.30 and $8.72, respectively. As of March&#160;31, 2023, total unrecognized compensation cost related to restricted stock units was $6.2 million, which is expected to be recognized over a remaining weighted-average vesting period of 3.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statements of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Costs of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ia4840a5daec942e9baf60b20b64f05d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTY0OTI2NzQ0Nzc2MA_e5c2bde3-35b7-42f8-8f79-708758de115f">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia4840a5daec942e9baf60b20b64f05d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTY0OTI2NzQ0Nzc2Ng_0ca7e9c9-32da-424d-b5de-d410a06feea1">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage
      contextRef="i9f4d0fe871b84f4bbc6b2e49f7ca8aa6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTY0OTI2NzQ0Nzc3MQ_24de149e-134b-4499-8709-560b7ebcfe47"
      unitRef="number">0.04</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9f4d0fe871b84f4bbc6b2e49f7ca8aa6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfNzE4_d9239c9e-3544-4350-b6d4-a7e1903ed715"
      unitRef="shares">1851836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i35ee5d15536b446d8e71cf4f2712b1ad_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTY0OTI2NzQ0ODQ2NA_4b6bd214-2bc2-48a9-beb9-746f7be3d523"
      unitRef="number">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage
      contextRef="i35ee5d15536b446d8e71cf4f2712b1ad_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTY0OTI2NzQ0ODQ3Mg_2e09b011-4a2d-46c4-875d-57f74bd38397"
      unitRef="number">0.01</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i35ee5d15536b446d8e71cf4f2712b1ad_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTE0OQ_e43feb42-0cf1-4ce0-8563-278b94519455"
      unitRef="shares">508608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMjk1OQ_cb6673f8-e79f-4018-91c0-7adeeee8ece6">Stock option activity under the Company's 2019 Plan is set forth below:&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(93,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(277,805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,019,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,019,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;804,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6cd5e724cdb246d89edfa68105eaed87_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfMS0yLTEtMS02MjQ1NQ_526ab5d8-b3eb-4a10-a65b-a4aef16a9d37"
      unitRef="shares">1421235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6cd5e724cdb246d89edfa68105eaed87_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfMS00LTEtMS02MjQ1NQ_abe5cc60-92c8-427f-93d1-03120e25432d"
      unitRef="usdPerShare">12.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i55497019afe7489891af1088e9d0a6da_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfMS02LTEtMS02MjQ1NQ_7959b734-cfd6-41f0-8fe0-986496f22d4f">P7Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i6cd5e724cdb246d89edfa68105eaed87_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfMS04LTEtMS02MjQ1NQ_6af0144c-61bb-40d8-809d-8cc6d67a9c48"
      unitRef="usd">483000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfMi0yLTEtMS02MjQ1NQ_599e3d89-46be-4475-b44e-c008cec27dde"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfMi00LTEtMS02MjQ1NQ_5e474fb5-b3d4-4147-9bec-6f288a6b7723"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfMy0yLTEtMS02MjQ1NQ_a8c36fd7-1cfc-49d3-9586-2710fec23382"
      unitRef="shares">93335</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfMy00LTEtMS02MjQ1NQ_a8000dc7-9597-4dc9-8b96-a565a537c9e7"
      unitRef="usdPerShare">0.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNC0yLTEtMS02MjQ1NQ_ab3f01d2-87fe-45c4-aec1-ffdc162e63eb"
      unitRef="shares">31019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNC00LTEtMS02MjQ1NQ_e37fdbc7-b0ec-433e-ab64-111733f6da51"
      unitRef="usdPerShare">14.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNS0yLTEtMS02MjQ1NQ_b2761165-5567-4a3e-844a-6ebf2e74f432"
      unitRef="shares">277805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNS00LTEtMS02MjQ1NQ_a4b7c15c-1f4d-4e30-8d67-d0ab89885b23"
      unitRef="usdPerShare">17.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNi0yLTEtMS02MjQ1NQ_e8091f7d-9715-459a-90ac-a14f6b7d60e9"
      unitRef="shares">1019076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNi00LTEtMS02MjQ1NQ_7f54e92e-b1d2-4dbb-827b-6bb696f63666"
      unitRef="usdPerShare">12.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNi02LTEtMS02MjQ1NQ_29fbc8ac-9c31-4360-acee-c147378b4663">P6Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNi04LTEtMS02MjQ1NQ_c755a2fa-e54b-409b-8cc3-d6e1d4b394f9"
      unitRef="usd">287000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNy0yLTEtMS02MjQ1NQ_6693caa5-d70d-4eec-a929-5efa7e446594"
      unitRef="shares">1019076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNy00LTEtMS02MjQ1NQ_0de947a2-e27c-4798-b0dc-99ebf2ca01bf"
      unitRef="usdPerShare">12.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNy02LTEtMS02MjQ1NQ_36db5a80-9123-4789-9887-9e97dfb649b1">P6Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfNy04LTEtMS02MjQ1NQ_7bf8cbbf-7447-44b3-bd29-b0b5470d3614"
      unitRef="usd">287000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfOC0yLTEtMS02MjQ1NQ_f0989c13-f5e2-4c05-b274-b9f54912a6e0"
      unitRef="shares">804742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfOC00LTEtMS02MjQ1NQ_e1d8cfda-e5fc-49ec-9b0e-b70d9c28b593"
      unitRef="usdPerShare">12.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfOC02LTEtMS02MjQ1NQ_4fdb9d0a-60b8-4364-935e-3186a50a9b1e">P6Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOmM2N2E2OWIzZjNmNDRjNDJiYWE3MDM0NDE0YmYwODE3L3RhYmxlcmFuZ2U6YzY3YTY5YjNmM2Y0NGM0MmJhYTcwMzQ0MTRiZjA4MTdfOC04LTEtMS02MjQ1NQ_c092b208-ad54-4399-9ac6-d6c298e9fa23"
      unitRef="usd">287000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTA5OTUxMTYzNzM3Mg_2c420f9a-81bd-4bef-bcce-cdebc4c2d7e0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1acc384230fc42e6a9d187464e747867_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTA5OTUxMTYzNzM3Mg_538bc143-3e55-4fb6-835b-9b2c9562a7a6"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ic10d09e997d04be59819eb9f739c540e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfNTQ5NzU1ODIyNDk0_432cf4ce-2b31-4795-84fe-f4aaf0079fb2"
      unitRef="usd">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="iadb1d70ecbc74354bdb6fb9ab98a4188_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTUzOA_0303ec79-910e-4c7a-aa66-e9404f245a2f"
      unitRef="usd">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTYzNw_65b8d828-490e-4966-b316-31b4c65001c0">P0Y9M25D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMjk2Mg_0c5e0f2e-a30a-4273-9df5-882dd1167d82">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,036,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;638,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(113,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66,903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,494,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i385f1d93cdab453180c8c50401ec671d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfMS0yLTEtMS02MjQ1NQ_1cb8ba4e-3b12-4dda-8494-9db66a371963"
      unitRef="shares">1036208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i385f1d93cdab453180c8c50401ec671d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfMS00LTEtMS02MjQ1NQ_0b964873-ea6b-4090-80a7-d952767adcb4"
      unitRef="usdPerShare">7.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i385f1d93cdab453180c8c50401ec671d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfMS02LTEtMS02MjQ1NQ_05af3117-c7fd-48b4-95f3-0ae0217835f2"
      unitRef="usd">2487000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfMi0yLTEtMS02MjQ1NQ_9ddeb35d-dd49-405c-a0dc-0973435f9efd"
      unitRef="shares">638500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfMi00LTEtMS02MjQ1NQ_67dd47f2-0d4b-42a0-87fa-ea6c032d0ae5"
      unitRef="usdPerShare">2.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfMy0yLTEtMS02MjQ1NQ_590d5795-47c6-4a02-be6d-2e394cc9b090"
      unitRef="shares">113720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfMy00LTEtMS02MjQ1NQ_e87bdb74-1e33-48fb-b8db-80e2d5bd9edf"
      unitRef="usdPerShare">11.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfNC0yLTEtMS02MjQ1NQ_c83ef3e2-b363-4213-a9ec-b6f67c4531ad"
      unitRef="shares">66903</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfNC00LTEtMS02MjQ1NQ_75ab58c9-49e6-40ca-9f8f-bc6b6406e48f"
      unitRef="usdPerShare">11.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia1400e06e8cb4cce8e16afdae774fbd6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfNS0yLTEtMS02MjQ1NQ_0b791f9a-4600-4aba-aa96-be9a96326e7c"
      unitRef="shares">1494085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia1400e06e8cb4cce8e16afdae774fbd6_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfNS00LTEtMS02MjQ1NQ_77e21367-ab28-4324-82f2-5fa02b3cc8e2"
      unitRef="usdPerShare">4.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="ia1400e06e8cb4cce8e16afdae774fbd6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjUwMGVhYWE4NGM2YzQxZWNhNDIxZmIyYThjZTZkNTE0L3RhYmxlcmFuZ2U6NTAwZWFhYTg0YzZjNDFlY2E0MjFmYjJhOGNlNmQ1MTRfNS02LTEtMS02MjQ1NQ_c5d0e6f5-82a6-4d60-8320-827abf7715ce"
      unitRef="usd">3631000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTA5OTUxMTYzNzExNQ_29ab61ca-a365-4cfd-aac7-795e685d9d8f"
      unitRef="usd">300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i59cad19a4f2e4767b2e7f56240d61b72_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTA5OTUxMTYzNzExNQ_89038c12-1973-45ad-abc8-8d89a94b5b69"
      unitRef="usd">300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfNTQ5NzU1ODIzMTk1_39aaf77a-a32f-4165-bcd6-d604cb2e294b"
      unitRef="usdPerShare">2.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i59cad19a4f2e4767b2e7f56240d61b72_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTA5OTUxMTYzNzA5Mw_84a9ccef-4536-4ae1-b410-9a27976df71d"
      unitRef="usdPerShare">8.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia1400e06e8cb4cce8e16afdae774fbd6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTgzOA_10928c0e-8716-4039-9725-3fd56c7458be"
      unitRef="usd">6200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i940161a675a84ecc928e4b88f8bfd110_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMTkzNw_103a4f46-6c02-407b-8bd9-f9b275339b31">P3Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RleHRyZWdpb246ZTllN2I0MWYyMzg2NDRiZTk5OTU4ZWZiYTYyMmJjOGZfMjk2Nw_4319a48a-0382-4016-b8a5-0d8a7ce22d21">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statements of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Costs of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic458c78631fa444ea666b52d5645ae1d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjAxMTQxYjdlMjFiOTQ5YTU5ZjA2NDlhZjcyMzczOTc4L3RhYmxlcmFuZ2U6MDExNDFiN2UyMWI5NDlhNTlmMDY0OWFmNzIzNzM5NzhfMi0yLTEtMS02MjQ1NQ_b0d3c9a5-6c8d-47a0-9124-24905315717d"
      unitRef="usd">53000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic58dee38f10d467fbc953d0b8e7713b1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjAxMTQxYjdlMjFiOTQ5YTU5ZjA2NDlhZjcyMzczOTc4L3RhYmxlcmFuZ2U6MDExNDFiN2UyMWI5NDlhNTlmMDY0OWFmNzIzNzM5NzhfMi00LTEtMS02MjQ1NQ_8d894c99-594b-4f96-8bc7-30d5cc1cdddc"
      unitRef="usd">44000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i23da898f496444b2a82b5eefd3e7d4f2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjAxMTQxYjdlMjFiOTQ5YTU5ZjA2NDlhZjcyMzczOTc4L3RhYmxlcmFuZ2U6MDExNDFiN2UyMWI5NDlhNTlmMDY0OWFmNzIzNzM5NzhfMy0yLTEtMS02MjQ1NQ_ec21bb91-aba4-444c-8484-b980c1698fde"
      unitRef="usd">831000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7f1e21f8e6db4d83b4cb8e0ef40e4ebe_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjAxMTQxYjdlMjFiOTQ5YTU5ZjA2NDlhZjcyMzczOTc4L3RhYmxlcmFuZ2U6MDExNDFiN2UyMWI5NDlhNTlmMDY0OWFmNzIzNzM5NzhfMy00LTEtMS02MjQ1NQ_7c2ae6c4-0cd4-422b-895f-787f5e4c7570"
      unitRef="usd">1118000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie60dda0bce3a4221b4328da9ade954c1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjAxMTQxYjdlMjFiOTQ5YTU5ZjA2NDlhZjcyMzczOTc4L3RhYmxlcmFuZ2U6MDExNDFiN2UyMWI5NDlhNTlmMDY0OWFmNzIzNzM5NzhfNC0yLTEtMS02MjQ1NQ_da6f9325-813f-46aa-a4f5-4848be15d947"
      unitRef="usd">102000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5e8041ed528a46088f0c79a375de1fae_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjAxMTQxYjdlMjFiOTQ5YTU5ZjA2NDlhZjcyMzczOTc4L3RhYmxlcmFuZ2U6MDExNDFiN2UyMWI5NDlhNTlmMDY0OWFmNzIzNzM5NzhfNC00LTEtMS02MjQ1NQ_eb6c9e11-b407-4de0-a5d8-9d253ed00b79"
      unitRef="usd">214000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjAxMTQxYjdlMjFiOTQ5YTU5ZjA2NDlhZjcyMzczOTc4L3RhYmxlcmFuZ2U6MDExNDFiN2UyMWI5NDlhNTlmMDY0OWFmNzIzNzM5NzhfNS0yLTEtMS02MjQ1NQ_4727bcd0-c6f4-4097-9ff8-404d5f0173ea"
      unitRef="usd">986000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idfa8c47f957f488c8fcdf6e9a888e9ea_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF81OC9mcmFnOmU5ZTdiNDFmMjM4NjQ0YmU5OTk1OGVmYmE2MjJiYzhmL3RhYmxlOjAxMTQxYjdlMjFiOTQ5YTU5ZjA2NDlhZjcyMzczOTc4L3RhYmxlcmFuZ2U6MDExNDFiN2UyMWI5NDlhNTlmMDY0OWFmNzIzNzM5NzhfNS00LTEtMS02MjQ1NQ_9660ebc1-f0fd-4333-bdab-585dbf17bfa2"
      unitRef="usd">1376000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF82MS9mcmFnOmYyMjkzOGFiNjRkNjQ3NDM4NmYzZGY1OGM3ZGY0MmY4L3RleHRyZWdpb246ZjIyOTM4YWI2NGQ2NDc0Mzg2ZjNkZjU4YzdkZjQyZjhfMjIx_0ca4df6d-3d56-4492-982d-eef66d4d623b">Subsequent Events&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 28, 2023, the Company and Innovatus entered into the Third Loan Amendment.  Pursuant to the Third Loan Amendment, the Company prepaid $10.0&#160;million of principal (Prepayment) and amended the 2017 Term Loan by, among other things:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt"&gt;waiving the Prepayment Fee (as defined in the 2017 Term Loan, as amended) with respect to the Prepayment;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt"&gt;revising the interest rate to the sum (the Basic Rate) of (a) the greater of The Wall Street Journal prime rate (the Prime Rate) or 8.0%, plus (b) 2.0%, of which 1.5% will be payable in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until April 1, 2026;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt"&gt;extending the interest-only period through March 2026 and the maturity date to December 31, 2026;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt"&gt;decreasing the specified levels of revenue, as measured on the last day of each quarter on a rolling twelve-month basis, that the Company must achieve to satisfy the related financial covenants (the Revenue Covenant) in the 2017 Term Loan;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt"&gt;removing the obligation to comply with the Revenue Covenant during any fiscal quarter if the Company maintains a minimum aggregate cash balance equal to fifty percent of the aggregate principal amount of the loan at all times during such quarter;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt"&gt;providing the Company with a cure period in the event it breaches certain covenants; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt"&gt;revising the definition of &#x201c;Permitted Indebtedness&#x201d; to permit the Company to broaden the limits on the Company&#x2019;s ability to incur capitalized lease obligations, finance lease obligations, purchase money indebtedness or equipment financings without Innovatus&#x2019;s prior written consent.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i0587f1e7aef2471cb273055cd67d1cb1_D20230428-20230428"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF82MS9mcmFnOmYyMjkzOGFiNjRkNjQ3NDM4NmYzZGY1OGM3ZGY0MmY4L3RleHRyZWdpb246ZjIyOTM4YWI2NGQ2NDc0Mzg2ZjNkZjU4YzdkZjQyZjhfMzg0ODI5MDY5OTcyOA_f94e28ad-d083-48ad-9423-97d444fd49d6"
      unitRef="usd">10000000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib55a36a6d42741f28786ba980d9e68d7_D20230428-20230428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF82MS9mcmFnOmYyMjkzOGFiNjRkNjQ3NDM4NmYzZGY1OGM3ZGY0MmY4L3RleHRyZWdpb246ZjIyOTM4YWI2NGQ2NDc0Mzg2ZjNkZjU4YzdkZjQyZjhfMzg0ODI5MDY5OTc0Mw_08ebea45-64fd-4942-b53f-7a0535065814"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7e4dbcbbf1954393ba5599909a82c6ed_I20230428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF82MS9mcmFnOmYyMjkzOGFiNjRkNjQ3NDM4NmYzZGY1OGM3ZGY0MmY4L3RleHRyZWdpb246ZjIyOTM4YWI2NGQ2NDc0Mzg2ZjNkZjU4YzdkZjQyZjhfMzg0ODI5MDY5OTc0OQ_8118eb80-1f0b-4ce6-8309-3dce5910d0de"
      unitRef="number">0.020</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <exdx:DebtInstrumentStatedInterestRatePaidInKind
      contextRef="i7e4dbcbbf1954393ba5599909a82c6ed_I20230428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM2YTVlN2IwZWRjOTRjMzk5NTQ5ZmU4ZjgwZTk0NTY4L3NlYzpjNmE1ZTdiMGVkYzk0YzM5OTU0OWZlOGY4MGU5NDU2OF82MS9mcmFnOmYyMjkzOGFiNjRkNjQ3NDM4NmYzZGY1OGM3ZGY0MmY4L3RleHRyZWdpb246ZjIyOTM4YWI2NGQ2NDc0Mzg2ZjNkZjU4YzdkZjQyZjhfMzg0ODI5MDY5OTc1NQ_78a72369-0756-412b-9f45-74997589441b"
      unitRef="number">0.015</exdx:DebtInstrumentStatedInterestRatePaidInKind>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M5^LK$<K598,V=A<>@ME<FPNM_L6"S\1$Z#\68P5GK=S%#R(1)X&,B1+3R\:
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M$ZF3(W6J(7U*N=)"A6OR(!92:1L>;J55:JN4(:JJB=?-\;K5\,9"!=(W@Y#
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M*/, W)]*J7<GY@?RS?G^OU!+ P04    "  "BJ]6/(EVQL(%  #Y%P  &
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;+58;7/;-@S^*SROM[5W3BQ2[ZGC
MN\:YWO:A7:YIM\^T1,>\2J)+4DFS7S]0=B1;I!2WRSXDU@L /0!!/ #G#T)^
M51O&-/I>%I6ZG&RTWE[,9BK;L)*J<[%E%;Q9"UE2#;?R;J:VDM&\42J+&?&\
M:%927DT6\^;9C5S,1:T+7K$;B51=EE0^7K%"/%Q.\.3IP2=^M]'FP6PQW]([
M=LOTE^V-A+M9:R7G):L4%Q62;'TY>8<OEB0Q"HW$7YP]J(-K9%Q9"?'5W/R1
M7TX\@X@5+-/&!(6?>[9D16$L 8YO>Z.3]IM&\?#ZR?K[QGEP9D456XKB;Y[K
MS>4DF:"<K6E=Z$_BX7>V=R@T]C)1J.8_>MC+>A.4U4J+<J\,"$I>[7[I]WT@
M#A1P,*! ]@KD5 5_K^ WCNZ0-6Y=4TT7<RD>D#328,U<-+%IM,$;7IEEO-42
MWG+0TXLO%:USKEF.EJ+*87G@ZHH6M,H8NC56%3I#7VZOT>M7;] KQ"OT>2-J
M1:M<S6<: !@SLVS_L:O=Q\C QSY0>8Y\/$7$([Y#?3FN?LVR5IT<J\_ [=9W
MTOI.&GO^@+UE+26K-*)*@9\7+G]V!@*W ;/%+M269NQR GM(,7G/)HM??\&1
M]];EW0L9._+5;WWUQZPOEE1M$*P:RLP%^U;S>UJ \\Y5W)F*&E.F#MPO0H*3
M8#Z[/W3'EHJ(G^)6Z@AGT.(,1G&^RS)1 RPH$1D#C*N"35'%M OFSE)X "#U
M/;^'TA:*O#AV@PQ;D.$HR!O)MI3GB'W?FAVCFL *O6$2MNQA3KE0AQ:@@)"T
MA]HAA /?C3IJ44>CJ#\+38L3 $9VQ,(81SV$ME1,(CRP^G$+,7XFL,!/4C\V
M 35)N@7&T(,)$%L8$A+UT]0AA-.!!$A:G,DHSC\!)=6\ND,% PY!TI#%F5B?
MU7 S'-G$7M4HQ#V\#J$D"=UXTQ9O.HZWR<UA8*ECD_0WDBT3DL0-"WL=^W@G
MY.0PL+WZ49JEQ.^OL4,LB0@9R$9\0([X)(8H.%WQ@FO.W#2Q-_-"//%2UHZ=
M[E@1CQ)15X*W]-'47Z?#Q HX3N*DORRVE.\%T<"J=%2&Q[D, ,H:^A2[ZAZL
MDQ.U[\ASJV XI$(_&*@8N",V/,YL_9KQ'%:;N+ 7DSY6EU3@#6#M^ V/$]R5
MD* #6-794VBW0IJ^VPG59BL26E&UA7 Z!+2C-/PCG/9<2&W.2DED):U#*B(#
MW(L[9L/CU'80TDI4_; V%(?$&N5<[7>?R>Z<K33B2M5-/YX)-5 E;8XCJ9=:
MR>(02^)XJ(AW9(C'V?#C@3_B![/<P78$]RG1)16D0TO2D2(^A14/5^,YM#8'
M0M/3!VL+)=% ]2 =49)3B/(9?,2FP< G!\W.?@YQB<71 %N2CBW)*#$MEJ(L
MN38=VRY[,U&93&!5!GC1ZX]",Q2^<0+_"<9#SA'KOQLZ=OY@EAP?)F^UR+YN
M1)$SJ7YK>E?]Z!XI7W:F_#^&2M)1,1FG8IB$U@SV3HZ4\7^*7GGGGH>A=9 (
M!LR:O478FWI>\X?4ADHS+=5Z(R3_A^50]L334U/FP(Z02-1::4@@4T6H,E7Q
M Y799@?[Z?B@R;!K&!++%6QB]ZG /N VGWO]'3$F<AR:CN_).-^;W2"JX;@0
M;R0P/^HWA#F:)B2>>CAH). V#-)IF@2]^#9-T\\'> J#N=JRYO"M>'2&V]&2
M6!5H5.8XX%W30L:;EG=YS@V70ITTT_D9KU!&MQSJIA.FHVE)4^R'?:@NN3B-
MA_*C:UW(>.L"76Q=U@4U9V\Y6_.,.V=<8K<C9R3R";: N@3#,"1#@>U:%S+>
MNNRX1SD*G!.PW67X8>I;*6"+!22(AL+:-2-DO!FQB++)XY/!)]:AEFO>=(BY
MYLW9P;FL.12'77;'*P6MT1KTO/,8O)>[<^;=C1;;YJAV);0697.Y811 &P%X
MOQ; H?L;<_K;GO8O_@502P,$%     @  HJO5NJ_.C;A @  M H  !@   !X
M;"]W;W)K<VAE971S+W-H965T,RYX;6RM5EUOVR 4_2O(FZ96VN*/?'>)I375
MM#U,BAIU>Z;V38R*P0.<=/OUNV#7BUOGXR%YB '?<S@'N/C.=E(]Z0S D.><
M"SWW,F.*&]_7208YU3U9@, W:ZER:K"K-KXN%-#4@7+N1T$P\G/*A!?/W-A2
MQ3-9&LX$+!7199Y3]><6N-S-O=![&;AGF\S8 3^>%70#*S /Q5)ASV]84I:#
MT$P*HF ]][Z$-XO0 5S$3P8[O=<FULJCE$^V\SV=>X%5!!P28RDH/K:P ,XM
M$^KX79-ZS9P6N-]^8?_JS*.91ZIA(?DOEIIL[DT\DL*:EMS<R]TWJ T-+5\B
MN7;_9%?%C@8>24IM9%Z#44'.1/6DS_5"[ '"0X"H!D3G OHUH.^,5LJ<K3MJ
M:#Q3<D>4C48VVW!KX]#HA@F[C2NC\"U#G(D?!"U39B E"RE2W!YLW5).10)D
M95DUN5I2!<)D8%A"^37Y1-X3G^@,1_7,-RC"4OE)/>%M-6%T8,(?5/5(/_Q(
MHB#J=\ 7Q^%WD#3PJ WWT7KC/VK\1XZO?X!OB:<&E$+7N-3)4Y>?BF#036#3
M[$87-(&YAWFD06W!BS^\"T?!YRYW%R)K>>TW7OO'V&/<1[*EO 1RQ01))>=4
M:5* JC;SNLM\Q3AVC/9*V,9!+PC"F;_==W4JJB5WT,@=')6[<B>,T-)D4K&_
MN$56=G7N.K56=,,]%6%0_5[)/2.PI7C8*!Z>HQAO2VVH2)G8G)(\?*/DM=9C
M$2V1HT;DZ!R13.OR])*.3NH[%M'2-V[TC8]FY$+F.=[O!]-Q?,ETO!!9R^BD
M,3JY>#I.SDK'4U$MN=-&[O2RZ3A]<S*BH#L?SXEL:0Z#_Y^WX'*GO>9J70RC
M230.PL$KQ9V1P\%T.AD<4+SW00XO?(G4A.?([HKLE.WOE12VGL//]H8)33BL
M$1KTQLBAJA*IZAA9N"KC41JL65PSP[(2E W ]VLIS4O'%BY-H1K_ U!+ P04
M    "  "BJ]6E+QDW"D$   J#P  &    'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;*V7;6_;-A#'OPJA%4,+))$H64^9;2!Q5RS V@9)L[X8]H*V:%NH1&HD
M96???D?*EA6+TC(@;VP]W!U_?Q[%XTWW7/R06TH5>BX+)F?.5JGJVG7E:DM+
M(J]X11F\67-1$@6W8N/*2E"2&:>R<'W/B]R2Y,R93\VS>S&?\EH5.:/W LFZ
M+(GXYY86?#]SL'-\\)!OMDH_<.?3BFSH(U5/U;V .[>-DN4E93+G# FZGCDW
M^'J!8^U@+/[(Z5YVKI&6LN3\A[ZYRV:.IXEH05=*AR#PMZ,+6A0Z$G#\?0CJ
MM&-JQ^[U,?HG(Q[$+(FD"UY\SS.UG3F)@S*Z)G6A'OC^-WH0%.IX*UY(\XOV
M!UO/0:M:*EX>G(&@S%GS3YX/$]%Q@#AV!__@X)\[3 8<@H-#8(0V9$;61Z+(
M?"KX'@EM#='TA9D;XPUJ<J;3^*@$O,W!3\V?&*FS7-$,+3C+(#UP]:B(HI J
M)1%?HZ\5%41/N427Z.GQ(WK_[@-ZAW*&OFUY+0G+Y-15@*(#NJO#L+?-L/[
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M<]X'F8FZ'(N#CL5!+:IW!O4]><RK*J\>Q;E0X"HEX+4@FVUP3=@-P%R$2M\
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MQ??/9ID1XTNP?;K+%C;@9IP>6_P4(<<&^%Y;&\87#C#]N-G^"U!+ P04
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M&$#?X_5S_@\L$-Y_^O7_ E!+ P04    "  "BJ]6OHG7B&<$  #&"@  &
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MUZDLI:&^Q_UNJ-%$90GH?"6EV2^L@*%U7?P+4$L#!!0    (  **KU9YWD:
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M<VAE970Q,2YX;6RE6-MRVS80_16,FK;VC*J;[21-;,_83C-QITDS3MH^=/H
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MLVOA6!K:^"*Z&D\#G#(<E'?!X:W"N7!^9>M:!; <A#2%N+(F*%.2R17YTVF
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M#?BXCI<5(<Z.!?!^:6WH;]C \/^1\W\!4$L#!!0    (  **KU:U58(RP00
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MAM,YFX:+&5Z2^<SU.HH$T .=5+@! %E&K?#K!'7A&;379P+FT22831+//H_
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MP"D2E=6*TI'H/:YSNHFZE6.37% ;E9(0'-0@H?3/4,+_8NI(QT="%&L2;2$
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M13=>=/-!TB8#6)J"KKX/BGS-+>Q]+-])NCC!X '(SZW;6KFRI)VHZI0;ZS1
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M9^K\YP\OY_3-Q<%=DI'Y,B-99M&.+,"#-L:MB.\5+(+NDX?R<:JP^)TM 3&
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M>C;Q0'6MLYL8V;AVM96&FI\;EO2W064-:'\GI3E,;(#A_[7Z#U!+ P04
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MX+W,,?_5/R1V/<6DH[A(#@)>,GT":3R )$K2 WAIGW+J\=(_IWS.32:4R]K
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M1OW1( #=%M VL*KV16NE+)5 WRSIGX/:3:#QM5)V'[@%NK_8_!]02P,$%
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MH""- .YOA-#[B3$P-+7SOP%02P,$%     @  HJO5J!!$QZ* @  !@<  !D
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M&LC["TK%]D1UD'](,OX?4$L#!!0    (  **KU;GG6@Y;0,  -T/   9
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M^HMX^IT6-S2VO$2DROU'3\6U@QY*<J5%5@2;'&2,'W[)CZ(@:@'#T1L!N C
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MR9KR/$!]OF%,/I_D3S+43ZZL_@-02P,$%     @  HJO5L$I7__, @  F @
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MT#VJ=8]:O_M,JQ0@0[+42A"DW!>XK^PFW179<*_N!J^%5ZEI]?=6->'>Y2]
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MAA%VA2"T 3Y?<JZ>)GJ#LL^<_ 502P,$%     @  HJO5@TUWP[" P  \Q(
M !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULM9AK;Z,X%(;_BL6,1C-2
M)UQR:=I)(K5A1ENI747-7#ZLYH,#)XE5L!G;)*VT/WYM("14U J2]TN"C=_7
MYSR .7BR9_Q); $D>DX3*J;.5LKLVG5%M(44BQ[+@*HS:\93+%63;UR1<<!Q
M(4H3-_"\D9MB0IW9I.A;\-F$Y3(A%!8<B3Q-,7^YA83MIX[O'#H>R68K=8<[
MFV1X TN0/[(%5RVW=HE)"E001A&']=2Y\:]#?Z %Q8B?!/;BY!CI5%:,/>G&
M73QU/!T1)!!);8'5WP[FD"3:2<7QIS)UZCFU\/3XX/ZM2%XEL\("YBSY16*Y
MG3IC!\6PQGDB']G^+Z@2&FJ_B"6B^$7[:JSGH"@7DJ656$60$EK^X^<*Q(E
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M"  "BJ]69/SC"[,#  #Z'   #P   'AL+W=O<FMB;V]K+GAM;,692U/;,!"
M_XK&E])#F_A!> SI# 1HF6E+AE"N'<7>)!ID*95D*/SZ2G93-A!V>A$Y)98<
MY?,FWD^[/KK7YG:J]2W[74MEA\G"N>5AKV?+!=3<?M1+4'YFIDW-G3\T\YY=
M&N"570"X6O:R?G_0J[E0R:>CU5ICT\,'VD'IA%9^, S<"+BW3_/AD-T)*Z9"
M"O<P3-KW$A)6"R5J\0C5,.DGS"[T_1=MQ*-6CLM):;24PR3M)F[ .%&^&)X$
MR&L^M>V(X],K[D&&R:#O%YP)8UU[1KL^]XQWX$_NCAJGSX5T8$ZY@\]&-TNA
MYF$9?Q4]=!EM'%:O71 /S?^$4<]FHH13738U*-?%T8 ,@,HNQ-(F3/$:ALE(
MWX$)U^._X*+JKLUY*!0I<RC\A+FH6KQX*#\4;RKAH&(CK2I0UK\[X9*K$IB/
M)(+,",ALBY _,P29$Y#YVT-. DOXG&4(LB @BRU"KD5REX#<W29DCB '!.0@
M+N2EF7,E'ML)1+1'$.W%)9HT=<W- ],S-A%S)?S'N'+LN"QUHYQ D/L$Y'[D
ML+D%&'8NE+]Y!9?L0G7+K$?Q@  \B MXHHW1]]X,%B?H/I6A^W&)1KJNA0LG
M,:[:>\)Y//#Q@S5&TB*1-7+.A6$W7#; O@&WC>FR'L:C_)%&%LC$Z?)VH64%
MQKYC9[\:ORW!;)0VTLC>:-G8Y3),L+&7&@:C5)%&=L6DF5KXU83_W=G=\U^3
MTD,:V0]DHEN36$H)(HUL"!H3:RREK)%&U@:1D=G.-<>8E#?2R.)XRLN!RG^W
M?8_1*&.DD97Q2O);<>(]-.61++)'-B7!3;',*)%DD47R(AMN)"1KD<@NP1L_
MMG,*C@NY3D?9)(MM$S+I%!B3<DL6W2T4YB[&I$R3;=4T XQ)F2;;JFGV,"9E
MFFR;!<K/?8Q)F2;;7HG"/K QQJ2LDT6V#HFYWA2AK)-'M@X=S>\8D_).'MD[
M-.8QQJ3DDT>6#]H%^>!Q8WAH<?[3$,8D6V&1+;2&>=XXOR5BWT+OMZG9F./2
M*Z<LE$>V$%59^YAB3,I">60+O;J_['YUC$E9*(]MH4W[RZ=_*<:D+)3'MM!F
MS(E?NFHD[GCGE(7RR!9ZN1%>N^$Q)F6A/+*%-F&B,=SUIBQ4O$7M\PSS"JPS
MH@Q]9HQ)6:AX\^KG;S0_G' +%<:D+%3$;J<][PQMK(,*RD!%:Z#>ZEE;!3.A
MH/KNE[=^O.2R'!L67KK>8;$;*OQ9(^7(CUVJKYI7JT=WJ\>.G_X 4$L#!!0
M   (  **KU;N2=W_G@$   @:   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'/-V;MNPD 0A>%707X EIE9;A%0I:&-> $+EHL V_)N%'C[6%# 02G2
MH#V5M6MY_!?6)\N>?853F0YU%?>')O8NYU,5Y\4^I>;#N;C>AW,9^W43JN[,
MMF[/9>J6[<XUY?I8[H+3P6#DVN<9Q6+V/+.WNC;A/Q/K[?:P#I_U^OL<JO3'
M8/=3M\>X#R$5O579[D*:%^YR>FQ'=SM(OYM<]):;>=$N-U*XW$$*09H_R"#(
M\@=Y"/+Y@X80-,P?-(*@4?Z@,02-\P=-(&B2/V@*0=/\03) &0<$22]8$V@M
MR+40>"T(MA"(+4BV$)@MB+80J"W(MA"X+0BW$,@M2+<0V"V(MQ#HK:BW$NBM
MJ+<2Z*TO+]L$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z
M&^IM!'H;ZFT$>AOJ;01ZV\O'$@*]#?4V KT-]38"O0WU-@*]#?4V KT-]38"
MO0WU-@*]/>KM"?3VJ+<GT-NCWIY ;X]Z^W?J'=/U%.*CY[[&^[^3ZM1=&QZW
MORWOFR^/R@UG!S]^%K]02P,$%     @  HJO5JC*A]FK 0  01H  !,   !;
M0V]N=&5N=%]4>7!E<UTN>&ULS9G-;L(P$(1?!>6*B+&=TA\!E[;7ED-?P$TV
M)"*)+=M0>/LZX4=J1:,B*G4NL1+OSHR]TG?)]&UGR VV==6X651X;QX8<VE!
MM7*Q-M2$G5S;6OGP:I?,J'2EEL3$>#QAJ6X\-7[D6XUH/GVB7*TK/WC>AL^N
MU,TLLE2Y:/"X+VR]9I$RIBI3Y<,^VS39-Y?1P2$.G5V-*TKCAJ$@8F<=VIV?
M#0Y]KQNRMLQHL%#6OZ@Z5+%MQ9S?5>3B?HDS&76>EREE.EW7H25VQI+*7$'D
MZRK>BP[[G7VX8=H_^=7^G4R?8:A<6&U<F)BER^V.(VF[1R8(D?5E_Q%/CD'Z
MZO-1.^V,LE]ZA^O]T';5S<.Q;KG^CK_.^*1_80X!DD."Y$A <MR Y)B Y+@%
MR7$'DN,>) <?HP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M
M(:M (:M (:M (:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$
M(:M$(:M$(6N"0M8$A:P)"EF3_R3KN]:KO_ZIT:YQK<KFZ,^Z/T?S3U!+ 0(4
M Q0    (  **KU8'04UB@0   +$    0              "  0    !D;V-0
M<F]P<R]A<' N>&UL4$L! A0#%     @  HJO5MO$$:3N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @  HJO
M5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    "  "BJ]6D8)$IMT%  "H'P  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @  HJO
M5CR)=L;"!0  ^1<  !@              ("!( X  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    (  **KU;JOSHVX0(  +0*   8
M      " @1@4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M"  "BJ]6E+QDW"D$   J#P  &               @($O%P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @  HJO5L:M4<+O!0  1B4  !@
M             ("!CAL  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    (  **KU;65QCK$ <  $(?   8              " @;,A  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  "BJ]6);L'K;@%  #H
M#   &               @('Y*   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @  HJO5O]"\X3C'   "U4  !@              ("!YRX
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (  **KU:^B=>(
M9P0  ,8*   8              " @0!,  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    "  "BJ]6>=Y&@)4*  !=&P  &0
M@(&=4   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (  **
MKU:#2JO30@<  "L1   9              " @6E;  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @  HJO5K55@C+!!   60P  !D
M         ("!XF(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    "  "BJ]6U^0*S]@#  !B"0  &0              @(':9P  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  **KU;229,% 0@  !@6
M   9              " @>EK  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @  HJO5G[SXLCR!   +0L  !D              ("!(70
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  "BJ]6NR,M
M>NP5  !900  &0              @(%*>0  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    (  **KU;J+G0,1@4  $8.   9
M  " @6V/  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M HJO5IJ)1N!/!   $0L  !D              ("!ZI0  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    "  "BJ]6U1C!%!T#  #+!@  &0
M            @(%PF0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    (  **KU;]*\VC'0,  -0'   9              " @<2<  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @  HJO5KM9?Z#W @
MT08  !D              ("!&*   'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    "  "BJ]6T412?',$  #@"@  &0              @(%&
MHP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (  **KU:@
M01,>B@(   8'   9              " @?"G  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @  HJO5ILL;IK> P  XA8  !D
M     ("!L:H  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  **KU9MMJ_:QP(  /T'   9              "
M@2"_  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @  HJO
M5@%,_$7[ P  !Q0  !D              ("!'L(  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    "  "BJ]6@Y4Y#UL"  #'!0  &0
M        @(%0Q@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   (  **KU:=Y:WV6 ,  )T*   9              " @>+(  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @  HJO5F3<V3EV!@  LS$
M !D              ("!<<P  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    "  "BJ]6>-%F;5@#   X#   &0              @($>TP
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (  **KU9):V(W
M4@4  (4H   9              " @:W6  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @  HJO5LU5PU2G!   Q2(  !D
M ("!-MP  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  "
MBJ]6P2E?_\P"  "8"   &0              @($4X0  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (  **KU8@W[XI!@0  -05   9
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M970T,BYX;6Q02P$"% ,4    "  "BJ]6#37?#L(#  #S$@  &0
M    @(& _   >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M  **KU94%E6O1P,  ,H4   -              "  7D  0!X;"]S='EL97,N
M>&UL4$L! A0#%     @  HJO5I>*NQS     $P(   L              ( !
MZP,! %]R96QS+RYR96QS4$L! A0#%     @  HJO5F3\XPNS P  ^AP   \
M             ( !U 0! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  **
MKU;N2=W_G@$   @:   :              "  ;0( 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  **KU:HRH?9JP$  $$:   3
M          "  8H* 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     S #,
*W T  &8, 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>136</ContextCount>
  <ElementCount>247</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Unaudited Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedBalanceSheets</Role>
      <ShortName>Unaudited Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Unaudited Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical</Role>
      <ShortName>Unaudited Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Unaudited Condensed Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedStatementsofOperations</Role>
      <ShortName>Unaudited Condensed Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Unaudited Condensed Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity</Role>
      <ShortName>Unaudited Condensed Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Unaudited Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows</Role>
      <ShortName>Unaudited Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Stock Option Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlan</Role>
      <ShortName>Stock Option Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Other Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/OtherFinancialInformation</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Borrowings</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/FairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockholdersEquity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Stock Option Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanTables</Role>
      <ShortName>Stock Option Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockOptionPlan</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Organization</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Other Financial Information - Prepaid Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails</Role>
      <ShortName>Other Financial Information - Prepaid Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Other Financial Information - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails</Role>
      <ShortName>Other Financial Information - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Other Financial Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails</Role>
      <ShortName>Other Financial Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Other Financial Information - Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Financial Information - Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Borrowings - Future Minimum Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails</Role>
      <ShortName>Borrowings - Future Minimum Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Commitment and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesDetails</Role>
      <ShortName>Commitment and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/CommitmentandContingencies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Stockholders' Equity - Schedule of Outstanding Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Outstanding Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Stock Option Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanNarrativeDetails</Role>
      <ShortName>Stock Option Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails</Role>
      <ShortName>Stock Option Plan - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails</Role>
      <ShortName>Stock Option Plan - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Option Plan - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exdx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SubsequentEvents</ParentRole>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="exdx-20230331.htm">exdx-20230331.htm</File>
    <File>exdx-20230331.xsd</File>
    <File>exdx-20230331_cal.xml</File>
    <File>exdx-20230331_def.xml</File>
    <File>exdx-20230331_lab.xml</File>
    <File>exdx-20230331_pre.xml</File>
    <File>xgn311-33123.htm</File>
    <File>xgn312-33123.htm</File>
    <File>xgn321-33123.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="430">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exdx-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 430,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 136,
   "dts": {
    "calculationLink": {
     "local": [
      "exdx-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exdx-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "exdx-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exdx-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exdx-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "exdx-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 413,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 27,
   "keyStandard": 220,
   "memberCustom": 25,
   "memberStandard": 34,
   "nsprefix": "exdx",
   "nsuri": "http://www.exagen.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.exagen.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Borrowings",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.exagen.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Commitment and Contingencies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.exagen.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.exagen.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.exagen.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Stock Option Plan",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.exagen.com/role/StockOptionPlan",
     "shortName": "Stock Option Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.exagen.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "16",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Other Financial Information (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.exagen.com/role/OtherFinancialInformationTables",
     "shortName": "Other Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Borrowings (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.exagen.com/role/BorrowingsTables",
     "shortName": "Borrowings (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Unaudited Condensed Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.exagen.com/role/UnauditedCondensedBalanceSheets",
     "shortName": "Unaudited Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.exagen.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.exagen.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Stock Option Plan (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.exagen.com/role/StockOptionPlanTables",
     "shortName": "Stock Option Plan (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Organization (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.exagen.com/role/OrganizationDetails",
     "shortName": "Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "icde0546e33bc4e4dbdee35365b9dbeec_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue by Major Payers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "icde0546e33bc4e4dbdee35365b9dbeec_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
     "shortName": "Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "iae6ce9aaec2a446c9c116ff73b70f8b3_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Other Financial Information - Prepaid Expenses (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails",
     "shortName": "Other Financial Information - Prepaid Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Unaudited Condensed Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical",
     "shortName": "Unaudited Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Other Financial Information - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails",
     "shortName": "Other Financial Information - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Other Financial Information - Narrative (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
     "shortName": "Other Financial Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Other Financial Information - Accrued and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails",
     "shortName": "Other Financial Information - Accrued and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i94ecd2ce87e1410596492d2b66fe3d3d_D20170901-20170930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Borrowings - Narrative (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.exagen.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ibb33abf78bcd4170a8b0655f9f35138a_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Borrowings - Future Minimum Payments (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails",
     "shortName": "Borrowings - Future Minimum Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i140c8595c10a41eeb48e5be8f884c4cb_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Commitment and Contingencies (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.exagen.com/role/CommitmentandContingenciesDetails",
     "shortName": "Commitment and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i140c8595c10a41eeb48e5be8f884c4cb_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "id41f690f8baf4faba442062c5cd09d97_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Fair Value Measurements (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.exagen.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "id41f690f8baf4faba442062c5cd09d97_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Stockholders' Equity - Schedule of Outstanding Warrants (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails",
     "shortName": "Stockholders' Equity - Schedule of Outstanding Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7dbf9a0fcf934366948459c15f4770d1_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic10d09e997d04be59819eb9f739c540e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Stock Option Plan - Narrative (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
     "shortName": "Stock Option Plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic10d09e997d04be59819eb9f739c540e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Unaudited Condensed Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations",
     "shortName": "Unaudited Condensed Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i6cd5e724cdb246d89edfa68105eaed87_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Stock Option Plan - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
     "shortName": "Stock Option Plan - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ifc948c5716764b10b51b41de0e3069ff_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i385f1d93cdab453180c8c50401ec671d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
     "shortName": "Stock Option Plan - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i385f1d93cdab453180c8c50401ec671d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
     "shortName": "Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i94ecd2ce87e1410596492d2b66fe3d3d_D20170901-20170930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.exagen.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i7e4dbcbbf1954393ba5599909a82c6ed_I20230428",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i90a82a0082294a76aa4b428dfc020494_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Unaudited Condensed Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity",
     "shortName": "Unaudited Condensed Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "i90a82a0082294a76aa4b428dfc020494_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Unaudited Condensed Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows",
     "shortName": "Unaudited Condensed Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Organization",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.exagen.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Other Financial Information",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.exagen.com/role/OtherFinancialInformation",
     "shortName": "Other Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20230331.htm",
      "contextRef": "ic79a24b946674719a6cb1f6100a407d2_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 61,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exdx_AHNCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AHN Collaboration",
        "label": "AHN Collaboration [Member]",
        "terseLabel": "AHN Collaboration"
       }
      }
     },
     "localname": "AHNCollaborationMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_AVISECTDTestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVISE CTD Test",
        "label": "AVISE CTD Test [Member]",
        "terseLabel": "AVISE CTD Test"
       }
      }
     },
     "localname": "AVISECTDTestMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_AccruedLiabilitiesClinicalStudyCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities, Clinical Study, Current",
        "label": "Accrued Liabilities, Clinical Study, Current",
        "terseLabel": "Accrued clinical study activity"
       }
      }
     },
     "localname": "AccruedLiabilitiesClinicalStudyCurrent",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AccruedPurchaseGoodsAndServicesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Purchase, Goods and Services, Current",
        "label": "Accrued Purchase, Goods and Services, Current",
        "terseLabel": "Accrued purchases of goods and services"
       }
      }
     },
     "localname": "AccruedPurchaseGoodsAndServicesCurrent",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdvancePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance Payment",
        "label": "Advance Payment",
        "terseLabel": "Advance royalties payment"
       }
      }
     },
     "localname": "AdvancePayment",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AlleghenyHealthNetworkResearchInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allegheny Health Network Research Institute",
        "label": "Allegheny Health Network Research Institute [Member]",
        "terseLabel": "Allegheny Health Network Research Institute"
       }
      }
     },
     "localname": "AlleghenyHealthNetworkResearchInstituteMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_BlueShieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Blue Shield",
        "label": "Blue Shield [Member]",
        "terseLabel": "Blue Shield"
       }
      }
     },
     "localname": "BlueShieldMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ClientMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Client",
        "label": "Client [Member]",
        "terseLabel": "Client"
       }
      }
     },
     "localname": "ClientMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_CollaborationAgreementAnnualCollaborationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Annual Collaboration Fee",
        "label": "Collaboration Agreement, Annual Collaboration Fee",
        "terseLabel": "Collaboration fee"
       }
      }
     },
     "localname": "CollaborationAgreementAnnualCollaborationFee",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_CollaborationAgreementCollaborationExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Collaboration Expenses",
        "label": "Collaboration Agreement, Collaboration Expenses",
        "terseLabel": "Collaboration agreement, collaboration expenses"
       }
      }
     },
     "localname": "CollaborationAgreementCollaborationExpenses",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment and Software",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_CowenEquityDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cowen Equity Distribution Agreement",
        "label": "Cowen Equity Distribution Agreement [Member]",
        "terseLabel": "Cowen Equity Distribution Agreement"
       }
      }
     },
     "localname": "CowenEquityDistributionAgreementMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance",
        "label": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance",
        "terseLabel": "Term loan covenant, minimum unrestricted cash balance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)",
        "label": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)",
        "terseLabel": "Term loan covenant, increase to interest rate"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met",
        "label": "Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met",
        "terseLabel": "Term loan, covenant, number of days to cure covenant if performance measure is not met"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exdx_DebtInstrumentCovenantRevenuePerformancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Revenue Performance Period",
        "label": "Debt Instrument, Covenant, Revenue Performance Period",
        "terseLabel": "Term loan, covenant, revenue performance period"
       }
      }
     },
     "localname": "DebtInstrumentCovenantRevenuePerformancePeriod",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exdx_DebtInstrumentNumberOfMonthlyInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Monthly Installments",
        "label": "Debt Instrument, Number Of Monthly Installments",
        "terseLabel": "Number of monthly installments"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfMonthlyInstallments",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exdx_DebtInstrumentPaidInKindLoansIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Paid In Kind Loans Issued",
        "label": "Debt Instrument, Paid In Kind Loans Issued",
        "terseLabel": "Term loan, paid in-kind loans issued"
       }
      }
     },
     "localname": "DebtInstrumentPaidInKindLoansIssued",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentPrepaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Premium Percentage",
        "label": "Debt Instrument, Prepayment Premium Percentage",
        "terseLabel": "Term loan, prepayment premium percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentage",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Premium Percentage, Annual Reduction",
        "label": "Debt Instrument, Prepayment Premium Percentage, Annual Reduction",
        "terseLabel": "Term loan, annual reduction in prepayment penalty percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentageAnnualReduction",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentStatedInterestRatePaidInKind": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Stated Interest Rate, Paid In-Kind",
        "label": "Debt Instrument, Stated Interest Rate, Paid In-Kind",
        "terseLabel": "Term loan, paid in-kind, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentStatedInterestRatePaidInKind",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_EquipmentNotesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment Notes Payable",
        "label": "Equipment Notes Payable [Member]",
        "terseLabel": "Equipment Notes Payable"
       }
      }
     },
     "localname": "EquipmentNotesPayableMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_EquipmentPurchasedUnderNotesPayableObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment Purchased Under Notes Payable Obligations",
        "label": "Equipment Purchased Under Notes Payable Obligations",
        "terseLabel": "Equipment purchased under notes payable obligations"
       }
      }
     },
     "localname": "EquipmentPurchasedUnderNotesPayableObligations",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_ExpirationApr12026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Apr 1, 2026",
        "label": "Expiration Apr 1, 2026 [Member]",
        "terseLabel": "Warrant expiration April 1, 2026"
       }
      }
     },
     "localname": "ExpirationApr12026Member",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationDec72025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Dec 7, 2025",
        "label": "Expiration Dec 7, 2025 [Member]",
        "terseLabel": "Warrant expiration December 7, 2025"
       }
      }
     },
     "localname": "ExpirationDec72025Member",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationJan192026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Jan 19, 2026",
        "label": "Expiration Jan 19, 2026 [Member]",
        "terseLabel": "Warrant expiration January 19, 2026"
       }
      }
     },
     "localname": "ExpirationJan192026Member",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationMar312026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Mar 31, 2026",
        "label": "Expiration Mar 31, 2026 [Member]",
        "terseLabel": "Warrant expiration March 31, 2026"
       }
      }
     },
     "localname": "ExpirationMar312026Member",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationSep72024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Sep 7, 2024",
        "label": "Expiration Sep 7, 2024 [Member]",
        "terseLabel": "Warrant expiration September 7, 2024"
       }
      }
     },
     "localname": "ExpirationSep72024Member",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_Government1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government1",
        "label": "Government1 [Member]",
        "terseLabel": "Government"
       }
      }
     },
     "localname": "Government1Member",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_HealthcareInsurersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthcare Insurers",
        "label": "Healthcare Insurers [Member]",
        "terseLabel": "Commercial"
       }
      }
     },
     "localname": "HealthcareInsurersMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_IncentiveAwardPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Award Plan, 2019",
        "label": "Incentive Award Plan, 2019 [Member]",
        "terseLabel": "2019 Incentive Award Plan"
       }
      }
     },
     "localname": "IncentiveAwardPlan2019Member",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Prepaid Expense and Current Other Assets",
        "label": "Increase (Decrease) in Prepaid Expense and Current Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_InnovatusLifeSciencesLendingFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovatus Life Sciences Lending Fund",
        "label": "Innovatus Life Sciences Lending Fund [Member]",
        "terseLabel": "Innovatus Life Sciences Lending Fund"
       }
      }
     },
     "localname": "InnovatusLifeSciencesLendingFundMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares",
        "label": "Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares",
        "terseLabel": "Issuance of stock from vested restricted stock units and payment of employees' taxes (in shares)"
       }
      }
     },
     "localname": "IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Value",
        "label": "Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Value",
        "negatedTerseLabel": "Issuance of stock from vested restricted stock units"
       }
      }
     },
     "localname": "IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_LongTermDebtIncludingUndiscountedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Including Undiscounted Interest",
        "label": "Long-term Debt, Including Undiscounted Interest",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtIncludingUndiscountedInterest",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LongTermDebtUndiscountedInterestAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Undiscounted Interest Amount",
        "label": "Long-term Debt, Undiscounted Interest Amount",
        "negatedLabel": "Interest"
       }
      }
     },
     "localname": "LongTermDebtUndiscountedInterestAmount",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_MedicareAdvantageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Advantage",
        "label": "Medicare Advantage [Member]",
        "verboseLabel": "Medicare Advantage"
       }
      }
     },
     "localname": "MedicareAdvantageMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_NoExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No expiration",
        "label": "No expiration [Member]",
        "terseLabel": "No expiration"
       }
      }
     },
     "localname": "NoExpirationMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_NonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Lease Expense",
        "label": "Non-Cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NonCashLeaseExpense",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.exagen.com/20230331",
     "xbrltype": "stringItemType"
    },
    "exdx_OtherLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long Term Debt",
        "label": "Other Long Term Debt [Member]",
        "terseLabel": "Other Long Term Debt"
       }
      }
     },
     "localname": "OtherLongTermDebtMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities",
        "label": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]",
        "terseLabel": "Other Financial Information"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exdx_PrepaidMaintenanceAndInsuranceContracts": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Maintenance and Insurance Contracts",
        "label": "Prepaid Maintenance and Insurance Contracts",
        "terseLabel": "Prepaid maintenance and insurance contracts"
       }
      }
     },
     "localname": "PrepaidMaintenanceAndInsuranceContracts",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_PrometheusLaboratoriesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prometheus Laboratories, Inc.",
        "label": "Prometheus Laboratories, Inc. [Member]",
        "terseLabel": "Prometheus Laboratories"
       }
      }
     },
     "localname": "PrometheusLaboratoriesIncMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Obligation, Annual Increase In Commitment, Percentage",
        "label": "Purchase Obligation, Annual Increase In Commitment, Percentage",
        "terseLabel": "Annual increase in purchase commitments"
       }
      }
     },
     "localname": "PurchaseObligationAnnualIncreaseInCommitmentPercentage",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_RoyaltyObligationPercentageOfSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Obligation, Percentage of Sales",
        "label": "Royalty Obligation, Percentage of Sales",
        "terseLabel": "Royalty obligation, percent of net sales"
       }
      }
     },
     "localname": "RoyaltyObligationPercentageOfSales",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage",
        "terseLabel": "Shares authorized, percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised, Net",
        "label": "Stock Issued During Period, Shares, Warrants Exercised, Net",
        "terseLabel": "Exercise of common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercisedNet",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_Term2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term 2017",
        "label": "Term 2017 [Member]",
        "terseLabel": "2017 Term loan"
       }
      }
     },
     "localname": "Term2017Member",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_TwoMajorSuppliersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Major Suppliers",
        "label": "Two Major Suppliers [Member]",
        "terseLabel": "Two Major Suppliers"
       }
      }
     },
     "localname": "TwoMajorSuppliersMember",
     "nsuri": "http://www.exagen.com/20230331",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r156",
      "r157",
      "r252",
      "r281",
      "r482",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r209",
      "r500",
      "r556",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r307",
      "r453",
      "r461",
      "r477",
      "r478",
      "r497",
      "r508",
      "r513",
      "r555",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r307",
      "r453",
      "r461",
      "r477",
      "r478",
      "r497",
      "r508",
      "r513",
      "r555",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r209",
      "r500",
      "r556",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r207",
      "r454",
      "r498",
      "r512",
      "r550",
      "r551",
      "r556",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r207",
      "r454",
      "r498",
      "r512",
      "r550",
      "r551",
      "r556",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r300",
      "r307",
      "r337",
      "r338",
      "r339",
      "r429",
      "r453",
      "r461",
      "r477",
      "r478",
      "r497",
      "r508",
      "r513",
      "r547",
      "r555",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r300",
      "r307",
      "r337",
      "r338",
      "r339",
      "r429",
      "r453",
      "r461",
      "r477",
      "r478",
      "r497",
      "r508",
      "r513",
      "r547",
      "r555",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r156",
      "r157",
      "r252",
      "r281",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r10",
      "r511"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails",
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r14",
      "r481"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r14",
      "r481"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued\u00a0payroll\u00a0and\u00a0related\u00a0expenses"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r5",
      "r511"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r346",
      "r347",
      "r348",
      "r534",
      "r535",
      "r536",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r87",
      "r88",
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising and Marketing Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r271",
      "r404",
      "r495",
      "r496",
      "r528"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r104",
      "r115",
      "r133",
      "r155",
      "r192",
      "r201",
      "r205",
      "r216",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r360",
      "r362",
      "r385",
      "r511",
      "r553",
      "r554",
      "r593"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r129",
      "r139",
      "r155",
      "r216",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r360",
      "r362",
      "r385",
      "r511",
      "r553",
      "r554",
      "r593"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.exagen.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Costs incurred, but not paid, in connection with capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r37",
      "r131",
      "r479"
     ],
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds, included in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r32",
      "r37",
      "r42"
     ],
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r32",
      "r98"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of deposit, included in cash and cash equivalents"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r77",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Class of warrant or right, exercise price of warrants or rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants issued to purchase redeemable convertible preferred stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r20",
      "r108",
      "r120"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r60",
      "r233",
      "r234",
      "r476",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r534",
      "r535",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r4",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r4",
      "r511"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized as of March\u00a031, 2023 and December 31, 2022; 16,827,014 and 16,549,984 shares issued and outstanding as of March\u00a031, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r51",
      "r52",
      "r95",
      "r96",
      "r209",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r51",
      "r52",
      "r95",
      "r96",
      "r209",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r51",
      "r52",
      "r95",
      "r96",
      "r209",
      "r475",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r113",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risk and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r51",
      "r52",
      "r95",
      "r96",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenue"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r51",
      "r52",
      "r95",
      "r96",
      "r209",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r24",
      "r454"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Costs of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r25",
      "r155",
      "r216",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r385",
      "r553"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Costs of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Shipping and Handling Costs"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r49",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Refund liability"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r65",
      "r153",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r265",
      "r272",
      "r273",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r105",
      "r106",
      "r114",
      "r158",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r405",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r263",
      "r384",
      "r493",
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt instrument"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Term loan, fee incurred upon payment of final installment"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r16",
      "r100",
      "r278",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Term loan, effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r16",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Term loan, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r18",
      "r158",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r405",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r18",
      "r70",
      "r73",
      "r74",
      "r75",
      "r99",
      "r100",
      "r102",
      "r112",
      "r158",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r274",
      "r405",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r101",
      "r261",
      "r276",
      "r493",
      "r494"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r35",
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r298",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r311",
      "r342",
      "r343",
      "r345",
      "r350",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Option Plan"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r146",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r176",
      "r178",
      "r180",
      "r181",
      "r182",
      "r184",
      "r375",
      "r376",
      "r459",
      "r460",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r146",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r178",
      "r180",
      "r181",
      "r182",
      "r184",
      "r375",
      "r376",
      "r459",
      "r460",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock options, unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Stock options, cost not yet recognized, remaining weighted average vesting period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r69",
      "r125",
      "r142",
      "r143",
      "r144",
      "r159",
      "r160",
      "r161",
      "r164",
      "r172",
      "r174",
      "r185",
      "r220",
      "r296",
      "r346",
      "r347",
      "r348",
      "r355",
      "r356",
      "r374",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r419",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r263",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r379",
      "r426",
      "r427",
      "r428",
      "r493",
      "r494",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r381",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r263",
      "r301",
      "r306",
      "r379",
      "r426",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r263",
      "r301",
      "r306",
      "r379",
      "r427",
      "r493",
      "r494",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r263",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r379",
      "r428",
      "r493",
      "r494",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r263",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r426",
      "r427",
      "r428",
      "r493",
      "r494",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease obligations, current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r412",
      "r413"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Principal payments on finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r214",
      "r215",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r274",
      "r292",
      "r364",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r490",
      "r539",
      "r540",
      "r541",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture\u00a0and\u00a0fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r528"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Loss on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r527"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r527",
      "r592"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r527"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r101",
      "r110",
      "r145",
      "r190",
      "r403"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r148",
      "r150",
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r155",
      "r216",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r361",
      "r362",
      "r363",
      "r385",
      "r488",
      "r553",
      "r593",
      "r594"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r9",
      "r107",
      "r119",
      "r511",
      "r532",
      "r542",
      "r588"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r130",
      "r155",
      "r216",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r361",
      "r362",
      "r363",
      "r385",
      "r511",
      "r553",
      "r593",
      "r594"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r11",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r11",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r11"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loan payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r2",
      "r106",
      "r116",
      "r262",
      "r277",
      "r493",
      "r494"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total borrowings, net of discounts and debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedTerseLabel": "Less: Borrowings-current portion",
        "terseLabel": "Borrowings-current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails",
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r63",
      "r158",
      "r267"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "order": 4.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r63",
      "r158",
      "r267"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r63",
      "r158",
      "r267"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "order": 3.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2023 (remaining)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Borrowings-non-current portion, net of discounts and debt issuance costs",
        "verboseLabel": "Borrowings-non-current portion, net of discounts and debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails",
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Notes payable, noncurrent"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r18",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r61",
      "r62",
      "r235",
      "r236",
      "r237",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds, included in cash and cash equivalents"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r32",
      "r33",
      "r36"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r22",
      "r36",
      "r109",
      "r121",
      "r128",
      "r140",
      "r141",
      "r144",
      "r155",
      "r163",
      "r167",
      "r168",
      "r169",
      "r170",
      "r173",
      "r174",
      "r179",
      "r192",
      "r200",
      "r204",
      "r206",
      "r216",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r376",
      "r385",
      "r489",
      "r553"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncement, Early Adoption [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r44",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r169",
      "r175",
      "r184",
      "r212",
      "r213",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r346",
      "r347",
      "r348",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r401",
      "r402",
      "r406",
      "r407",
      "r408",
      "r409",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r455",
      "r456",
      "r457",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncement, Early Adoption [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements and Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r2",
      "r106",
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Notes payable, current"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r192",
      "r200",
      "r204",
      "r206",
      "r489"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r43",
      "r45",
      "r54",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r138",
      "r511"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Diagnostic\u00a0testing\u00a0supplies"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCustomerMember": {
     "auth_ref": [
      "r604",
      "r606",
      "r607",
      "r608",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer classified as other.",
        "label": "Other Customer [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r524",
      "r543"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentInKindPIKNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured.",
        "label": "Payment in Kind (PIK) Note [Member]",
        "terseLabel": "Paid in-kind note"
       }
      }
     },
     "localname": "PaymentInKindPIKNoteMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "terseLabel": "Payment for Debt Extinguishment or Debt Prepayment Cost"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Payments of taxes withheld on vested restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r3",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r3",
      "r511"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding as of March\u00a031, 2023 and December 31, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r525"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRoyalties": {
     "auth_ref": [
      "r480",
      "r491",
      "r543"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Royalties",
        "terseLabel": "Prepaid product royalties"
       }
      }
     },
     "localname": "PrepaidRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Term loan borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r86"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from common stock issued under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r545",
      "r590",
      "r591"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r546",
      "r591"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails",
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r523",
      "r544",
      "r589"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year One",
        "terseLabel": "Purchase obligation, due in year one"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Two",
        "terseLabel": "Purchase obligation, due in second year"
       }
      }
     },
     "localname": "PurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Principal payment on note payable obligations"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r89",
      "r122",
      "r601"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r522",
      "r529",
      "r602",
      "r603"
     ],
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r6",
      "r76",
      "r118",
      "r468",
      "r473",
      "r511"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r125",
      "r159",
      "r160",
      "r161",
      "r164",
      "r172",
      "r174",
      "r220",
      "r346",
      "r347",
      "r348",
      "r355",
      "r356",
      "r374",
      "r464",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r188",
      "r189",
      "r199",
      "r202",
      "r203",
      "r207",
      "r208",
      "r209",
      "r297",
      "r298",
      "r454"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the entity has committed to make for future royalty guarantees.",
        "label": "Royalty Guarantees, Commitments, Amount",
        "terseLabel": "Future minimum royalty commitment"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "verboseLabel": "Proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r209",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Non-cash Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r42",
      "r103",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r308",
      "r310",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r76",
      "r135",
      "r136",
      "r137",
      "r186",
      "r279",
      "r280",
      "r281",
      "r283",
      "r287",
      "r292",
      "r294",
      "r497",
      "r521",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/StockholdersEquityScheduleofOutstandingWarrantsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r77",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r48",
      "r51",
      "r52",
      "r53",
      "r95",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration of Risk, by Risk Factor and Significant Payer"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Awards canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awards canceled, Weighted-Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awards granted, Weighted-Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, March 31, 2023 (in shares)",
        "periodStartLabel": "Outstanding, December 31, 2022 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, March 31, 2023 (in dollars per share)",
        "periodStartLabel": "Outstanding, December\u00a031, 2022 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Awards released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awards released, Weighted-Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee payroll deduction percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares that remain available for future awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, March 31, 2023 (in shares)",
        "periodStartLabel": "Outstanding, December 31, 2022 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, March 31, 2023, Weighted Average Exercise Price (in dollars per share)",
        "periodStartLabel": "Outstanding, December 31, 2022, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options exercisable, March 31, 2022 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercised, March 31, 2022 (in shares), Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest, March 31, 2022 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, March 31, 2022 (in shares), Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r315",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by supplier.",
        "label": "Supplier [Axis]",
        "terseLabel": "Supplier [Axis]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.",
        "label": "Supplier [Domain]",
        "terseLabel": "Supplier [Domain]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Aggregate intrinsic value, vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock options, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShippingAndHandlingMember": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Packing and transport of product.",
        "label": "Shipping and Handling [Member]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r43",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r21",
      "r69",
      "r125",
      "r142",
      "r143",
      "r144",
      "r159",
      "r160",
      "r161",
      "r164",
      "r172",
      "r174",
      "r185",
      "r220",
      "r296",
      "r346",
      "r347",
      "r348",
      "r355",
      "r356",
      "r374",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r419",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r185",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r3",
      "r4",
      "r69",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "verboseLabel": "Issuance of stock under Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r3",
      "r4",
      "r69",
      "r76",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r3",
      "r4",
      "r69",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r69",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r4",
      "r7",
      "r8",
      "r55",
      "r511",
      "r532",
      "r542",
      "r588"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r78",
      "r154",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r296",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r400",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r400",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r400",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r400",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r420",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash items:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]",
        "terseLabel": "Supplier Concentration Risk"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r214",
      "r215",
      "r274",
      "r292",
      "r364",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r539",
      "r540",
      "r541",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r177",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average number of shares used to compute net loss per share, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r176",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of shares used to compute net loss per share, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(5)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r515": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r516": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r517": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r518": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r519": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124505477&loc=SL117422543-158416",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782768-158439",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=122147696&loc=SL65671395-207642",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=SL117422267-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001274737-23-000049-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001274737-23-000049-xbrl.zip
M4$L#!!0    (  **KU9."T+%\%L! %&T#0 1    97AD>"TR,#(S,#,S,2YH
M=&WL?>E7&TF6[_?Y*_28>=-5YQ X]H6JYAW*8#<UEK!!M@>^^,0*"5IH2:Q_
M_8M(2>R834*9<O:IQI(R,S(B[KV_N\2-&W_^O[-VJW;B>_VLV_GG EJ""[7_
MM_+G_P'@?__:^E1;Z]KCMN\,:N][7@^\JYUF@_W:=^?[A[70Z[9KW[N]P^Q$
M Y _\[Y[=-[+]O8'-0PQN76QMZPD-Q)3!YA3&E#I)=":!2 XM5 1PAD2BWO+
M@2EF,4) ,T$ ]90!B8@'0BL9E/968[OHEBW7S L#O;.*6J(4HRIX&23TBC(N
MTVOW!W%T<82=_G)V-@!];_^YL#\8'"V_>W=Z>KH4OR_M=4_>99U6UO%IQ.\&
M/=WIAVZOK0=Q1MYAB!B $A"T,&KGN _VM#ZZ;"?HOEGJ]O;>C2[$1S >WWP6
MVSV\\<I3DM^,E%+O\JNC6Q^^*8UAX7(0-^X[,[U6?F?L)KDVBLO7][/[VL40
MHG?_6_^T;?=]6X.LTQ_HCO673\56LX?> ]-[;M[O_-7=^9WC:8T7;LQ&),']
MS?YL_C$$$ -TU4B_2S$2/^O?\([Q W=(<//N=-GH_N5H_)F[.<G^3._YSI+M
MME-O""17O-#O#>[R0?SQ)@_$U[E;,S1Z.W\WO)C?NMS2G;U_+O@.^+J]$%G7
M:[?R9]L/="T]"?R_C[.3?RZ\[W8&42!!\_PH=MD.O_US8>#/!N]R3GFW\A__
M\1]_#K)!RZ^DL8!QI_]\-_SQSW?#IDW7G:_\Z;*36G]PWO+_7'!9_ZBESY<[
MW8Z/'<C.EM.-OC?\F#GG._G'>+T14:&7V>'[SP9;/OQS(;-":4R-HIP+*I#2
MW!H4.()04R@<_K&6=P5!!*XFLJ/;Z=4^6U[OQ/Z=OX_#Z>G61L?YL__QYPNU
MS,6F'?EV;M:Z)Y_PULD.J1^[@_63W8_J8+-=QSO-;ZT&WCC=_;YUL-G<.JA?
M'+)&\PO;;7^ENP=[I[O-0]AH[M!/I-':N3@Z:+37T6[39?6/WPYW+@[ASD6=
M;3:_PLWONZW-CSNT_O$K:ZQ]Q9L?)/R$=\]WOEM>_]XX:%PT6HWV!MYM6M18
M.SS=.6AEFVL;9[MK7TEC;2O;_?@MMO_EQ'W\D)F/7WDCOG<'?V@U+G9@XV*K
MU?CX=[OQ?8,U+M9/=W#C8/?CA_WZVAZL-^NC9[[%=['.;K.+TCAVOL=V#[Z0
MQL>O<*>]@W8.#DF]^==!?/9PY_OZZ>;:E[,ZDA>?FNN#^C8\^]3<.8_]1C^L
M$MQ[38&"$;FB*%@028$!U\)B[KF#7BZLP @".-*)B#_?W2#J-&G\_KC7BP3^
MD/6M;NUXW5OON+6H6!9J0Y&/;S@;++OX"VC'U^X#IRL6>)0%X!T6,!!9A#P"
MD%$$*(\J5-E($^^T"!9KJ#E:6$$8)%AX,^J/K8DK\G^(O_0K C]&8'2'P,%C
MS:DF@!@5;20=M:06V *K5. .*8=IE/%$A)G1]W-LO^LJ"C^)PO@.A1W1R$&B
M %:< 1HP!L8;"ZB--(I6+F;6+*Q\>4OY78W$=3F!6WKO)F2'[,P[$'0K&5(5
ML7].;'*'V)X''R*Y@=<HBC.Q)*IL'WTD* 32 DF)U<+*A]5/V^MWZ/WNIG76
M\\%''6M]_QZC,AF[R_W<[(\<4<L=D.5!-"7_N=#/VD>M9 7GO^WW$L/<L!^7
MSOHN-O'N9AO#]U^]=-2'?O>XEW_+G8GE$1<..>,E7#ANR.=&XOA;YM+WD/E>
M+>^0O]>[>[_Q/S?-G=L/KXQ_NMGZ40Y@XV_1Y^D-DJV2HRJ(G8-H_-S5M<MN
MNFNWDES-WKPR_CY^R;L;$W7_O!G/H794<B@IT5@;3@VSCA#H@X#BQT8^70P5
M8;J&3N)@- ,,H,L9&%]YV@P<=[+A\/O[.K+5Y<C:7O>/>WYE1(#\XKB)\;7Q
M]]3&O3,JG E*PV"#(I1PKJBD3%G$ A4".C2:T6(PX,T9O<Y3+YS1XUR>;T[9
MR'=>_KJ]]NS9C)(<V1-*[$*@!FE)0R ">F*Y<,'Q?#8QPD6;S11=F,AL1HMG
M.S'BY?"B<QV[=?W6'+7UH-M[X<3?>3[]N.8[W7;6N:_9IXK'C2;>W>S]8W1W
M04M+15!,!"JEE<&ZP+W24DJOO,[Q'(_Q'!=$G&[@.7XZGN.)X3DWACM#()8^
MFO+.:6<%P9*:$(0TC+Z=O(Q&[?>2<3?\ZN++SHY:F<T&==\V\14NBU>'8>)1
MJ'-Y>Q"'GIY9__=QBMUTVT?=3OS:7SW+(E2/;XN_1V]^>]"UA\.V_GQW[RLN
M9^VR)V\HR#=(HR&GR@=KN&2466Z$449XRREFFILP-Z19=2Y+@=;HKNG,;73>
MZZ-LH%LE(1,4D$534@9M(O(0(YU"UB@DE%'"*S@W9-KR YUUO%O7O4[6V>N7
MA#XX>&@\C.8I511Q9!QD5!DN4(B7E)F!I5]FJ)N]"\*Q0<Y0"RURU*H@*?+1
M8J:1F,)8K.>/H&\&D+,G;A!(,A6<A%%:G7.&<642K#)B86!S**W3A]794U4:
MJ!RR0F 7K1>+C>?,&40I9#*%8-[.QRTS]$[*^;Y)&BJ@L@1[!"6%7"I'D))"
M(<JA#5$]S@MI9F%E3HY,T#)AI" L&I;42J,E51 AJ;WD7D;_=E[(]*96YN3H
MHZ"66$,H,594"ZXU-11+%RS$297E]$%SX 6\%<*A"3H 4 MOB'$N^M%*:XL1
MM1QC'IT KN>'-+- N,F1*6#%"284"1ME!V+EA$Y4P5X*K1V>&S*]*<)-CCZ(
M0BM35B2".GI</EKEGIF4ZRBII=:\'7UF-0,J#MT0Q#73**6S2.^\<LQ9@96V
MDLX@QEQFL)]]\!L9CCAA*)*14V*40H1ZQ+V.6CNR.)\_@LXFDC 3XBICH0F8
M8ZNC <:)P<+A^!U9CP4V;OZ(^\:1A)E0-6"BF./,1JN.^JB1L".,&D:PI5B9
MT7K5'!#S[=:K)N4"B>A_2AW_HSS:"E$E(AWA%"LAA).:F[DAS6S6JR9%)DVA
M-(1BSR*EA*%&!6T$$U!IHNC(SIX',KWQ>M6DZ!.-3 >55THX2(UG2B+E(Y$$
M4991Z-^./C.; ><AH]P38BSUU!GG/6&$,Z.<\=Z6: W@?;=C?=I,DO!B*^L?
M_G7^E^_8_;;N'=[DUFW=\OTM?^([Q[[A!X\PZVLZD';MW-(UQ_U!M^U[=VY^
M;2_ZO<%R71]T>^,WC$0TY70NU[W+K.[Y.5GPN$S"ZARGCC^0)'@4/XX;>')2
M&R/!&TX@5"A$Y:HT0YA[RV2@Q&HI2F3*5@(Q<X&8B=UNH\VN'0J2"D9U6@'$
M-%"K% TR$.LJ3)\K%EYU)U'YZ[UY ?>;%C37QFD5E.>.4BX5]L+"0*")GBET
MI(+CBI?+@LN&"QBHQIX$3@46D:>MLA+IP$0(%E6\/!>\_%?KV&_O9[[EYI&)
M0THG(A)KCW5D8J0H41Y'=Y%%^YA366[CHB@\]$3S= KRNFIM][@SB")K?7:B
M36LNS0HJB72,0H;S!7"HB0K(<NUE8#8X=@N*B[P27G%Q$;CX65A\8Y'\-0:%
M,T2+0(/!AFJHHC&AC=*8,Q0H=JK"XN(P6+GLXYF ,G(R\J\0DF)$HXTA(ULS
M& PSAEIA;OMZ%2A7[%QD=-;10 Y($!PXIH9*E8P+:+GCAGHJV;RA\^=>UQW;
M00&X><(^9V+ET> V>]N^=Y)9?XV95[]M;*^_;ZXU??^Q5Y42EKUUB%@A.<>0
M"AHT)]9AS@VCFAA1IE2\BH^+P<<SB5P0J'0@#AD?(N=*HK5FT&/+41!(8UIN
M/'[;\%M>]N(OW??N8[?K^JL=U^AV?/NHU3WW?L1:_68J[:EMZN-?Y]O'1[%1
MW[O&<,W3;FXAC"\]EC4R63$?O_6Y<EY*#%=0$.B-8 0Z:JW,B^ P+10-B?FK
MT'/%^V_!^S/!?>VY]4IK;Z-!3M.2"T(\LGVT76"0([>RV+C_4V?J7UZW!OO)
MG=KHI!R71WFIE CFN.8B5<=+*PU8:6D-I](HS 0S$L$2(%BQJ#@;&XQ!Q70T
MQ*23E"*L."9.(A5L0%;;,I0<^"D5/W9/?*^36D+S*(0",J=)RH_C40B9,0(Y
M(@Q-F]&<#V7(QB@(^6:S38=$N\_J=(P"IY@KQ9$AS")IJ$)<P[)+W_MHTW3F
M,@9#HKF>RJ7B2+>TIT"[*'<L+6)ZBN/_RBYX;T*YF<B<=*GB*'.,$D.QXXJG
M F;":"*-H*6(.CQ$N;$WL3G8]Y?7YE'Z@J1<>V]D((@:IU)%P"B&5B'J/,.S
M*'A99AK.QO(,4EJL0F!*4 J)"0$S$IT'#7$T75SQB[I\T%GOFVX=^[_.Z\/=
M#*F!#SW_[V/?L><WZ7EY\[5;T^K><:^7=?8F%6Q8\V80W95![SBU?SV\X7OM
M*!!B4B^Z-O;+C_^*LZE[=O_\DS_QK0>&O]$Y.A[T\SOPY-EZ*N5M.$?0"2N(
M08$J)@UGRJ0 'F%:1G8M?I'+BE.+S*F3*_>I+/'8"*<IMQ03(HG!,BVL.!90
M,"4HE/6IV]D;1 Y(['$5)LT9(]>(Z7IS=+TD\*&3I:FE9()H&@0W)$2U)X3%
MEE*ERQ+NO'^A\BH&GQT=17A8[;A_Z8YK/8X4I30\%3?",D@A@YCZX#4U\0?/
M?*!"NSL9414M"VR *@H11YI'BU-2;ZW"TE,C99 F.(3*$'RYS!8[U3UW=U5I
MRT?]FMF!=WDIC:^=+"KR[:_S*)@R+XS"#<944(VDCAY%5'F.4&0XY:),Q(PM
MN*QU/,A._'8RN[)!YOOK9[9U[+S[T.NV4]&'XT&^1K@9QA4>QF=?_'5^?P,W
M6>.[[O7T?(;FN(E:%@G!&304>:TX(1&MG5*,6$ID"3!Z#EEA-C$&)Q$C&AEI
M(16!&8VTX9*X()0U(E2H<$OS)S6Q>92:F$=D(- [ X,E 4;W2&C#E*+&6^5H
M6KPN0]AP3MEA-GDHP7*/#/60>\J"-<I(I%(E<*8#\65PS-Z4'7XA<Q(IC!GD
MT$#)*4NGV83H)S@EG(LN C$54A2!-6:"&DQ0JY7D./Y#H_^?-EL3&4SP'@5=
MBNRU-V6-]7$BYKP>R4.PQ91@)Z.%22F!R<B$VAF)9;#"W]ZZ7#'$&S+$6R'$
MU2&IPY[>*8"61[!'%\=M//V4U&2:(&8<821MO%1,A62\*.<0X;8$8?W/O6Z<
MP,'YYU;T-%<[+A6O/$IMW)<,_>$XLM4@SDR\\4-VECZ5Y20,[1CC 5+)&:=1
M241OPV."D9*.16.B!$N%Q:;4Y);*O%904^ZT-##.8;3\C4/Q ]70<PGG1:9R
MW/FD33<_L_;\\IZ2R).7AB)E#+<VZE9#)<,DG5P2(!.0430G\C03*DU.ED*(
M**<)5@1S2IDW 4GND#/!*J$DF2=9&AI OG=Y1[Q[NQL&IU.I73F=?)9(F,"C
ME:IAU%0H>C,X_N<X%HP;.:Y5/A]"-3-R3?",W6CQ466AH\I3I*UA::\L,8)(
M19 7<R)=EQD@T2KV^]V6VV@?];HGP_2CDDB6MPY;I"#W.% $E<&1,)!P[03W
MQOHYD:S9D6IR4F4]-")*#S?&48^]I)((B[W16,BHT.9,JMYW\UR[?/_K1B<^
MNA=-];*(E0LP>5"I4HND1HAHK >&1'2'H8R6!Y\SL9H!K2:8@DAS$/12>!0A
MD*GH!V.'#>?!$T?R6M=(0)5'P](' HM*M$]9QV^&]SWOLL$';;-6[-PUTV*C
MT^F>Z,%Q_U,6_+;-?,?Z_B??<5EG[\-QY[%BHT_NQIMERMZ?>WEU57?ZG_7Y
M]&OW(0&@>EK4;G@K@1,(XQI#B#9!2&,=C8R9 @.<L: "88C($@0$*GY].WZ=
MSG'43'F$D$R'35)JH$)8&\*B">F%Q&1\6"NJ(+-BP1LLB !"UU#P-<YFBE-'
M\%-.:\HU2V7R*&%:"$6H'=7(BRPX7,RJ>+'BQ3OJ>\B-3UMTN\6X+UQTR_F]
MU7IXX>W:#<]>?-/&*\BLP"%(ZIA4DC#/E+(6$F9U&?8+%TPB?LZHD4?3L#8Z
M_Y-UW.>-_VET!Q.K5_U:67RM9,PD/P%J$IG7!6>$IA)SS:T)00M. F18EBD?
MNF+@&3/P3#*NL!9!8N:,%XX&9B66A%#'(0N(^%)MU"D( _]Z-LEL=J)P!X5$
MEA+(DC\GHU]GN(:(R* ,'Y]FRHK+KP\RRF4 ,Z';F_@X$4_8A!;43)#.!V-1
MT)0Z*3&2BHBT5YHJ+G!Q(SUI[^:6[NR-Y"BO(9)ULO9Q^[4"FYIZGRK.^]Y1
M%(WSAFY?7T;]W.NV_6#?1V0:9REDOK_1L26)K.AHP/,@D5/64:B\049J!:,Z
M\51:5N UU#DG#,V7L(GVQDD*(XFT2KK=,>2,L>R7E,5K2?4^5:E8C1HH5:'H
M#A,8TFZ]O7RM]7TWE8JU@V;WL^^%;J_]H=O+JR3T[UVMS6Q\@U_=Z_G\Z:3K
MR[("2$@ZJ$$(@0*GW'+#2$CI]S)PX3B1Y6(3?5:QR538Q! ?B4>#C3!"?8 J
M/SPZI"-* Z9Z>- N@FP4O2RBY?4(WJ^V6GYOWW?.A^5I&WYPVNT=CED@F6K9
MX/A1?_/U$;YHBSTUPG?#;'M-',-3I;SPFFM-"8(FU<VTFCB=?$%:AE*U8QE+
M4K<9KHGH=0K_J_&^VVH-M?F<;L3ECAC';;2^,*;8!BD"1CXR2\1YJC$O44BJ
M0*2<S?&C$6V1UY9 &/W<Z-T*@D7$8 .Y<T&KXFKFRTT,64=W;*9;MQW=\0WU
M;L>?UW7OT ]2$&9B)P.\756VHNAGAHF5CK%H[D.*A)?,"\RMEU HJ86MF*4
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M#O/^'N97T1^+X]ON]FETQ_B&!_LWOB])Y\(#G5Q(.WAS_$#8 /Q$"V"I5KI
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M3"HAR-/J&%<61F$[75C<6+\_*E%!XA,@<3QW'_.I>S^.YU30^#)HA'>@D>
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M*E@(,'5"TT QLVYAA;\^6;:*AA1,+B=F151R.0FYO&T@1(I Y06P 1) O15
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M,:"HA4#R0)QR4(; %E8XD:_ TBK+JFAB.?&H5"66KQ/+VT:.D9):QQ$@GD)
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M&(OC&H'M\R]8M^@4@-Z$86<R^>LS<)T_QD-W8JK0^:-KVF)V:V[TWZK&_$3
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MJB3 ))9^.,[<\NH,45,E=' &0AI=SW'= 55Q*4&D"UE_=CJS+S,@Q%2>(Z_
M)V;4*4>=\[+;G4)5FH&Y-?#6T:01, $&:48DORDL%2&'I,5Q\K#N='9SP?5]
M,W0GM?N.D>U.6HJV.Z-KW:P/_M=3=CY# #SAOQ[^C+=8=N(1EK>YHXR[HY=F
M.$R6Q-^F.[XJ=%%\9VO=P>GKBP\I/9+RI$ $2XXX-@%I8B,2P(B5%1IC3]-9
MZYU%;VX']*6;))E$GN0/Z@5VVK@WS@6>03(1)N/H\81_0Q*\-V%D0$7]*S-,
M&;>JW:LV[M5-_(ZGP%_\ W8B,5"%K)$!<:(=TD)H%"(3EEK'"@]V$2W8%^;
M3N?M=5R:1X=J4H#0 R95$V@#MMHY \O # %ZX8[A8'Q\4B^K%BZ?$(0$):/+
MJYS_U79:)D>S10"&PY2+,-L1VTU"$EC2 / RDE8@W:IQ#DP:]3_IU0,_=J-J
MIY.KCJ=:1M<OR+#='W5LPU Z9UT#70.3V]0OZ]C0+>%-4[BM.N&BK#)H3V(T
M %,'XZ&#:S(4VY"7_$2SX7Y WCB&YEY_[TP\<#X0"(].=1OA\O/0A96B!PIS
MDK[JPFK1K.>YCG0N\7A+)\B3K?5?7CL',(*P3(+IE$;SVLA7UV=5SUS",@:]
M2QM$:;"@>VDP\X ,8)3/S@;#6BC-^I<3[EU-O31/SL;#:ER_ZW@X.!^=0#?A
M^W!\N0,6[*B$$1N[D\RN.J:Z]GZ7 >\DR3]C3PE"A17XIG5\D-I?PFS^%(;;
M:65.P3LP^_(<:*ISSNG&1"/26],<3J)-E^3"X?-* '<..X/$["9= '('O_2K
M6EEAFN]V1R?3!\XJIPU <J&C,$NK..ZFD*.A*:O9:5S6RG$&TS"+89AF7*<_
M@%&IQL/<^FN4(\_SV0<.;,+A],@\HK-"F^IQTL P[%5I(0$@R4RD(2=-<_,0
MPFM,MUMSG_IZ&)C4EZLGI<EA/ QUE5BQR0E*\W-.!ET_&:WT=]X]7 (.>8S3
MQ?"(G<[K:U^GGH_[D];5'9M,O>MS% SKKD]C 6KL:@O AZZ!;@ ?'"=E'78
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M0@J#*;S.?WB]U.<BYI'UWS":J;%[P8YN9P(4WQO&'NVFMESL'[E+: />/_Y
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MDA.:.Q2\\-7VG%%8HR YELEZJQ6^+QCPF-)+I8UFI>6=7B9'W1_$8<-<=O-
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ML>S%RE 7 J&*V6/R*F.NL:,8,BZ"?VGW>^!'=ORP\*H.ZVO>]<]L=W36^N?
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M)NSU..;N,F$WYY<+*7*DF:%BAGI9-W6EYY8;<<NEDNXH])S MW7./ (",O3
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MLCYZ5G8KK&PQ/QIS-)PX#'4W1."S-/3T((I]W382-X[-.$F2^."%X]QO5O8
M%.;5A91[IC!_Y*,1U0Z>\IR7;$2N7I:,LSRKINBC/;^>#OT(82RV8+V6G; @
M#%(G]$")C"P66)$+URVQN9\XZ>J(4,]Z;Y?U+D.;\=@RHR@T=18Q1X>3B_7
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M=<*4!VE@\-!QO>!OSSRX_9*Z2POHWA93KH7#2VM!=U$;-XLJ_I\9SZ>OS['
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M#4GWM+,3VIF40#JU7%"'3?3"M!AXBY(.\@(C_4RU;*JA[S4^@[.)>8ETT;"
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ML"[U?R(R>)^*$@1!;"L*^_GP=+BJJG]P94G_0./3>+BZL+\YA76E_6 6M7]
MTS@K*NJY D,+SE)K=C0A^;H6* "66*8ZC"']V&+MPFNKRG9G$]GQ1::K"3^)
MP.NH4WF%'!/Y_ 3EO'3D5'E:9J>GF!L6R41Y56@O7]PG4W22*<Q[D$QQVP+E
M73=#L9-@J"1(*[UQ15*C"N&I=$1A<2^D ZWH$[ B?KB8X;BJ;P"I 6A_"+R-
M)@._SO[<R)"^[7T^$G=>Q6I:P!5UTY !06E1L7HR:"H:.FTYL=R]:*G"C$*Q
M[_\XA)U)FMH8V-,IAY5*#'O8GSL!VKR'LOL/1-8=:F^!Q2<9=E7'[3P^?#D0
M'H)$E$G5&P[B[A=S8 0NVNY2Z*..IE1<^A55^O%Y44.2X#GC&8YE=Y"X+*KJ
M@HT(1;T_IXW/27MBV*;UUU.\$_^&VU(R[4E@.J'Q5!0$EM(V^25PC*'7.2.!
MIBG.!J$[T,,AT@D*U3'3LK67?[SYJ$#LF@M)&O6_6#Y#OXH"G%'938N]@%RI
M(2'P1B7XE8C^-G@Y(ME*>'A(-1(^FL7*4I5T4=5!>.6^&6@8EYF>"7<004W@
M2#/T5 ZUPWJABBR%MTA"1%3SO,CG8&95=?M!E075>7ZH_:^$II!92ZWJ_]KV
M[G BC $U.)M"QTD*+E\KLPSJC*M%=B]T&3C'9DS<]UI_DR]0K7,6*L7V50B@
MU4S)8NWT+H+0A\GS/)ZW&O742ZV37^ZDF.>^<@>JP/C7#$L^PD$#!E7-(MFY
MD6F$6# BKX#,\E:,G\AO,1VPW_S-63/=]J8.6:DI+PLL9NT@^5A^ZW3J*FS@
M$1E%;X #U(=R1NXC/I9.>=G A+B98#C:'R]?R2IJRC@::G\M.J$$"TO9.5AR
M:-_B+[)5OO"(@CU<KUDI@8%1QCIEJ0H@1^$&%UZE,7J\,"[5=+:A65$O.54.
MJKH# V^E@F[5:$P@ RF_3I-=2UD,2+(-/XA'+!L+6=*3Y!;\ .B%(S TSQ&C
M1D4P)H5PD$@N(/:U56O1:DVSEU+E$T>/9P<)H!VT7/2Q".I1"HG20NJBE;?%
M19W>@;2F7 M-<P8ECP?JD3JP+MW"M0U'=2ABKV6P?)8W%Z^._19PB67O8W4'
MJ>_:$MP>*FUUB;]LLHOZTOXA1JWI[5.'\A83??=FXJM=)R\I: E2<(L0T:TG
M>]23;)*Y9 9457<9I-3'1<6UJX_7?@GETD/,7]!(I:L3>7>1*T#N)C3<>J]L
M)EHW[JI4R\$$A$0LD<,'3=]ES&Y(2U9-2ZS?+YN9(E!<)KH"P.4N94Z;T!91
M'ZRG-M"B$78O5!^T_"05(CI@.\1BSD:B,V*"^Q*+_!91DS!2".:J$D![TB1<
MU(X;D;<+0^QI(YG7F ,GXT$*]J;A?FV_\("R;'.8=Y;,\*O:]*@0A@6X7]U)
M0$6@5#1)?4'HM3)UI DF@;75]#<;K"8/@=?1R4A17S6YS,V0*I=9)@T)KH?_
MDBQ5 5A+B2PR4\B)39DRM"?T@W_6?N([SS596ZM:<WHV7;UY H%,"1C*K,)3
MU:D;;PMI5;8UE'JH1/]0O[O#5,XM&>]'3@<VT'X7\1FZAX<):*,9]7)$#?2N
M9<EF"SAM+8!U%U SYE9DJ$Z%D23PI-W4MHB_2=<F$C[\5K R.<[3FM$V4,0-
M1\6,@5E>-YP;@;4]:GU-ROZH2;<9;,@@!VTUL=5Z; 6WW7<VNN(:5MN<H@P7
M;'Y%V_T@J>"A$HZF5@6@#'A%<%IYT_ 2(P\+$!IWUWI[:_30#6O ]HHV/JRK
MDJE/7RD_RPESJHQ=!*F;"T(<NA.MKML<8:4YYCM05FL'^FQY>*GRM INE'8D
M(T?K:]OJ GLLO92^MKK+ZF734DJ!F,W.V%>M. [:N80XLU&VFDG)6LX%Q;;B
M4WIH-FEO0:<N3^W"]=1 !7&08YK-:'1%SVUU<94G),L;!.4Y69+J/.\-8UR[
MX#WAAIJJJJ38K<C2ZNLE-SAK"7Q<%J<E&TL/R8BM*B3ODRPZ21;6/4BRV -7
MT!%AJU:UN-]+AE=/4O%X*>&J3M,'Q&6E/[+%QY<<+4TJ.:K?98D%$V/1Y+N+
M+ Y"KRPN"+F@<3PR&2X?%2R7, D@+B@+OD;XI_<<B>[,LWVT\ZX@AZ,<RZ'W
MFQHRFF.'&+*%[T"@Y4WEU=K^(-<O%?#V#2;^0U,*\:XNA;@GU$=-',JL:DI(
M3JC+SG%!779>7]EEIP9S%]G"M1C#I%0=%7,VJ?AS]8]?DZR:C-C\>9;37.A'
MO\HMD;)OA5) (DY\W<B!H2%DP;2$_R;JS?+K(7WU;)HL?^>&0\?RUGYM#,UK
M?N?:ZU]ZV2\OFZQI#6WW>L/VD[UTLN'0"IR-1GU&%%9K,.K^.'1YIY29B%?@
M_QW8!XV60^7_SZW)=\U4L B"EA$18$GI)=+>#2L(KN+HQHK>!W(++EF)@>LX
M6/%HN,FBA6)ZF\M>8G>T['7,#5.V=K$9\"@H+^+?UGW:& &<T-F"-61O]63?
M?53*.A+H$VJ#E"6:FO\].'H4YQOLR$;+W'R[I+!?'NH!;*=U70*35ZZ_7@>F
M^V#NUQ-RTQ4S&"*IGJYBL6NO2MUG6)<SC&/.T_2R5:\B!-BZVZ2"Q4R12WC!
M50M<I(]M-L;0]O:>_+*X-UNMJ[V>$D>]^P69YL"RC=77?TMBUK9<8T]>CX"\
MC($=.CUY]>1U(PL*;._N:&MK'2"E_^RY#M#DNZIPZ/-KZ0,+B]W$ONC'^(DQ
M'J9&NI@??!.J:3V&M=UNK63T>\(8W4%HW2%K[$_FDI,)3+\_F3T\&=,(>V5B
MMUNZ32;QC6H9EY'IBIW<:S(U!T&PK4FUFEINE(,\QJ.Q!J9K]4>SAT?SQ/*"
MIW=Q)@]3+[\RI[Q7U#=D&0.S5]3W\F2 EQOWWW/Y$$_F2>AOP<MO3TE7*7)Y
M@5GPEQWCXWCR8=HT)\44#)EBR4UZU_;+VFC[O;G79C (MW;H;[7Z>Z18W__C
MM(R!X=O]<3Z0XWP"JJKM;VU#W>Q)/DSKZH\"40>I-<5R6<(=*8</@(#]@6]X
M6RN.^\&*^I/L&  #SP_[D[S_)VD.PJU5A%LYS8=INRP6A]ZUS7)?R/2)9]^-
M][@_D_5GXH;]F>S;F3C&/@99]L\U=L\<<_?":EJH=;]K@^F^W%G/[>-/^W@N
M;G\J>W@JGFON;9+8_@F:O19S^S?AO=ZN>VKRON53;514-Q*>V]#W+2NF[0FV
M4IDAV,K6)=,/HJAH][NRAP+BB3_P@NT-T]UMRAV;M?V=Z._$<NC0&%B^U5^*
M_E+TEZ+)+W2OF\9_]_>"=,5G! +W8M^1\O:Y_\F'IOT(@0TGVB_&,!!4,<;&
M#T5.?2^"H?&/0=TJ>$I@6.."P+#X6J0_ZL,LD;8W_IDU:+6_ENTJ%OH#M=HS
M#$2S0&I"7:1IQ:DC.VO D^'QPX_O11N6?$:]P^ZF(]X]A#-6/<E;?7('$D9:
M=D2 $T2:"/Q_=)J5Y(D6./_HMK?9AG 41"0U3YN(#IJC^:!%I4 4MC^P36MQ
M@EN^J4VBMC$(#7O=@!4;<P&/+:#([PU,[+[W83*M57V8.@S)U-J\R!R&M\6+
M9-/7FOE@U]=+N1,VCC6&MIHO$@^A\2O,_57<2O&J2O[:;/^ZZ0>E&@V,%/3^
MXJ/+4/Q#[7?L$JR)D[VLB5#G9CG^T/K'EAL\Z.RPXX"\V&Z$/6S"L?H^/:[V
M.HHXB=SL9<7  E*YW<M8B_:5E[%[F<SN#>'CR:B8<U[C\M?+;/?:8",8$5MF
M1+ _:28;>:QKP?%T]:6NVT;)2^VUYX$-QK*JPK3*P=(UGI1%RNE+[!? R_,L
MWN+";T)QGK+.,MCJ?/K<<@@H_V ],'Z-FG]W.O3#['S3NE[FT*@/=U_ODS'T
MVP38=[%H'78+"_5Q=;&X=%<4R]6ORW*UE2QWD176#5:F..56;[;%!UN]D9K>
MGBMXZRHN3%TQ[XN:<C^;A91\S#+L E'-HFJ*#:Y)KLJV$<@Z;X<UWK=#OD<M
M0!I3 ]2DCD2Y*_=2F56B69:<:(EMVEKM2++\'#[FR58]26YUYU=3QQ\9S#"A
M7C<PYY=L@G2E?9#]Z/=39?HD>]G77?IR&3_GV,8[!R:,S6'P'Q-JKJZ]V8YH
M&M?21>LEK'X-J3E^BRA).)C+MD_7,[70=+P00[<[PLLUX(/-#5BNXD79D\ZH
MH[-L>0=J&JAA0)(T9=H<8;B1XI\#&8^R<89_2&.^G@UV!L[A,YA'?);!/VIS
MOYJE:193JVJ8J[1:<&/5-*@G,6S%2DN?II&@WX/%\6P\$X(]X3@DM:#[Q?+L
MH=79L.;:K+H_]",7;$FU[4,@5^H.!3/"EO/4+VB,W=_A7; ,^&DIND!IY)^1
M%S2C*15EPI!2ZOY1XGO2O$7C^#83H*>8=IZ!&@B;,>I<FEA>&FH*7IXS07,O
MD6JPR[+HUIS.\J2B7H1G?$23P/4-D!CY7#:450_AF.CHQ3[-4Z%5)YR4W;OF
M(6N<!73G(@[,%LET,HM@_\2RQ1;.-<E.1'\OL5U$I1'G8B>PS>VHN) EA:HC
M)BA]U*T<_Z]IBSZ&39.*'^S5@/QK&CP!TP=2F%+7W)6-OBS#]+43[(?X1\'@
MC(YR[1!F.&IH-L5FA[QI"=;]!9#$K*QF3%P)X>6^P&:>?,(RP0(:^PR[=9:P
M,]E$N4_DF*T+C[T9*]4;J6XV-M0^ IMZ6P 5ATIPS7(&>C )F (M<N0,LN49
MM0P$0I&D+OJD2I\T$/Z?HG,C4/$'3AU(86[ $,>::>A_DCQM3:C5;'CO:(V<
MP._@& N@KU-1<2H/E]I/RNW%@](.Z\9M>.6HGYM0)EC3W*W56VQ!E<26HY+:
M&%!5MXV<8!933EUA9W3OD45/YR* M&8:<&I3T%HK+9X!Y=*=P(/,Q"K@D&N"
M'6C(@*?RVJ>,&KZ+-JOP.5MH:E=_*!D>?C:C 5%)QE=JZ+0;S\8MKD7L=V@L
M2*MF*+Q04AH@(VH/(KO6M_W"3V3O5:(<Y 1JH*<+\Q9"2.TAB[#=ZYP<"%DU
M*81G7.TWG>LI7NR8FL<(EU@^+8L1,$WX2K%N%%S$Z;6";BYL'361'4CQFO!H
MJOX] FE&#G90Z[+S#*X1L%L80?PR0==F%LWJ(SDK1C")AO%(QD6<!X4[, .8
M7,4;7@2;_HVW1(GH+\QA,Y')H4R-ODKAKS8691>I*:+I+YDQ<)(\E^PR91EZ
M8MMGLFZ_14_8"#X@:L_2 1C03VF?!#, (@4M8;[MN,098>IP>*0%76B_%:P$
M1C8!TC_O,*+)B%$;Y;I3HKR@-:_$ZR@T(*&4DYN#*![Y$A.R "4!VO09.9M0
M>1-,$!B3N+I"U<$-?Y*M72%%Y'#69*+C)]4,)M&=K-#QJ@I#D@T;Q*L$(TE6
M@<$4F 2,!5H#_%IH,I%L"HE:(>Q#S#D04U=I0GD.LYRW5B4T(#C=>4M#6RBC
M'V 4!A_,F]#B:K9RE0IVP4MY<\:34=8H/,C@FFNI^O>NYER+G2^/FH;9<$TG
MA9A?$9.:3,IWBFH?,;$.#ZO'&" 702Y UPZ/[A1;3<./$AZ/D$)P?NAXCF!W
M<E3M$ADRAJM+G0!K/0_U*TE<Q6R$PA5TV0H^AD<F+!8::U=?@[LQBP6ULW.X
M!8H1U==<GE55'^%%47XC9BLY0(YG/:C_)(48AH=;)[0WL3 5.@%=<X+^)([:
M _*Y.VP?>KELS4'QF( B@1D0IJML8=PHZN0(A$S.4Z)*>24_DFI64\LJ#:G]
M>S0WP)1 #8OZK(Z FQ/U3[,QV=GX_Z#PG;%2L#_UPX[6=R8Z5Z-Q<0IO/L6]
MI5%)_2PS082S"0[XB]M2R@2+56,">\F+J5(G!#_"*=&5O6(*\EJJMUYZ$=L;
M /*"7EH5HV3A/1FU>F^]H[V5*_9Z[Q0T,@: B-X"9Q$T9- 6&$*USD9D1<-Y
MR1@B+50JKK56^E&WM2<?P4C"9(36DQ_5DT^)<]%1MT]@)1TU5&"Z"[IY>Z?1
MU.,P#%*V_(#X>\/_80745EAZG6<Y'!:Q0M'@#Q9ITB*)T?(I+53800UAH@"J
M#WO1DE%<3#Y!C)MHI%%P+]N4H?:V+8;$5K1V1PQ( OM[-B:^J?WB.8T/XZZ)
M:<D[11SI#:P>9_^A9<SO)]6W;-V9T&2%5=L($3SQ1L:CB"=Z 74U%R[&4]#_
MZ:EH5F4H]8;:I[:[J/VLT&<;UY#T'$FNE'-6DFU))$IZT!E8?CI^-&CYH.+%
MC!HQL@CUS6$0'6^:CO_"^?:AO'8HS^E#><N[TDJ[;-(;VG1<;9-8(K2UJ^+C
MK0CT"J)%@8,=M 7/K]"G="X\^4!P]+Y*LMX(%(E<7:&T0$^0]A_A/,$?BW#X
M)_19C<A<4I[6EL[?BAR"<LAB:=]B2A9Z7EH95,T^23?F3"96"5ZQPN=;28U6
M^#'(G9V-I5RY. /["3U1;-Z*:S)T"J0C86O)=376-/&CV13='L1C9;IF5>O8
M=#)Q7,Y:$=F[%A-K P**39XQH?(C"]1I"2,P-3#/')UXC2'0<0^3W=QFKS*6
M2%N[H/OCD,N:?4.R557$&6F39#CAGB-C1U=%VN'N;2\.;+F<B?#(1[7_.A&N
MG&^\,;6DN3Z6]A6H+N=9,:M&Z,@_+:;BY;"W0&)%OF)**YU7-36#RD+>Q4$S
M*166AYGD1:[':$>.B$1J#TC;)2?\,CE7F8@E.1F!\$^%1V35N-)7W/*6UMZY
MQGV+)TEBK7&6::25G?+QPM#XQI9T%-DI"^\K\-H*,F_=6Z#:F.['OX$ V  N
MYRB#T?*,"=.N^6']Y$M6CJJ()>V'!\I<;>8C' ]\S6S:20=P\A.AU?TF0D#B
MM@H+>UI34./ 4"RI)G_^'68OR'9=.$6M!KV>N.WDB!!1I3I(I!Q*7;?&F,M(
M4/NG-'[G5I%K>4K+G4JUY/M4,U7,1T3A:DTU$4:<\%FGY)O:3V:#JA[0)6G1
MRG4BPG#T%]D?9V4Q.SV3<H7"/[73J52AU7IS60*[AH.U),6"LIBA'(/]!",D
MT4=%01RIL9W$?0%Q@L*LS*IORDJ13D:T8,!"%3=>B$,T-=%?<HX:ZX*89*TJ
MB!0D3E&VF=7S34[%1C50U/#H6-GUW%Y,*-3-X)8/[K__*[ L[]:+)+K[8#I#
M2J-<\( K%VSKHLF8($A@/IDBXQ >^A*SLH72),FFY-DXFI65H 5YH3(@%,PY
MG2,/@@/L_D2.3<:FU+*$ 4!\<U:2?B*<*12(JW[M#WWWAUY':$BG0.NO$^A\
MW 5(X8;'VZY-O%T[IWT_!L*>1]]A)?1L,JT752\,^<'C))A5-F(U!;:JS!B0
MBF0&"??T;-KQ3*N7U64>*"FZMY^G<(/[Z[J;ZYJ.9B@RI0C.%TV!?I-WL<G-
M9:%8$=GW*D2LTD FV8383-MDVNB2D1J5GQ8B6E#KMZ "9PF3$2QYQX0Z/*7T
M0W4E%^YT-8M5GE%!D>66,T+>.QRF)XL=D87(Y>FDV@#;!<,S0YNFB=:BG@,&
M>76632A0"WLLK=A!DQR@,KSJ<"@Q3-1^E3DEHKP-D[WT\&L#J_-R./UGG0GL
MJ</D+S )1B(<+@(E68H!VW*@W-(P$16>;CN'V^:)N'P@K9!)EGS0S6U4QNZ"
M(:,L(QE@5^&)2@9<I)F$65MU6D:==B',IH[;I$ "4>G?(VE"BQ"Z.H!60+;*
M8 /1*]CR&0RU5YT7TU;(L/ (%H7>&&E:-0E:E3"T9:K5R@07='A@.DF\*M]E
MBOX<3 W%%#\@43EE.@]6R913XED-D8L\EC'K.*,ZD>>BE/%S?*+.;Z'4T/9M
MPIG#494LJSHY#VI,=42BH'E$-JXZ+CSUG'1 ]/XLQ<@HXG0A;T/CP9%7AN)<
M*J=&>KF2#)W]B?"6D$^SE1%7\78&AC@)L>/"CR=B8#6AB!B>2)RA53:Y  SH
M+!9." *.6!F"DU,;:D=I>U]2&8/*JL8G1UM=953LCN\6-P;6DQ<HCF8ET;Z<
M1&>DEMFOB PI8E91^HNP]>@SL0^8$H,W%-9 ^3""/*>8($&EE>HT:=#ZQK:L
M2)'-T,TO(8-3FH(P\&)T"M9*"0XBMTK8I93^4I&Q@E4O0"B"FFFS9%K/+%>K
M64M;1;FK2=*%40O'Z0K]><3F Y7@ 2_C>"%S>AO*=5Q0D]JW-K( *SPMV1C]
MB4H! ::7%J.LP!L'?!?I#IUOE;@2XS$OT;F3_1 D*;4!X"VD>52%F.8H^X9+
M(3<KD,LL3]DY,"S<-"X(5#KZ6JR"?X<;@(ZFO.,\%HE6(KL.W3AB3'0 BQ"*
M2G[):RH7,Y0U4W@ I\!ZA(D'>XG22YTED#)F*-!*E\*6ZK9=X G+8P7!LS2_
M@@0%QLGQ[D8\9A@6A=%'+/[6/7L:8[#@&V\<9G6:Y$#%@\A]A8?83$OL CG3
MNG>>)W<M@=<@+B#)O\$LHSZJVHZJNGU4=7E73B@@.1J)D(<0$-5LC,4)/U#P
M=[/65(F4K W!1#HJ)$AJSZT<05$+X3"1_C2I^'/UCU\5_F:6TXSH1[_*;9 D
MML(E1)0DOFZV>VB(+9?(G?+-\NLA?;6 *R6^\XVA:_MKOS:&YC6_<^WU+[WL
MEY=-UK2&MGN]8>]HLO9&PUZ!N;HEM.KM@YBMQB^[9"5K,:+#318M^.=M+GM)
MPH@>D%3L=BS";*^;8C?--@>=S>C/=P5ZXA;@=/MX^)AXN@F:\";+W'R[I%18
M'NH!;*=U3^_,Z@4]R7)Q;:9GQ0S&2:HEX-.?8Y#;4];#;/B!:;EQG=^5Y<\W
MN977;F)PW\?8[;6ZY:-^5[M/T*-W3I;O3URJ%6N^A\"Y^XYP^R0<^,[:-HTW
M!\_<G_J=GGHP<'WG)D_]84JS(PJA;<WB^JX\2'-VN'UCW[Y3T@V#_@^,8(M^
MX;?7)VF_^< ;%2[=C:JS@K3N#05Y:UM&W+[R<)_WT5[;E;,7QY<:EPT\!@$*
MK<SS5[D(,D__)D3V5;_KVX?<\*[LXZ7&GCK&]O+U[GN'])>BOQ0WYW'P0O,>
MWHGK]--9 Q2^7QD8(O6H<=\=+NNT^Y0-L.A2;N5M-=KXMD"I".S]2]C@0;31
M#T7*#8Y/&X684J+$=AT<9O)U5JF^+Z)B%&8+BDIY*C'"K1861_L]=47D.B1]
MS!.=E!S3O45&T+@ BOTA_ZK?1266-6 P:D#U5W568HT>)32H2M5$X[):.TIX
M9#1I9VAVX2I7SAQ_W@#[2[#)F2AWC3EH98NEU4U^JJKO'&4B 8QR*E<U#L!W
M-*#K[7>T:[<7ZE_;PPH<G':_I%6S7 GV+K;HHLX*CN?Q" O*<B8R:EN%]0I#
M34NS$C9<U=+'(Y:-$1@,<Y IRY1CCE?]/9Y#2: G\+8)%KG_$'G$;#+AV.6$
M8$ZJ/4VMWLWMU!04L;B80=,;8MN+:;9;S6QR,QN(\SV_C\;0N9R);'(5-[UA
M"N.S@TW1O;9R:K2ZM6^6%_3.B7<SF=CX>^^;3,Q6>*JWE8D*!UK<02"W9;1B
M[!YS*>BSY)H$$BC!$BJ!VB!Q%W"4IN#_7E!%X_V[;U21KO!;7DM3\JP!3/@2
M7EPC/Q1Y%_A!<C_$=5;"N@6>L9H;=7&]7G]\_[XAIKLFF9O<^04I:!O7WO0V
M/DD+F(,*3=AW+D!+")D;?BJ!PEM.,X''1ZAO]^^$UEQJ+*O!^N-#(9IP$]\C
M\+EJ'?<1+$""((=M.F[4N]<2^F(_;SR"<S2Z*%8TFOZO%4+[QC,! TNJ=\Y&
M<T27E94@*XH-+JDU@-]%'5B62P&Y%;!? W=.JD2Y&HG^]\-#V8B4D*QXWL;[
MCMB(GJS.."H:"9LRNAB@*V?G"D96P82OGDLT0[\!%QB4JIH*:V)PAT!GI$*R
MNLP)"+N9D)BVK+E2]5DK(<CE[ZL:B/H;KQ%3)!!%5<W&$U42B/5,K0(M0BE'
MPZB!FFZI5BTKIBX::R8O4+Z(FA=4LL[OI@N0,ZL7LE347T]-&3\-A"^)\:8_
M@^P9D<QJG$KQ6ZI:5#T;VD@RHC= AZ[.,F [)=U1'+G,"%V7],X<<5L0]$FJ
MH!*EI2X'4WA C,!\6%6(TJP&2S+.RG@VK@A71!;NM8A=4"SB0-,W HD9F;4L
M/_PZ2T[%4;.HF(G-C%E9SO'+<S::\4L.39QWR8D$87(),G(P[5A9PY?(<DU1
M\+D$7#,F^&X"D57H056;P,0JQ1.2"&IB$Q6,$G9]()G!7%1>JE_$O"Y/5)TU
MU[/P1UFDX_5%.LN[@DUFL*ET%9?91'%)D@]*TK)&TDZDI 5M0B@H%>?*%R)*
M"!'&'@%S#VZD'I_&6=5#:O7:&OG_STI[U16FARUA^J;FHB\[@O1#PUO>-8)4
MUU8I(4L*QNT=X8%JTR ]-PC"D^<S:HBTV#KC_VKME9 FA=;ZBL<"^;C=/Q'+
M@QOIGQ=:U=*L%IP=E]&*D#$UFVO)EDWMV6JI']8V[Q-"MH&2/%[6LZY!&BUZ
M:+<NV<'>2\3I&H;QX^N7.(A";!:;LI_*^0>.#+ZCFI=%7B"@V_YB(+]O.!GU
MKK%NI7>-+(0DD*3696K?L16TO9_'_J]WOWU$;:?##D="(NSED:-=\"]0KN ,
MX7!0G_U-%8!_Q(]FDXK60_"YIB5:Q:A5/ATT77&PD4A6U?; Z@X1LJY?=4YI
M-.IEV,E<.^#8)0:_E?"KL4#@'QZ0-5-O-;"?L6@FNO8G!S4RAS!H"+Z#)>>L
M;I&._2X07@-I=UHB0 #Q-PD+28"RXXGJ(X;1$\('@17SI$V=A,7+2NP!ALBI
ML<)3D$CR8CJ9!%0FD<)'=2<5K*^G2W/)3!H#H%Y_$X8!5DIHK=(B(NL(;(DG
MV5,A1X3.+O%T:<FKMPL7AXY\^:LTS:BCU#D5Y2-2)9A&YP4N;H[Q'41=4N^\
M9.I$(4DC?=0"J/."0J\4* *7F<"BX1U8'A&7PE!M<KV[PD+9[,0F';:,)(*^
MW?9QS26V \;#<$OOG/6LA5 FC K17/6RTVT(9H3 K@F;-VZ4"E4)DLFM<G6R
MKE/L.I/G&:(S2&Z];(*7U;2&G&FALRQWXVEWQF!Y:X?7-)=H-5%H!I&,R0QM
MFRQ]U9_MR?)S3^LF,[A'U.L&Z1 4"&>H_6]Q(;"3LK3IZB1;>-&3G1Y&Z-)I
M8&[/N0 J%T3>QC;*4F'($R 9TPY&&*,CA)B1ZAH$ZDUYL- KZ,-LQ,7%,ZU(
MMUHK?_U=I@K">N0]$?H5G&]5*9=&10VI1*]QRW;%4)%JFU$VW9+&14D(-SEU
M)5]X+A7QO46L("*LN5!7N^M62"XQJ1#8%XI?1H.M'45HW(:N5ERN+/E_!UGL
M,9?[D<&3.'1B.PQ=)TQYD 8&#QW7"_[VPX/6CS9*7OD)<WP'NL(1D+9F#U%%
M0E-1!-R1O<('(_7WJY97[Y!<-<<"^?5#5GW;2SX$FF-+^&W$*YT%Y#RXD[Z[
M:0;2H_3?^.O]-YO?F, ZV ^GS[IMW?_K"\(#C&'L:2B,[?<814KPMNY_;W'3
MQ2!2@?**[/T/_)25-3+G:R61<XF9V'"B?5OR56I1C=+<BC+$[25,ZB4TOFU$
MASO-A6(.!N^LY HRL.ZOVNGP$/&N?T7@DZ%]TSCU4=[+/H38B7&U9!<P=1A4
MHA8.(E,*_UGC!24RM"5#&77O1"ZPZQ5JD(0G;!3NCZ]?UGZ><C:2_B%<3J7@
M^V1<I;W("Q6$:-:J%BKZKL9G]4)1E+>:10MTL_%XE@OX(I5]UL3W%MNR-ATD
M!&P:BD#1K*&4)Z6^;TP#]7U!RDB%%JCL@4D6F82,3$'';WHS4A\M&(RZ4*(*
MBKJNPNE+8-^$)5O65Z)>?D-#&XFV\!8[ +I+X=-!XSNCF#>U>F@YMJ_:[NXS
M2UN.C6[9"/']DH&TG#H*<MU6@6#O5=N;J[Q"(IC%%_D/ ?9>?8&?+&O3E6;:
M3#?=)_PI/6VZB?QK]0U\VNK:05="KI*2@WZ62LGHCPOE)Q/\9GWGP0U73<WA
M"/.O-J1PW';H<(3XB#*J)^ M!XN\;<NK?Y_8F\SBDCUH*20(4V;?B+HDNZ9$
MQESD$. N:TBUG<8?RETE8D014C0'QG%G#H$MA?VQ6ODGN?*]Y&#M]I.V:F':
M2D]6.0/D)"+YDDVGO'8Y1-39&*'(@69%4#WA",9*+$'1ZI@EC1^2ER4^1B0M
MT@(6TI+P@9QCM)Z01F=DW4S!N,^H%UJG%5#+A2V_!BK'E*E896W+U]&=;=$E
MT)GJ[B&4CP&"@$J4ZSK:0KFZJAWR(L4NJS-%S:)%=^LBSZ8R\M)R@HGV3FKI
M<7&:DT&TX)E33\C<]^5L<UP0WAERV[3SXMO9 _04\0;YF(H$J>QQ_!FY%I#=
M4--=>>.%<^=?LYQKMB&C<_NJ<RYP>)'A0$NOV4]#=>O25UH=X>D4FE:K0KIV
M RE-')$@8K/OW7AB=]_VKG\Q;=PA)5/!>C'QMG7ES]CR)29%0G'J5E-N[/PV
MS:8ST<)UF=G#Y@S:_9*67M0]NL%5TGESJ7$A.P<W,CIJU P1R<6Y(D4<J4&E
MJ44?G JOX9N2C3EVLM">6(9I/Q7NO+JGX,LV0_PX@=THB(+>E:<LEXG]H":]
M?/?QW5-%2">8Q0-FOO@QA7_O@4R3@5;11QPYXGO9N_XP24H\:A'C7I!YF]FI
MMRCU%O(SB ;K#$,*MR@IP(7@:SSS96OQ$[EXUEK\"NJO%I67C;J!A7VW"_7B
MU=TN7BM#2.0 33%H1G5;H'2#;OL-- $AG/^#SET,:RL[K"6&$SSTJ4 P)TLV
MY[*]:LF5G) :,_[R3(J&O W4SH%8BCFO&X2N'+X_\ET<>7Z&5E2RT*Y1,NRZ
MK4:CDE&#DC6JUJ9M9_I3N>)4CL889Y;W$'0&1BE$&/CE%^W+(_QSR^<P+A(^
MJC;3CVY;2)#Q,)*Z8;V&!1& ?2R*?$39KWCY@1]DU1F2*>HEHED,DJ1L$D,-
M7%9TO1 ::Z?',H;WT"J2W>?)DR$,%QGS%XJ-M')JD2,:/*B ?5YE"?F"U,31
M]C]3 =@F--W*GZB-&Y'"S^NTH;H%P4+W3K)TUBAU@Z8]BB@O&[37V]A1:,HT
M/9R5QC9:$9^\-%9QM\K1R\867=(HWR$Y-#E]'Y2:NI>&P8H<S(6\RRV<-UNG
M71*!T,N50M7J3D%=7#II^G/5)X1*)Q9^L*71L((1[3&]'>5G(F/_#VRCI!J.
MY,O!I&TC2(\RR!OT2?K+N_*;;$0C+==,4=RH17&8I4+=S?3&U*[ULGDUY6,P
M^L',;1PMT@U'+AF\SVG)9@EEFHD$(%GR25$^/A5=:=HU=5*#^%%'$//Y.I\<
M%M4C6T!7%\@]49Y41QL;V ?D+"B@9=J<D.DM?WXCK\F(P"Y/DJUEL(3HJUAW
MTR6\)1!SCEJ0*, D.8ML%'9!505IE/\D8AZM1HUZ!/<WS::=ID.4+E=45=:1
MU-TE]TD@-\(?PITD@;A]$LCUDT#>8];TT=%0>T=^[J,F>+;UA->M<\-C# X>
MRIY28HTYU/[@IZ )O1=UV1AEV4O-]).(D4H(D9%(36::Z-Q.R:WSQ@TWHB5-
MFB4-M3=4 (E6"X:!R#JC\!39;[)O)84XEWXK0ZU?9;]."<J#D>=$-EVE;H[H
M3\=\W;C 'M/(KE6/MJ%,^1E)I8P>%PUT92O+A;?)5Z!44BWP9+>V5KNZ6=,L
MCOH!IS5B3,6G4V&]BM:C ^QQ";^6CC 0%*)>M!4XDF6Q=7?)U7T:I=!MFO')
M532M&HM(%(7=H"3:[)Z&Y@.[IX=#2D75WHB3NE-K96U<V5IM0M;W4MF2\LZ4
MN"!5D=W)ZA+\?J#)M0^T@_;B#Y13YB?KW@9UV0RZ],\*JLF:XD^G9]LY[>\X
M.*.*7(@CB62-52&YK4UXT>^S&P_<)E,&?M7DR:P/[U&CZ3R7!;UU*M5")+:+
M/]$R*L3(,@EER_#LD8P*S^K.S-0]5^SCO.WP7]I.OM#C,V7H4BN:-,A.O86P
MAU8E$ZS??G1XU*D*5VZYJKS !8B0*V[LBC#XVHU$T4,"151OU0OB7!R[=/^U
M)MB Q>Q;EMX*D).?S=+;+$/O9[+JANWLWW4W2]9^BM5@I4)CD@_6_NC.TFP'
M.TI$VU6:[=I%1G,D^\>=:8OL4%"*XOX+[HE-N-#X;MTUTH.DW N7^&]49_*&
M$=?>'-H)&#4^4TE!E^9WKO'YM!NAXY%,L$[R1AU .&TELP;U&D]% !SA6VHI
MU(PPJHH&J0D!'%'WFDW@KJB\O38N3(-C0\[W[*P0 2$A064YWQ5V1$,,<G9D
M/L"]HWHZ GM2QX2[)?/73@N$-!5<!H&8)L44I32UBY]*BI1X-;^V@W#J=(6M
M1U6"K13 E@W5BG2TH6^D3I'PTY)+V"2,]3505#4,!-[7AN42^@XJ3UF!=+N?
M K)/ GW82:"LVET.*-;2PX_S%2F".)G[EG5YVW>M3[J\K:3+]=F6HF0=<S+K
M&3W=2\;<BGF1"BI1(7A^"A_7*C FHN22IPRZ.8S*LAET,E?@=(0*?T7^HN"=
M2SDOTO2HGA."]H+FLL-DO(' M^8B\ZOM -A%_A<.#J-GE,'4Z(+73F&Z+^E"
M?52O=<%LXQY$_6^;ZQREJA9-F% -WHL">%E(&>O@"4FV^Y&5$0,FHK_[/N+S
M!M7(L%!!SNI7S'+U@MICU@B/C05/[;.3:0,U$E!9$ :2M("E&C43>6UKG%^G
MH!6Q?,JW\8W4;H-I#5VZX"%IPZIMX@T97*,N#Q';%GP@H$^"@84^/(GVNIT\
M+S;R\@(7'R72:2C&1TAH EA%_".1Z9>B.S6N,Z4%Z ]9[7*)K8T>R,&$5"($
MCDF9Q?4"!+XT:JL\1OH=(.)K4;LL@?CC&K]4(MLK-&NI0A"XG?3;HCL$/3M%
M"10RFYX5I>PE@K^6D39BYBO0C;=,4%QQN[VK8ET["80YMQ (Z[-&EN6+N8NL
MD=#?DZP1V(98AZU%X_JY!!+\=0_BHMY0>_W]+(NR2Z >5TV3FG,U9$8-P6"Z
M(S:I^'/UCU^! X+R-G^>Y?1Z^M&O\@9+VL1]7>QMB>\37\LM#]RA:82XZ[*S
MIGRQ/) A'<A"?S/QG3]T#'_MM\;07/O=9:/:UM *O)T/&PR]</TOKSNJ:0U=
MQ[Z!R1I.N/O)&D,KW/W.FO;0L(*-AMVP7?+:CKA;/&JN[IZ[T%M1W+G;;">X
MQ"]D2W90NR:%\#-$"(DA0<ROVX]YMXVI;W]#)./4WL[0_[O%+NS]BEXUV.*;
M=/!=UP]RVZ;&M[]@])$^\!6B"?6V&#[L54K"?12+U.!(T<)\!8SX(3 =I-#D
MV9M9F0N'WO^"5$&CO;.VJ]JJ[^I4;[FONCTT;Y-FQ>HN2VA,T]TN4<PH08\-
MF?W/*9J&3\%$V$KKB LR__5N9J6=E3P%DWLZG3Q_]NSBXF((<QN>%N?/#LOX
M##W&SWARRLIGV!3IF6GYCF_[SV".IAG:IN6:H>5:MN<]2WPOM#PSX=]M<W@V
MA2MU*&%_99\*$5%\B2>4B@AMD6J-DB6P+=BB8;EC*EFM7-[R+0CT_[NI6[ 7
MZP/BT.T0S*4'O<H;Y&5[L;[PF64_LPQS-Z=X@Y;0K9^[M7LUI)=4-RBIQ#\M
M$R=L^L]00ND2DQYDDTPE2:+YZ!*Y]=M\Q"ZJ[234OM_PS>30OJ]B&VFS[VO9
M3*;L_2J>619(#FN;M3P<^>#\[!GV\N&N+!G'< S[60*&3. X8,DXTI+YB+%S
MD HRG!RW;!A^3M'J.JGIC)6B#[ELL4*_>%ABXZ-N/CM\"&S*MG7+MAW'>P"+
M^6FNLQ>K")^%FYH<#U%P](;%/14<5@!_M 6'=8DI<:22GOZI?<#Y5=HAEHJ(
M:K"$'OG7;#373 M3J\UP@-%'2DBCUGTRKWF"]3!47R8+);#D@*I?0."<%2-,
MXN_ESCZNXX')G9]D6GNQBD<N=^Q>[CP0N6-?(G<^MB3#/WN9T\N<^[J8GV98
M>[&*1RYSG%[F/!"9XPB90_6WA"%+CB^2-MK[&0R+G6<_L1)K951]YK1HU7XT
MQ9HD8%; ^TS*[)S*C4=,UO?)&A3$:NL%SAZNXX$)G)_D5GNQBD<N<-Q>X#P0
M@1-L(W"PME-]UH[);"B)X,)XO839QW4\, D3/(!5/'()\Y.$V$N8.\P+"YUG
M(%E<'2O+BW12\N\IOB*Y0#'2E3<U7*$4,0]*.B" T@/@1 \I*>RG5=>]6$5
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M,$N[BSFK^',8.;/LUR@9!U?_ 5!+ P04    "  "BJ]6N:VP[/(,  #AA
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MV2S16DN)KCS*;)V6A"D'S-CLE: ]S?W;< UIGUU_/:BFD8I!N TO+G.AO4(
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M/=)?6,<BK[VOO1/4+CQ2/SJ/NBCJ 0ZZ;FOZJ%142H9R<8$IFY[L2D$D)S$
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M=R8ZH3+H[ ,HAPY"T 6L48EY*8WF]G]]_DO17B?!.01M)2A4&AR7"#9X5WS
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MF HKDWA[2(8L1%H4!-;5Z?5H-AF.IL,T;X/%!ZEN(C :J+*VJE(BTKA-]<[
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M H721J)O?>WF#0B[7[Z[6N76\93[JW3;#F&+']<_:GOF__RW_Q]02P,$%
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M2GB<<LY4&KK0N4_AID;J&TEW3DR:#FIA'<U&7@?1CM-?:F@&9O:>H^),T4/
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MS",ODX+E?$7&-]_EDN>EO%OF7'XJYG-5+,V+LX2C),Q$!**48GV^2#!@*$%
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MQ.ZU'K;T=U6+^9.L+O^,:3X*(6F^<YQRJ9A*0()C!) (4T"0"2V-!>$*49E
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MI]^RJ!=>/1=7SW?Z(U@9Y[Z_K_/'VAOPBVZQ3@8%,28D30%3B?&S(RF@$<Y
M$L-$494F@B4NJZ-%GU-;)%N1]?[3"%W[";=BWP1&[%X)H6S@MZ,7SZ .S#([
MT4-?].]S<V%2A9)XSP/E@(LGKK'I<53*<8#@D'E<7NUIN2A6LKRCSU7:CS1"
M*(85T[#0>!!)P/3NV]1PD!G)(A'#T,DJL=/XU"BEDLW4CS'".1H-=C&S- CT
M1&+HPWX%PMT%$-P/\">T]74XWVUZW(/W":6.#M6GGNE[8"Y7']5?BD*8'/Z?
MY?(IY[+\7,S%:_FXE#ROXP<6XO:A6*[R_Z[]GU2,]6F."\!300$BA ,2)PG
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MUCF!$FS_KDO6R!MQ#F:?[JBYW-2_$N7[HK0UMBI>>F]^5LX@(XE&ABPP21,
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M(FH-:))CMD$DU@;/:-=>@^5&>X,/P< ,6(-;&Q#5%FP[%3:=-'H-A'^$YRU
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M?ETT$<5FF5&4PKHBGU;JJ=@\W2]D=6FS-5"UPOFHUC,J8YIAE0&<46*F"*(
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M<BA9#!*>" !3@0 34@&$"&%2QH1KKSS&\V*FYN9MZYD_UVKZD=,%*-U8Z':
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MXM6AM,/P7DU*SSUOM#ZE'<;LMRKMNJSG5'L8K7U8T'=OD\W631,SQ"%,A((
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M[HZOPQG$(*@-?<AY5"IPJW>TK_BV1N<@T'H<+0P"\4BG":&@]CL^\$:L\\3
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MV3KWU)&/MCH,.SW;ZKJX;YF5<OV@/ZMO:K%1LYSG,DW,VHXA9#YX3E) :2J
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M29SZ4.\5>5-C5MMOXJ=E6=K6 77NF!^%7H/7C2$#@C8P ;::[O :)XG$$:%
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M?_R?_]'^Q/QAPYO^S__X_P%02P,$%     @  HJO5NQPPG]D;P  S@P% !4
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MW 7+8G-T/4#2R'/=AT%62S%T@*JZAG?E(QF=-U9BI3%"U]IP+B,HK)U04U#
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M@>%-%;Q;C7'">RTL.)9I-;*6M#H6(-=)F;($*VQL#*O[*=H+5NXGA%5#070
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MBM.!9RA!)QX+LT+JYCT7[R!EG,J=I]-(A_&\+]US<7IO[BNK0XQY8AQZ:Y0
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M9UKZY96\7<S3V5!&4GY!&P&H>6VQS8@YB,2<Q)4*O)0!^B'=2DD'2:\#8N=
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M[)SC^NBCJH<B]D1O0$Y531NC[R36OWPBNN>3RH/5-_XQG2P7[?:_O/3;VR^
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M_]N_^U>N$@YQ<LFM!\M^K=CX]G@J4W_,4SN7_%7<*^'VY?2S_P%02P,$%
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MNYVCAG=XH@L0%Q(0#T(911PN+5+ZA"IF,0D8X[Y@B!W"@ B^X#K&[M@M@2"
M@0"O0ZX#(74.XS \*"D<.#,E Q;";4UV 8LA W [P/5N@YBF0T8Z</)>YP)Z
M>$U:\?9WV9X=ZNV'[LI=<A33J2,%SD_P>%[@BL,NVK+Q0M'20A$LA/N\RR#H
M@>)I8XD\4T <(E(*/\31,]-DE^Z]\61;GIPS#7H5$&.UP^-P+J.L"6BN-Q^"
M^L)G ,UB):=89*Y@ CB31US;DQYZL=3.@YG9/$8LQAG%!+58+R3+'*_E(@9A
M(X=X ;9H*7AH2U Z]S4/.54<-\"=L+*1+\69<HUBQQX-VBHC&Q>D9F"0@3B$
M@S+(&7B0"XKA#+9EC9B+)ACA)-BB<H1O/L..$'%@/ NWSR9^&)?\Y^<2^;^A
MT<9G]@J;-C_M-R85$''$0^0*U3*E&-:H!IYA^H $HBJ<@AGHQ:G/!3<3U%3K
MED5J6]Q;2#M6+G5=2#]L]+PM-I3E*@-*::L!@T"JT!I@$Q'(MD':"6 6M+ ,
M*8M=(,ER[ %J\PP"V"OB3_ 6B[8F46]$16X/;$08BR)(#?@(L*'72/R9I-L@
M +G+]:K?<@8&0O#0+K?P96[NMV"3$$EGO1DF3M'CZ37QIRF9/0:8\P388R&/
M"[P.V(>O'?8_+H(X7*WB$\M-A9*W+6M)L$7<0'$E@R!7B,(%);-FUD1J _>Q
MH ]SZ0 F^M,53\GN/4,BH!.<Z'=Z%X9#RLYLI0R+:&D^LVO/6153/9-]& LL
M_5AH@Z3U1Q' )D3P&R:*LMF=_N7_V47W/W/Z@36 _;<:P#/5 .P3@W#*QO+\
M9,9 L<B(^2&-F-Y"\ZTD+S/3*"0P1BH]DUGV!DR9)-P8QAX(@[X$(8?M(0?[
M["2[P!N(.AJC&OS'-&I*=O9GSL%\2^P\#6Q5;>_A5'_Q>3DH.5N?:[N$;,16
MGJ!/1_G2&)FTZ_,AU(?$+#>K0QYYZ.X^8S6=.:-#5O'A4+BIT A\WZ9B3">Z
M])T>]+^H,/M6Z=C^-.@(2$X@6>) =BQP8:DLX S862C$6<5A#)A"R>>2%2OZ
M;)IEG^A,B]!;<;XH#KCRXIHH1D,8J-DLB-U[/A3)&0P!DD,.57:Z4X/HU'D"
M& 6/V,T4XF%MN7YC35F0%_'^HN#_ XH3KQ_^(",C!?&D#&!D-@0"G.UCP0+W
M9:?">#J28L10BJ5PQ+JGFZJ(FBS)A)PP:!W'TH5*NL0J8,&3Z-1'15B!S89G
MP6=L76,6<U3(5 4<*FBF67OZY02B>B;HI,U3ZR [Z&1YOGWPY@BE <C7XEF^
MQ;IK+N+'T7'UH'6$(<1 W##A=.$BNE1M=*F9<+6M=5QM- [N;:Y7O7O;'ISV
MJ+I_V-IHVIHUV9D-CM$93=^7FJ5Y5 VQ'-1N9+?$6WZG0;!HU3<R*SWG&STV
M<)\#8*U6(;_2B2.4MU^V;Q+>">*%,YYJG\^WQ7<[+:"+_5Q\>VFVO2U^R3IQ
M%+F?0LO'^_Q-IW6RZ'Z/%JRS;TMEX":LOI.I?UZXNU^)BU^X%[LQ9Q&YF!WF
M5RZO>O/HW_;H[F=7^P9GSMV*\JXS+X\77MY;=7/-!KB'<YGF0XY[<=E?S;W]
M;=]#/_L+4$L#!!0    (  **KU; UN\W0@8  #$E   0    >&=N,S(Q+3,S
M,3(S+FAT;>U:;5/;1A#^WE]Q-5,",]:;)1NP'69<8R9N$Z#$:=I/G9-TLJZ<
M=<K=">/^^NZ=)#!Q2)PT\4!J/GAL[=V^W>[MLROZ/YZ<#R=_7HQ0JF8,7;SY
M^>5XB!J6X[SUAXYS,CE!+R:O7J+ =CTT$3B35%&>8>8XH[,&:J1*Y5W'F<_G
M]MRWN9@ZDTM'LPH<QKDD=JSBQG%?/X%/@N/C'_H_6A8ZX5$Q(YE"D2!8D1@5
MDF93]#8F\@I95K5JR/.%H--4H9;;\M%;+J[H-2[IBBI&CFL^?:?\W7>,D'[(
MX\5Q/Z;7B,;/&[23M-LN:05!ITV"@\,@# *<A'X4MWW?ZP317QXHZ<#R<H]4
M"T:>-V8TLU*BY7<#/U>].8U5VO5<]Z>&67?<3WBF0)B S>77DL<*)T5NE(49
MG69=8T^CW%J3(\ZXZ.ZXYJ^G*5:"9Y0MNL\&@F+VK"G!\Y8D@B8E6=)_"&@"
M2IF?\U++ ]C-:$9JK5NN!ZJ.;E(:4H7\ENW=U_/3&G[ N&4'83$%'RF>=[T6
MZ++$)()#(6)#=GJ= [!S.+J<C$_'P\%D?'Z&SD_1\,5X=(I&?XR&;R;CWT?P
M"*BCRW5\<$_]M9UPE'^KDPT^:/%%(62!09KBR#M$;^S7]M!&KTFD<W1WQ^NX
M/<]ONTV$)<(QSW6BY4M[[JT\<CN()TBE!+W&(L09D=;Y#2,+-(B4IK1<M]4T
M]"*+B9#@)^#'DX1&1.@%HQL\)1D:9Y&-]O2ZW1T_Z WY+,?9PGS?1RD1)%P@
MV*%H0HEL:CUD$:4UHV<2765\SD@\)5H:5KL[[</>FN[OY3B.X2:Q&$E4U^]L
M^$ \N];S*\CTUQ)9'MYF/K^B<6LZ%$T@C' 4E3&D2\2[ @M(3;9 @N1<0&1F
MZ)2+&?)<Z[<Z@*N80PD7YO?=IASTX#$B$,$Q>H5%E):F^5ZS+#)W@7MI^%=Q
MFQ0,=FL]&$0MFE.5&LZ"O"NH(+H&22W]O>3;P_L(=/#:>_%^F88Y,(APR""X
MZVPC42&@K +;T4V4XFQ*ZI3SCOR@W#8S&D,J'/40SN*GD0ZM;3I\@W2@&83U
M#.LP@X#,%*;Z'J:9":8R:%&"J8EV0:2.S*8F8\80;"-:#8A;F4.HRO)"3VB&
MLT@_!X:Q@7@ZRO2J@I6!S2%SC$SY4)*5J25KH:"3TK<]S>QU*N[?A82*L/AH
MR=V0J_TC</6)AJ6F], UL:CRN5U>$I^#HI3.]9H><@&5TP+-&<XEZ=9?>C&5
M.<.++LV,)F93K\KED"O%9]TVJ'VMRV:$627#B"O)%3@-?-OM=#0^5> _%=>"
M*^AJ&^CJJ'B5=G1H'[D/DUW;NZ4YAG?)'RR0$ 7/&WZCWE#=.=U6?H.\^ZA0
M7T,K1O!\4Y>2L6]W)SCH2?.)?N%IA@8A9 :]/=,U+*R.T>#>'-3FC,:HUO>1
MF_^%)G^F5650-AXJ3:V5TK3T0)2]R^9J54O[Y0)N+1KKEE1??,.4$@UHH30K
M>DW0>0E./U5VJU1]A.;M70@*-WP.5_R*5?OO=:^WX>"8>^CC**/EUM% ,^V^
MS:,,71.A!I$IU_BPZBRBLCY2B4*B'R>%R*A,H2A!MA(HC=!VW.+*Y<J9?ZRG
M0E4[!1$"G#.N:NX4^A53"&%[SB59QH*:S>=#O7M20)=0%_Z( W=A!B:A!L )
MU-<LTA1MCJ[%E&E][E?H)IJG1-=B*/\Q 4[:6QJ6X@30@%D9 T_3F_&D"7RG
M6,2,2&.%9@MM'51_MJ2!MHN!_@6T?!I<F!:NE&ZC :J;0PAV@!:L5 B,F8/U
M"GI$J4"@&0!5 -H85#M,MZ(IUD<'2W/!KZE&ZV#B,NS0[IE3P#2A1N$5"@H7
M*VON3KYBL'0(FGY[$+!I1J74"H!O*, >T#))4)'#$ZTFD>IA*/,D9B&GX[/!
MV7 \>+F=A6QG(=M9R!-L_K:SD.TL9)L.W],LY$D//)9?CP'N-=[J"L*P[B]6
M7IC=]<^F37+OMN 08'FA5K=\XAU;^9F*NS9U2JQ0$'QE&7#;Q6R.%[*QN?=Z
MVWG/(QMX+,][?L4SR.M!C.?_FWG/%YK\W<][R@G/Z>UE7\U"T-*@Y(ZH[_\!
M(*\B4QIW;><FV[G)=F[RW^8FZXP3'@>Z<,I_)C+_UG3\+U!+ 0(4 Q0    (
M  **KU9."T+%\%L! %&T#0 1              "  0    !E>&1X+3(P,C,P
M,S,Q+FAT;5!+ 0(4 Q0    (  **KU:YK;#L\@P  .&$   1
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M;%!+ 0(4 Q0    (  **KU;L<,)_9&\  ,X,!0 5              "  1:
M @!E>&1X+3(P,C,P,S,Q7W!R92YX;6Q02P$"% ,4    "  "BJ]6& Y!.XP(
M  #W+@  $               @ &M[P( >&=N,S$Q+3,S,3(S+FAT;5!+ 0(4
M Q0    (  **KU8;^@1T? @  .(N   0              "  6?X @!X9VXS
M,3(M,S,Q,C,N:'1M4$L! A0#%     @  HJO5L#6[S="!@  ,24  !
M         ( !$0$# 'AG;C,R,2TS,S$R,RYH=&U02P4&      D "0!$ @
&@0<#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
